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FOREWORD
The purpose of the Occupational Safety and Health Act of 1970 (Public Law 91-596) is to 
assure safe and healthful working conditions for every working person and to preserve our 
human resources. The Act authorizes the National Institute for Occupational Safety and 
Health (NIOSH) to develop and recommend occupational safety and health standards and 
to develop criteria that will ensure that no worker will suffer diminished health, functional 
capacity, or life expectancy as a result of his or her work experience.
Through criteria documents, NIOSH communicates recommended standards to regulatory 
agencies, including the Occupational Safety and Health Administration (OSHA) and the 
Mine Safety and Health Administration (MSHA). In addition, NIOSH distributes these 
documents to health professionals in academia, industry, organized labor, public interest 
groups, and other appropriate government agencies. Criteria documents provide the scien­
tific basis for the occupational safety and health standards. These documents generally 
contain a critical review o f the scientific and technical information available on the 
prevalence o f hazards, the existence of safety and health risks, and the adequacy of control 
methods.
This criteria document reviews available information about the health risks for workers 
engaged in the manufacture and use of ethylene glycol monomethyl ether (EGME), ethylene 
glycol monoethyl ether (EGEE), and their acetates, ethylene glycol monomethyl ether 
acetate (EGMEA) and ethylene glycol monoethyl ether acetate (EGEEA). Evidence from 
case reports clearly establishes the risk of adverse effects on the blood, central nervous and 
hematopoietic systems, liver, and kidneys. The results of studies in animals have demonstrated 
dose-related embryotoxicity and other reproductive effects in several species o f animals 
exposed to EGME, EGEE, and their acetates by different routes of administration. Of 
particular concern are studies in which exposure o f pregnant animals to airborne concentra­
tions of EGME or EGEE at or below their current OSHA permissible exposure limits (PELs) 
led to increased incidences o f malformations, growth retardation, and embryonic death. 
Concern was also caused by testicular atrophy and infertility resulting from exposure of 
male animals to airborne concentrations o f EGME or EGEE at or below their PELs.
A known metabolism precedes the reproductive and developmental toxicity of EGME and 
EGEE in animals. Because the same metabolic pathways exist in humans, NIOSH considers 
it prudent to assume that humans and animals are similarly subject to the reproductive and 
developmental effects of these chemicals. EGMEA and EGEEA have the same potential 
for reproductive and developmental effects as the parent compounds because they are 
metabolized to EGME and EGEE, respectively.
Because limited data are available from studies in humans, NIOSH bases its recommended 
exposure limits (RELs) for EGME, EGEE, and their acetates on data from studies in animals. 
The data were adjusted to allow for uncertainties in the extrapolation from animals to 
humans. NIOSH recommends that worker exposure to EGME and EGMEA in the workplace 
be limited to 0.1 part per million parts of air (0.1 ppm) (0.3 mg EGME/m^ and 0.5 mg
EGME A/m ) as a time-weighted average for up to 10 hr/day during a 40-hr workweek ( 10-hr 
TWA). Exposure to EGEE and EGEEA in the workplace shall be limited to 0.5 ppm (1.8 
mg/m3 for EGEE and 2.7 mg/m3 for EGEEA) as a 10-hr TWA. Exposure to these glycol 
ethers shall be reduced using state-of-the-art engineering controls and work practices. 
Dermal contact is prohibited because EGME, EGEE, and their acetates are readily absorbed 
through the skin.
The Institute takes sole responsibility for the conclusions and recommendations presented 
in this document. All reviewers’ comments are being sent with this document to OSHA and 
MSHA for consideration in standard setting.
3
Occupational Safety and Health 
Centers for Disease Control
ABSTRACT
This document examines the occupational health risks associated with exposure to ethylene 
glycol monomethyl ether (EGME), ethylene glycol monoethyl ether (EGEE), and their 
acetates, ethylene glycol monomethyl ether acetate (EGMEA) and ethylene glycol monoethyl 
ether acetate (EGEEA). Criteria are also provided for eliminating or minimizing the risks 
encountered by workers during the manufacture and use of these glycol ethers.
These glycol ethers adversely affect the blood, central nervous and hematopoietic systems, 
liver, and kidneys. Studies in animals have demonstrated dose-related malformations, growth 
retardation, and embryonic death in the offspring of pregnant animals exposed to airborne 
concentrations of EGME or EGEE at or below their current Occupational Safety and Health 
Administration (OSHA) permissible exposure limits (PELs). In addition, testicular atrophy 
and infertility occurred in male animals exposed to airborne concentrations of EGME or 
EGEE at or below their current PELs. EGMEA and EGEEA have the same potential for 
reproductive and developmental effects as the parent compounds because they are metabo­
lized to EGME and EGEE, respectively.
The National Institute for Occupational Safety and Health (NIOSH) therefore recommends 
that exposure to EGME and EGMEA in the workplace be limited to 0.1 part per million 
parts of air (0.1 ppm) (0.3 mg EGME/m3 and 0.5 mg EGMEA/m3) as a time-weighted 
average for up to 10 hr/day during a 40-hr workweek (10-hr TWA).
NIOSH also recommends that exposure to EGEE and EGEEA be limited to 0.5 ppm (1.8 mg 
EGEE/m3 and 2.7 mg EGEEA/m3) as a 10-hr TWA. Exposure to these glycol ethers shall 
be reduced using state-of-the-art engineering controls and work practices. Dermal contact 
is prohibited because EGME, EGEE, and their acetates are readily absorbed through the 
skin.
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GLOSSARY
Biological monitoring: The measurement and evaluation o f hazardous substances or their 
metabolites in the body tissues, fluids, or exhaled air o f exposed workers.
Developmental toxicity: Any adverse effects on normal growth, development, or acquisi­
tion of organ function in (1) the conceptus o f a pregnant woman exposed to a chemical or 
physical agent, or (2) an immature (prepubertal) individual exposed to a chemical or physical 
agent
Lowest observable adverse effect level (LOAEL): The lowest concentration of a chemical 
or physical agent that produces an observable adverse health effect in exposed animals or 
workers.
No observable adverse effect level (NOAEL): The concentration o f a chemical or physical 
agent that produces no observable adverse health effect in exposed animals or workers.
Recommended exposure limit (REL): An occupational exposure limit recommended by 
NIOSH as being protective o f worker health and safety over a working lifetime; the REL is 
used in combination with engineering and work practice controls, exposure and medical 
monitoring, labeling, posting, worker training, and personal protective equipment The REL 
is frequently expressed as a time-weighted average (TWA) exposure for up to 10 hr/day 
during a 40-hr workweek. The REL may also be expressed as (1) a short-term exposure 
limit (STEL) that should never be exceeded and is to be determined in a specified sampling 
time (usually 15 min), or (2) a ceiling limit (C) that should never be exceeded even 
instantaneously unless specified over a given time period.
Reproductive hazard', Any chemical or physical agent capable o f causing an adverse effect 
on reproduction.
Reproductive toxicity*. Any adverse effects on gametogenesis, fecundity, or sexual func­
tions (e.g., libido, menstrual cyclicity, potency) that result when a postpubertal individual 
of either sex is exposed to certain chemical or physical agents.
Skin: The notation “skin” indicates that airborne or direct exposure by the cutaneous route 
(including mucous membranes and eyes) contributes to overall exposure.
Time-weighted average (10-hr TWA): An airborne concentration o f a chemical or physical 
agent in the worker’s breathing zone for up to 10 hr/day during a 40-hr workweek.
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1 RECOMMENDATIONS FOR STANDARDS
The National Institute for Occupational Safety and Health (NIOSH) recommends that 
worker exposure to ethylene glycol tnonomethyl ether (EGME), ethylene glycol monoethyl 
ether (EGEE), and their acetates, ethylene glycol monomethyl ether acetate (EGMEA) and 
ethylene glycol monoethyl ether acetate (EGEEA), be controlled in the workplace by 
complying with the recommendations presented in this Chapter. These recommendations 
are designed to protect the health and provide for the safety of workers for up to a 10-hr 
workshift and a 40-hr workweek over a working lifetime. Compliance with all sections of 
the recommended standard, including the recommended exposure limits (RELs), should 
prevent or greatly reduce the risk o f adverse effects on exposed workers.
SECTION 1.1 RECOMMENDED EXPOSURE LIMITS FOR EGME, EGEE, 
AND THEIR ACETATES 
1.1.1 Exposure
Exposure to EGME and EGMEA in the workplace shall be limited to 0.1 part per million 
parts of air (0.1 ppm, or 0.3 mg EGME/m3 and 0.5 mg EGMEA/m3) as a time-weighted 
average for up to 10 hr/day during a 40-hr workweek ( 10-hr TWA). Exposure to EGEE and 
EGEEA in the workplace shall be limited to 0.5 ppm (1.8 mg EGEE/m3 and 2.7 mg 
EGEEA/m ) as a 10-hr TWA. Exposure to these glycol ethers shall be reduced using 
state-of-the-art engineering controls and work practices.
Dermal contact shall be prohibited because EGME, EGEE, and their acetates are readily 
absorbed through the skin.
1.1.2 Sampling and Analysis
Workplace air samples shall be collected and analyzed for EGME, EGEE, and their acetates 
as described by Occupational Safety and Health Administration (OSHA) Method No. 79 
[OSHA 1990] (discussed in Section 5.2 and Appendix A) or by any other methods with at 
least equal accuracy, precision, and sensitivity. The NIOSH Occupational Exposure Sam­
pling Strategy Manual [Leidel et al. 1977] provides guidance for the number of samples to 
be collected and is discussed in Section 8.8.
SECTION 1.2 EXPOSURE MONITORING
Exposure monitoring shall be conducted as specified in Sections 1.2.1 and 1.2.2. Results 
of all exposure monitoring shall be recorded and maintained as specified in Section 1.9.
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1.2.1 Industrial Hygiene Surveys
In work areas where airborne exposures to EGME, EGEE, or their acetates may occur, the 
employer shall conduct initial industrial hygiene surveys to determine the magnitude of 
exposure by using personal sampling techniques for an entire workshift. The employer shall 
keep records of these surveys. If the employer concludes that exposure concentrations for 
all glycol ethers are less than one-half the REL, the records must show the basis for this 
conclusion. Surveys shall be repeated at least annually and whenever any process change 
is likely to increase concentrations o f airborne EGEE, EGME, EGEEA, and EGMEA. The 
employer shall also look for, evaluate, and record the potential for dermal exposure.
1.2.2 Personal Monitoring
If workers are exposed to any glycol ether at or above one-half the REL, a program of 
personal monitoring shall be instituted to identify and to measure or calculate the exposure 
of each worker (see Section 8.8). Source and area monitoring may be a useful supplement 
to personal monitoring. In all personal monitoring, samples representative o f the TWA 
exposures to airborne glycol ethers shall be collected in the breathing zone of the worker. 
Procedures for sampling and analysis shall be in accordance with Section 1.1.2. For each 
determination of an occupational exposure concentration, a sufficient number of samples 
(as determined in Leidel et al. [1977]), shall be collected to characterize each worker’s 
exposure during each workshift. Although not all workers must be monitored, a sufficient 
number o f samples must be collected to characterize the exposure of all workers. Variations 
in work and production schedules as well as worker locations and job functions shall be 
considered when determining sampling locations, times, and frequencies.
If a worker is exposed to EGME, EGEE, or their acetates at concentrations below the REL 
but at or above one-half the REL, the exposure of that worker shall be monitored at least 
once every 6 months or more frequently, as indicated by a professional industrial hygienist. 
If a worker is exposed to one o f these glycol ethers at concentrations exceeding the REL, 
the worker must wear a respirator until adequate engineering controls and/or work practices 
are instituted. Controls shall then be initiated, the worker shall be notified o f the exposure 
and of the control measures being implemented, and the worker’s exposure shall be 
evaluated at least once a week. Such monitoring shall continue until two consecutive 
determinations at least 1 week apart indicate that the worker’s exposure no longer exceeds 
the REL. At that time, semiannual monitoring can be resumed; if concentrations of the 
glycol ethers are less than one-half the REL after two consecutive semiannual surveys, 
sampling can be conducted annually.
All episodes of skin contact shall be reported to a supervisor. These reports and the results 
of any investigation or corrective action are to be retained with other records.
1.2.3 Biological Monitoring
Measurement o f two glycol ether metabolites—ethoxyacetic acid (EAA, the metabolite of 
EGEE and EGEEA) andmethoxyacetic acid (MAA, the metabolite of EGME and EGMEA)—
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may help characterize occupational exposure to EG EE, EG ME, and their acetates when the 
potential exists for airborne concentrations at or above one-half the REL, or for dermal 
contact from accidental exposure a  breakdown of chemical protective clothing (see Section 5). 
Guidelines for biological monitoring are presented in Appendix G.
SECTION 1.3 MEDICAL MONITORING
The employer shall provide the following information to the physician performing or 
responsible for the medical monitoring program:
• The requirements o f the applicable standard
• An estimate of the worker’s potential exposure to glycol ethers, including any 
available results from workplace sampling
• A description of the worker’s duties as they relate to exposure
• A description of any protective equipment the worker may be required to use
1.3.1 General
• The employer shall institute a medical monitoring program for all workers who are 
exposed to airborne concentrations of EGEE, EGME, or their acetates at or above 
one-half the REL, or who have the potential for dermal exposure.
• If a worker has had a dermal exposure, the employer shall provide this information 
to the physician responsible for or performing the medical monitoring program.
•  The employer shall ensure that all medical examinations and procedures are 
performed by or tinder the direction of a licensed physician.
•  The employer shall provide the required medical monitoring at a reasonable time 
and place without loss of pay or other cost to the workers.
• The employer shall institute a biological monitoring program for all workers who 
are exposed to airborne concentrations o f EGME, EGEE, or their acetates at or 
above one-half the REL, or who have the potential for dermal exposure. Guidelines 
for biological monitoring are presented in Appendix G.
1.3.2 Preplacement Medical Examinations
Preplacement medical examinations shall include at least the following:
• A comprehensive medical, work, and reproductive history that emphasizes iden­
tification of existing medical conditions (e.g., those affecting die reproductive, 
hematopoietic, and central nervous systems, skin, liver, and kidneys) and previous 
occupational exposure to chemical or physical agents
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• A medical examination giving special attention to the reproductive, hematopoietic, and 
central nervous systems, skin, liver, and kidneys
• Routine urinary monitoring for MAA and EAA before job placement, which may 
be a useful adjunct to environmental monitoring because it indicates both airborne 
and dermal exposures
• A judgment of the worker’s ability to use positive- and negative-pressure respirators
1.3.3 Periodic Medical Examinations
Periodic medical examinations shall be provided at least annually to all workers occupation­
ally exposed to airborne concentrations of EGME, EGEE, and their acetates at or above 
one-half the REL, and to workers with the potential for dermal exposure. These examina­
tions shall include at least the following:
• An update of medical and work histories
• A medical examination and tests as outlined above
1.3.4 Medical Consultation
Workers who have a dermal exposure or who are exposed to concentrations of EGME, 
EGEE, or their acetates above the REL should be given the opportunity to consult with a 
physician regarding possible adverse health effects, including reproductive and develop­
mental effects. OSHA Form 200 shall be modified to include any reports of dermal 
exposure.
SECTION 1.4 LABELING AND POSTING
All labels and warning signs shall be printed both in English and the predominant language 
of workers who do not read English. Workers unable to read the labels and warning signs 
shall be informed verbally regarding the instructions printed on labels and signs in the 
hazardous work areas of the plant.
1.4.1 Labeling
Containers of EGME, EGMEA, EGEE, or EGEEA used or stored in the workplace shall 
carry a permanently attached label that is readily visible. The label shall identify the glycol 
ether and give information regarding its effects on human health and emergency procedures 
(see Figure 1-1).
1.4.2 Posting
Signs bearing information about the health effects o f EGME, EGMEA, EGEE, or EGEEA 
shall be posted in readily visible positions in work areas and at entrances to work areas or
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building enclosures where the potential exists for exposures at or above the REL or where 
skin exposures may occur (see Figure 1-2).
If respirators and personal protective clothing are needed during the manufacturing or 
handling of these glycol ethers or during the installation or implementation o f required 
engineering controls, the following statement shall be added in large letters to the signs 
required in this section:
Respirators and protective clothing are required in this area.
In any area where emergency situations may arise, the required signs shall be supplemented 
with emergency first-aid procedures and the locations of emergency showers and eyewash 
fountains.
SECTION 1.5 PROTECTIVE CLOTHING AND EQUIPMENT
Engineering controls and good work practices shall be used to keep the airborne concentra­
tions of EGME, EGEE, and their acetates below the REL and to prevent skin and eye contact. 
When protective clothing and equipment are needed, they shall be provided by the employer 
at no cost to the worker.
1.5.1 Eye and Face Protection
The employer shall provide chemical splash-proof safety goggles or face shields (20-cm  
minimum) with goggles and shall ensure that workers wear the protective equipment during 
any operation in which splashes o f these glycol ethers are likely to occur. Devices for eye 
and face protection shall be selected, used, and maintained in accordance with 29 CFR 
1910.133 and 30 CFR 56.150004, and 57.150004.
1.5.2 Skin Protection
* Workers at risk o f dermal exposure to these glycol ethers shall be provided with 
appropriate protective clothing such as gloves and disposable clothing. Informa­
tion presented in Section 8.6.1 provides guidance in the selection of appropriate 
materials for gloves and clothing.
•  Clothing contaminated with these glycol ethers shall be cleaned before reuse. 
Anyone who handles contaminated clothing or is responsible for its cleaning shall 
be informed of the hazards of these glycol ethers and the proper precautions for 
their safe handling and use.
Code of Federal Regulations. See CFR in references.
5
EGME, EGEE, and Their Acetates
EGME
WARNING! Exposure may be harmful to the reproductive system and blood.
CAUTION! Combustible
Harmful if Ingested, Inhaled, or absorbed through skin. Irritating 
to skin, eyes, nose, throat, mouth, and lungs.
* In case o f sldn contact, immediately wash the affected area with soap and water; wash clothing before 
reuse.
*  In case o f eye contact, immediately flush the eyes with large amounts o f  water for 15 min. If irritation 
persists, seek medical attention.
*  Keep containers closed when not being used.
*  Use only with adequate ventilation.
*  Keep away fiotn heat, sparks, and open flame. Place cleaning tags in fireproof containers.
*  In case o f fire, use water spray, carbon dioxide, dry chemical, or “alcohol-type* foam.
* Use appropriate chemical protective clothing to avoid skin contact when handling.
Figure 1-1. Example o f a container label identifying the glycol ether and listing information 
about its effects o f human health and emergency procedures.
EGME
WARNING! Exposure may be harmful to the reproductive system and blood.
CAUTlONI Combustible
Harmful If Ingested, inhaled, or absorbed through the skin, irritating 
to skin, eyes, nose, throat, mouth, and lungs.
Figure 1-2. Example o f a sign containing information about the health effects o f a glycol 
ether.
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• The employer shall ensure that all personal protective clothing and equipment is 
inspected regularly and maintained in a clean and satisfactory working condition.
• Protective clothing or gloves shall be evaluated on a routine basis to ensure that 
they are in good condition and no breakthrough has occurred.
1.5.3 Respiratory Protection
Engineering controls and good work practices shall be used to control respiratory exposure 
to airborne contaminants. The use of respirators is the least desirable method of controlling 
worker exposures and should not be used as the primary control method during routine 
operations. However, NIOSH recognizes that respirators may be required to provide 
protection in certain situations such as implementation of engineering controls, short-duration 
maintenance procedures, and emergencies. Respirator selection guides for protection 
against EGEE, EGME, and their acetates are presented in Tables 1-1 through 1-3.
• Respirators shall be provided by the employer when such equipment is necessary 
to protect the health of the worker. The worker shall use the provided respiratory 
protection in accordance with instructions and training received.
•  The employer shall ensure that respirators are properly fitted and that workers are 
instructed at least annually in the proper use and testing for leakage of respirators 
assigned to them.
• Workers should not be assigned to tasks requiring the use of respirators unless it 
has been determined that they are physically able to perform the work and use the 
equipment. The respirator user’s medical status should be reviewed at least 
annually or more frequently as recommended by the physician responsible for the 
physical examination. See Appendix H for additional information about the 
medical aspects of wearing respirators.
• The employer shall be responsible for establishing and maintaining a respiratory 
protection program as follows:
1. Written standard operating procedures governing selection and use of respirators 
shall be established.
2. The worker shall be instructed and trained in the proper use of respirators and 
their limitations.
3. Where practicable, the respirators should be assigned to individual workers for 
their exclusive use.
The OSHA minimum requirements for a respiratory protection program for general industry may be found 
in29CFR 1910.134, and the minimum Mine Safety and Health Administration (MSHA) requirements for the 
mining industry may be found in 30 CFR 56.5005,57.5005,70.305, and 70.305-1.
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Table 1-1.—NIOSH-recommended respiratory protection for workers 
exposed to EGME and EGMEA
Condition Minimum respiratory protection
1 ppm or less 
(10 x REL)
Any supplied-air respirator equipped with a half-mask*
2.5 ppm or less Any supplied-air respirator equipped with a hood or helmet and operated
(25 x REL) in a continuous-flow mode
5.0 ppm or less 
(50 x REL)
Any supplied-air respirator with a full facepiece, or 
Any self-contained breathing apparatus with a full facepiece
100 ppm or less Any supplied-air respirator equipped with a half-mask^ and operated in
(1,000 x REL) a pressure-demand or other positive-pressure mode
200 ppm or less Any supplied-air respirator equipped with a full facepiece and operated
(2,000 x REL) in a pressure-demand or other positive-pressure mode
Greater than 200 ppm Any self-contained breathing apparatus equipped with a full facepiece 
and operated in a pressure-demand or other positive-pressure mode, or
Any supplied-air respirator equipped with a full facepiece and operated 
in a pressure-demand or other positive-pressure mode in combination 
with an auxiliary self-contained breathing apparatus operated in a 
pressure-demand or other positive-pressure mode
Fire fighting Any self-contained breathing apparatus equipped with a full facepiece 
and operated in a pressure-demand or other positive-pressure mode
Escape Any air-purifying,* full-facepiece respirator (gas mask) with a chin-style 
or front- or back-mounted organic vapor canister, or
Any appropriate escape-type, self-contained breathing apparatus
Only NIOSH/MSHA-approved equipment shall be used.
*If eye irritation occurs, a respirator equipped with full facepiece, helmet, or hood shall be used.
* Air-purifying respirators are used for escape only because EGME and EGMEA do not have good 
odor-warning properties.
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Table 1-2.—NIOSH-recommended respiratory protection for workers
exposed to EGEE
Condition Minimum respiratory protection
5 ppm or less 
(10 x REL)
Any supplied-air respirator equipped with a half-mask*
12.5 ppm or less Any supplied-air respirator equipped with a hood or helmet and operated
(25 x REL) in a continuous-flow mode
25 ppm or less 
(50 x REL)
Any supplied-air respirator with a full facepiece, or 
Any self-contained breathing apparatus with a full facepiece
500 ppm or less Any supplied-air respirator equipped with a half-mask* and operated in
(1,000 x REL) a pressure-demand or other positive-pressure mode
1,000 ppm or less Any supplied-air respirator equipped with a full facepiece and operated
(2,000 x REL) in a pressure-demand or other positive-pressure mode
Greater than 1,000 ppm Any self-contained breathing apparatus equipped with a full facepiece 
operated in a pressure-demand or other positive-pressure mode, or
Any supplied-air respirator equipped with a full facepiece and operated 
in a pressure-demand or other positive-pressure mode in combination 
with an auxiliary self-contained breathing apparatus operated in a 
pressure-demand or other positive-pressure mode
Firefighting Any self-contained breathing apparatus with a full facepiece and 
operated in a pressure-demand or other positive-pressure mode
Escape Any air-purifying,* fuli-facepiece respirator (gas mask) with a chin-style 
or front- or back-mounted organic vapor canister, or
Any appropriate escape-type, self-contained breathing apparatus
Only NIOSH/MSHA-approved equipment shall be used.
^If eye irritation occurs» a respirator equipped with full facepiece, helmet, or hood shall be used.
* Air-purifying respirators are used for escape only because EGEE does not have good odor-warning 
properties.
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Table 1-3.—NIOSH-recommended respiratory protection for workers
exposed to EGEEA
Condition Minimum respiratory protection
5.0 ppm or less 
(10 x REL)
Any air-purifying respirator* equipped with organic vapor cartridges* or 
Any supplied-air respirator equipped with a half-mask*
12.5 ppm or less 
(25 x REL)
Any supplied-air respirator operated in a continuous flow mode,* or
Any powered, air-purifying respirator* equipped with a loose-fitting hood 
or helmet and an organic vapor cartridge or canister
25 ppm or less Any powered, air-purifying respirator* equipped with a tight-fitting
(50 x REL) facepiece and organic vapor cartridges, or
Any air-purifying, full-facepiece respirator* equipped with organic vapor 
cartridges or canisters, or
Any supplied-air respirator with a full facepiece, or
Any self-contained breathing apparatus with a full facepiece
500 ppm or less Any supplied-air respirator equipped with a half-mask* and operated in
(1,000 x REL) a pressure-demand or other positive-pressure mode
1,000 ppm or less Any supplied-air respirator equipped with a full facepiece and operated
(2,000 x REL) in a pressure-demand or other positive-pressure mode
Greater than 1,000 ppm Any self-contained breathing apparatus equipped with a full facepiece and 
operated in a pressure-demand or other positive-pressure mode, or
Any supplied-air respirator equipped with a full facepiece and operated in a 
pressure-demand or other positive-pressure mode in combination with an 
auxiliary self-contained breathing apparatus operated in a pressure-demand 
or other positive-pressure mode
Fire fighting Any self-contained breathing apparatus equipped with a full facepiece and 
operated in a pressure-demand or other positive-pressure mode
Escape Any air-purifying, full-facepiece respirator* (gas mask) with a chin-style 
or front- or back-mounted organic vapor canister, or
Any appropriate escape-type, self-contained breathing apparatus
Only NIOS H/MS HA-approved equipment shall be used.
*Air-purifyiing respirators should be used with EGEEA (which has good odor-warning properties) only 
when the other glycol ethers (which have poor odor-warning properties) axe not present in the workplace. 
*If eye irritation occurs, a respirator equipped with a full facepiece, helmet, or hood shall be used.
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4. Respirators shall be regularly cleaned and disinfected.
5. Respirators shall be stored in a convenient, clean, and sanitary location.
6. Respirators used routinely shall be inspected during cleaning. Worn or deteriorated 
parts shall be replaced. Respirators for emergency use (e.g., self-contained devices) 
shall be thoroughly inspected at least once a month and after each use.
7. The respiratory protection program shall be regularly evaluated by the employer 
to determine its continued effectiveness.
8. Additional information about the selection, maintenance, and use of respirators 
can be found in the NIOSH Respirator Decision Logic [NIOSH 1987b] and the 
NIOSH Guide to Industrial Respiratory Protection [NIOSH 1987a].
SECTION 1.6 INFORMING WORKERS ABOUT THE HAZARDS OF GLYCOL 
ETHERS 
1.6.1 Hazard Communication
If workers have the potential for dermal exposure or are assigned to areas where airborne 
exposures to EGME, EGEE, EGMEA, and EGEEA are one-half or more o f the REL, they 
shall be kept informed of the hazards, relevant signs and symptoms o f toxicity, and proper 
conditions and precautions for the safe use and handling of these glycol ethers. Workers 
shall be made aware o f possible reproductive, developmental, and hematologic effects of 
exposure to these glycol ethers.
The employer shall notify the worker when exposure exceeds the REL in the work area to 
which he is assigned.
1.6.2 Training
The employer shall institute a continuing education program conducted by persons qualified 
by experience or training in occupational safety and health. The program shall ensure that 
all workers exposed to EGME, EGEE, or their acetates have current knowledge o f glycol 
ether hazards, proper maintenance, cleanup methods, and proper use of protective clothing 
and equipment, including respirators. The instructional program shall include oral and 
written descriptions of the environmental and medical monitoring programs and o f their 
advantages to the worker. The employer shall maintain a written plan of these training and 
monitoring programs. In addition, employers shall follow the OSHA regulations in 29 CFR 
1910.1200, Hazard Communication.
Workers shall also be instructed about their responsibilities for following proper work 
practices and sanitation procedures to help protect their health and provide for their safety 
and that of their fellow workers.
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All workers in areas where exposure to EGME, EGEE, or their acetates may occur during 
spills or emergencies shall be trained in proper emergency and evacuation procedures.
1.6.3 File of Written Hazard Communication
Required information shall be recorded on the material safety data sheet (see example in 
Appendix D) or on a similar OSHA form that describes the relevant toxic, physical, and 
chemical properties o f the glycol ethers and mixtures of glycol ethers that are used or 
otherwise handled in the workplace. This information shall be kept on file and shall be 
readily available to workers for examination and copying.
SECTION 1.7 ENGINEERING CONTROLS AND WORK PRACTICES 
1.7.1 Engineering Controls
Engineering controls shall be used as needed to maintain exposure to airborne glycol ethers 
within the limits prescribed in Chapter 1.
1.7.1.1 Local Exhaust Ventilation
Local exhaust ventilation may be effective when used alone or in combination with process 
enclosure. When a local exhaust ventilation system is used, it shall be designed and operated 
to prevent accumulation or recirculation of airborne glycol ethers in the workplace. Exhaust 
ventilation systems discharging to outside air shall conform with applicable local, State, and 
Federal air pollution regulations and shall not constitute a hazard to workers or to the general 
population. Before maintenance work on control equipment begins, the generation of 
airborne glycol ethers shall be eliminated to the greatest extent feasible.
1.7.1.2 Maintaining Design Airflow
Enclosures, exhaust hoods, and ductwork shall be kept in good repair to maintain designed 
airflows. Measurements such as capture velocity, duct velocity, or static pressure shall be 
made at least semiannually, and preferably monthly, to demonstrate the effectiveness 
(quantitatively, the ability of the control system to maintain exposures below the REL) of 
the mechanical ventilation system. NIOSH recommends the use o f continuous airflow 
indicators such as water or oil manometers marked to indicate acceptable airflow. A record 
shall be kept showing design airflow and the results of all airflow measurements. Measure­
ments of the effectiveness of the system in controlling exposures shall also be made as soon 
as possible after any change in production, process, or control devices that may increase 
airborne concentrations of EGME, EGEE, and their acetates.
1.7.1.3 Forced-draft Ventilation
Forced-draft ventilation systems shall be equipped with remote manual controls and should 
be designed to shut off automatically in the event of a fire.
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1.7.2 General Work Practices
• Operating instructions for all equipment shall be developed and posted where 
EGME, EGEE, and their acetates are handled or used.
• Transportation, use, and disposal of these glycol ethers shall comply with all 
applicable local, State, and Federal regulations.
•  These glycol ethers shall be stored in tightly closed containers and in well-ventilated 
areas.
• Containers shall be moved only with the proper equipment and shall be secured to 
prevent loss of control or dropping during transport.
• Storage facilities shall be designed to prevent contamination of workroom air and 
to contain spills completely within surrounding dikes.
• Ventilation switches and emergency respiratory equipment shall be located outside 
storage areas in readily accessible locations.
• Process valves and pumps shall be readily accessible and shall not be located in 
pits or congested areas.
• Glycol ether containers and systems shall be handled and opened with care. 
Approved protective clothing and equipment as specified in Section 1.5 shall be 
worn by workers who open, connect, and disconnect glycol ether containers and 
systems. Adequate ventilation shall be provided to minimize exposures o f such 
workers to airborne glycol ethers.
• Glycol ether storage equipment and systems shall be inspected daily for signs of 
leakage. All equipment, including valves, fittings, and connections, shall be 
checked for leaks immediately after glycol ethers are introduced therein.
• When a leak is found, it shall be repaired promptly. Work shall resume normally 
only after necessary repair or replacement has been completed and the area has 
been well ventilated.
1.7.3 Confined or Enclosed Spaces
• A permit system shall be used to control entry into confined or enclosed spaces 
holding containers o f glycol ethers (e.g., tanks, pits, tank cars, and process vessels) 
where egress is limited. Permits shall be signed by an authorized representative o f 
the employer and shall certify that preparation of the confined space, precautionary 
measures, and personal protective equipment are adequate and that precautions 
have been taken to ensure that prescribed procedures will be followed.
• Confined spaces that hold containers of EGME, EGEE, and their acetates shall be 
thoroughly ventilated, inspected, and tested for oxygen deficiency and for airborne 
concentrations of these glycol ethers. Every effort shall be made to prevent the
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inadvertent release o f hazardous amounts o f these glycol ethers into confined 
spaces in which work is in progress. Giycol ether supply lines shall be discon­
nected or blocked off before such work begins.
•  No worker shall enter a confined space holding containers o f glycol ethers without 
an entry large enough to admit a worker wearing a safety harness, lifeline, and 
appropriate personal protective equipment as specified in Section 1.5.
•  Confined spaces shall be ventilated while work is in progress to keep the concentra­
tion o f glycol ethers below the RELs, to keep the concentration o f other con­
taminants below toxic or dangerous levels, and to prevent oxygen deficiency.
• If the concentrations o f these glycol ethers in the confined space exceed the RELs, 
respiratory protective equipment is required for entry.
• Anyone entering a confined space shall be observed from the outside by another 
properly trained and protected worker. An additional supplied-air or self-contained 
breathing apparatus with safety harness and lifeline shall be located outside the 
confined space for emergency use. The person entering the confined space shall 
maintain continuous communication with the standby worker.
1.7.4 Emergency Procedures
Emergency plans and procedures shall be developed for all work areas where there is a 
potential for exposure to EGME, EGEE, and their acetates. These plans and procedures 
shall include those specified below and any others considered appropriate for a specific 
operation or process. Workers shall be instructed in the effective implementation of these 
plans and procedures.
• The following steps shall be taken in the event of a leak or spill o f these glycol 
ethers:
— All nonessential personnel shall be evacuated from the leak or spill area.
— Persons not wearing the appropriate protective equipment and clothing shall 
be restricted from the leak or spill area until cleanup has been completed.
— All ignition sources shall be removed.
— The area where the leak or spill occurs shall be adequately ventilated to prevent 
the accumulation of vapor.
— EGME, EGEE, EGMEA and EGEEA shall be contained and absorbed with 
vermiculite, sand, paper towels, or equivalent materials.
— Small quantities of absorbed material shall be placed under a fume hood and 
sufficient time shall be allowed for the liquid to evaporate and for the vapors 
to clear the ductwork in the hood.
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— Large quantities o f absorbed material shall be burned in a suitable combustion 
chamber.
— Absorbed materials shall be disposed of as hazardous waste.
— The spill area shall be cleaned with water.
• Only personnel trained in the emergency procedures and protected against the 
attendant glycol ether hazards shall clean up spills and control and repair leaks.
* Personnel entering the spill or leak area shall be furnished with appropriate personal 
protective clothing and equipment. Other personnel shall be prohibited from 
entering the area.
♦ Safety showers, eyewash fountains, and washroom facilities shall be provided, 
maintained in working condition, and made readily accessible to workers in all 
areas where skin or eye contact with EGME, EGEE, EGMEA, or EGEEA is likely. 
If one of these glycol ethers is splashed or spilled on a worker, contaminated 
clothing shall be removed promptly, and the skin shall be washed thoroughly with 
soap and water. Eyes splashed by these glycol ethers shall be irrigated immediately 
with a copious flow o f water for 15 min. If irritation persists, the worker should 
seek medical attention.
1.7.5 Storage
EGME, EGEE, and their acetates shall be stored in cool, well-ventilated areas and kept away 
from acids, bases, and oxidizing agents.
1.7.6 Waste Disposal
All waste material shall be securely packaged in double bags, labeled, and incinerated. The 
incinerator residue shall be disposed of in a manner consistent with Federal (EPA), State, 
and local regulations, or it shall be disposed of in a licensed hazardous waste landfill.
1.8 SANITATION AND HYGIENE
1.8.1 Food, Cosmetics, and Tobacco
The following shall be prohibited in areas where EGME, EGEE, EGMEA, or EGEEA is 
produced or used: the storage, preparation, dispensing, or consumption of food or beverages; 
the storage or application of cosmetics; and the storage or use o f all tobacco products.
1.8.2 Handwashing
The employer shall provide handwashing facilities and encourage workers to use them 
before eating, smoking, using the toilet, or leaving the worksite.
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1.8.3 Laundering
•  Protective clothing, equipment, and tools shall be cleaned periodically.
• The employer shall provide for the cleaning, laundering, or disposal o f con­
taminated work clothing and equipment.
•  Any person who cleans or launders this work clothing or equipment must be 
informed by the employer that it may be contaminated with EGME, EGEE, 
EGMEA, or EGEEA—chemicals that may cause adverse reproductive, develop­
mental, hematologic (blood), and central nervous system (CNS) effects.
1.8.4 Cleanup of Work Area
The work area shall be cleaned at the end o f each shift (or more frequently if needed) using 
vacuum pickup. Collected wastes shall be placed in sealed containers with labels that 
indicate the contents. Cleanup and disposal shall be conducted in a manner that prevents 
worker contact with wastes and complies with all applicable Federal, State, and local 
regulations.
1.8.5 Showering and Changing Facilities
Workers shall be provided with quick-drench shower facilities and with facilities for 
showering and changing clothes at the end of each workshift.
1.9 RECORDKEEPING
1.9.1 Exposure Monitoring
The employer shall establish and maintain an accurate record of all exposure measurements 
required in Section 1.2. These records shall include the name of the worker being monitored, 
social security number, duties performed and job locations, dates and times of measure­
ments, sampling and analytical methods used, type of personal protection used (if any), and 
number, duration, and results o f samples taken.
1.9.2 Medical Monitoring
The employer shall establish and maintain an accurate record for each worker subject to the 
medical monitoring specified in Section 1.3. Pertinent medical records (Le., the physician’s 
written statement, the results of medical examinations and tests, medical complaints, reports 
of skin exposure, etc.) shall be retained in the medical files of all workers subject to airborne 
concentrations of EGME, EGEE, EGMEA, or EGEEA in the workplace at or above one-half 
the REL. Copies of applicable environmental monitoring data shall also be included in the 
worker’s medical file.
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1.9.3 Record Retention
In accordance with the requirements of 29 CFR 1910.20(d) (Preservation of Records), the 
employer shall retain the records described in Sections 1.2, 1.3, and 1.6 for at least the 
following periods:
• 30 years for exposure monitoring records, and
• the duration of employment plus 30 years for medical surveillance records
1.9.4 Availability of Records
• In accordance with 29 CFR 1910.20 (Access to Employee Exposure and Medical 
Records), the employer shall allow examination and copying o f exposure monitor­
ing records by the subject worker, the former worker, or anyone having the specific 
written consent of the subject or former worker.
• Any medical records required by this recommended standard shall be provided 
upon request for examination and copying to the subject worker, the former worker, 
or anyone having the specific written consent of the subject or former worker.
1.9.5 Transfer of Records
If the employer ceases to do business and no successor is available to receive and retain the 
records for the prescribed period, the employer shall notify the Director o f NIOSH at least 
3 months before record disposal and transmit them to the Director if  instructed to do so 
[29 CFR 1910.1028],
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2.1 PURPOSE
This document presents the criteria and recommended standards necessary to prevent health 
impairment from exposure to ethylene glycol monomethyl ether (EGME), ethylene glycol 
monomethyl ether acetate (EGMEA), ethylene glycol monoethyl ether (EGEE), and ethylene 
glycol monoethyl ether acetate (EGEEA). The document was developed in accordance with 
Section 20(a)(3) of the Occupational Safety and Health (OSH) Act of 1970. In this Act, the 
National Institute for Occupational Safety and Health (NIOSH) is charged with developing 
criteria for toxic materials and harmful physical agents, and describing exposure concentra­
tions at which no worker will suffer impaired health or functional capacities or diminished 
life expectancy as a result of work experience. This document also responds to Section 
2.2(c)(1) o f the OSH Act, which authorizes NIOSH to develop and establish recommended 
occupational safety and health standards.
NIOSH has formalized a system for developing criteria on which to base standards for 
ensuring the health and safety of workers exposed to hazardous chemical and physical 
agents. Simple compliance with these standards is not the only goal. The criteria and 
recommended standards are intended to help management and labor develop better engineer­
ing controls and more healthful work practices.
Recommended standards for EGEE, EGME, EGEEA, and EGMEA apply only to workplace 
exposures arising from the processing, manufacturing, handling, and use of these glycol 
ethers. The recommendations are not designed for the population at large, and any extrapolation 
beyond the occupational environment may not be warranted. The recommended standards 
are intended to protect workers from the acute and chronic effects of EGEE, EGME, 
EGEEA, and EGMEA. Exposure concentrations are measurable by techniques that are 
valid, reproducible, and available to industry and government agencies.
2.2 SCOPE
The information in this document assessed the hazards associated with occupational ex­
posure to EGEE, EGME, EGEEA, and EGMEA. Chapter I presents the recommended 
standards and describes their requirements. Chapter 3 gives information about the chemical 
and physical properties of EGEE, EGME, EGEEA, and EGMEA, production methods, uses, 
and the extent of worker exposure. Chapter 4 discusses and summarizes the effects of 
exposure to these glycol ethers on humans and animals. Subsequent chapters describe 
environmental sampling and analytical methods, medical monitoring, biological monitor­
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ing, existing occupational health standards, and a correlation o f exposure and effect. In 
addition, methods for worker protection are discussed, including suggested work practices, 
engineering controls, personal protective clothing and equipment, and exposure monitoring 
and recordkeeping.
3 PROPERTIES, PRODUCTION, AND POTENTIAL 
FOR EXPOSURE
3.1 CHEMICAL AND PHYSICAL PROPERTIES
EGME, EGMEA, EGEE, and EGEEA are part of a family o f ethylene glycol monoalkyl 
ethers represented by the general formula RjOCt^CHjORj where Rj represents the alkyl 
moiety and R2 either H or acetate. In this document, unless otherwise specified, the term 
“glycol ethers” will refer to EGME, EGEE, and their acetates.
EGME (ethylene glycol monomethyl ether), also known as methyl C ellosolve® , 
2-methoxy ethanol (2~ME), or Jeffersol EM® [NIOSH 1987c], is an organic compound with 
the chemical formula CH3OCH2CH2OH. It is a colorless liquid with a mild, nonresidual 
odor; the odor threshold is 2.3 ppm [Amoore and Hautala 1983]. EGME is miscible with 
water and many organic solvents.
EGMEA (ethylene glycol monomethyl ether acetate), also known as methyl Cellosolve® 
acetate or 2-methoxyethyl acetate (2-MEA), is the acetate ester of EGME with the chemical 
formula CH3OCH2CH2OCOCH3 and is prepared by esterifying EGME with acetic acid. It 
is a colorless liquid with a mild, ether-like odor; no data are available on the odor threshold 
of EGMEA. It is miscible in water and with many organic solvents.
EGEE (ethylene glycol monoethyl ether), also known as Cellosolve®, 2-ethoxyethanol (2-EE), 
or Jeffersol EE® [NIOSH 1987c], is an organic compound with the chemical formula 
C2H5OCH2CH2OH. It is a colorless liquid with a sweetish odor, the odor threshold is 2.7 ppm 
[Amoore and Hautala 1983]. EGEE is miscible with water and many organic solvents.
EGEEA (ethylene glycol monoethyl ether acetate), the acetate ester o f EGEE, is also known 
as Cellosolve® acetate, 2-ethoxyethyl acetate (2-EEA), and has the chemical formula 
C2H5OCH2CH2OCOCH3. It is a colorless liquid with a mild, nonresidual odor; the odor 
threshold is 0.056 ppm [Amoore and Hautala 1983]. EGEEA has a low solubility in water, 
but is miscible with many organic solvents.
Other chemical and physical properties are listed in Table 3-1.
3.2 PRODUCTION METHODS AND USES
The ethylene glycol monoalkyl ethers EGME and EGEE are usually produced by a reaction 
of ethylene oxide with methyl or ethyl alcohol, but may also be made by the direct alkylation
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Table 3-1.— Chemical and physical properties of EGME, EGEE, and their acetates*
Property EGME EGMEA EGEE EGEEA
RTECSt  number KL57750OO KL5950000 KK8050000 KKS225000
CAS* number 109-86-4 110-49-6 110-80-5 111-15-9
Molecular formula C5H 10®3 ^4^10^2 c 6h 12o 3
Molecular weight 76.1 118.1 90.1 132.2
Specific gravity 250/4 ° C 0.962 1.007 0.926 0.975
Evaporation rate 0.62 0.30 0.41 0.2
(butyl acetate = 1.00)
Boiling point (°C ) 124.2 144.5 135.0 156.3
Freezing point (°C ) -8 5 -65 .1 -1 0 0 -61 .7
Vapor pressure (mm H g 25 °C) 9.7 2.0-3.7 5.75 2.8
Refractive index 1.400 1.402 1.406 1.406
Flash point (°C ), closed cup 39 49 43 52
Autoignition temperature (°C ) 285 392 235 379
Flammability limits (vol. % in air) 1.8-14.0 1.5-12.3 1.70-15.6 1.7
Water solubility (% by weight) Miscible Miscible Miscible 23
Vapor density (air = 1) 2.6 4.1 3.1 4.6
ppm in saturated air (25 °C) 12,800 2,600-4,900 7,600 3,700
m g/m 3 at 25°C, 760 mm Hg = 1 ppm 3.11 4.83 3.69 5.41
ppm at 25°C , 760 mm Hg = 1 m g/m 3 0.32 0.21 0.27 0.19
Adapted from Rowe and W olf [1982], UCC [1983], NFPA [1987]. 
^Registry o f Toxic Effects of Chemical Substances [NIOSH 1987c}. 
^Chemical Abstract Sendees.
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of ethylene glycol with an alkylating agent such as dimethyl or diethyl sulfate [Rowe and 
W olf 1982]. Temperature, pressure, reactant molar ratios, and catalysts are selected to give 
the product mix desired. Ethylene glycol monoalkyl ethers are not formed as pure com­
pounds, but must be separated from the diethers of diethylene glycol, triethylene glycol, and 
the higher glycols. Ethylene glycol monoalkyl ether acetates are prepared by esterifying the 
particular glycol ether with acetic acid, acetic acid anhydride, or acetic acid chloride.
Glycol ethers and their acetates are widely distributed and have been used commercially for 
more than 50 years. Table 3 -2  presents production figures for these glycol ethers. The most 
importantsingleuseofEGM Eisasajetfueldeicer[M eridianResearch,Inc. 1987]. Because 
military jets lack the inline deicers found on commercial jets, all JP-4 jet fuel contains 0.1 % 
to 0.2% EGME as a deicing agent. JP-5, a new jet fuel, uses 0.15% diethylene glycol 
monomethyl ether (DEGME) in place of EGME as a deicer [Meridian Research, Inc. 1987]. 
EGME is also used in the manufacture of printed circuit boards, as an intermediate in the 
manufacture of plasticizers, in inks and coatings, and in photography and dyeing applica­
tions. EGMEA is a low production chemical that is used as an intermediate for plasticizers 
and also in specialty solvent applications. Approximately 50% of EG EE produced is utilized 
as a chemical intermediate for EGEEA production; it is also used as a solvent for surface 
coatings (especially those based on epoxy resins) and as a solvent in cleaning and printing 
ink formulations. EGEEA is used as a solvent in coating applications for automobiles, coils, 
machinery and equipment, and metal furniture and appliances.
3.3 PROCESS AND WORKER JOB DESCRIPTIONS
The usefulness of glycol ethers and their acetate derivatives can be attributed to their physical 
properties, particularly their miscibility or high solubility in water and other organic 
solvents, and their low vapor pressures. These properties allow them to serve a number of 
functions in a variety of products. The following information was obtained during surveys 
conducted in various industries to determine occupational exposures to glycol ethers [Cal 
OSHA 1983; Meridian Research, Inc. 1987].
3.3.1 Paints and Coatings
Although frequently comprising less than 10% of the final product, glycol ethers serve a 
variety of important functions in paints and coatings. One function is as a solvent to keep
Table 3-2.—U.S. production of EGME, EGEE, and their acetates
Production
Compound (lb)
EGME 79,849,000
EGMEA 1,000,000
EGEE 121,808,000
EGEEA 84,028,000
Sources: TSCAPP [1977], Industrial Economics, Inc. [1985], and USITC [1986].
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the various paint components in solution. Latex coatings contain glycol ethers or their 
acetate derivatives to enhance the coalescing properties of the product when applied. By 
slowing the evaporation rate, glycol ethers reduce moisture condensation or “blush.” They 
also improve the penetration and bonding qualities of paints and coatings. Specialty 
products, such as aircraft or electrostatic paints, may contain 18% to 35% glycol ethers [Cal 
OSHA 1983].
The manufacture o f paints and coatings is a batch process. Components are added manually 
or through a closed piping system to the mixing tank. Because glycol ethers generally 
constitute a small percentage of the total formulation, they are often added manually. After 
mixing, the product is packaged according to customer specifications. Maximum exposures 
occur during weighing, mixing, and filling operations. During the compounding and mixing 
of a batch, exposures to the glycol ethers are low, mainly due to low vapor pressures and 
short exposure times. If ventilation is required to control other more volatile components, 
glycol ether exposures will be coincidentally reduced. During filling operations, exposures 
depend on whether the process is manual or automated and vary with the size o f the 
containers [Cal OSHA 1983].
A variety of industries use paints and coatings, but as previously noted, these products 
usually contain a small percentage of glycol ethers (i.e., less than 10%). Lacquer containing 
less than 1 % glycol ethers is used to coat wood products. However, electrostatic paints used 
in a spraying process for metal parts may contain 20% to 30% glycol ethers. Glycol ethers 
are also used in the manufacture of coated fabrics. These fabrics pass through a dip pan to 
pick up the coating and then rise through a ventilated drying tower [Cal OSHA 1983].
The use of EGEE and EG ME in protective coatings declined by more than 80% and 50%, 
respectively, between 1980 and 1984. Reformulation has virtually eliminated the use of 
EGEE, EGME, EGEEA, and EGMEA in consumer paints [Meridian Research, Inc. 1987].
3.3.2 Inks
Printing inks and solutions are formulated in batch-type operations and hence exposures are 
similar to these found in the manufacture of paints and coatings. Glycol ethers modify the 
drying rate, viscosity, fluidity, and penetrative ability o f inks. Flexographic inks, such as 
alcohol-dilutable inks, acrylic inks, and water-based inks, contain glycol ethers in low  
concentrations, usually 5% to 10%. Ballpoint and marker inks may contain as much as 40% 
glycol ethers. Glycol ethers are also found in printing chemicals (e.g., “fountain solutions”).
Printing press operators can receive exposure to glycol ethers through inhalation as well as 
skin contact because of their intimate contact with printing materials and machinery. Glycol 
ethers are used in several phases o f printing and silkscreening operations. A few ounces 
used as a retarding agent may be added directly to the ink tray or pan, which is often left 
uncovered. Press and plate cleaning solvents may also contain glycol ethers. The most 
extensive dermal contact occurs when trays and other parts o f the press are cleaned [Cal 
OSHA 1983].
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In recent years, ink companies have reformulated away from glycol ethers. The use o f EGEE 
in printing inks declined by 60% between 1977 and 1984 [Meridian Research, Inc. 1987].
3.3.3 Cleaners and Cleaning Solvents
Cleaning agents that contain glycol ethers are spot removers, carburetor cleaners, metal 
cleaners, and glass cleaners. In these products, glycol ethers function as surface active 
agents, enhancing the penetration o f the product, clarifying the appearance, and in glass 
cleaners, increasing the viscosity. The percentage of glycol ethers in these products is less 
than 5% [Cal OSHA 1983].
3.4 NUMBER OF WORKERS POTENTIALLY EXPOSED
Based on information from the National Occupational Exposure Survey (NOES) [NIOSH 
1983c], the estimated number of workers potentially exposed to glycol ethers in the 
workplace during the period 1981 to 1983 is as shown in Table 3-3. Among industries 
labeled by the 4-digit Standard Industrial Code (SIC), 34 were identified as having workers 
potentially exposed to EGEE, 26 to EGEEA, 24 to EGME, and 10 to EGMEA. NOES 
identified 102 occupations in which workers were potentially exposed to EGEE, 99 to 
EGEEA, 80 to EGME, and 27 to EGMEA. Table 3-4  presents the six industries and six 
occupations with the most workers potentially exposed to EGEE, EGME, and their acetates.
Appendix C presents representative information about the occurrence o f airborne EGEE, 
EGME, and their acetates in the workplace.
Table 3-3.—Estimated number of U.S. workers potentially exposed to 
EGME, EGEE, and their acetates
Number of
Compound workers
EGME 130,608
EGMEA 9,892
EGEE 247,691
EGEEA 244,639
*Souice: NIOSH [1983c].
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Table 3 -4 .—Six industries and six occupations with the most workers potentially exposed
to EGEE, EG ME, and their acetates*
Compound and industry
Workers exposed
%of
Number total
Workers exposed
Compound and occupation Number
%of
total
EGEE:"!-
Health services 40,893 16.5
Business services 26,476 10.7
Printing and publishing 23,634 9.5
Instruments and related products 19,419 7.8
Rubber and miscellaneous 
plastic products 16,781 6.8
Chemicals and allied products 14,251 5.8
EGEEA:*
Printing and publishing 37,431 15.3
Transportation equipment 30,256 12.4
Transportation by air 16,143 6.6
Special trade contractors 11,934 4.9
Electric and electronic equipment 11,892 4.8
Machinery, except electrical 11,702 4.7
EGME:§
Chemicals and allied products 29,014 22.2
Business services 22,537 17.3
Printing and publishing 16,619 12.7
Machinery, except electrical 11,047 8.5
Fabricated metal products 10,697 8.2
Paper and allied products 6,934 5.3
EGEE:+
Janitors and cleaners 40,086
Printing machine operators 19,321
Assemblers _ 15,747
Miscellaneous machine operators, N.E.C. 11,513
Registered nurses 
Engineers, N.E.C.
EGEEA:*
Painting and paint spraying 
machine operator 
Printing machinc operators 
Assemblers
Laborers, except construction 
Machine operators, not specified 
Hand packers and packagers
EG ME:5 
Assemblers 
Janitors and cleaners 
Printing machine operators 
Machinists
Typesetters and compositors 
Chemists, except biochemists
10,988
8,805
27,924
23,191
17,412
9,823
9,783
9,190
21,844
20,379
10,874
7,325
5,416
5,267
16.2
7.8
6.4
4.6
4.4
3.6
11.4
9.5
7.1
4.1 
4.0 
3.8
16.7
15.9
8.3
5.6
4.1
4.0
(Continued)
See footnotes at end of table.
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Table 3 -4  (Continued).—Six industries and six occupations with the most workers potentially exposed to
EGEE, EG ME, and their acetates
Workers exposed
Compound and industry Number
% of
total
Workers exposed
Compound and occupation Number
% of 
total
EGMEA:
Fabricated metal products 3,142 31,8
Electric and electronic equipment 1,743 17.6
Miscellaneous manufacturing 
industries 1,605 16.2
Chemicals and allied products 1,276 12.9
Machinery, except electrical 938 9.5
Rubber and miscellaneous 
plastics products 465 4.7
EGMEA:
Assemblers
Janitors and cleancrs
Packaging and filling machine operators
Metal plating machine operators
Miscellaneous machine operators, N.E.C.
Hand engraving and printing
2,775 28.1
1,160 11.7
783 7.9
638 6.4
592 6.0
526 5.3
‘Source: NIOSH [1983b].
?Total workers exposed to EGEE = 247,691. 
¿Total workers exposed to EGEEA = 244 639. 
.fTotal workers exposed to EGME = 130,608. 
Total workers exposed to EGM EA = 9,892.
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4 EFFECTS OF EXPOSURE
4.1 EFFECTS ON HUMANS
4.1.1 Case Studies and Miscellaneous Reports
The first known case study involving occupational exposure to EGME was reported in 1936 
[Donley 1936]. A female worker was employed in a shirt factory where she “fused” collars 
by dipping them into a solvent mixture, followed by application of pressure to dry and stiffen 
them. The solvent mixture used in the collar fusing contained EGME (<3%), dimethyl 
phthalate (<3%), isopropyl alcohol (74%), and water (20%). The patient had worked at this 
job for six months without ventilation or respiratory protection when die was admitted to 
the hospital with symptoms of encephalopathy (i.e., headache, drowsiness, forgetfulness, 
and general apathy), signs of respiratory infection with coughing and sneezing, and blurred 
vision. Blood tests for erythrocytes, leukocytes, and hemoglobin were within normal ranges. 
Her diagnosis included psychosis, encephalopathy, acute rhinitis (inflammation of the nasal 
mucosa), bronchitis, and phlegmasia alba dolens (extreme edematous swelling o f the leg) 
caused by occupational exposure to vapors from the solvent. An inquiry three months after 
the patient’s discharge from the hospital revealed that she had fully recovered.
Parsons and Parsons [1938] reported case studies of two brothers, ages 22 and 20, who fused 
collars in the “dipping room" of a New York shirt factory. Rubber gloves were worn during 
this operation. The dipping fluid at the shirt factory contained two substances, EGME and 
“Solox” which contained ethyl alcohol (90%), methyl alcohol (4.4%), ethyl acetate (4.7%), 
and petroleum naphtha (0.9%). Both men were admitted to the hospital with symptoms of 
toxic encephalopathy (including personality change, dizziness, sleepiness, and apathy), 
nausea, weakness, burning eyes, and headache. An examination in the hospital revealed 
moderately severe anemia with leukopenia and lymphocytosis. A neurologic examination 
revealed general hypertonicity of all skeletal muscles, transitory right ankle clonus, moderate 
ataxia, and persistent dilation of pupils. The patients completely recovered one month after 
they were removed from exposure and treated for anemia. When followup blood tests were 
conducted about one year later the older brother, who was exposed to the dipping fluid for 
about one year, had an abnormal differential count (i.e., a relative lymphocytosis). The 
younger brother, who was exposed for only three months, had a normal differential count.
All ten workers in a small printing shop in Germany experienced discomfort when a printing 
press that used aniline-dye-based inks containing EGME was placed in operation [Groetschel 
and Schuermann 1959]. After one month o f exposure, the workers experienced vomiting, 
intoxication, and deterioration o f vision, hearing, and sense of taste. Attending physicians
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also reported exhaustion, slowed reactions, irritability, vertigo, and disturbance o f sleep 
patterns in the workers. Anemia and lymphopenia were found in the one individual whose 
blood was tested.
Zavon [1963] described case histories for five workers exposed to EGME in the printing 
department of a plant where plastic materials were made. EGME was used as a cleaning 
agent for the printing machines and the floor, and as a solvent in the printing ink, which also 
contained diethylene glycol monomethyl ether (DEGME). Few of the workers wore gloves 
while working and they were not required to wear clean work clothes or wash their hands 
before leaving work. Each worker saw a different private physician when symptoms 
developed and Zavon [1963] summarized the case reports. All five workers had worked in 
the printing department for the five months that EGME had been in use. The signs and 
symptoms reported were consistent with those reported previously in workers exposed to 
EGME, including drowsiness, personality change, memory loss, ataxic gait, tremors, slurred 
speech, hearing loss, loss o f appetite, and apathy. A ll workers had low erythrocyte (RBC) 
counts and low hemoglobin (Hb) values. White blood cell (WBC) counts ranged from low 
to high. Two workers had abnormal differential counts and a third worker’s differential 
count was slightly outside normal limits, but his bone marrow smear showed a hypocellular 
marrow with a decrease in the percentage o f erythroid elements. Breathing zone samples 
taken under simulated conditions using EGME to clean the floor and equipment ranged from 
61 to 3,960 ppm. Process changes and safe-handling requirements resulted in a reduction 
of EGME concentrations to below 40 ppm and the elimination of any reported health effects.
Nitter-Hauge [1970] reported the accidental poisoning of two men who each ingested about 
0.1 liter of pure EGME that they believed was ethyl alcohol. They were admitted to the 
hospital with general weakness, disorientation, muscular restlessness, nausea, and vomiting. 
Clinical signs and symptoms appeared from 8 to 18 hr after ingestion and included cerebral 
confusion, pronounced hyperventilation, and profound metabolic acidosis (reduced alkali 
reserve in the blood and body fluids). Moderate renal failure developed in the older of the 
patients, along with a marked oxaluria (abnormally large amounts of oxalates in the urine). 
Both patients were treated intravenously with sodium bicarbonate and ethyl alcohol, and 
fully recovered over a period of approximately 4 weeks. The author [Nitter-Hauge 1970] 
concluded from this information that EGME hydrolyzed to methanol and ethylene glycol, 
which are metabolized to formic acid and oxalic acid, respectively.
Dermal absorption of EGME has caused a range o f adverse health effects similar to those 
produced by the inhalation or ingestion of it [Ohi and Wegman 1978]. Two male workers 
were employed in an electroplating operation where they washed equipment by hand without 
protective gloves. EGME was substituted for acetone in the solvent bath. Air samples 
collected during the washing operation averaged 8 ppm; no estimate was made o f the 
magnitude of skin absorption. The first worker, who was 48 years old, was hospitalized 
following 6 months exposure to EGME in the workplace. His symptoms included con­
fusion, lethargy, sleepiness, impaired hearing, anorexia, weight loss, and personality change. 
On admission to the hospital, he had tremors of both upper extremities and reduced RBC 
and WBC counts. Bone marrow aspiration showed marrow depression consistent with a 
marrow toxin. His condition was diagnosed as metabolic encephalopathy and pancytopenia
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(a reduction in the numbers of all formed elements of blood). Recovery was slow but 
uncomplicated, and within several weeks his blood count returned to normal. The second 
worker was a 45-year-old m an  who was admitted with s im ilar symptoms following one 
month of using EGME on the job. His neurologic examination revealed poor concentration, 
orientation, reasoning, and memory. In addition, he had bone marrow depression. His 
symptoms disappeared within one week [Ohi and Wegman 1978],
Cohen [1984] described subacute hematopoietic effects in a male worker exposed to EGME 
in the microfilm production industry. The subject was a 32-year-old microfilm coating and 
mixing operator. His job entailed mixing chemicals and often standing directly over open 
1,500-gallon kettles that contained 33 % EGME. Methyl ethyl ketone (MEK) and propylene 
glycol monomethyl ether (PGME) were also present in small quantities. EGME was also 
used as a solvent in the m anual cleaning o f the kettles, usually done without gloves. 
Breathing zone samples revealed time-weighted average (TWA) concentrations o f 18 to 
58 ppm EGME (average, 35 ppm), 1 to 5 ppm MEK, and 4 to 13 ppm PGME. The worker 
had been employed for less than one year when signs and symptoms of EGME exposure 
appeared. His WBC and RBC counts, Hb, hematocrit (Hct), and platelets dropped to 
abnormally low levels. He also slept more, gained weight, had a decrease in appetite, felt 
fatigued, and was apathetic. The worker was removed from skin and inhalation exposure 
to EGME after 20 months on the job. Blood counts 1 and 3 months later revealed a return 
to normal limits. This case illustrates the development of reversible macrocytic anemia and 
subjective central nervous system (CNS) complaints (i.e., increased sleep needs, decreased 
appetite, fatigue, and apathy).
Bolt and Golka [1990] reported the occurrence of hypospadias at birth in two young boys 
whose mother had been occupationally exposed to EGMEA during her pregnancies. The 
woman had worked since 1974 in an industrial laboratory that produced lacquers and 
enameled wire. During her first pregnancy in 1980 to 1981, she cleaned the glassware 4 hrs 
a day using EGMEA as a solvent. Gloves were usually, but not always, worn. She cleaned 
the surfaces of laboratory desks by spreading EGMEA on a cloth and rubbing the desk 
surfaces with it. This was frequently done without the use of gloves. During her second 
pregnancy in 1983 to 1984, she cleaned the glassware for about an hour a day, generally 
under a laboratory hood. As before, EGMEA was used to clean the surfaces in the 
laboratory.
In 1981, the woman delivered a boy of normal birth weight with the following malforma­
tions: perineal hypospadia, micropenis, and pronounced bifid type of scrotum. Hie sex 
could not be determined without chromosomal analysis. Analysis of the chromosomes did 
reveal a normal male karyotype. Clinical examinations showed no further malformations. 
In 1984, the woman delivered a boy of normal birth weight with penile hypospadia and a 
bifid type o f scrotum. Chromosomal analysis revealed a normal male karyotype.
Both children underwent surgery in the following years. The perineal and the penile 
hypospadias were corrected, chordee was removed in both children, and the undescended 
testes were removed to the scrotum. 'Hie older child was treated with chronic gonadotrophin, 
which led to normal-sized testes.
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The authors stated that the risk of isolated hypospadia was between 1 in 300 and 1 in 1,800, 
while the risk for a boy whose brother has hypospadia was 1 in 24. They indicated that both 
the family history and medical examinations showed no overt risks other than the pronounced 
exposure o f the mother to EGMEA during fetal development. The authors concluded that 
the hypospadias were actually caused by exposure to EGMEA.
There is only one case report that describes the effects of EGEE [Fucik 1969]. A 44-year-old 
woman who mistakenly ingested 40 ml of EGEE experienced adverse effects on the CNS, 
liver, and kidneys. After ingesting the EGEE, she suffered chest pains and vertigo, and lost 
consciousness. Upon hospitalization, signs and symptoms o f EGEE exposure included 
restlessness, tachycardia, cyanosis, swelling of the lungs, tonoclonic spasms, and breath that 
smelled like acetone. Oxygen and chemical therapy were administered; 6  hr later the woman 
regained consciousness but was confused and markedly agitated. Her urine was positive 
for protein, acetone, and RBCs; liver enlargement and jaundice developed. After 44 days 
her condition improved. However, insomnia, fatigue, and paresthesia of the extremities 
persisted for one year.
4.1.2 Clinical and Industrial Hygiene Studies
4.1.2.1 Groenburg et a/. [1938]
Greenburg et al. [1938] described a cross-sectional study of 19 workers exposed to EGME 
during the manufacture of fused shirt collars at the same factory studied by Parsons and 
Parsons [1938]. Greenburg et al. undertook this study following reports to the U.S. 
Department o f Labor that two brothers employed in a collar fusing plant were hospitalized 
with aplastic anemia [Parsons and Parsons 1938]. The Greenburg et al. study included (1) a 
clinical examination with occupational history and (2 ) an environmental assessment o f the 
loft area where EGME exposure took place during the collar fusing process. In the fused 
collar processing area, workers wearing rubber gloves rinsed shirts by hand in large open 
vats o f the solvent containing EGME.
Air sampling was done after improvements were made to the exhaust and ventilation 
systems. EGME concentrations were 25 ppm with the windows open and 76 ppm with the 
windows partially closed. The authors stated that previous worker exposures were undoubt­
edly higher than the concentrations they measured. The occupational histories showed that 
the duration of exposure for the 19 workers ranged from 1 to 112 weeks prior to the 
examinations. Four of the 19 were exposed longer than 75 weeks; the other 15 workers 
were exposed fewer than 15 weeks. Sixteen of the 19 workers were employed in the collar 
fusing area when the medical e xam in ation  was conducted.
Two clinical examinations o f the exposed workers were conducted about 2 months apart. 
During the first exam, 11 exposed workers were examined. About 2 months later, 8 o f the 
11 original workers were reexamined and 8  additional workers were examined for the first 
time. Social, medical, and occupational histories were taken. Then the workers were given 
a complete medical examination with special attention to funduscopic teste, capillary
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fragility tests, detailed hematologic studies, and neurologic findings. The results were 
normal for the funduscopic tests, capillary fragility tests, blood pressures, temperatures, 
pulse rates, and general physical status.
All 19 workers had abnormal hematology results, including low blood platelet counts. Nine 
of the workers* blood tests showed disturbed production of RBCs (erythropoiesis) including 
six subnormal RBC counts. The anemias were thought to be caused by a bone marrow toxin 
rather than hemolysis or peripheral toxicity. All 19 blood tests showed immature neutrophilic 
granulocytes indicative o f bone marrow toxicity. Other results were normal, including Hct, 
bleeding time, coagulation time, erythrocyte sedimentation rate, and erythrocyte fragility.
Physical examinations o f the workers revealed severe neurologic abnormalities. Two 
workers who were hospitalized for severe anemia and one who filed workman’s compen­
sation for multiple neuritis were not included in the physical findings. Four of the remaining 
16 workers had symptoms of drowsiness or fatigue and the following neurologic abnor­
malities: clonus (rapid muscular contractions and relaxations) in one worker, mental 
retardation in two workers, exaggerated reflexes in four workers, and tremors of the hands 
in four workers. Four other workers did not complain of any symptoms; however, at 
examination two of these workers had abnormal reflexes, one had exaggerated knee and 
ankle reflexes, one had decreased knee jerks, and four had tremors of the hands. The 
remaining eight workers exhibited no abnormal symptoms.
4.1.2.2 Cook et al. [1962]
Cook et al. [1982] conducted a cross-sectional study of 65 male workers (40 with potential 
exposure to EGME during its manufacture and packaging) to determine if anemia, leukopenia, 
or infertility were present, and if these conditions were more prevalent among the exposed 
workers. The unrestricted, concurrent, nonexposed population consisted of 25 workers from 
plants where alkanolamines and salicylic acids were produced. In the EGME plant, the 
chemical was manufactured by a continuous enclosed process along with related products 
such as EGEE, polyols, polyoxy propylene glycols, brake fluids, butylene oxide, and 
polyglycols. In a separate packaging and distribution facility, EGME was loaded into drums, 
tank trucks, or mil cars; although drums were filled automatically, they were capped 
manually. Because o f the potential for skin contact and absorption, continued use of rubber 
gloves was recommended during sampling and maintenance. There was also potential for 
exposure to ethylene, propylene, and butylene oxides, chlorobenzenes, and other ethylene 
glycol ethers. The control population had the potential for exposure to phenol, sodium 
phenate, potassium hydroxide, ammonia, propylene ethers of ethylene glycol, ethylene 
oxide, and propylene oxide. Industrial hygiene measurements taken in the production area 
indicated personal 8 -hr TWA exposures of 0.4 ppm EGME or less. TWA air samples 
collected in the packaging and distribution facility for EGME indicated personal exposures 
of 5 to 9 ppm EGME and area concentrations of 4 to 20 ppm.
The clinical measures included Hb, WBC, RBC, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCHb), mean cell hemoglobin concentration (MCHC), hormone 
levels [i.e., luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone] and
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sperm counts. Semen samples were available from six EGME-exposed workers and nine 
controls. Hematology results revealed no anemia or leukopenia in the EGME-exposed 
workers. No statistically significant differences were found in hematology test results, 
hormone levels, or sperm counts between the exposed workers and the controls. The 
investigators suggested that testicular size may have been reduced; however, the decrease 
in size approached but did not reach statistical significance (P<0.05) in either length 
(F -0.19) or width (P-0.08).
4.1.2.3 Market and Moody [1982]
In a Health Hazard Evaluation [Markel and Moody 1982], NIOSH investigators evaluated 
exposure of workers to surfactant and emulsifier products used in a wet scrubbing system of a 
newspaper pressroom and reel room. The nonionic surfactant used in the air washer/demisting 
system was nonylphenoxy polyethylene oxyethanol and contained ethylene oxide and EGME. 
Although the surfactant was not used per se in the demisting system, it could have been 
present in pressroom air as a result of aerosolization of the surfactant solutions. Twenty 
workers were interviewed; half of them were asymptomatic. Five workers reported inter­
mittent runny nose, nasal congestion and/or eye irritation at work. Of these five workers, 
three had histories of allergies or “sinusitis”; one of the five workers attributed his episodes 
of burning eyes to exposure to the mist produced by the de-mist system. The remaining five 
all complained of a “peculiar taste" in the mouth following exposure to the mist system. 
During splashing or siphoning by mouth of the surfactant solution, two workers noted an 
anesthetic effect on their lips. One worker experienced progressive ill health over a 
10-month period. His symptoms consisted of headaches, fatigue, sores in the mouth, chronic 
eye irritation, shortness o f breath, nausea, vomiting, trembling, and staggering. However, 
he stated that following termination o f his work with the de-mist system, these symptoms 
abated. Environmental monitoring (five breathing zone and three general area measure­
ments) indicated that the concentrations of EGME ranged from 0.3 to 0.5 ppm for six o f the 
samples and were below the lower limit of detection (0.003 ppm) of the analytical method 
for the remaining two. The authors concluded that there was no evidence of EGME 
concentrations exceeding recommended levels and no evidence of ethylene oxide exposure.
4.1.2.4 Boiano [1983]
NIOSH conducted a health hazard evaluation in 1983 to evaluate worker exposure to two 
solvent cleaners, an image remover, and the paint remover used in a silk screening process 
[Boiano 1983]. The silk screener using the image remover was monitored for exposure to 
EGEEA and cyclohexanone, while the worker using the paint remover was monitored for 
a variety of organic solvents, one of which was EGEEA. Although the workers were 
primarily exposed by inhalation, they may have also been exposed by skin absorption 
because personal protective clothing was not always worn. The workers complained of 
headaches, lethargy, sinus problems, nausea, and heartburn. When they were away from 
work, their symptoms improved. The silk screener using image remover had TWA ex­
posures to EGEEA ranging from 1.3 to 3.3 ppm, with short-term excursions to 3.8 ppm. 
The silk screener using paint remover had TWA exposures to EGEEA ranging from 0.5 to 
3.9 ppm, with a short-term excursion to 4.0 ppm. Measured airborne exposures thus were
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below occupational standards, but absorption through the skin may have contributed to the 
workers’ overall exposure [Boiano 1983].
4.1.2.5 Gunter [1985]
In 1985, NIOSH conducted a health hazard evaluation of production areas at a plant that 
manufactured solid-state electronic circuits [Gunter 1985]. Soldering, degreasing, and 
circuit-board coating areas were evaluated. Workers in these areas had previously com­
plained of narcosis, burning eyes, and dermatitis. Personal and area air samples were 
collected on charcoal tubes and analyzed for EGHE, EGEEA, Freon 113, toluene, MEK, 
xylene, petroleum distillates, methyl isobutyl ketone (MIBK), and methyl chloroform. 
Samples were also collected and analyzed for lead, zinc, and toluene diisocyanate (TDI). 
Six personal air samples taken for EGEE averaged 1.7 ppm; 14 personal air samples for 
EGEEA averaged 0.15 ppm. Samples taken for lead, zinc, and TDI were found to contain 
concentrations below even the lowest of the established limits (the NIOSH REL, the OSHA 
PEL, or the ACGIH TLV®).
4.1.2.6 Ratctiffe e ta l. [1986]
NIOSH conducted an evaluation for possible adverse effects on testicular function in male 
workers potentially exposed to EGEE during the preparation of ceramic shells used to cast 
metal parts [Ratcliffe et al. 1986]. The binder slurry included 50% EGEE and 50% ethanol. 
About 80 workers were employed in the investing departments at each of the sites where 
these ceramic shells were prepared. The potentially exposed male workers included those 
engaged in the preparation o f binder slurry, hand dippers and grabbers who dipped molds 
into the slurry, shell processors who prepared and handled ceramic shells, supervisors, and 
process engineers. Although gloves were worn by some workers, no other chemical 
protective clothing or respirators were used. The comparison group consisted o f men who 
worked elsewhere in the plant and who were not exposed to EGEE. Air samples, most of 
which were from the breathing zone, were collected. Because the potential for skin exposure 
existed, spot urine samples were taken and sent frozen to a laboratory to analyze for the 
presence of ethoxyacetic acid (EAA); blood samples were also drawn and analyzed. An 
evaluation o f semen quality (pH, sperm concentration, and viability, motility, velocity, and 
morphology) was conducted. Brief examinations of the urogenital tract were also done. In 
addition, questionnaires were administered to determine personal habits and medical and 
work histories.
The NIOSH survey showed full-shift, breathing-zone exposures of EGEE ranging from 
nondetectable to 24 ppm. Collection o f general area air samples at two sites revealed higher 
concentrations of EGEE (10 to 17 ppm) in the investment rooms, which contained open tanks 
of slurry, than in the mixing and storage rooms (5 to 7 ppm). However, analysis of quality 
control samples indicated that the measured airborne concentrations could be underes­
timated; recovery of analyte from field samples was below 1 0 0%, and as low as 60%. 
Analysis of blood samples collected at the end of the work shift from nine EGEE-exposed 
and four nonexposed workers revealed no detectable levels of EGEE in any of the samples. 
The concentrations of EAA in the urine of EGEE-exposed workers ranged from 16 to
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163 mg/g creatinine for individual voids. No statistical testing was attempted because o f 
the few data points.
A cross-sectional evaluation of semen quality was conducted among 37 men exposed to 
EGEE and a group o f 38 men who were not exposed to EGEE. The average sperm count 
of the EGEE-exposed group was considerably lower than that of the nonexposed group (113 
vs. 154 million per ejaculate, P<0.05). The mean sperm concentration o f the unexposed 
group (60 million/ml) and that of the exposed group (48 million/ml) did not differ statistically 
from each other. It should be noted however, that the average sperm concentration for both 
groups was considerably lower (P<0.001) than the 70 million/ml these investigators had 
observed in similar studies of other working populations. No differences were observed 
with respect to other characteristics of semen quality or testicular size. It was concluded 
from this study that there was a possible effect o f EGEE on semen quality.
4.1.2.7 Welch etal. [1988], Sparer etal. [1988], and Welch and Cullen [1988]
The effect o f combined EGME and EGEE exposure on the reproductive potential of men 
who worked in a large shipbuilding facility was recently studied [Welch et al. 1988]. This 
site was selected for study because o f a previous health hazard evaluation [Love and 
Donohue 1983] in which evidence of glycol ether exposure had been obtained. The shipyard 
employed 900 painters, 600 o f whom were men. The painters were divided into four crews 
that included the shop men who mixed the paint formulations, interior and exterior painters, 
and the tank crew that painted interiors of ballast tanks and other confined spaces. The 
interior painting crew members were involved in a variety of jobs, using spray and brush 
painting; half-face cartridge respirators were available to these men, but their use was at the 
discretion of the individual painters. The tank crew applied paint primarily in spray form 
and wore supplied-air respirators. Cotton gloves were available for use. In the course o f a 
year, many painters rotated from crew to crew. At the completion of a boat’s construction, 
exterior painting was done; often all the painters were assigned to this job for a brief period 
of time. Prior to painting, exterior painters wearing air-supplied respirators sandblasted the 
boats. The entire study population for the semen, hematologic, and male reproductive 
studies consisted of 94 painters and 55 nonexposed controls, but only 73 o f the 94 painters 
and 40 of the 55 nonexposed controls participated in the semen study. Urine was collected 
for the determination o f EAA and methoxyacetic acid (MAA), the principal metabolites of 
EGEE and EGME (Section 4.2), respectively. At the clinic site, participants filled out 
questionnaires revealing personal habits and medical and work histories; a medical examina­
tion was performed at the same time.
Personal air samples were collected over six workshifts for three consecutive days and analyzed 
for EGME and EGEE [Sparer et al. 1988]. Because no tanks were being painted at the time 
of the study, sampling was performed only for the interior work. The industrial hygiene 
survey revealed that the painters were exposed to EGME at a TWA concentration o f 0 to
5.6 ppm with a mean of 0.8 ppm and a median of 0.44 ppm, and to EGEE at 0 to 21.5 ppm 
with a mean o f 2.6 ppm and a median of 1.2 ppm. Urine samples were obtained from each 
participant during the medical examination and when the participant brought his semen 
sample. Measurement of the urinary metabolites MAA and EAA [Smallwood et al. 1988]
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confirmed that the painters had been exposed to EGME and EGEE; none of the controls’ 
specimens had detectable MAA or EAA. Two other reproductive toxins, lead and epichloro- 
hydrin, were present in the work environment Epichlorohydrin was not detected in the air 
sampling. Exposure to lead was limited to sandblasting operations. Although there were 
significant air lead levels during blasting, the painters wore air-supplied respirators during this 
operation. A review o f the shipyard biological monitoring data revealed that most blood 
lead levels were below 20 microgram (|ig)%, with the highest single level being 40 fig% 
[Welch etal. 1988].
Serum samples were analyzed for testosterone, FSH, and LH. It was concluded that there 
was no pituitary or hypothalamic dysfunction in the exposed group relative to controls. 
Semen samples were analyzed for pH, sperm density, viability, count, motility, and mor­
phology. The authors reported that although the semen of the exposed group had a 
significantly lower pH, no significant differences were found in measures of sperm motility, 
viability, and morphology (no statistics presented). They compared mean sperm density 
and count using analysis of variance. Sperm counts per ejaculate and per cubic centimeter 
(cc) o f semen were lower (but not statistically significant) in the painters. The proportion 
of men with a sperm density i 2 0  million/ml was higher in the exposed group than in the 
unexposed group (13.5% vs. 5%, /M ).12). The authors also compared the proportion of 
each group with oligospermia (defined as a count per ejaculate ¿100 million). Eight o f the 
controls (20%) and 24 of the painters (32%) had oligospermia (P -0.2). The authors 
concluded that exposure to EGME and EGEE caused functional impairment by lowering 
sperm counts in this group of painters. In addition, when the authors controlled the analysis 
for the effects of smoking, they concluded that there was an increased odds ratio for a lower 
sperm count per ejaculate [Welch et al. 1988].
The effect o f combined EGME and EGEE exposure on hematologic parameters was also 
assessed in these 94 painters and 55 controls [Welch and Cullen 1988]. Mean values for 
Hb, Hct, total and differential W6 C count, and platelet count were assessed for painters and 
controls. Statistical analysis revealed no difference between exposed and nonexposed 
groups in mean Hb and Hct levels, and polymorphonuclear leukocyte and platelet counts. 
However, nine painters, and no controls were anemic. Similarly, five painters and no 
controls had mild to moderate granulocytopenia. A review o f company medical records 
indicated that these abnormalities were acquired during employment Analysis o f blood 
lead levels appeared to eliminate lead as the cause o f the abnormalities. Exposure to EGME 
and EGEE was suspected as being the cause of the hematologic disorders. However, because 
of the authors’ inability to establish an exposure-effect relationship, they concluded that 
further investigation was necessary.
4.2 METABOLISM, UPTAKE, AND ELIMINATION
4.2.1 Studies in Animals
Studies have been conducted in animals to determine the metabolites of EGME and EGEE. 
Investigations by Tsai [1968] and Blair and Vallee [1966] demonstrated that EGME is a
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possible substrate for alcohol dehydrogenase (ADH). Miller et al. [1982,1983b] concluded 
that EGME was oxidized via ADH to methoxyacetaldehyde and via aldehyde dehydrogenase 
to MAA. In studies using radio-labeled EGME, MAA was identified as the major metabo­
lite, and the urine as the major route of elimination [Miller et al. 1983b; Moss et al. 1985].
The metabolism of EGME to MAA has been evaluated as a bioactivation mechanism for 
EGME [Miller et al. 1982,1983b; Fester et al. 1983; Brown et al. 1984]. Oral administration 
of MAA caused testicular changes; increases in embryo-fetal death; decreased fetal weights; 
increases in structural malformations; and urogenital abnormalities; and heart, tail, and limb 
defects [Miller et ai. 1982; Foster et al. 1983; Brown et al. 1984; Ritter et al. 1985]. The 
preceding effects were similar to those caused by corresponding EGME doses.
Pretreatment o f rats with pyrazole, an ADH inhibitor, inhibited the metabolism of EGME 
to MAA; however, pretreatment of rats with disulfiram, an aldehyde dehydrogenase in­
hibitor, had no significant effect on plasma or urinary metabolic profiles [Moss et al. 1985], 
Administration of EGME by i.p. injection demonstrated extensive degeneration and necrosis 
of rat primary spermatocytes in the early and late pachytene stages of development. 
Pretreatment o f rats with pyrazole appeared to protect against spermatocyte damage, while 
pretreatment with disulfiram had no effect on the degree of spermatocyte damage.
The role of EGME metabolism in the induction of paw malformations was also examined 
[Sleet et al. 1988]. Single oral exposures o f mice to EGME or MAA produced comparable 
digit anomalies. The incidence of digit malformations was lower in i.v.-treated mice than in 
gavage-treated mice. When orally administered 1 hr before EGME, 4-methylpyrazole (4-M P), 
a potent ADH inhibitor, reduced the incidence of paw malformations in a dose-dependent 
manner. Oral administration of ethanol with and after EGME also caused reduced incidences 
of digit anomalies [Sleet et al. 1988], These data are compatible with those of Romer et al.
[1985], which demonstrated that ADH has a higher affinity for ethanol than for the glycol 
ethers [Sleet et al. 1988].
Administration o f EGEE by gastric intubation or inhalation resulted in two major urinary 
metabolites in rats, EAA and N-ethoxyacetyl glycine [Jonsson et al. 1982; Cheever et al. 
1984]. In rats, the metabolism of EGEE proceeded chiefly through oxidation via ADH to 
EAA, with some subsequent conjugation of the acid metabolite with glycine [Jonsson et al. 
1982; Cheever et al. 1984]. EAA was found in rat testes 2 hr after oral administration of 
EGEE. The data suggested that adverse testicular effects exerted by EGEE may be caused 
by its active metabolite EAA [Cheever et al. 1984].
Foster et al. [1987] examined the toxicity of MAA and EAA. Oral administration of 
equimolar doses of MAA or EAA in rats determined the initial target for testicular toxicity. 
Histologic examination of testes revealed testicular damage in all MAA-treatment groups, 
while EAA exerted testicular damage only at the highest dose. Pachytene spermatocytes 
were targets for reversible MAA and EAA toxicity. The addition of MAA or EAA to in vitro 
Sertoli cell and germ cell cultures caused depletion of pachytene spermatocytes within 24 hr 
[Foster et al. 1987].
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An in vitro culture system utilizing rat embryos was used to assess potential adverse effects 
of MAA and EAA on fetal development [Rawlings et al. 1985]. At the highest dose used, 
both metabolites exerted adverse effects on fetal development in vitro. These effects 
included significant reductions in crown-rump length, head length, yolk sac diameter, and 
protein content of the embryo.
4.2.2 Studies in Humans
Recently EAA has been identified in the urine of workers exposed to EGEE vapor during 
physical exercise and at rest [Groeseneken et al. 1986a; Groeseneken et al. 1986c]. These 
findings are consistent with the previously described biotransformation studies in animals 
which identified EAA as the major metabolite o f EGEE [Jonsson et al. 1982; Cheever et al. 
1984]. The total amount o f urinary EAA was related to the EGEE concentration in inspired 
air, uptake rate, pulmonary ventilation rate, oxygen consumption during exposure, and heart 
rate during and after exposure [Groeseneken et al. 1986c]. After the end o f a 4-hr EGEE 
exposure period, maximal EAA excretion was achieved within 3 to 4 hr. EAA excretion 
then declined slowly with a biological half-life o f 21 to 24 hr [Groeseneken et al. 1986c]. 
On the average, 23 % of the absorbed EGEE was recovered as EAA within 42 hr. Respiratory 
frequency was also a contributing factor in urinary EAA concentration. About 64% of 
inhaled EGEE vapor was retained at rest, and retention increased as physical exercise was 
performed during exposure. The rate o f EGEE uptake increased as exposure concentration 
or pulmonary ventilation rate, or both, increased. Individual uptake o f EGEE appeared to 
depend on pulmonary ventilation or cardiac output, or both and not on anthropometric 
factors [Groeseneken et al. 1986b].
Groeseneken et al. [1988] compared urinary EAA excretion in man and rats after EGEE 
exposure (oral in rats and by inhalation in man). The human data were taken from 
Groeseneken et al. [1986c]. In rats the mean elimination half-life was determined to be
7.2 ± 1.5 hr; in man the half-life mean was 42 ± 4.7 hr. (This half-life o f 42 hr differs from 
23 hr reported in Groeseneken et al. [1986c].) The authors [Groeseneken et al. 1988] 
attributed the difference in half-lives to the averaging effect o f pooling urine collections 
[Groeseneken et al. 1986c], especially during the first 12 hr.
EAA has also been identified in man as a metabolite o f EGEEA [Groeseneken et al. 1987b]. 
EGEEA is believed to pass through the same metabolic pathway as EGEE after hydrolysis 
of the ester moiety. EAA excretion in workers exposed to EGEEA vapor was similar to 
EAA excretion in workers exposed to EGEE [Groeseneken etal. 1986c]. The maximal EAA 
excretion rate was achieved 3 to 4 hr after the end of the EGEEA exposure period; however, 
unlike EGEE exposure, a second peak EAA excretion appeared 3 hr later. On average, 
within 42 hr, 22.2% of absorbed EGEEA was metabolized and excreted as EAA [Groeseneken 
et al. 1987b]. In beagle dogs exposed to 50 ppm EGEEA for 5 hr, 80% o f EGEEA was 
absorbed in 10 min and reached a plateau in 3 hr [Guest et al. 1984]. The pharmacokinetics 
o f respiratory uptake were more complicated for EGEEA than for EGEE. Individual uptake 
of EGEEA was determined by pulmonary ventilation, cardiac output, height, and body fat. 
During exposure to EGEEA vapor, partial respiratory elimination of EGEE was observed.
37
EGME, EGEE, and Their Aceuues
This finding confirmed the hypothesis that EGEEA is first converted to EGEE by esterases 
[Groeseneken et al. 1987a].
MAA was detected in the urine of seven male volunteers exposed at rest to 5 ppm EGME 
[Groeseneken et al. 1989a]. MAA was present in the urine during and up to 120 hr after the 
beginning of exposure. The elimination half-life of MAA was estimated to be 77 hr. By 
extrapolation the total amount of MAA was estimated to be 85.5 % o f inhaled EGME.
No studies are available on the metabolism o f EGMEA. However, based on the metabolism 
of EGEEA to EAA [Groeseneken et al. 1987a,b], EGMEA would be expected to act similarly 
and be metabolized to MAA.
A detailed description of the preceding studies may be found in Appendix B.
4.3 EFFECTS ON ANIMALS
Although kidney and liver damage, hematologic, CNS, reproductive, and teratogenic effects 
have been observed in experimental animals exposed to glycol ethers and their acetates, the 
type and severity of the response induced by each glycol ether are not identical. Therefore, 
each glycol ether and its corresponding acetate will be discussed separately following 
Section 4.3.1.
4.3.1 Acute Toxicity
Many experiments investigating the acute toxicity of glycol ethers to animals have been 
performed. These investigations led to the establishment of a lethal concentration or lethal 
dose for 50% of the exposed animals (LC50 or LDjq) in a variety of species by a variety of 
routes (inhalation, oral, dermal, injection). A summary of the available data by animal 
species is presented in Table 4-1.
4.3.1.1 Oral Administration
The toxicity of glycol ethers has been studied more extensively by oral administration than 
by any other route. Hematuria, narcosis, and digestive tract irritation were reported after 
oral administration o f near-lethal or lethal concentrations o f EGEE, EGEEA, EGME, or 
EGMEA in rats, mice, rabbits, and guinea pigs [Laug et al. 1939; Smyth et al. 1941]. 
However, the principal effect exerted by these glycol ethers in animals that did not die 
immediately was damage to the kidneys. Pathological examination revealed extreme tubular 
degeneration along with almost complete necrosis of the cortical tubules.
4.3.1.2 Inhalation Exposure
Waite et al. [1930] examined the effect on guinea pigs of a single inhalation exposure to 
EGEE vapor. The EGEE concentrations and periods of exposure ranged from those that 
produced death to those that caused no apparent effect after 24 hr o f exposure. EGEE
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Table 4 -l.-L eth a l doses or concentrations o f glycol ethers
Species
LD50
oral
(mg/kg)
LDjq
oral
(mg/kg)
LD50
i.p.
(mg/kg)
LD50
i.v.
(m g/kg)
LD50
dermal
(mg/kg)
inhalation
(ppm)
and
sex EGME EGMEA EGEE EGEEA EGME EGEE EGEE EGME EGEEA EGME EGEE
Rat:
Male 2,460 3,930 
3,250
3.000
5.000
3,900
5,100
— — — —
Female 3,400 2,300
5,400
2,900 — — — —
Not stated — 3,204 — — 2,691 — —
Rabbit:
Male 890 3,100 — —  — — 1,300 —  —
Not stated — — — — 840 —  10,500 —
Guinea pig: 
Male and 
Female 950 1,250 1,400 1,910 ......................... _ ..........................
Not stated — 2,584 — — — — —
Mouse:
Female — — — 2,150 1,709 — — 1,480 1,820 
(7 hr)
Not stated — 3,991 — —  — 3,600 3,600 — —  —
’Abbreviations: i.p. = intraperitoneal; i.v.= intravenous; LD50=median lethal dose; LC50=median lethal concentration.
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concentrations ranged from 500 to 6,000 ppm and were administered over a period of 1 to 
24 hr. Guinea pigs exposed to 6,000 ppm for 24 hr exhibited inactivity, weakness, and 
dyspnea, and died by the end of the exposure; 3,000 ppm for 24 hr caused death within 24 hr 
following exposure; and exposure to 6,000 ppm for 10 hr, and 3,000 ppm or 1,000 ppm for 
18 hr, caused death 1 to 8 days following exposure. Exposure to 6,000 ppm for 1 hr,
3.000 ppm for 4 hr, and 500 ppm for 14 hr caused no apparent harm. Gross pathological 
examinations of animals that died during and up to two days after exposure revealed 
congestion and edema of the lungs, distended and hemorrhagic stomachs, and congested 
kidneys.
Werner et al. [1943c] demonstrated an adverse effect of EGME and EGEE on the hematopoietic 
system. Groups o f 14 or 16 white Swiss mice were subjected to single, 7-hr, inhalation 
exposures to EGME (930 to 6,800 ppm) and to EGEE (1,130 to 6,000 ppm). Although these 
vapors produced no typical narcotic action in mice, there was marked dyspnea. His- 
topathological examinations revealed slight damage to the lungs. The spleen consistently 
showed marked follicular phagocytosis, which indicated toxic action on the WBC [Werner 
etal. 1943c].
Groups o f female rats developed increased osmotic fragility o f erythrocytes when exposed 
by inhalation to EGEE, EGEEA, EGME, or EGMEA for 4-hr periods [Carpenter et al. 1956]. 
Of the four compounds, EGMEA (32 ppm) was the most toxic in terms o f erythrocyte 
fragility, followed by EGEEA (62 ppm), and EGEE (125 ppm); EGME at 2,000 ppm only 
slightly affected erythrocyte fragility.
Ten male and ten female rats and two male and two female rabbits were exposed to
2.000 ppm EGEEA for 4 hr [Truhaut et al. 1979]. Only in rabbits was there a slight and 
transient hemoglobinuria or hematuria; no gross pathological lesions were noted in either 
species.
4.3.1.3 Dermal Exposure
A modified Draize “sleeve” technique was used to study the acute dermal toxicity o f EGEEA 
in rabbits [Truhaut et al. 1979]. Death generally occurred 24 to 48 hr after the application 
o f 10,500 mg EGEEA/kg. Although hemoglobinuria and/or hematuria were observed, there 
was little variation in Hb concentration and the number of RBCs (less than 15% to 20%) in 
blood; however, there was a considerable decrease in the number o f WBCs (50% to 70%). 
In surviving animals, the WBC counts gradually returned to normal. Necropsy revealed 
bloody kidneys and blood in the bladder. When survivors were examined after the 2-week 
observation period, no gross lesions were noted.
4.3.1.4 Intraperitoneal, Intravenous, and Subcutaneous Administration
Karel et al. [1947] conducted the fust toxicity study of the glycol ethers administered by 
intraperitoneal (i.p.) injection. Female albino Carsworth Farms mice (9 to 10 animals/dose) 
were injected intraperitoneally with varying doses o f either EGEE or EGME and were 
observed for 7 days following injection. Gross and microscopic pathological studies were
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conducted on animals that died during the first 7 days after injection or were sacrificed 
at the end o f the 7-day observation period. The LD5q for EGME was 2,150 mg/kg and 
the LD50 for EGEE was 1,709 mg/kg. During the first 72 hr after injection o f either 
EGME or EGEE, toxic reactions in the lymph nodes and spleen (lymphocyte degenera­
tion followed by reticulum cell proliferation and phagocytosis o f cellular debris) and 
mild renal glomerular and tubular degeneration were noted. During the fifth through seventh 
day, lymphoid regeneration occurred while renal tubular damage continued. Pulmonary 
congestion and atelectasis (collapse of the alveoli or a portion of the lung) were also observed 
in EGEE-treated mice.
Dogs and rabbits were given three 7 .1-g injections (unspecified as to type or site) o f EGME 
[Wiley et al. 1938]. At necropsy (2 to 3 days after last injection) histological examination 
of the dogs’ organs revealed damage to the kidney, bladder, liver, and spleen. Multiple 
organs of the rabbits also demonstrated tissue damage—the lungs showed multiple hemor­
rhages, the spleen and liver were damaged, and the kidneys had various degrees o f tubular 
degeneration.
Another group of investigators [Stenger et al. 1971] determined the acute LDj0 for EGEE 
in the mouse, rat, and rabbit by intravenous (i.v.) administration o f 3,600, 2,691, or 
840 mg/kg, respectively. The following symptoms were observed: dyspnea, somnolence, 
ataxia, stomach distending to the side, and convulsions.
The acute toxic effects o f EGME, EGMEA, EGEE, and EGEEA are summarized in 
Table 4 -2 .
4.3.1.5 Summary o f Acute Toxicity
The acute toxicity o f EGEE, EGEEA, EGME, and EGMEA has been investigated in a 
number of experiments with a variety of species and routes o f exposure. Animals exhibited 
inactivity, weakness, and dyspnea. Necropsies revealed congested lungs, hemorrhagic 
stomachs, congested kidneys, and damage to the bladder, liver, and spleen [Waite et al. 1930; 
Wiley et al. 1938; Karel et al. 1946; Carpenter et al. 1956; Truhaut et al. 1979]. The principal 
toxic effect of these compounds was damage to the kidneys [Waite et al. 1930; Laug et al. 
1939; Smyth et al. 1941; Gross 1943], which included extreme tubular necrosis and 
degeneration. Additional adverse effects included increased erythrocyte osmotic fragility 
and damaged spleens [Werner et al. 1943c; Carpenter et al. 1956; Truhaut et al. 1979],
4.3.2 Male Reproductive Effects
A number of experimental animal studies have demonstrated the adverse effects of glycol 
ethers on the male reproductive system. These effects include testicular atrophy, decrease 
in fertility, germ cell depletion, decrease in sperm motility, and an increase in the number 
of abnormal sperm cells. Although a brief summary o f these studies follows, a detailed 
description o f them may be found in Appendix B.
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Table 4 -2 .—Acute toxicity of EGEE, EGEEA, EG ME, and EGMEA
Route of 
administration
Compound Species and dose Observed effects Reference
Mouse i.p.: LD50* 1,709 m g/kg Damage to lymph nodes and spleen, renal glomerular 
and tubular degeneration, pulmonary congestion
Karel et al. 1947
Mouse i.v.: LDS0 3,600 m g/kg Dyspnea, somnolence, ataxia, distended stomach Stenger et al. 1971
Mouse Oral: L D ^  3,991 m g/kg Hematuria, renal tubular degeneration and cortical necrosis Laug et al. 1939
Mouse Inhalation: 1,130-6,000 ppm 
for 7 hr
Dyspnea, damaged lung, toxic effect on white blood cells Werner et al. 1943c
Mouse (F) Inhalation: LC$0 1,820 ppm 
for 7 hr
Death Werner et id. 1943a
Rat i.v.: LD50 2,691 m g/kg Dyspnea, somnolence, ataxia, distended stomach Stenger et al. 1971
Rat Oral: LDjq 3,204 m g/kg Hematuria, renal tubular degeneration and cortical necrosis Laug et al. 1939
Rat (M) Oral: LD50 3,000 m g/kg Narcosis, digestive tract irritation, kidney damage Smyth et a3. 1941
Rat (M) Oral: LDjq 5,000 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rat (F) Oral: LD50 5,400 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rat (M) Oral: LDS0 2,300 m g/kg Death Cheever et al. 1984
Rat (F) Inhalation: 125 ppm 
for 4 hr
Increase in osmotic fragility Carpenter et al. 1956
Rabbit i.v.: LDjq 840 m g/kg Dyspnea, somnolence, ataxia, distended stomach Stenger et al. 1971
Rabbit (M) Oral: LDjq 3,100 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rabbit (M) Dermal: LDjq 3,296 m g/kg Death Carpenter et al. 1956
Guinea pig Oral: LD50 2,584 m g/kg Hematuria, renal tubular degeneration and cortical necrosis Laug et al. 1939
EGM
E, EGEE, and 
Their Acetates
EGEE
EGEEA
EGME
Guinea pig 
(M,F)
Oral: LDS() 1,400 m g/kg
Guinea pig 
(M,F)
Oral: L D ^  1,400 m g/kg
Guinea pig Inhalation: 0.05%, 0.3%, 
for 1-24 hr or 0.06%
Rat (M) Oral: L D ^  5,100 m g/kg
Rat (F) Oral: LDJ0 2,900 m g/kg
Rat (M ) Oral: LDjq 3,900 m g/kg
Rat (F) Inhalation: 62 ppm 
for 4 hr
Rat
(M,F)
Inhalation: 2,000 ppm 
for 4 hr
Rabbit
(M,F)
Inhalation: 2,000 ppm 
for 4 hr
Rabbit
(M,F)
Dermal: LDS0 10,500 m g/kg
Guinea pic 
(M ,F)
Oral: LDjq 1,910 m g/kg
M ouse (F) i.p.: LD50 2,150 m g/kg
Mouse Inhalation: 930 to 6,800 ppm 
for 7 hr
’Abbreviations: LC50 = median lethal concentration; LD
Narcosis, digestive tract irritation, kidney damage Smyth et al. 1941
Narcosis, lung and kidney damage. Carpenter et al. 1956
No effect (0.05% for 14 hr; 0.3% for 4 hr; 0.6% for 1 hr); Waite et al. 1930
death (0.6% for 24 hr; 0.3% for 24 hr); inactivity, 
weakness, dyspnea (0.6% for 18-24 hr); congestion and 
edema o f  the lungs, hemorrhagic and distended stomachs, 
congested kidneys (0.6% for 18-24 hr; 0.3% for 18-24 hr)
Narcosis, digestive tract irritation, damaged kidneys Smyth et al. 1941
Hemoglobinuria, hematuria, renal lesions Truhaut et al. 1979
Hemoglobinuria, hematuria, renal lesions Truhaut et al. 1979
Increased osmotic fragility Carpenter et al. 1956
No effect Truhaut et al. 1979
Slight, transient hemoglobinuria and/or hematuria Truhaut et al. 1979
Hemoglobinuria, hematuria, decreased white blood cell Truhaut et al. 1979
count, blood m kidneys and bladder
Narcosis, digestive tract irritation, damaged kidneys Smyth et al. 1941
Damage to lymph nodes and spleen, renal glomerular Karel et al. 1947
and tubular degeneration
Dyspnea, damage to lungs and white blood cells Werner et al. 1943c 
(Continued)
= median lethal dose.
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Table 4 -2  (Continued).—Acute toxicity of EGEE, EGEEA, EGME, and EGMEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGM E Mouse (F) Inhalation: LC™ to  
1,480 ppm
Death Werner et al. 1943c
Rat (M) Oral: LD50 246 m g/kg Digestive tract irritation, damaged kidneys Smyth et al. 1941
Rat (M) Oral: LD50 3,250 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rat (F) Oral: LD50 3,400 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rat (F) Inhalation: 2.000 ppm 
for 7 hr
Slight increase in osmotic fragility Carpenter et al. 1956
Rabbit Injection: 2,130 mg Damage to tissues o f kidney, bladder, liver, and spleen 
degeneration of testes
Wiley et al. 1938
Rabbit (M) Oral: LDJ0 890 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Rabbit (M) Dermal: LDS0 1,289 m g/kg Death Carpenter et al. 1956
Guinea pig 
(M,F)
Oral: LD5(j 950 m g/kg Digestive tract irritation, damaged kidneys Smyth et al. 1941
Guinea pig 
(M,F)
Oral: LD50 950 m g/kg Narcosis, lung and kidney damage Carpenter et al. 1956
Dog Injection: 2,130 mg Damage to tissues of kidney, bladder, liver, and spleen Wiley et al. 1938
EGM EA Rat (M) Oral: LDS0 3,930 m g/kg Narcosis, digestive tract irritation, damaged kidneys Smyth et al. 1941
Rat (F) Inhalation: 32 ppm 
for 4  hr
Increased osmotic fragility Carpenter et al. 1956
Guinea pig 
(M,F)
Oral: LD5Q 1,250 m g/kg Narcosis, digestive tract irritation, damaged kidneys Smyth et al. 1941
EGM
E, EGEE 
and 
Their Acetates
4 Effects o f  Exposure
4.3.2.1 EGEE and EGEEA
EGEE administered by a variety of routes (subcutaneous, intravenous, oral, and inhalation) 
produced a marked toxic effect on the testes of many animal species. The testicular effects 
included edema [Morris et al. 1942; Stenger et al. 1971], an absence o f testicular germ cells 
[Stenger et al. 1971; Nagano et al. 1979], and testicular atrophy [Morris et al. 1942; Nagano 
et al. 1979; Barbee et al. 1984; Terrill and Daly 1983a; Melnick 1984]. EGEEA has also 
caused testicular atrophy and depletion of spermatocytes in mice [Nagano et al. 1979]. 
Testicular degeneration in rats treated orally with EGEE or EGEEA was restricted to the 
later stages of primary spermatocyte development and secondary spermatocytes [Foster et 
al. 1983]. In detailed toxicologic studies, Creasy and Foster [1984] and Oudiz and Zenick
[1986] concluded that primary spermatocytes in the pachytene stage of meiosis were the 
initial and major sites of morphologic damage from EGEE. Exposure o f rats to EGEE has 
also resulted in reversible impairment of testicular function that was reflected in significantly 
decreased sperm counts (P<0.01) and increased abnormal forms (P<0.05) in the semen 
[Oudiz et al. 1984]. EGEE treatment has also resulted in lowered epididymal weights [Oudiz 
et al. 1984]. Oral treatment of rats with single doses of EAA affected diplotene, diakinetic, 
and secondary and early pachytene spermatocytes [Foster et al. 1987].
4.3.2.2 EGME and EGMEA
The testicular toxicity of EGME has been demonstrated in a number of species by a variety 
of routes. Adverse effects on the testes included the degeneration of germinal epithelium 
[Wiley et al. 1938; Miller et al. 1981; Foster et al. 1983; Chapin and Lamb 1984; Hobson 
et al. 1986], testicular atrophy [Nagano et al. 1979; Miller et al. 1981; Chapin and Lamb 
1984; Hobson et al. 1986; Anderson et al. 1987; Exon et al. 1991; Smialowicz et al. 1991], 
and depletion of germ cells [Nagano et al. 1979; Miller et al. 1981 ; Foster et al. 1983; Hobson 
et al. 1986; Anderson et aî. 1987], In one inhalation study, microscopic testicular lesions 
were observed in rats only at the highest exposure level (300 ppm), but concentration-related 
testicular lesions were observed in rabbits at 30, 100, and 300 ppm [Miller et al. 1983a]. 
Miller et al. [1983a] concluded from this study that male rabbits were more sensitive than 
male rats to EGME vapor. A single 4-hr inhalation exposure to 625 ppm EGME damaged 
spermatids [Samuels et al. 1984].
Oral administration of 500 mg EGME/kg/day for 4 days caused maturation depletion of 
middle and late stage spermatids and maturation arrest of pachytene spermatocytes; partial 
recovery occurred four weeks after treatment and full recovery was achieved at 8 weeks 
[Foster et al. 1983]. A definite order of spermatocyte sensitivity to EGME has been 
demonstrated: dividing spermatocytes > early pachytene spermatocytes > late pachytene 
spermatocytes > midpachytene spermatocytes > Ieptotene/zygotene spermatocytes [Creasy 
and Foster 1984]. Anderson et al. [1987] concluded that testicular degeneration was 
restricted to later stages of primary spermatocyte development and secondary spermatocytes.
A partially reversible decrease in fertility was observed in male rats exposed to EGME by 
inhalation [Rao et al. 1983] or ingestion [Chapin et al. 1985a; Anderson et al. 1987]. 
Changes in fertility were correlated with changes in testicular histology and sperm morphol­
ogy [Chapin et al. 1985b].
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Nagano et al. [1979] demonstrated testicular toxicity of EGMEA administered orally to 
mice. Adverse effects included decreased testes weights and varying dose-related degrees 
o f testicular seminiferous tubule atrophy.
The effects of EGEE, EGME, and their acetates on the male reproductive system are 
summarized in Tables 4-3  and 4-4 .
4.3.3 Effects on the Female Reproductive System and the Developing 
Embryo
A number of experimental animal studies have investigated the effects of the glycol ethers 
on the female reproductive system and the developing embryo. Adverse maternal effects 
include prolonged gestation, reduced body weight, and reduced body weight gain. Adverse 
developmental effects include lethality, skeletal and visceral malformations, cardiovascular 
defects, and altered behavioral test responses.
4.3.3.1 EGEE and EGEEA
Treating pregnant females of various species with EGEE has caused adverse maternal and 
developmental effects. Effects on the dams included death [Schuler et al. 1984], reduced 
food consumption [Andrew et al. 1981; Hardin et al. 1981], reduced body weight and body 
weight gain [Andrew et al. 1981; Hardin et al. 1981], and prolonged gestation periods 
[Nelson etal. 1981]. Effects on the offspring included embryolethality [Stenger et al. 1971; 
Tinston 1983]; fetal skeletal, renal, cardiovascular, and ventral body wall defects [Stenger 
et al. 1971; Andrew et al. 1981; Hardin et al. 1981; Doe 1984a]; and reduced body weights 
[Andrew et al. 1981; Hardin et al. 1981; Hardin et al. 1982], Altered behavioral test 
responses and altered neurochemical concentrations in the brain were also observed in the 
offspring of dams exposed by inhalation to EGEE [Nelson et al. 1982a].
Pregnant rabbits exposed by inhalation to EGEEA exhibited reduced body weight gain and 
food consumption and an increase in fetal resorptions [Doe 1984a; Tyl et al. 1988]. 
Embryolethality, visceral and skeletal abnormalities, and reduced fetal weights were ob­
served in the offspring of dams treated with EGEEA [Doe 1984a; Nelson et al. 1984a; Hardin 
et al. 1984; Tyl et al. 1988].
A.3.3.2 EGME and EGMEA
Treating pregnant females of various animal species with EGME by various routes has 
caused adverse maternal and developmental effects. Effects on the dams included lethality, 
increased gestation period, decreased food consumption, and decreased body weight gain 
[Doe et al. 1983; Hanley et al. 1984a; Wickramaratne 1986]. Effects on the offspring 
included lethality, decreased fetal weights, decreased litter sizes, skeletal and visceral 
malformations, digit anomalies, and cardiovascular defects [Nagano et al. 1981; Doe et al. 
1983; Hanley et al. 1984a; Horton et al. 1985; Toraason et al. 1985; Wickramaratne 1986; 
Greene et al. 1987; Hardin and Eisenmann 1987; Scott et al. 1989]. Although rabbits
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Table 4-3.—Reproductive effects of EGEE and EGEEA
Compound Species
Route of  
administration 
and dose Observed effects Reference
EGEE Mouse (M ) Oral: 500, 1.000, 2,000, or
4,000 m g/kg per day,
5 days/wk tor 5 wk
Mouse (M ) Oral: 0 .5 ,1 , or 2 g /k g  per day 
for 2 yr
Rat (M) s.c.: 93, 186, 372, or 744
mg/kg per day for 4  wk
Rat (M) Oral: 1.45% in diet for
2 y r
Rat (M ) Oral: 46.5, 93, 186, 372
or 744 m g/kg per day for 
13 wk
Rat (M) Oral: 250, 500 or 1,000
m g/kg per day for 11 days
Rat (M) Oral: 250, 500, or 1,000
m g/kg per day for 11 days
Rat (M ) Oral: 0.5, 1, or 2 g /k g  per
day for 2 yr
Testicular atrophy (1,000 and 2,000 mg/kg per day); death 
(4,000 mg/kg per day)
High mortality rate (2 gm/kg); testicular atrophy at 
1 or 2 g/kg
Microscopic testicular changes (372 and 744 mg/kg per day) 
Testicular enlargement, edema, and tubular atrophy 
Microscopic testicular changes (186 and 744 mg/kg per day)
Decreased testes weights, spermatocyte depletion 
and degeneration (500, 1,000 m g/kg per day)
Microscopic testicular lesions (500 and 1,000 mg/kg per day)
High mortality rate (2 gm /kg); testicular atrophy 
at all doses
Nagano et al. 1979
Melnick 1984 
Stenger et al. 1971 
Morris et al. 1942 
Stenger et al. 1971
Foster et al. 1983
Creasy and Foster 
1984
Melnick 1984
'Abbreviations: M =» male; F = female.
(Continued)
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Table 4-3  (Continued).—Reproductive effects of EGEE and EGEEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGEE
(cont’d)
Rat (M ) Oral: 936, 1,972, or 2,808 
m g/kg per day for 5 days
Increased abnormal forms of sperms and decreased sperm 
count (936 mg/kg); azoospermia and oligozoospermia. 
decreased epididymal wts (1,972, 2,808 mg/kg per day)
Oudiz et al. 1984
Rat (M) Oral: 0 or 936 m g/kg per day 
5 days/wk for 6 wk
Decreased sperm count and percent normal morphology 
at weeks 5 and 6; decreased sperm motility at week 6 
(pachytene spermatocyte the most sensitive target)
Oudiz and Zenick 
1986
Rat (F,M) Inhalation: 25, 100, or 
400 ppm, 6 hr/day,
5 days/wk for 13 wk
No biologically significant effects. Terrill and Daly 
1983b;
Barbee et al. 1984
Rabbit (F,M) Inhalation: 25, 100, or 
400 ppm, 6 nr/day,
5 days/wk for 13 wk
Testes weight was decreased (400 ppm) and 
microscopic testicular changes (males)
Terrill and Daly 
1983a;
Barbee et al. 1984
Dog (M) Oral: 46.5, 93 or 186 
m g/kg per day for 13 wk
Microscopic testicular changes (186 m g/kg per day) Stenger et al. 1971
EGEEA Mouse (M) Oral: 500, 1.000, 2,000, or 
4,000 m g/kg per day,
5 days/wk for 5 wk
Testicular atrophy, depletion of spermatocytes 
(1,000, 2,000, or 4,000 m g/kg per day)
Nagano et al. 1979
Rat (M) Oral: 726 m g/kg per day for 
11 days
Testicular atrophy, spermatocyte depletion and 
degeneration
Foster et al. 1984
EGM
E, EGEE, and 
Their Acetates
Table 4-4.—Reproductive effects of EGME and EGMEÀ
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGME Mouse (M) Oral: 62.5, 125, 250, 500,
1,000, or 2,000 m g/kg per day, 
5 days/wk for 5 wk
Mouse (M) Oral: 500, 750, 1,000, or 
1,500 mg/kg
Mouse (F) Inhalation: 10 or 50 ppm on 
g.d. 6—15; sacrifice on 
g.d. 18
Rat (M) 
Rat (M)
Rat (M)
Oral: 50,100, 250 or 500 
m g/kg per day for 11 days
Oral: 50,100, 250 or 500 
m g/kg per day for 11 days
Oral: 500 mg/kg per day for 
4 days, then sacrificed 
at 2-wk intervals
Abbreviations: M = male; F= female.
Testicular atrophy (250-2,000 m e/kg per day); 
no germ cells (1,000-2,000 m g/kg per day)
Reduced testes weight at wk 2 -5  (500-1,500 me/kg); 
increased abnormal sperm morphology (500-1,500 mg/kg); 
degeneration of late spermatocytes and spermatids 
(1,000-1,500 mg/kg)
Decreased maternal body weight gain
Decreased testicular weight at days 2, 4. 7, and 11 
(500 m g/kg per day group); decreased testicular weight 
at days 7 and 11 (250 m g/kg per day group)
De;^generation of pachytene spermatocytes at 24 hr 
(100, 250, 500 m g/kg per day); no testicular effects 
(50 mg/kg for 11 days); degeneration in spermatid 
population (500 m g/kg per day for 4 days; 250 m g/kg per 
day for 7 days); absence of spermatid and late spermatocyte 
populations after 11 days o f 250 and 500 m g/kg per day; 
partial depletion and degeneration o f spermatids and 
spermatocytes with 100 m g/kg per day for 11 days
Maturation depletion o f middle and late stage spermatids, 
maturation arrest o f pachytene spermatocytes (2 wk); 
partial recovery (4 wk); full spermatogenesis in 
majority of tubules from all animals (8 wk)
Nagano et al. 1979 
Anderson et al. 1987
Hanley et al. 1984a 
Foster et al. 1983 
Foster et al. 1983
Foster et al. 1983
(Continued)
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Table 4 -4  (Continued).—Reproductive effects o f EGME and EGMEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGM E Rat (M) Oral: 500 m g/kg per day for
(cont’d) 4  days; animals sacrificed
at 0, 2, 4, and 8 wk post­
exposure
Rat (M ) Oral: 150 m g/kg per day for
5 days; animals sacrificed 
on g.d. 1, 2 ,4 , 7, and 10 
after initial dosing
Rat (M) Oral: 50, 100, or 200 m g/kg
per day for 5 days then 
mated with 2 female rats/wk 
for 8 wk. After 8-wk interval, 
mated again for 5 days
Foster et al. 1983
Rat (M)
Chapin and 
Lamb 1984
Decreased testicular weights at 0, 2, and 4  wk; return 
to normal size in 8th wk; increased seminal vesicle 
weights at wk 8
Spermatocyte degeneration at day 1; no significant 
increase m production o f testis fluid and androgen- 
binding protein at day 2, 4, 7, and 10; reduced 
testes weight at day 2 and after
Decreased pregnancies at wk 4 (200 mg/kg per day); reduced Chapin et al, 1985a 
fertility at wk 5 (100 m g/kg per day); decreased number of 
live fetuses at wk 4-16 (200 m g/kg per day); fewer pups/ 
litter at wk 5 (100 m g/kg per Sty); increased numbers of 
resorptions at wk 5 and 6, and at wk 3-16 increase in pre-
implantation loss (200 mg/kg 
implantation loss at wk 2  anc
§er day); increase in pre- 
(100 m g/kg per day)
Rat (M) Oral: 50, 100, or 200 m g/kg per Decreased sperm /g cauda epididymis at wk 2 and remained Chapin et al. 1985a
day for 5 days at weekly ~ 
intervals, for 8  wk, efferent 
duct ligations, ana following 
day animal was sacrified
Oral: 50, 100 or 200 m g/kg per 
day for 5 days at weekly 
intervals, for 8 wk, efferent 
duct ligations, ana animals 
sacrificed 16 hr later
low for 8 wk (100, 200 m g/kg per day); lower counts only at 
wk 5 (50 m g/kg per day); decreased sperm motility at wk 
3-8  (200 m g/kg per day) and wk 4-8  (100 mg/kg per day); 
recovery began at wk 6. Increased abnormal sperm 
morphology at wk 3 (200 m g/kg per day) and wk 5 
(100 m g/kg per day) and remained so
Abnormal sperm morphology at wk 4 with recovery by wk 8  
(50 mg/kg per day); abnormal sperm morphology at wk 1 
with 50% recovery by wk 8 (100 m g/kg per day); severe 
testicular effects at wk 1, with 50% recovery by wk 7 
(200 m g/kg per day)
At wk 2 decreased numbers of sperm and increased numbers 
of immature germ cells (100, 200 m g/kg per day); transient 
mild increase in numbers of immature germ cells and 
decreased sperm density; elevated amount of protein in rete 
testis fluid at wk 2-5  (200 m g/kg per day) ana wk 4-6  
(100 mg/kg per day)
Chapin et al. 1985b
EGME
(cont’d)
Rat (M)
Rat (M) 
Rat (M) 
Rat (M)
Rat (M,F)
Rat (M)
Rat (F) 
Rat (M)
Oral: 500, 750, 1,000, 
or 1,500 rag/kg
Oral: 2,000 or 6,000 ppm in 
drinking water for 10 days
Oral: 50, 100, or 200 m g/kg  
per day for 10 days
Inhalation: 100, 300, or 
1,000 ppm, 6 nr/day for 9 
days
Inhalation: 30, 100, or 300 
ppm, 6 hr/day, 5 days/wk 
for 13 wk
Reduced testes weight (500-1,500 m g/kg) at wks 3, 4, and 5; 
reduced sperm counts at wks 4, 5, 6, T (500-1,500 mg/kg); 
increased abnormal sperm morphology (500-1500 mg/kg); 
100% sterility (750-1,500 mg/kg); depletion of early 
pachytene spermatocytes (1,000-1,500 mg/kg)
Reduction in testes weights (6,000 ppm)
Reduction in testes weights and elevated serum testosterone 
levels (200 mg/kg per day)
Microscopic testicular changes (1,000 ppm)
Inhalation: 30, 100, or 300 
ppm, 6 hr/day, 5 days/wk 
for 13 wk, then paired with 
unexppsed females for 
breeding
Inhalation: 30,100, or 300 
ppm, 6 hr/day, 5 days/wk 
for 13 wk, then paired with 
unexposed males for breeding
Inhalation: 100 or 300 ppm,
6 hr/day for 10 days
Reduced testicular weight and microscopic lesions 
(300 ppm) in males. Reduced body and thymus weights at 
300 ppm in males and females
Decreased male fertility (300 ppm), partially 
reversed when bred 13 and 19 wk after last exposure
No effect on female fertility
No effect at 100 ppm; testicular atrophy at 300 ppm
Anderson et al. 1987
Exon et al. 1991
Smialowicz et al. 1991
Müler et al. 1981
Miller et al. 1983a
Rao et al. 1983
Rao et al. 1983
D oe et al. 1983
(Continued)
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Table 4 -4  (Continued).—Reproductive effects o f EGME and EGMEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGME
(confd)
Rat (M) Inhalation: 150, 300, 625, 
1,250, 2,500, or 5,000 ppm 
for 4 hr; sacrificed on 
day 14
Microscopic testicular changes and atrophy (1,250, 
2,500, 5,000 ppm); damaged spermatids (625 ppm)
Samuels et al. 1984
Rat (M) Inhalation: 1800 or 2,500 
ppm for 4 hr; sacrificed 
on day 1, 2, 3, 4, 5, 8, 10 
15, and 19 post exposure
Reduced testes weight at 48 hr (1,000, 2,500 ppm) and 
testicular atrophy on days 1-19
Samuels et al. 1984
Rabbit (M) Injection: (route and dose 
not specified)
Microscopic testicular changes Wiley et al. 1938
Rabbit (M,F) Inhalation: 30, 100, or 300 
ppm, 6 hr/day, 5 days/wk 
for 13 wk
Reduced testicular weight and microscopic lesions 
(300 ppm); dose-related increase in incidence and 
severity or testicular lesions (30, 100, 300 ppm): 
reduced thymus and body weights at 300 ppm (M,F)
Miller et al. 1983a
Guinea 
pig (M)
Dermal: 1 e/kg per day, 
5 days/wk for 13 wk
Decreased testicular weights, severe testicular 
atrophy, degeneration of seminiferous tubules with 
complete loss of spermatogenic cells
Hobson et al. 1986
EGMEA Mouse (M) Oral: 62.5, 125, 250, 500, 
1,000, or 2,000 m g/kg per 
day, 5 days/wk for 5 wk
Testicular atrophy (500-2,000 m g/kg per day); no germ cells 
(2,000 m g/kg per day)
Nagano et al. 1979
EGM
E, EGEE, and 
Their Acetates
4 Effects o f Exposure
demonstrated a greater sensitivity to EGME vapor than rats or mice, the results established 
no-observed-effect levels of 10 ppm EGME in these three species [Hanley et al. 1984a], 
Oral EGME treatment of mice on different days of gestation caused exencephaly and digit 
anomalies [Horton et al. 1985]. The authors concluded that 100 mg/kg of EGME was the 
no-observed-effect level for digit malformations after a single oral dose o f EGME on g.d. 11. 
Oral EGME treatment of nonhuman primates during gestation resulted in a missing digit 
on each forelimb of one dead embryo [Scott et al. 1989]. An altered response in avoidance 
conditioning and altered neurochemical levels in the brain were observed in the offspring 
of dams treated with EGME vapor [Nelson et al. 1984a], Feuston et al. [1990] demonstrated 
that treatment of pregnant rats with a single dermal application of EGME caused statistically 
significant increases (P<0.05) in both the mean number of resorptions and the mean 
percentage of resorptions, as well as in visceral, external, and skeletal malformations. In 
this study, the authors established a NOAEL of 250 mg/kg on g.d. 12 for developmental 
effects. No studies have been reported using EGMEA; it would, however, be expected to 
have the same effects as EGME (see Section 4.2).
The effects of EGEE, EGEEA, and EGME on the female reproductive system and the 
embryo are summarized in Tables 4 -5 ,4 -6 , and 4-7.
4.3.4 Hematology
EGEE, EGEEA, EGME, and EGMEA exert adverse hematologic effects. These effects 
include increased osmotic fragility and decreased levels of Hb, Hct, platelets, RBCs, WBCs, 
and MCV. The following studies, which show these effects, are described in detail in 
Appendix B.
4.3.4.1 EGEE and EGEEA
Adverse hematological effects were observed in a number of species following administra­
tion of EGEE or EGEEA by oral, inhalation, and dermal routes. These effects included 
hemolysis [von Oettingen and Jirouch 1931] and increased osmotic fragility [Carpenter et al. 
1956]. Other investigations demonstrated that EGEE and EGEEA caused decreased Hb 
concentrations, decreased numbers of RBCs, WBCs, and platelets, reduced Hct levels, and 
decreased MCVs [Werner et al. 1943a,b; Stenger et al. 1971; Nagano et al. 1979; Truhaut 
et al. 1979; Terrill and Daly 1983a; Barbee et al. 1984; Doe 1984a; Tyl et al. 1988]. These 
effects were shown to be reversible in only one study [Werner et al. 1943b]. In another 
study [Tyl et al. 1988], EGEEA caused an increase in WBC levels.
4.3.4.2 EGME and EGMEA
The effect of EGME and EGMEA treatment on the blood and the hematopoietic system has 
been investigated in a variety of species by a variety of routes. Adverse effects o f EGME 
and EGMEA include decreased Hb, Hct, RBC, and WBC levels, and altered MCVs [Werner 
et al. 1943a,b; Miller et al. 1981, 1983a; Nagano et al. 1979; Grant et al. 1985; Hobson et 
al. 1986]. Carpenter et al. [1956] showed that EGME (2,000 ppm) and EGMEA (32 ppm)
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Table 4 -5 .—Developmental effects o f EGEE
Species
Route of 
administra tion 
and dose Observed effects Reference
Mouse (F) 
Mouse (F) 
Rat (F) 
Rat (F)
Rat (F)
Rat (F) 
Rat (F)
s.c.: 46.5 or 93 m g/kg per day 
on g.d. 1-18
Oral: 3.6 g /k g  per day on 
g.d. 7 -14
S.C.: 23, 46.5, 93 m g/kg per day 
on g.d. 1-21
Oral: 11.5, 23, 46.5, 93, 186 
or 372 m g/kg per day on g.d. 
1-21
Inhalation: before pregnancy, 
150 or 650 ppm 7 hr/day,
5 days/wk for 3 wk; then 
200 or 7651 ppm, 7 nr /day  
on g.d. 1-19
Inhalation: 900 ppm, 7 hr/day 
on g.d. 14-20;
Inhalation: 100 ppm, 7 hr/day 
on g.d. 7-13 or 14-20
No embryotoxic or teratogenic effects
Maternal death (10%); embryonic death (100%)
Fetal skeletal defects (93 m g/kg per day)
Complete resorption o f all litters (372 m g/kg per day); 
embryonic death increased (46,5-186 m g/kg per day); 
fetal skeletal defects and lower body weight 
(93-186 m g/kg per day)
No effect on fertility; slight maternal toxicity 
(765 ppm); embryonic death (100% at 765 ppm); fetal 
cardiovascular and skeletal defects and reduction 
in growth (200 ppm)
Extended gestation duration by 48 hr
Prolonged gestation (0.7 day); altered behavioral test 
results; altered neurochemical concentrations in brain
Stenger et al. 1971 
Schuler et al. 1984 
Stenger et al. 1971 
Stenger et al. 1971
Andrew et al. 1981 
Hardin et al. 1981
Nelson et al. 1981
Nelson et al. 1982a
EGM
E, EGEE, and 
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Rat (F) Inhalation: 200 ppm, 7 hr/day
on g.d. 7-13
Rat (F) Inhalation: 10, 50, or 250 ppm,
6 hr/day on g.d. 6-15
Rat (F) Dermal: 1.0 or 2.0 m l/day on
g.d. 7-16
Rat (F) Dermal: 1.0 m l/day on g.d. 7-16
Rabbit (F) s.c.: 23 m g/kg per day on
g.d. 7-16
Rabbit (F) Inhalation: 160 or 615
7 hr/day on g.d. 1-1;
Rabbit (F) Inhalation: 10, 50, or 175 ppm,
6 hr/day on g.d. 6-18
Rabbit (F) Inhalation: 50, 150. or 400
ppm on g.d. 6-18
F = female.
U)
Increased dopamine levels in cerebrum; increased 
norepinephrine levels in cerebrum and cerebellum
Fetotoxic, reduced ossification, skeletal variants 
(250 ppm)
Reduced maternal weight gain (2.0 ml/day); embryonic 
death (100% at 2.0 m l/day and 76% at 1.0 ml/day); 
fetal cardiovascular detects and skeletal variations 
and reduced fetal body weight (1.0 ml/day)
Increase of visceral malformations
No embryotoxic or teratogenic effects
Embryonic death (100% at 615 ppm and 22% at 160 ppm) 
fetal renal, cardiovascular, ana ventral body wall 
defects ana skeletal variations (160 ppm); reduced 
maternal food consumption (160, 615 ppm); maternal 
death (615 ppm)
Skeletal variations in fetus (175 ppm)
Decreased number o f live fetuses, gravid uterus 
weights and litter weights, increased post 
implantation loss, early and late fetal deaths 
(400 ppm)
Nelson et al. 1982b 
Doe 1984a 
Hardin et al. 1982
Hardin et al. 1984 
Stenger et al. 1971
; Andrew et al. 1981 
Hardin et al. 1981
D oe 1984a 
Tinston 1983
ViOn
Table 4 -6 —Developmental effects of EGEEA
Species
Route of 
administration 
and dose Observed effects Reference
Rat (F)* Inhalation: 130. 390, or 690 ppm, 
7 hr/day on g.d. 7-15
Embryonic death (100% at 690 ppm and 56% at 390 ppm); 
reduced fetal weights and increased visceral 
malformations (130 and 390 ppm)
Nelson et al. 1984b
Rat (F) Inhalation: 50, 100, 200, or 300 
ppm, 6 hr/day on g.d. 6-15
Reduced weight gain and food consumption, elevated 
liver weight (100-300 ppm); embryo/ietotoxicity 
(100-300 ppm), external (300 ppm), visceral, and 
skeletal malformations (200-300 ppm)
Tyl et al. 1988
Rat (F) Dermal: 1.4 ml/day on g.d. 7-16 Reduced maternal body, weight; embryonic death (100%); 
reduced fetal body weights and visceral malformations 
and skeletal variations
Hardin et al. 1984
Rabbit (F) Inhalation: 25, 100, or 400 ppm, 
6 hr/day on g.d. 6-18
Reduced maternal body weight gain and food consumption 
(400 ppm); Increased resorptions (400 ppm) and reduced 
fetal body wt (100 ppm); major vertebral column 
malformations (40u ppm)
Doe 1984a
Rabbit (F) Inhalation: 50, 100, 200, or 300 
ppm, 6 hr/day on g.d. 6-18
Decreased weight gain, reduced gravid uterine wt; 
elevated absolute liver wt (100-300 ppm); embryotoxicity 
(200-300 ppm}; fetotoxicity (100-300 ppm); external, 
visceral, and skeletal malformations (z00-300 ppm)
Tyl et al. 1988
*F = female.
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Table
Route of 
administration 
Species and dose
Mouse (F)* Oral: 31.25, 62.5, 125, 250, 500 
or 1.000 m g/kg per day on g.d. 
7-14
Mouse (F) Oral: 1,400 m g/kg per day on g.d.
7-14
Mouse (F) Oral: 250 m g/kg on g,d. 7-14
Oral: 250 m g/kg per day on g.d.
7-9, 8-10, or 9-11;
Oral: 250 m g/kg on g.d. 7-8 , 
9-10, or 10-11;
Oral: ¿50 or 50û’ m g/kg per day 
on g.d. 10, 11, 12, or 13
Oral: 100, 175, 250, 300, 350 
400, or 450 m g/kg on g.d. 11
Mouse (F) Oral: 250 m g/kg per day on g.d.
7-14; sacrificed on g.d 18
Mouse (F) Oral: 25, 50, or 100 m g/kg per
day on g.d. 7-13
*F = female.
4-7 —Developmental effects of EGME
Observed effects
Embryonic death (250-1,000 mg/kg per day); 100% dead 
(1,000 mg/kg per day). 1 alive (50u m g/kg per day); 
reduced fetal weights (125-250 m g/kg per day): gross 
anomalies and skeletal malformations (250 mg/kg per day); 
increased skeletal malformations (62.5-125 mg/kg per day); 
retarded fetal ossification (31.25-1,000 m g/kg per day); 
bifurcated or split cervical vertebrae
100% embryonic death
Exencephaly and paw lesions; reduced fetal weights, 
increased embryolethality in all dosage groups except 
single 500 m g/kg on g.d. 12 or 13; increased exencephalic 
fetuses (250 mg7kg on g.d. 7-9, or 8-10); increased digit 
malformations (250 m g/kg on g.d. 8-10, or 9-11, or 10 and 
11); increased paw malformations (500 m g/kg on g.d. 9, 10, 
I t  or, 12); forepaw anomalies (500 m g/kg on g.d. 9, 10, or 
11); hindpaw syndactyly (500 m g/kg on g.d. 12)
Increased digit anomalies (250-450 mg/kg); present 
at 175 mg/kg, but not statistically significant;
NOAEL = WO m g/kg
Gross malformations (exencephaly and paw lesions)
100% resorption (100 m g/kg per day); increased 
cardiovascular defects (50 mg/kg per day); increased 
numbers of fetuses with aberrant QRS complexes 
(25-50 mg/kg per day)
Reference
Nagano et al. 1981
Schuler et al. 1984 
Horton et al. 1985
Horton et al. 1985
Horton et al. 1985 
Toraason et al. 1985
(Continued)
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Table 4-7 (Continued).—Developmental effects of EGME
Species
Route of 
administration 
and dose Observed effects Reference
Mouse (F)
Mouse (F)
Mouse (F) 
Mouse (F)
Rat (F)
Rat (F) 
Rat (F)
Rat (F)
Oral: 100, 250, or 350 m g/kg on 
g.d. 11, then sacrificed 2, 6,
24, or 48 hr later and embryos 
removed
Oral: 100, 175, 250, 300, 350 
400, 450, or 500 m g/kg on 
g.d. 11 and embryos removed 
6 or 24 hr later
Oral: 304 mg/kg on g.d. 11, 
sacrificed on g.d. 18
Inhalation: 0, 10, or 50 ppm 
on g.d. 6-15; sacrificed 
on g.d. 18
Inhalation: 100 or 300 ppm,
6 hr/day on g.d. 6-17, 
then litters delivered
Inhalation: 3, 10, or 50 ppm on  
g.d. 6-15
Inhalation: 25 ppm, 7hr/day on
g.d. 7-13 or FI-2Ô
Dermal: 3%, 10%, 30%, or 100% 
solutions at 10 ml/kg, 6 hr/day  
on g.d. 6-17
No maternal toxicity^ forelimb bud cytotoxicity as early 
as 2 hr post EGM É treatment, with maximum effect at 
6 hr (35u mg/kg)
Paw malformations induced in dose-dependent m anner 
(all dose levels except 100 m g/kg)
No maternal toxicity; paw malformations
Slight fetotoxidty (50 ppm): minor skeletal 
variations
Reduced maternal body weight gain and 100% embryonic 
death (300 ppm), prolonged gestation and reduced 
number o f pups and live pups (100 ppm)
Minor skeletal variations (50 ppm)
Significant differences in avoidance conditioning 
of offspring from mothers exposed on g.d. 7-13; 
neurobehavioral deviations in offspring
100% maternal deaths (100% soln); 100% fetal 
death (30%); reduced litter sizes (10%)
Greene et al. 1987
Greene et al. 1987
Hardin and 
Eisenmann 1987
Hanley et al. 1984a
D oe et al. 1983
Hanley et al. 1984a 
Nelson et al. 1984a
Wickramaratne 1986
EGM
E, EGEE, and 
Their Acetates
Rat (F) Dermal: 250. 500,1,000 or 2,000
mg E G M E/kg on g.d. 12
2,000 mg EG M E/kg on g.d, 10, 
1 1 ,1 2 ,1 3 , or 14
Rabbit (F) Inhalation: 3 ,1 0 , or 50 ppm on 
g.d. 6 -18
Monkey (F) Oral: 12, 24, or 36 m g/kg on 
g.d. 20-45
Reduced maternal body weight gain day after EGME  
application (all EGME exposures and times except 
for 250 mg on g.d. 12)
Increase in mean number of resorptions, mean percentage 
resorptions (2,000 mg/kg on g.d. 10); decrease in fetal 
body weights (1,000 or 2,000 m g/kg on g.d. 10 and 12). 
Increases in external,visceral, or skeletal malformations 
(500, 1,000, or 2,000 m g/kg on g.d. 12)
Reduced maternal body weight gain, increased absolute 
liver weight, increased resorption rate, reduced 
mean fetal body weights (50 ppm); increased incidence 
of skeletal and visceral malformations (50 ppm);
10 ppm = no effect level
Embryonic death — 3 of 13 or 23% at 12 mg/kg, 3 of 
10 or 30% at 24 mg/kg, 8 of 8 or 100% at 36 mg/kg;
1 embryo (36 mg/Kg group) was missing one digit 
on each foreitmo
Feuston et al. 1990
Hanley et al. 1984a
Scott et al. 1989
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caused increased osmotic fragility of RBCs. Histopathology of EGME- and EGMEA-exposed 
animals revealed reduced bone marrow cellularity, lymphoid atrophy of the thymus and 
gut-associated lymphoid organs, decreased hepatocyte size, and reduced thymus weights 
[Miller etal. 1981,1983a; House et al. 1985]. In addition, serum total protein, albumin, and 
globulin levels were reduced [Miller et al. 1981,1983a], while serum creatinine kinase and 
lactate dehydrogenase activity were increased [Hobson et al. 1986],
The hematologic effects of EG EE, EGME, and their acetates are summarized in Tables 4-8  
and 4-9.
4.3.5 Immunology of EGME and MAA
Houchens et al. [1984] examined the effect of EGME and EG EE on cell-mediated immunity 
using an allograft rejection assay. In this model, mice that are allogenic in relation to the 
leukemic cell tumor used survive when challenged with the tumor unless they have been 
immunosuppressed; the tumor will grow in syngeneic mice unless chemical treatment has 
a direct cytotoxic effect on the tumor cells. Day zero was the tumor implantation day. 
Allogeneic B6C3F-t mice were given 600, 1,200, or 2,400 mg EGEE/kg or 300, 600, or 
1,200 mg EGME/kg orally on days -12 to -0, or 100 mg/kg cyclophosphamide (Cy) i.p. 
on day -1. Sham-treated controls were given oral doses of water on days -12 to -0 and -5 
to -1, respectively. The mice were then challenged with 100 (102), 3,000 (3x 103), 300,000 
(3*105), or 3,000,000 (3*106) L1210 cells i.p. on day zero. Syngeneic CD2Fj mice were 
challenged with 100,000 (10~*) L1210 cells on day zero and were treated on days 1 to 5 and 
8 to 12 with the same doses of EGME and EG EE used for the B6C3F^ mice. Water-treated 
syngeneic mice died with a median survival time of 8 days. In the syngeneic mice there was 
no direct antitumor activity of EGME or EGEE against the L1210 tumor at the doses tested 
because there was no effect on the median survival time. Neither EGME nor EGEE were 
toxic to the syngeneic mice, as determined by weight loss or early death. The authors 
[Houchens et al. 1984] suggested that higher doses might be tolerated and have some direct 
cytotoxic effect on the tumor.
The results for the allogeneic mice were more complex. All allogeneic mice receiving either 
water or Cy and challenged with 3><106 tumor cells died with ascites. However, no more 
than one animal per group died when the mice were treated with EGME or EGEE and 
challenged with 3* 10 tumor cells. Houchens et al. [1984] suggested that the compounds 
may in some way stimulate the immune system and provide a prophylactic action. Blood 
smears of allogeneic mice were made for differential counts the last day of dosing, the day 
of death when possible, and on survivors at day 43 after tumor implantation. In those mice 
not surviving until the day of sacrifice, differential counts showed evidence of monocytosis, 
which is indicative o f monocytic leukemia. All surviving allogeneic mice were sacrificed 
and necropsied on day 43. Cholecystitis was present in 7 % of the mice that had received EGEE 
and in 58% of the mice that had received EGME. The authors did not refer to the control group.
Exposure of laboratory animals to glycol ethers has been associated with thymus atrophy 
and leukopenia [Nagano et al. 1979; Truhaut et al. 1979; Miller et al. 1981, 1983a; Grant 
et al. 1985]. Because these effects could involve depletion o f immunoresponsive cells,
60
Table 4-8.—Hematologic effects of EGEE and EGEEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGEE Dog and in vitro (1 cc) 
beef blood
Mouse Oral: 0, 500, 1,000, or 2,000
m g/kg per day, 5 days/wk for 
5 wk
Rat Inhalation: 370 ppm 7 hr/day,
5 days/wk for 5  wk
Rat Inhalation: 125 ppm for 4 hr
Rat , Inhalation: 0, 25, 100 or 400 ppm,
(M,F) 6 hr/day, 5 days/wk for 13 wk
Rat (F) Inhalation: 0, 10, 50 or 250 ppm
on g.d. 6-15
Rabbit Oral: 186. 372, or 744 m g/kg per
day, 7 hr/day for 13 wk
Rabbit Inhalation: 0, 25, 100, or 400 ppm,
(M,F) 6 hr/day, 5 days/wk for 13 wk
Rabbit Inhalation: 0, 10, 50, or 175 ppm 
(F) on g.d. 6-18
Dog Oral: 186 m g/kg per day, 7 hr/day
for 13 wk
Dog Inhalation: 840 ppm, 7 hr/day,
5 day/wk for 12 wk
Hemolysis
Reduced WBC counts (2,000 ppm)
Increase in hemosiderin: fat replacement in bone marrow, 
decrease in myeloid cells
Increased erythrocyte osmotic fragility 
Decreased WBC in females (400 ppm)
Decreased Hb, Hct, and MCV (250 ppm)
Decreased Hb and Hct; increased hemosiderin; 
hematopoietic foci in spleens
Decreased Hb, Hct. and RBC in males and 
females (400 ppm)
No effects
Decreased Hb and Hct; increased hemosiderin; 
hematopoietic foci in spleens
Increased circulating immature granulocytes; increased 
hemosiderin
von Oettingen 
and Jirouch 1931
Nagano et al. 1979
Werner et al. 1943a
Carpenter et al. 1956
Terrill and Daly 
1983b;
Barbee et al. 1984
D oe 1984a
Stenger et al. 1971
Terrill and Daly 
1983a;
Barbee et al. 1984
Doe 1984a
Stenger et al. 1971 
Werner et al. 1943b 
(Continued)
’Abbreviations: M = male; F = female.
Table 4-8 (Continued).—Hematologic effects of EGEE and EGEEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGEEA Dog and 
beef blood
in vitro (1 cc) Hemolysis von Oettingen 
and Jirouch 1931
Mouse Oral: 0, 500. 1,000, 2,000, or 
4,000 mg/fcg per day, 5 days/wk, 
for 5 wk
Reduced white blood cell counts (2,000 mg/kg per day); 
reduced packed erythrocyte volume (4,000 mg/kg per day)
Nagano et al. 1979
Rat Inhalation: 62 ppm for 4  hr Increased erythrocyte osmotic fragility Carpenter et al. 1956
Rat Inhalation: 2,000 ppm for 4  hr No effect Truhaut et al. 1979
Rat (F) Inhalation: 0, 50, 100, 200 or 
300^»pm for 6 nr/day on g.d.
Increased WBC (200 and 300 ppm); reduced 
RBC, Hb, Hct, erythrocyte size (100, 200, and 
300 ppm); reduced platelet counts (200 and 300 ppm)
Tyl et al. 1988
Rabbit Inhalation: 2,000 ppm for 4  hr No effect Truhaut et al. 1979
Rabbit
(F)
Inhalation: 0, 25, 100, or 400 
ppm, 6 hr/day on g.d. 6-18
Reduced Hb; slight reduction in Hct, RBC, 
and MCV (400 ppm)
Doe 1984a
Rabbit Dermal: 10.5 g /kg Decreased white blood cell count Truhaut et ai. 1979
EGM
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Table 4-9.—Hematologic effects of EGME and EGMEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGME Mouse (M)* Oral: 500, 1,000, or 2,000 mg/kg,
5 times/wK for 5 wk
Mouse (F) Oral: 250, 500, or 1,000 ¿ig/g,
10 times during 2  wk
Mouse (M) Oral: 500, 1,000, or 2,000 mg/kg,
5 times/wk for 5 wk
Mouse Inhalation: 100, 300, or 1,000 ppm 
(M, F) 6 hr/day for b days
Rat (M) Oral: 100 or 500 mg/kg per day 
for 4 days; animals sacrificed 
on day 1, 4, 8, and 22 after 
last treatment
Rat Inhalation: 310 ppm, 7 hr/day,
5 days/wk for5w£:
Rat Inhalation: 32 ppm for 4 hr
Rat (F) Inhalation: 2,000 ppm for 4 hr
Rat (M, F) Inhalation: 100, 300, or 1,000 ppm
6 hr/day for $ days
Decreased WBC counts (500 mg); decreased RBCs and 
Hb (1,000 mg)
Reduced thymus wts (500 and 1,000 p.g /g)
Decreased WBC and RBC counts (1,000 mg/kg); 
decreased Hb (2,000 m g/kg)
Decreased WBC counts, packed cell volume, and RBC 
counts (1,000 ppm); simdar but less severe effects 
at 300 ppm
Day 1: (500 m g/kg per day) hemorrhagic bone marrow 
and sinus endothelial damage, return to normal on day 4;
Nagano et at. 1979 
House et al. 1985 
Nagano et al. 1979 
Miller et al. 1981
Grant et al. 1985
reduced WBC counts and no return to normal; (100 m g/kg 
per day) reduced WBC on day 1
Increased levels o f hemosiderin and immature 
granulocytes
Increased osmotic fragility (hemolysis)
Increased osmotic fragility
Decreased WBC counts, packed cell volume, and RBC 
counts (1,000 ppm); similar but less severe effects at 
300 ppm; decreased Hb (300 ppm in F): reduced total 
serum protein, albumin, and globin (1,000 ppm in M)
Werner et al. 1943a
Carpenter et al. 1956 
Carpenter et al. 1956 
Miller et al. 1981
o\w
(Continued)
* Abbreviations: M = male; F=fem ale.
Effects of 
Exposure
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Table 4-9 (Continued).—Hematologic effects of EGME and EGMEA
Compound Species
Route of 
administration 
and dose Observed effects Reference
EGME Rat Inhalation: 30, 100. or 300 ppm 
6 hr/day, 5 aays/wk for 13 wk
After 4 and 12 wks, decreased WBC counts, platelet 
counts, and HB, reduced total protein, albumin, and 
globin; thymic atrophy (300 ppm)
Miller et al. 1983a
Rabbit Inhalation: 30,100. or 300 ppm 
6 hr/day, 5 aays/wk for 13 wk
After 4 and 12 wks, decreased WBC counts, platelet 
counts, Hb, and RBC counts; thymic atrophy (300 ppm)
Miller et al. 1983a
Guinea
pig(M)
Dermal: 1 g /kg per day, 5 days/wk 
for 13 wk
Decreased RBC counts, increased MCV, 
lymphopenia, neutrophilia, and increased serum 
creatinine kinase and lactate dehydrogenase activity
Hobson et al. 1986
D og Inhalation: 750 ppm, 7 hr/day, 
5 days/wk for l2  wk
Microcytic anemia; decreased Hb and Hct (at 4 -6  wks); 
increased osmotic fragility (at 11-12 wks)
Werner et al. 1943b
EGMEA Rat Inhalation: 62 ppm for 4  hr Increased osmotic fragility (hemolysis) Carpenter et al. 1956
EGM
E, EGEE, and 
Their Acetates
4 Effects o f  Exposure
House et al. [1985] studied possible alterations in immune function and host resistance of 
mice following exposure to EGME or its metabolite MAA. Specific pathogen-free female 
B6C3Fj mice were treated orally 10 times over a 2-week period with EGME or MAA to 
yield total doses of 0, 250, 500, or 1,000 mg/kg. A statistically significant reduction in 
thymus weights was seen in the 500 mg/kg groups of both compounds (P<0.01). How­
ever, no reduction was found in bone marrow cellularity or leukocyte counts. No significant 
alterations in immunopathology, humoral immunity, cell-mediated immunity, macrophage 
function, and host resistance to Listeria monocytogenes challenge were found in mice 
exposed to EGME or MAA. The authors concluded that care must be taken in interpreting 
thymus atrophy as evidence of functional immunotoxicity because EGME and MAA 
produced thymic atrophy without a concomitant decrease in immune function or host 
resistance [House et al. 1985].
Exon et al. [1991] investigated the effects of EGME on the immune function of male and 
female Sprague-Dawley rats. The animals (six per group) were exposed to EGME (2,000 
or 6,000 ppm for males and 1,600 or 4,800 ppm for females) in deionized drinking water 
for 21 days; the unexposed group received only deionized drinking water. All rats were 
injected s.c. at the base of the tail vein with 1 mg of aqueous keyhole limpet hemocyanin 
(KLH) 7 days after beginning treatment with EGME; a second injection o f KLH was 
administered on day 13 to initiate the production o f immunoglobulin G (IgG) antibody. To 
determine the effect on delayed type hypersensitivity (DTH), the right footpad of each 
animal was injected with 100 pi of heat-aggregated KLH on day 20; the left footpad was 
injected with 100 fil of sterile saline.
On day 21, all animals were sacrificed by C 02 asphyxiation. Serum was then collected by 
cardiac puncture, and the thymus, spleen, liver, right kidney, and right testis were removed. 
The mean dose of glycol ethers actually consumed was calculated on the basis of mean body 
weight and water consumed during the entire study. The actual exposure concentrations of 
EGME for male rats were determined to be 161 mg/kg per day (2,000 ppm) and 486 mg/kg 
per day (6,000 ppm). The actual exposure concentrations of EGME for female rats were 
determined to be 200 mg/kg per day (1,600 ppm) and 531 mg/kg per day (4,800 ppm).
The authors [Exon et al. 1991] reported the following results. The body and testis weights 
of male rats exposed to 6,000 ppm EGME were significantly reduced (P<0.05). Male and 
female rats exposed to either concentration of EGME had a dose-dependent reduction in 
thymus weights (P<0.05). Spleen weights were reduced (P<0.05) in female rats treated with 
4,800 ppm EGME. Liver weights expressed as a percentage of body weight were sig­
nificantly increased (P<0.05) in male rats treated with 2,000 ppm EGME; however, this 
effect was not apparent when the actual weights of the livers were compared. EGME 
exposture did not affect kidney weights in either sex.
Natural killer cytotoxic responses were enhanced (P<0.05) in male and female rats at either 
concentration of EGME, but specific IgG production to KLH was suppressed (PiO.OS) in a 
dose-dependent manner in both sexes. Gamma interferon (ylF) production was decreased 
(P<>0.05) in all EGME-treated male rats and in female rats exposed to 4,800 ppm EGME. 
Spleen cell numbers were reduced (P<0.05) in female rats exposed to both doses of EGME
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and in male rats exposed to 6,000 ppm EGME. Interleukin-2 (IL2) production by spleen 
cells was decreased (P^O.OS) in female rats treated with 4,800 ppm EGME. No significant 
effects were observed on DTH reactions o f either sex. EGME appears to exert immuno­
modulatory effects.
Smialowicz et al. [1991] studied the effects of EGME on the immune function o f another 
strain of rat, the Fischer 344 (F344) rat. Adult male or female rats (six per group) were 
exposed by oral gavage to 25 ,50 , 100, or 200 mg/kg per day in a volume of 0.25 ml/100 g 
EGME in water for 2 or 10 consecutive days, depending on the experiments performed. 
Control rats were given 0.25 ml of water/100 g of body weight by oral gavage. Additional 
rats were treated by oral gavage with MAA (25 to 200 mg/kg per day) for 2 or 10 days. To 
generate an antibody response, the F344 rats were immunized in vivo on treatment day 9 or 
4 hr before two treatments (separated by 24 hr) with either the sheep erythrocyte (SRBC) 
antigen or the trinitrophenyl-lipopolysaccharide (TNP-LPS) antigen. Forty-eight hours 
after the last treatment of EGME or MAA, the animals were sacrificed by asphyxiation with 
C 02- Blood samples were obtained from the abdominal aorta, and the spleen, thymus, and 
mesenteric lymph nodes were removed.
Smialowicz et al. [1991] reported the following observations for male rats only (unless 
otherwise specified). EGME (50, 100, or 200 mg/kg per day for 10 days) caused a 
statistically significant (P i0.05) dose-dependent decrease in thymus weights with no change 
in body or spleen weights. In rats immunized on day 9 of EGME treatment, the antibody 
response to SRBC antigen was enhanced (P<0.05) at 50 mg EGME/kg per day; in contrast, 
the antibody response to TNP-LPS antigen was inhibited (P<0.05) in a dose-dependent 
manner at 50, 100, or 200 mg EGME/kg per day.
When rats were immunized with either SRBC or TNP-LPS antigens and then treated with 
EGME 4 and 28 hr later (2 doses of EGME), the antibody response to both antigens was 
inhibited (P<0.01). At 400 mg/kg per day, EGME inhibited the antibody response to SRBC; 
and at 100,200, or 400 mg/kg per day inhibited the antibody response to TNP-LPS. The 
authors [Smialowicz et al. 1991] then compared the effect of 10 daily doses of EGME (25, 
50, 100, or 200 mg/kg per day) on the antibody response to TNP-LPS in male and female 
rats immunized on day 9 of EGME treatment. The antibody response of both sexes was 
inhibited (P<0.05), but male rats were more sensitive than female rats to the immunosup­
pressive effects of EGME. At concentrations of 50, 100, and 200 mg/kg per day, EGME 
inhibited the antibody response in the male rats. Although 50 mg EGME/kg per day had no 
effect on the antibody response in female rats, 100 and 200 mg EGME/kg per day inhibited 
the response in a dose-dependent manner.
No alterations were observed in natural killer cell activity, mixed lymphocyte reaction, or 
cytotoxic T lymphocyte responses. Lymphoproliferative responses to concanavalin A and 
phytohemagglutinin were reduced at 50 to 200 mg EGME/kg per day, and the mitogen 
responses o f pokeweed and Salmonella typhimurium were reduced at 200 mg EGME/kg per 
day (P<0.05). Interleukin-2 production was reduced (P<0.05) in rats exposed to 50, 100, 
or 200 mg EGME/kg per day. Expulsion of adult Trichinella spiralis worms was reduced 
in rats treated with 200 mg EGME/kg per day and infected with T. spiralis larvae.
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The authors then demonstrated that MAA (the metabolite of EGME) plays a role in 
EGME-induced immunosuppression. MAA administered by gavage (50, 100, or 200 mg 
EGME/kg per day) to male rats suppressed (P<0.01) the antibody response to TNP-LPS in 
animals immunized on day 9 of MAA treatment. Concomitant exposure o f rats to EGME 
(100 or 200 mg/kg per day) and the alcohol dehydrogenase inhibitor 4-methylpyrazole 
(4-M P) blocked EGME-induced suppression of the TNP-LPS antibody response observed 
in rats treated with EGME only.
In this study [Smialowicz et al. 1991], the authors also examined the effect of EGME on 
male reproductive parameters. The results are presented in Section 4.3.2.2 and Table 4-4 .
4.3.6 Carcinogenicity
The National Toxicology Program (NTP) of the U.S. Department of Health and Human 
Services tested EGEE for carcinogenicity in male and female rats and mice at 500, 1,000, 
and 2,000 mg/kg/day administered by gavage [Melnick 1982]. Because mortality was high 
in the 2,000 mg/kg/day groups, survivors were sacrificed after 16 weeks; males had testicular 
lesions. The final report of this study has not been published. Currently, prechronic 
carcinogenicity studies are in progress for EGEE and EGME [NTP 1988].
4.3.7 Mutagenicity
A limited number o f studies of the potential mutagenicity o f EGEE and EGME have been 
performed. Most of these were in vitro tests with microorganisms or mammalian cell 
cultures. EGME did not appear to be mutagenic, and EGEE was positive in one test system. 
No data are available concerning the mutagenicity of EGEEA and EGMEA.
4.3.7.1 EGEE
EGEE was not mutagenic in the Ames test using S. typhimurium TA1538, with or without 
metabolic activation [Kawalek and Andrews 1980], or E. coli scl-4-73  [Szybalsld 1958]. 
EGEE was not mutagenic (up to 23 mg/plate) [Ong 1980] when tested in S. typhimurium 
strains TA1535, TA1537, TA98, and TA100 with and without Aroclor-induced rat liver S9 
supernatant NTP reported that EGEE was not mutagenic at concentrations up to 10 mg/plate 
in the same four Salmonella strains with and without microsomal fractions prepared from 
Aroclor-induced rat and hamster livers [Melnick 1982],
EGEE was also tested in an NTP study at concentrations up to 9 mg/ml and was found to 
induce sister chromatid exchange in Chinese hamster ovary (CHO) cells in both the presence 
and absence of rat S9 mix. The response was weaker in the presence o f rat S9 mix than in 
its absence. EGEE induced chromosomal aberrations in CHO cells in the absence of rat S9 
mix, but failed to do so in its presence. EGEE was not mutagenic in the Drosophila, 
sex-linked, recessive lethal test [McGregor 1984].
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4.3.7.2 EGME
Abbondandolo et al. [1980] assayed five organic solvents, including EGME, for their ability 
to induce forward mutations in the fission yeast, Schizosaccharomyces pombe, both with 
and without metabolic activation. An S 10 post-mitochondrial fraction from phenobarbital- 
induced mouse liver was used for metabolic activation. EGME gave negative results in all 
forward mutation experiments.
EGME was not mutagenic (up to 200 mg/plate) to S. typhimurium strains TA1535, TA1537, 
TA98, and TA100 with and without S9 mix [Ong 1980].
McGregor et al. [1983] tested EGME in various in vitro systems (i.e., bacterial and human 
embryonal intestinal fibroblasts) for mutagenic potential. In the bacterial mutation tests 
incubations were conducted both in the presence and absence of an adult male rat liver’s 
post-mitochondrial supernatant fluid and NADPH-generating system (S9 mix). There was 
no evidence of mutagenicity in the Ames plate incorporation assay at levels up to 3 mg 
EGME/plate. In another experiment, alcohol metabolism was mediated by yeast B NAD+- 
dependent alcohol dehydrogenase, and no mutagenic effect was observed. Human embryonic 
intestinal fibroblasts in the presence of ^H-thymidine were incubated with EGME both in 
the presence and absence of S9 mix. There was no indication of increased unscheduled 
DNA synthesis (UDS) in cells exposed to concentrations up to 10 mg EGME/ml. EGME 
had no effect on bone marrow cytogenetics and did not induce point mutations in the L 5178 Y 
mouse lymphoma TK /-cell assay in the presence of rat S9 mix [McGregor 1984]. In the 
sex-linked, recessive lethal test with Drosophila, results were inconsistent and reinvestiga­
tion was suggested. EGME was positive in both the mouse sperm abnormality test and the 
male rat dominant lethal test.
Mutagenic effects of EG EE and EGME are summarized in Table 4-10.
4.3.8 In Vitro Toxicity
The effects of EGME and MAA on lactate production and protein synthesis by cultured 
Sertoli cells were studied by Beattie et al. [1984], who suggested that alterations in Sertoli 
cell function induced by EGME or MAA could critically affect spermatocyte viability and 
maintenance of spermatogenesis. Sertoli cells were isolated from Sprague-Dawley CD rats 
and incubated with 3H-labeled leucine. EGME or MAA was then added at 0-, 3-, or 10-mM 
concentrations, and spectrophotometric lactate determinations were made after 0 ,1 ,3 ,6 ,9 , 
and 12 hr of incubation. EGME had no effect on lactate concentrations or rates of 
accumulation at any time point compared to controls. However, lactate concentration and 
rate of accumulation were both significantly decreased (P<0.01) by both 3 and 10 mM 
MAA at 6, 9, and 12 hr of incubation. No significant differences were seen between 
experimental and control plates in protein synthesis as measured by the incorporation of 
H-labeled leucine into acid insoluble material at the end of 12 hr of incubation.
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Table 4-10.—Mutagenic effects
T^pe of test Compound Test species and exposure Results References
Bacterial, mutation EGEE
Yeast, mutation
EGME
EGM E
Mammalian, in vitro, EGM E
unscheduled DNA  
synthesis
Mammalian, in vitro, EGEE
chromosomal 
aberrations
Drosophila, sex-linked EGEE
recessive lethal EGM E
S. trohimurium TA1538, with and without 
S9 mix
S. tvphimurium TA1535, TA1537, TA98,
~~TA100, with and without rat S9 mix, a 
hamster S9 mix
E* coli scl-4-73
S. t\~phimurnim TA1535, TA1537, TA98, 
ana TAlOO, with and without S9 mix
S. t\phinmriiim TAL535, TA1537, TA1538, 
TA98,7^ 1(55 , with and without rat S9 mix 
and with alcohol dehydrogenase
Srhrzosaccharomvces pombe. with and 
without mouse S9 mix
Human embryonic intestinal fibroblast 
cells, with and without rat S9 mix
CHO cells with S9 mix 
CHO cells without S9 mix
3-day-old males 
3-day-old males
Kawalek and Andrews 1980 
Ong 1980; Mclnick 1982
Szybalski 1958 
Ong 1980
McGregor et al. 1983
Abbondandalo et al. 1980 
McGregor et al. 1983
McGregor 1984
McGregor et al. 1983 
McGregor et al. 1983
(Continued)
Abbreviations: - =no significant response; + = significant response; ? = unclear, further testing recommended.
-Jo
Table 4-10 (Continued).—M utagenic effects
Type o f test Compound Test species and exposure Results References
Mammalian, in vitro, EGM E  
point mutations
L5178Y mouse lymphoma T K + /- cells 
with rat S9 mix
- McGregor 1984
Rat bone marrow EGM E  
cytogenetics
Rats (M,F) exposed to 25 or 500 ppm 
7 hr/day, for 1 or 5 days
- McGregor et al. 1983
Mouse sperm EGM E  
abnormality
Mice exposed to 25 or 500 ppm, 7 hr/day 
for 5 days
+
(at 500 ppm)
McGregor et al. 1983
Male rat dominant EGME  
lethal
Male rats exposed to 30, 100, or 300 ppm, 
6 hr/day, 5 days/wk, for 13 wk
Male sterility 
at 300 ppm 
reversible
McGregor et al. 1983
Male rats exposed to 30, 100, or 300 ppm,
7 hr/day, for 5 days, followed by 10 successive 
weekly matings
Male sterility 
at week 5 
(500 ppm), 
reversible
McGregor et al. 1983
EGM
E, EGEE, and 
Their Acetates
4 Effects o f  Exposure
4.3.9 Cytotoxicity
The in vitro cytotoxicities of EGME, EGEE, and their corresponding alkoxyacetic acids 
(MAA and EAA) were studied using CHO cells [Jackh et al. 1985]. CHO cells were seeded 
into culture flasks, and after 4 to 5 hr test material was added to the medium. After 16 hr 
the medium was renewed and the cells were allowed to grow in colonies for 6 to 7 days prior 
to counting. Cloning efficiency was used as an indication of cytotoxicity. Concentrations 
that allowed approximately 50% of the seeded cells to form colonies (ECjq) were calculated. 
The EC50 for EGEE was 0.22 mmol/ml or 21.5 mg/ml and for EGME the ECjq was 
0.49 mmol/ml or 37.5 mg/ml. EAA and MAA were more cytotoxic (EC^q » 0.04 to
0.05 mmol/ml or 4.6 mg/ml for both) than their parent compounds. The authors concluded 
that gross cytotoxicity to dividing cells is not the predominant mechanism for the reproduc­
tive, developmental, and myelotoxic effects of these glycol ethers [Jackh et al. 1985].
Chinese hamster V79 cells display a specific form of cell-to-cell communication called 
metabolic cooperation, which is characterized by the exchange of molecules between cells 
through permeable junctions formed at sites of cell contact [Hooper and Subak-Sharpe 
1981]. Blockage of metabolic cooperation has been proposed as a mechanism of action of 
some teratogens [Trosko et al. 1982], The effects of EGME and EGEE on cell-to-cell 
communication in Chinese hamster V79 cells were demonstrated in two separate studies 
[Welsch and Stedman 1984; Loch-Caruso et al. 1984]. In both studies, EGME and EGEE 
were able to block metabolic cooperation in vitro. The potencies were inversely related to 
the length of the aliphatic chain; in general, cytotoxicity increased with increasing aliphatic 
chain length. Loch-Caruso et al. [1984] concluded that because EGME was effective in 
blocking metabolic cooperation over a broad noncytotoxic range, blockage of intercellular 
communication may be its teratogenic mechanism. However, EGEE was more cytotoxic 
and interrupted cell communication over a narrower range of concentrations. The authors 
therefore concluded that interrupted intercellular communication may be mixed with 
cytotoxicity in the embryo and the dam, and thus is less specific as a mechanism of 
teratogenesis for EGEE.
Gray et al. [1985] also investigated the response of primary mixed cultures o f Sertoli and 
germ cells prepared from testes of immature rats that had been exposed to EGEE and its 
alkoxyacetic acid metabolite, EAA. EGEE had no effect when added to the culture medium 
at concentrations up to 50 raM (4.505 mg) for up to 72 hr. In contrast, the following changes 
were induced when 2 to 10 mM of MAA, the major in vivo metabolite of EGME, was added 
for 24 to 72 hr. After 24 hr incubation of cultures with 5 mM MAA, pachytene 
spermatocytes were reduced in number and many of those remaining showed degenerative 
changes consisting of rounding up, increased cytoplasmic eosinophilia, and nuclear pyknosis. 
The number of pachytene spermatocytes was further reduced after 48 hr o f incubation, and 
after 72 hr the cultures consisted of earlier spermatocytes, spermatogonia, and Sertoli cells 
with only occasional degenerate pachytene spermatocytes. At 10 mM MAA, pachytene 
spermatocytes were lost more rapidly, and cell debris in the Sertoli cells was observed more 
frequently. While no effect was observed at 1 mM MAA, 2 mM MAA caused a slightly 
increased frequency of pachytene spermatocyte degeneration. EAA, the major metabolite 
of EGEE in vivo, produced similar changes but was less potent than MAA. Although
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cultures treated with 5 mM EAA showed some loss of pachytene spermatocytes, even after 
72 hr frequent foci of these cells were still present and many appeared morphologically 
normal.
In view o f the differences in the toxicity of MAA and EAA in cell culture, they were 
administered orally to rats at equimolar doses of 6.6 mM (592 mg MAA/kg and 684 mg 
EA A/kg, respectively) to characterize their relative testicular toxicity in vivo. Only MAA 
reduced testis weight. The effects of MAA were found mainly on the pachytene sper­
matocyte population; maturation depletion of the early round spermatid population was also 
evident, while leptotene and zygotene spermatocytes appeared unaffected. EAA had less 
severe effects, with only focal depletion o f early pachytene spermatocytes and early round 
spermatids, while mid- and late-pachytene spermatocytes appeared normal. The authors 
concluded that the close correspondence between the testicular toxicity o f MAA and EAA 
in vitro and in vivo suggests a similar mode of action in both cases.
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5 RECOGNITION OF THE HAZARD
Each employer who manufactures, transports, packages, stores, or uses EGME, EGEE, or 
their acetates in any capacity should determine the potential for occupational exposure of 
any worker at or above the action level (one-half the REL).
5.1 ENVIRONMENTAL SAMPLING
Exposure monitoring and environmental sampling for EGME, EGEE, and their acetates can 
be performed according to OSHA Method No. 79 [OSHA 1990]. The sampling procedure 
involves the use of activated coconut shell charcoal sampling tubes connected by flexible 
tubing to a sampling pump. A total air volume of 48 liters is drawn by the pump through 
the charcoal tube at a flow rate of 0.1 liter/min.
5.2 ANALYTICAL METHODS
Laboratory analyses for EGME, EGEE, and their acetates can be performed by OSHA 
Method No. 79 [OSHA 1990], which is based on OSHA Method No. 53 [OSHA 1985]. 
Prior knowledge of certain types of interfering compounds will help the analyst select the 
appropriate analytical conditions for sample analysis. This list of compounds can be 
compiled from the material safety data sheets for the compounds that are used in or around 
the process where the sampling will occur. The principles of the method are as follows:
• The charcoal in the sampling tube is transferred to a small, stoppered sample 
container, and the analyte is desorbed. EGME, EGEE, EGMEA, and EGEEA may 
be desorbed from the charcoal with methylene chloride and 5% (v/v) methanol.
• An aliquot of the desorbed sample is injected into a gas chromatograph with a flame 
ionization detector.
• The area of the resulting peak is determined and compared with areas obtained 
from the injection of standards.
The detailed analytical method is described in Appendix A. Table 5-1 lists the quantitation 
limits of this analytical procedure for a 48-liter air sample.
5.3 MEDICAL MONITORING
EGME, EGMEA, EGEE, and EGEEA exert adverse effects on the blood and the reproduc­
tive, central nervous, hematopoietic, and renal systems in humans and animals; furthermore,
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Table 5-1.—Quantitation limits of OSHA Method No. 79
Compound
Limits of  
quantitation (ppm)
EGME
EGMEA
EGEE
EGEEA
0.0067
0.0017
0.0021
0.0012
48-1 iter air sample.
exposure to these glycol ethers may impair liver function, Workers who may be exposed 
to them should therefore receive preplacement and periodic medical examinations. Medical 
monitoring should include the following:
• An initial medical examination. A complete medical history and examination will 
establish a baseline for further monitoring and detect any pre-existing conditions 
that may place the exposed worker at increased risk. Special attention should be 
given to tests of the following systems and organs:
— Blood and hematopoietic system. A complete blood count should be done. 
Because of adverse effects of glycol ethers on the blood and the hematopoietic 
system, workers with blood diseases may be at increased risk from exposure to 
these glycol ethers.
— Skin. These glycol ethers are readily absorbed through the skin, but workers 
with chronic skin disease characterized by eczema or fissures may be at increased 
risk o f absorbing them.
— Liver. Although these glycol ethers are not known as liver toxins in humans, 
they are metabolized primarily in this organ, and workers with impaired liver 
function should receive special consideration.
— Kidneys. A urinalysis should be done to ascertain whether renal function is 
impaired. Because of the importance of the kidneys in the elimination of toxic 
substances, special consideration should be given to workers with impaired renal 
function who may be exposed to glycol ethers.
— Central nervous system. The need for examinations of the central nervous 
system should be emphasized because of the adverse effects of glycol ethers on 
this system.
— Reproductive system. The need for examinations o f the reproductive system  
should be stressed (i.e., semen quality, sperm count).
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• Periodic medical examinations. The aforementioned medical examinations should 
be performed annually for all workers occupationally exposed to EGEE, EGME, 
or their acetates at or above the action levels, and for all who have the potential for 
significant skin exposure.
5.4 BIOLOGICAL MONITORING
Biological monitoring may be a useful adjunct to environmental monitoring in assessing 
worker exposure to EGME, EGEE, and their acetates. Biological monitoring includes the 
influence of workload and percutaneous absorption.
5.4.1 Justification for Biological Monitoring
Human experimental inhalation studies have demonstrated the uptake of EGEE [Groeseneken 
et al. 1986b], EGEEA [Groeseneken et al. 1987a], and EGME [Groeseneken et al. 1989a]. 
Studies that included different workloads in the experimental design [Groeseneken et al. 
1986b, 1987a] demonstrated a linear relationship between the workload and uptake o f each 
glycol ether; a linear relationship was also found for the exposure concentration and uptake. 
Table 5-2  illustrates the effects o f a 4-hr inhalation exposure to EGEE under a variety of 
exposure and exercise conditions. Each group consisted of five subjects; experimental 
details are provided in Appendix B of this document [Groeseneken et al. 1986b].
Data presented in Table 5 -2  show that an exposure to EGEE at 5.4 ppm (20 mg/m ) with 
exercise at 30 W is comparable to an exposure of 10.8 ppm (40 mg/m3) at rest. Johanson 
[1988] concluded that the uptake of glycol ethers by inhalation is directly related to 
pulmonary ventilation.
EGME, EGEE, and their acetates exhibit high solubilities in both lipids and in water. These 
characteristics make them candidates for significant absorption through the skin. In vitro 
dermal absorption of EGME, EGEE, and EGEEA has been shown in human abdominal skin 
[Dugard et al. 1984]. Relative absorption rates are shown in Table 5-3.
Table 5 -2 .—Absorption of EGEE at various workloads
Group
EGEE exposure 
ppm mg/m3
Workload
(W)
Total EGEE absorbed 
(mg)
1 2.7 10 0* 16.7 ± 4.2
5.4 20 0 35.1 ± 7.6
10.8 40 0 64.1 ± 14.5
2 5.4 20 0 33.3 ± 8.3
5.4 20 30 57.0 ± 11.8
5.4 20 60 94.4 ± 13.9
0 watts is defined as “at rest.”
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Table 5-3.—In  vitro skin absorption of selected glycol ethers in humans
Rate of absorption Relative rate
Compound (mg/cm2 per hr) (EGBE - 1 )
EGME 2.82 ±2.63 14.2
EGEE 0.796 ± 0.460 4.02
EGEEA 0.800 ± 0.430 4.04
Nakaaki et al. [1980] demonstrated that 10 times more EGME was absorbed through the 
forearm than acetone or methanol.
Johanson [1988] described the relative importance of the inhalation of EGME, EGEE, and 
EGEEA at 5 ppm or at 1% of the saturation concentration at room temperature compared 
with the dermal route of absorption. Uptake rates were calculated by assuming a pulmonary 
ventilation o f 10 liters/min and a relative respiratory uptake of 60% for inhalation exposure, 
and by extrapolation of in vitro human skin penetration rates to an area o f 50 cm (an area 
of about 4 x 2  in.) for dermal exposure.
Figure 5-1. Relative uptake rates of glycol ethers under different exposure routes. Source: 
Johanson [1988].
Examination o f Figure 5-1 shows that, based on uptake rates, absorption through the skin 
is a major route of absorption of EGME, EGEE, and EGEEA. The rate of absorption through 
this small 8-in. area of skin would be far greater than pulmonary absorption in an 
atmosphere containing 5 ppm of these glycol ethers.
Metabolism studies in animals (described in Section 4.2) demonstrated that EGEE and 
EGME are metabolized to their corresponding alkoxyacetic acids, EAA and MAA, which
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are excreted in the urine. These metabolites produced reproductive and hematologic toxicity 
in a variety of animal species. Thus measurement of these metabolites can be viewed as an 
indicator of potential health effects as well as an assessment o f total uptake through 
inhalation and dermal absorption.
Assessment of worker exposure to EGEE, EGME, and their acetates should include 
biological monitoring. Industrial hygiene measurements are used to assess the workroom 
concentrations, and the inhalation exposures may be measured with personal breathing zone 
samples. However, dermal absorption may be the principal route of exposure, and workload 
can dramatically affect the actual inhalation uptake of EGEE, EGME, and their acetates. 
Therefore biological monitoring should be considered an additional technique to assess the 
total exposure of the worker.
5.4.2 Selection of Monitoring Medium
A variety of biological monitoring media can be used to assess uptake (e.g., expired air, 
blood, urine). Groeseneken et al. [1986b, 1987a, 1989a] studied the respiratory elimination 
of EGEE, EGEEA, and EGME, and concluded that less than 0.5% o f the dose was 
eliminated by the lungs. Respiratory elimination half-lives were short and the expired air 
concentrations low. These glycol ethers were not found in the blood.
According to Johanson [1988], the concentrations of alkoxyacetic acids (EAA and MAA) 
in urine are the best indicators of exposure by all routes. The advantages of using urinary 
alkoxyacetic acids for biological monitoring of EGEE, EGME, and their acetates are:
• The acid metabolites EAA and MAA are not normally present in human urine.
• Expected concentrations for these metabolites at the proposed RELs can also be 
measured by the recommended analytical method (see Appendix F).
• The acid metabolites are associated with the reproductive and hematologic toxicity 
of EGEE, EGME, and their acetates, and may reflect the concentration of the 
“active agent” at the target sites.
• The half-lives of the acid metabolites in urine are suitable for exposure monitoring 
and can reflect integrated exposures over a workweek [Groeseneken et al. 1989a, 
1988]. The half-life for MAA is 77 hr and for EAA is 42 to 48 hr.
• Collection of urine samples is a noninvasive procedure.
5.4.3 Limitations of Biological Monitoring
Limitations and possible sources of error exist in the biological monitoring of the acid 
metabolites of these glycol ethers. Biological monitoring assesses uptake and not exposure 
concentration. In addition to the lack of well-designed field evaluations of workers exposed 
to EGME, EGEE, and their acetates, the following factors limit the use of biological 
monitoring to assess exposure [Johanson 1988]:
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• Variability in uptake through inhalation caused by workload-dependent uptake
* Variability in extent of skin exposure
* Intraindividual variations in excretion rates of the metabolites, possibly caused by 
fluid intake or the effects of alcohol consumption
• Inter-individual variations in excretion rates of the acid metabolites, possibly caused 
by differences in body fat, sex, personal habits (e.g., smoking, dietary factors, 
ethanol consumption), and coexposure to other chemicals
Johanson [1988] concluded that monitoring acid metabolites in the urine is appropriate even 
if the uptake or metabolism is influenced by other factors. The concentration o f the acid 
metabolite in the urine may not be linearly correlated to the absorbed dose, but it may be 
well correlated to the concentration at the target sites and thus related to the potential toxicity.
5.4.4 Correlation of Glycol Ethers' Uptake with Acid Metabolite Excretion
Urinary EAA excretion in subjects exposed to EGEE at rest and during physical exercise 
was described in Section 4.2 [Groeseneken et al. 1986c]. The relationship between total 
uptake of EGEE (pulmonary ventilation x concentration o f retained EGEE x exposure time) 
and urinary excretion o f EAA is shown in Figure 5-2.
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Figure 5-2. Relationship between uptake o f EGEE and EAA excretion. Correlation 
between time*weighted individual uptake of EGEE at rest (o, • )  and during physical exercise 
(A, A ), and urinary excretion of ethoxyacetic acid at maximal excretion (open symbols) and 
next morning (closed symbols). Source: Groeseneken et al. [1986c].
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Figure 5-2  shows the linear relationship between the uptake of EGEE during rest and 
physical exercise and the concentration of EAA, expressed as mg/g creatinine, in urine 
samples collected 4 hr after exposure and 18 hr after exposure (prior to the next shift). Good 
correlations between EAA excretion and EGEE uptake were found 4 hr postexposure 
(r=0.792, P<0.001), and 18 hr postexposure (r=0.848, P<0.001). A better correlation was 
shown 18 hr postexposure (corresponding to a preshift urine sample collected the next day), 
based on the observed correlation coefficients. Biological monitoring using the preshift 
specimen the next day may be preferred because of the long elimination half-time of EAA 
in the urine. In addition, as a result of its long biological half-life, EAA will not be cleared 
from the urine before the next shift and accumulation can be expected through repetitive 
exposures [Groeseneken et al. 1986c].
Groeseneken et al. [1986c] also showed the relationship between exposure, workload, 
uptake, and urinary EAA (expressed as mg/g creatinine) for urine samples collected at the 
end of the exposure period and 18 hr after the end of the exposure period (Table 5-4). The 
5.4-ppm exposure group at 0 W represents the combined data from both groups, n=10 
[Groeseneken et al. 1986c]. This table reveals the impact of physical exercise on the uptake 
of EGEE and the amount of EAA excreted in the urine. Note that volunteers exposed to
5.4 ppm EGEE at 30 W exercise excreted slightly more EAA in urine samples than subjects 
exposed to twice the concentration of EGEE while at rest.
Urinary EAA excretion in subjects exposed to EGEEA both at rest and during physical 
exercise was described in Section 4.2 [Groeseneken et al. 1987a], Figure 5-3  shows the 
linear relationship between uptake of EGEEA during rest and physical exercise, and the 
concentration of EAA, expressed as mg/g creatinine, in urine samples collected 4 hr and 
18 hr postexposure. Good correlations were found between EAA excretion and EGEEA 
uptake 4 hr after exposure (r=0.82, P<0.001) and 18 hr postexposure (r=0.77, P<0.001). 
Similar correlations were seen with EGEE [Groeseneken et al. 1986c]. Although the 
correlation is slightly lower for urine specimens collected 18 hr after exposure, collection 
at this time may be preferred for biological monitoring because of the long EAA elimination 
half-life. As with EGEE, EAA would be expected to accumulate with repeated daily exposures.
Table 5 -4 .—Relationship between exposure to EGEE, workload, 
uptake, and EAA in urine
EGEE EGEE EAA (mg/g creatinine)
exposure Workload uptake End of 18 hr
(PPm) (W) (mg) exposure postexposure
2.7 0 16.7 ± 4.2 1.72 ± 0.58 1.12 ±0.34
5.4 0 35.1 ±7.6 3.85 ± 1.73 2.61 ± 0.50
10.8 0 64.1 ± 14.5 5.23 ± 1.67 4.54 ± 1.36
5.4 0 33.3 ± 8.3 3.85 ± 1.73 2.61 ± 0.50
5.4 30 57.0 ± 11.8 7.42 ± 2.84 6.26 ± 1.92
5.4 60 94.4 ± 13.9 10.49 ±4.18 8.64 ± 3.05
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EGEEA uptake (mg)
Figure 5-3. Relationship between EGEEA uptake and urinary excretion of EAA. Source: 
Groeseneken et al. [1987b],
Groeseneken et al. [1987b] also showed the relationship between exposure, workload, 
uptake, and urinary EAA (expressed as mg/g creatinine) for urine samples collected at the 
end of exposure and 18 hr after exposure (Table 5-5). The 5.2-ppm exposure group at 0 W 
represents the combined data from both groups, n=10.
The data in Table 5-5  show the influence of exercise on EGEEA uptake and EAA excretion 
in the urine. Note that subjects exposed to 5.2 ppm EGEEA at a 30-W workload produce 
about the same amount of EAA as subjects exposed to almost twice the concentration 
(9.3 ppm) at rest.
Table 5 -5 .—Relationship between exposure to EGEEA, -workload, uptake,
and EAA in urine
EGEEA EGEEA EAA (mg/g creatinine)
exposure Workload uptake End of 18 hr
(ppm) (W) (mg) exposure postexposure
2.6 0 23.3 ±2.1 2.35 ± 0.50 1.81 ± 0.60
5.2 0 44.9 ± 1.3 3.20 ± 0.35 2.12 ±0.20
9.3 0 85.1 ±5.5 5.87 ± 0.57 4.15 ±0.52
5.2 0 37.1 ±2.4 3.20 ±0.35 2.12 ±0.20
5.2 30 84.4 ± 2.5 6.04 ± 1.45 5.32 ± 0.62
5.2 60 121.5 ±5.4 9.82 ± 2.23 7.78 ± 1.21
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In spite of the differences in respiratory uptake and elimination between EGEE [Groeseneken 
et al. 1986b] and EGEEA [Groeseneken et al. 1987a], the same relationships existed 
between EAA excretion and time-weighted uptake of EGEE or EGEEA (expressed as 
EGEE equivalents, abbreviated as EGEEeq below) [Groeseneken et al. 1987b]. These 
relationships for urine samples collected 4 hr after the cessation of exposure were 
expressed by the following equations:
EAA (mg/g creatinine) * -0.75 + 0.152 mg EGEE uptake
[Groeseneken et al. 1986c] (1)
EAA (mg/g creatinine) = 0.29 + 0.140 mg EGEEeq
[Groeseneken et al. 1987b] (2)
EAA (mg/g creatinine) -  0.29 + 0.095 mg EGEEA
[Groeseneken et al. 1987b] (3)
Equation 3 was taken from Figure 5-3 and demonstrates the relationship between EAA 
excretion and EGEEA uptake, expressed as EGEEA. The similarity of the slopes and 
intercepts for equations 1 and 2, which are expressed in equivalent units, supports the 
authors’ conclusions that EAA can be used as an index of exposure to both EGEE and 
EGEEA, and that the same relationship exists when EGEEA uptake is calculated as EGEE 
equivalents. The authors suggested that these relationships are probably valid only for single 
exposures to EGEE and EGEEA because of the long elimination half-lives for EAA and the 
likelihood of accumulation of EAA during repeated exposures.
MAA was found in the urine of male volunteers exposed at rest to 5 ppm EGME [Groeseneken 
et al. 1989a]. This study was described in Appendix B, Section B.4.1, and is discussed in 
Section 5.4.5.2.
5.4.5 Assessment of Biological Monitoring Results in Various Studies
5.4.5.1 EGEE and EGEEA
Urinary EAA excretion was examined in female silk-screen printing operators exposed to 
a mixture of EGEE and EGEEA [Veulemans et al. 1987a]. Veulemans et al. [1987a] stated 
that the half-life o f elimination of EAA was longer (42 hr) than previously determined (21 
to 24 hr) by Groeseneken et al, [1986c, 1987b]. In a subsequent publication, Groeseneken 
et al. [1988] reported that the half-life in this occupational exposure study was up to 48 hr, 
which is in agreement with the average 42-hr half-life recalculated by Groeseneken et al. 
[1988]. Veulemans et al. [1987a] concluded that the increasing EAA concentrations seen 
during the workweek were caused by accumulation of EAA. The higher preshift EAA 
concentrations seen in the majority of week-1 specimens may have been due to the slow  
release of EAA from a fat compartment caused by buildup from exposure in previous weeks. 
The lack o f such a pattern in the second observation period, after 12 days with no exposure, 
supports this hypothesis.
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Few details are included about the level of work activity by the females working in the silk  
screen operation [Veulemans et al. 1987a]. Based on the assumption that silk screening 
operations involve standing and moderate work with both hands, this activity can be 
classified as light to moderate work and is approximately equivalent to the expenditure o f 
4 kilocalories (kcal)/min [ACGIH 1988]. Groeseneken et al. [1986b, 1987a] reported that 
males exercising at 30 W had an average oxygen uptake of 0.6 liter/min, while those 
exercising at 60 W had an average of 0.82 liter/min, approximately equivalent to 3 and 
4 kcal/min, respectively [McArdle et al. 1981]. Therefore, one can assume that the women 
working on the silk screening process were working at the equivalent of 60 W.
The experimental studies in males exposed to EGEE [Groeseneken et al. 1986c] or 
EGEEA [Groeseneken et al. 1987b] demonstrated end-of-exposure concentrations of EAA 
that were much lower than those seen in the occupational study with women [Veulemans et 
al. 1987a]. For example, the mean concentration o f EAA was 10.5 mg/g creatinine in 
urine specimens from male subjects exposed once to 5.2 ppm (20 mg/m3) for 4 hr at 60 W of 
exercise [Groeseneken et al. 1986c]. Silk screen operators exposed to 3.9 ppm ( 14.4 mg/m3) 
for 5 workdays showed an average end-of-w eek urine EAA concentration of 105.7 mg/g 
creatinine. In order to reconcile the apparent discrepancies between the experimental data 
developed for males and the workplace data for females, the following assumptions were 
made:
• Women working in the silk screen process were exposed to EGEE and EGEEA 
levels, as EGEE equivalents, of 14.4 mg/m3 (3.9 ppm), and exerted the equivalent 
of 60 W of energy.
• The only EAA data that were comparable with experimental exposure data were 
EAA concentrations in urine samples collected after the 12-day break. The 42 to 
48 hr half-life of EAA elimination resulted in significant EAA accumulation 
during the week and possibly from week to week Preshift urine samples on the 
first day following the 12-day break were the lowest observed during the entire 
study (1.2 to 2.6 mg/g creatinine). Data from these days thus were suitable for 
comparison to the experimental exposure data for males.
• The metabolism of EGEE and EGEEA was linear at occupationally relevant 
exposures. Groeseneken et al. [ 1988] demonstrated linear kinetics with EGEE at 
exposures expected in the workplace.
• The EAA elimination half-lives of females were similar to those of males. 
Groeseneken et al. [1988] stated that the EAA elimination half-life for males was 
42 hr, and that the estimate of EAA half-life for females in the silk screening 
operation was about 48 hr.
• Skin absorption by the female employees was not significantly different from skin 
absorption by the male subjects exposed under experimental conditions.
Using these assumptions, one can extrapolate the expected EAA concentration in urine from 
experimental exposure data for males exposed to 5.4 ppm (20 mg/m3) EGEE for 4 hr at
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60 W of exercise, to exposure for 8 hr by using the principle o f superposition [Gibaldi and 
Perrier 1982]. This principle assumes that the kinetics of E AA excretion do not change with 
EAA concentration. Using this extrapolation technique, the estimated EAA urinary con­
centration following an 8-hr exposure is equal to the urinary concentration 4 hr after the end 
of a 4-hr exposure, plus the urinary concentration at the end of the second 4-hr exposure. 
Actual data from Groeseneken et al. [1986c] are 14.38 and 10.49 mg EAA/g creatinine, 
respectively, for a total of 24.87 mg EAA/g creatinine.
A pharmacokinetic approach can be used to extrapolate the 4-hr exposure data to a full-shift 
exposure. If simple first-order EAA kinetics are assumed following a 4-hr EGEE exposure, 
the estimated EAA urinary half-life can be used to project urinary EAA concentrations at 
time points later than the peak urinary EAA concentration (which occurred 8 hr after the 
start of a 4-hr exposure period). Estimated EAA urine concentrations (see Table 5 -6) were 
determined by using a 42-hr half-life [Groeseneken et al. 1988] to extrapolate the urinary 
EAA concentration following a 4-hr EGEE exposure, and then applying the principle of 
superposition [Gibaldi and Perrier 1982] to combine two extrapolated 4-hr exposures into 
one extrapolated 8-hr exposure. (An 8-hr workday beginning at 8:00 a.m. and ending at 
4:00 p.m. was assumed.) Under these conditions, the projected maximal EAA urinary 
concentration would occur at approximately 8:00 p.m., reaching 27.84 mg/g creatinine. The 
estimated urinary EAA concentration 16 hr after an 8-hr work exposure is 22.84 mg/g creatinine.
Data from the occupational study by Veulemans et al. [1987a] were for the first Thursday. 
The average EAA concentration was 22 mg/g creatinine (range of 10 to 39.5) and the average
*
Table 5 -6 .—Estimated EAA urine concentrations from 8-hr EGEE exposures
EAA concentration (mg/g creatinine)
Total EAA*
Elapsed First 4-hr Second 4-hr from 8-hr
Time hours exposure exposure exposure
8 a.m. 0 0 0.00
10 a.m. 2 5.25 5.25
Noon 4 10.49 0.00 10.49
2 p.m. 6 12.44 5.25 17.68
4 p.m. 8 14.38 10.49 24.87
6 p.m. 10 13.91 12.44 26.35
8 p.m. 12 13.46 14.38 27.84
10 p.m. 14 13.02 13.91 26.94
Midnight 16 12.60 13.46 26.06
2 a.m. 18 12.19 13.02 25.22
4 a.m. 20 11.80 12.60 24.40
6 a.m. 22 11.41 12.19 23.61
8 a.m. 24 11.04 11.80 22.84
Source: Groeseneken et al. [1986c],
*10- to 24-hr EAA concentrations were estimated using 42 hr as the EAA half-life.
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3 3exposure concentration (expressed as EGEE) was 14.1 mg/m (range o f 11 to 18.9 mg/m ).
The estimated value of 22.84 mg EAA/g creatinine is consistent with the workplace 
measurements of Veulemans et al. [1987a]. Furthermore, this estimate suggests that the 
urinary EAA concentration would be expected to drop very little from the end o f 1 8-hr 
workday to the start of the next (i.e., from 24.87 to 22.84 mg/g creatinine, under the test 
conditions), and that EAA would be expected to accumulate from day to day. This is also 
consistent with the observation of Veulemans et al. [1987a] that urinary EAA levels in 
occupationally exposed workers tended to rise throughout the workweek. Although there 
is some general similarity between EAA concentrations found in the urine of workers 
exposed to EGEE [Veulemans et al. 1987a] and EAA concentrations extrapolated from 
single 4-hr experimental exposures, one should not infer that these results are in agreement. 
Extrapolations of experimental data are based on assumptions that have not been experimen­
tally verified. Data for EAA concentrations in preshift urine samples collected on the 
following day (Friday morning) were approximately 42 mg/g creatinine (range o f 13 to 66), 
compared with the extrapolated concentration of approximately 23 mg/g creatine from the 
same experimental studies.
Veulemans [ 1989] presents the following explanation for the lack of agreement between the 
field study data and experimental data. The high urinary concentrations in the field study 
compared with the experiments can largely be explained by the combination of repeated 
exposures and the long biological half-life of excretion. A rough approximation by a single 
compartment model with a half-life of 42 hr already gives an agreement within 70% of the 
observed results. To explain all the observed facts (e.g., delayed excretion maxima, 
circadian variations) a more complex model is needed. The design and testing of such a 
model, however, requires data on the plasma concentrations o f the metabolite and its parent 
compound. At the time of the experiments the available analytical methods were not 
sensitive enough to measure the plasma concentrations at low exposure concentrations.
The following exposure assessments at two worksites were conducted by NIOSH during 
two health hazard evaluations.
1. A study of worker exposure to EGEE was conducted at a plant where precision cast metal 
parts were produced using the “lost-wax” process [Ratcliffe et al. 1986; Clapp et al. 1987].
2. A study was conducted of the potential exposure to EGEE and EGME for workers 
associated with various types of painting operations in a shipyard. This study included a 
health hazard evaluation [McManus et al. 1989] and a separate research study [Sparer et 
al. 1988; Welch et al. 1988]. Preliminaiy biological monitoring results wete published 
separately [Lowry 1987].
NIOSH conducted a health hazard evaluation (described in Section 4.1) to determine 
possible adverse reproductive effects in male workers potentially exposed to EGEE in the 
preparation of ceramic shells used to cast metal parts (“lost-wax” process) [Ratcliffe et al. 
1986]. The binder slurry included 50% EGEE and 50% ethanol. About 80 workers were 
employed in the investing departments at each o f the two sites where these ceramic shells 
were prepared. The potentially exposed male workers included those engaged in the preparation
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of binder slurry, hand dippers and grabbers who dipped molds into the slurry, shell 
processors who prepared and handled ceramic shells, supervisors, and process engineers. 
Although gloves were worn by some workers, no other chemical protective clothing or 
respirators were used. Air samples, most of which were breathing zone, were collected. 
Because the potential for skin exposure existed, spot urine samples were taken at intervals 
and analyzed for EAA [Smallwood et al. 1984]. Surveys were conducted in April 1984 and 
June 1984 [Clapp et al. 1987].
In the April survey, general area air samples revealed higher concentrations o f EGEE (10 
to 17 ppm) in the investment rooms, which contained open tanks of slurry, compared with 
the mixing and storage rooms (5 to 7 ppm). Full-shift personal breathing zone exposures 
of EGEE ranged from 3 to 14.5 ppm for workers in the investing areas. Ratcliffe et al. [1986] 
reported that recoveries o f EGEE in three quality control samples were as low as 69% 
indicating that the measured airborne concentrations could have been underestimated.
Urine samples were collected as voided during a 24-hr period from three EGEE-exposed 
workers and two controls (unexposed workers). Table 5-7  presents personal breathing zone 
EGEE data and urinary EAA concentrations. Environmental data represent the mean value 
for all workers in the specific job classification; urinary EAA data present the average and 
range found in each subject [Ratcliffe et al. 1986; Clapp et al. 1987]. No EAA was detected 
in the urine of the two control subjects.
In the June survey, area samples averaged 2.4 to 14.9 ppm. Personal breathing zone 
samples averaged 8.1 ppm for grabber operators, 4.5 ppm for shell processors, and 5.0 ppm 
for investment room supervisors. In this case, spot urine samples were collected at random 
over a 7-day period. Table 5-8  summarizes the findings. EGEE values represent the 
geometric mean values for a job classification, while the urinary EAA results represent the 
average of all urine specimens collected during the 7-day period for one worker [Ratcliffe 
et al. 1986; Clapp et al. 1987],
This study [Ratcliffe et al. 1986; Clapp et al. 1987] is not well-designed for biological 
monitoring because it provides no appropriate match of environmental samples with urine 
samples and no information on the time of urine collection in relationship to exposure. In 
addition, it includes no documentation concerning the extent of skin exposure or the 
assessment of work practices. The potentially low recovery of EGEE from personal 
samples,
Table 5 -7 .—Comparison of EGEE exposure concentrations and urinary EAA
Job
classification
EGEE 
(ppm, geometric mean) Mean
EAA 
(mg/g creatinine)
Range over 24 hr
Hand dipper A 14.5 40.8 26-66
Hand dipper B 14.5 30.2 21-40
Investment supervisor 6.0 28.0 18-35
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Table 5-8.—Comparison of worker exposure to EGEE and urinary EAA
Job classification 
and worker ID
EGEE  
(ppm, geometrìe mean) Mean
EAA 
(mg/g creatinine)
Range over 7  days
Grabber operator 1 8.1 88 59-108
Grabber operator 2 8.1 95 52-163
Grabber operator 8.1 58 52-121
Shell processor 1 4.5 79
Shell processor 2 4.5 83 78-87
Shall processor 3 4.5 60
Investment supervisor 5.0 25 16-40
identified through a quality control problem with “spiked” EGEE samples, placed the environ­
mental data in question. Nevertheless, this study does indicate that EAA in urine reflects exposure 
to EGEE in the workplace at full-shift exposure concentrations in the range of 4 to 14.5 ppm.
Studies were recently conducted to determine the effects of combined EGME and EGEE 
exposure on the reproductive potential of 600 men who worked in a large shipbuilding facility 
[Sparer et al. 1988; Welch et al. 1988]. NIOSH also conducted a health hazard evaluation of 36 
male painters at the same site using environmental and biological monitoring to assess their 
potential exposure to EGEE and EGME [McManus et al. 1989; Lowry 1987].
Work conditions and practices described in the health hazard evaluation varied consider­
ably among painters. Some painters worked in confined spaces below deck, while others 
worked in the open. The study was conducted in the winter, and the temperatures varied 
depending on the painters’ work areas. Information on work practices, such as the number 
of hours spent painting, the type of paint used, the work area locations, the use of respirators, 
and the potential for skin contact, was gathered from questionnaires. Personal environmen­
tal breathing zone samples were collected for each worker for 3 days and expressed as 8-hr 
TWAs. Table 5 -9  provides a summary of the environmental exposure data. Urine samples 
were collected for 1 week at the beginning and end of each workday [McManus et al. 1989; 
Lowry 1987]. EAA concentrations were determined using the method devised by Smallwood 
et al. [1988], Approximately six urine specimens were collected from each worker. Table 5-10  
presents the highest concentration of EAA recovered. MAA was detected in only one specimen.
Table 5 -9 .—Summary of environmental data
Type of EGEE EGME
data (ppm) (ppm)
Mean 2 .6 ± 4.2 0.8 ± 1.0
Median 1.2 0.44
Range 0-21.5 0-5.6
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Table 5-10.—Summary of urinary EAA data
Worker Number of Maximum EAA
group workers (mg/g creatinine)
Controls, shipyard workers 20 Not detected
Painters not using EGEE 5 6 .6 1 3 .9 1
Painters using EGEE 27 25.0 ± 20.7
A wide range of EAA concentrations was noted in workers using EGEE-containing paints; 
this was probably caused by variation in work assignments, work areas, work practices, and 
in the use of personal protective equipment. The author concluded that there appeared to 
be a relationship between urinary EAA excretion and the use of paints containing EGEE 
[Lowry 1987].
The health hazard evaluation demonstrated that the potential existed for exposure of 
painters to EGEE and EGME. Because of the complexity of the work environment and the 
variable use of personal protective equipment, no dose-response relationship could be 
developed. However, at the exposure concentrations measured, painters who used paints with 
EGEE did excrete more EAA in the urine than painters who did not use EGEE-containing 
paints.
Sparer et al. [1988] and Welch et al. [1988] examined some of the same workers from the 
health hazard evaluation. (These studies are discussed in detail in Section 4.1.) The authors 
concluded that exposure to EGEE and EGME lowered sperm counts in the painters. In 
addition, they concluded that when smoking was controlled the painters had an increased 
odds ratio for a lower sperm count per ejaculate [Welch et al. 1988],
However, it would be inappropriate to conclude that the EGEE and EGME exposure 
concentrations presented in the health hazard evaluation [McManus et al. 1989] were 
representative of the chronic exposure of shipyard workers who participated in the semen 
study [Welch et al. 1988]. In addition, it cannot be concluded that marginally (but not 
statistically significant) lowered sperm counts were caused by exposure concentrations 
measured in the health hazard evaluation [McManus et al. 1989].
5.4.5.2 EGME
No studies have evaluated the relationship between EGME exposure in the workplace and 
urinary MAA concentration. Results of the study by Groeseneken et al. [1989a] have 
provided the following information regarding MAA excretion in urine.
• The relatively long urinary elimination half-life of MAA (77 hr) suggests that MAA 
would be expected to accumulate during the workweek. If biological monitoring 
were done, urine specimens collected at the end of the week, or possibly prior to 
the first shift of the week, would be appropriate.
87
EGME, EGEE, and Their Acetates
• Sixty percent of the urine specimens from this study contained MAA at concentra­
tions below 2 mg/liter. If 4-hr exposures are extrapolated to 8~hr exposures, based 
on linear kinetics, then subjects exposed to 5.1 ppm at rest would be expected to 
have 60% of their urine samples with MAA concentrations below 4 mg/liter. If 
exposures were 1/10 of those from this study (i.e., 0.5 ppm) then 6096 of the urine 
specimens would be expected to have less than 0.4 mg/liter of MAA [Groeseneken 
et al. 1989a], The limit of quantitation for MAA was reported to be 0,1 mg/liter 
[Groeseneken et al. 1989b]. Higher concentrations of MAA would be expected 
with exercise.
Although dermal absorption was not studied, dermal uptake of EGME is a potential route 
of exposure. Dugard et al. [1984] demonstrated in vitro absorption of EGME through human 
abdominal skin. Nakaaki et al. [1980] also demonstrated dermal penetration of EGME 
through the forearm of human volunteers. Johanson [1988] suggested that dermal uptake 
of EGME is possibly the major route of exposure.
Thus, in spite of the lack of quantitative relationships between EGME exposure and MAA 
excretion in urine, measurement of MAA in urine is warranted. The potential for extensive 
skin absorption, and the potential buildup of the active urinary metabolite MAA during the 
workweek, are reasons to measure MAA in urine as an exposure index. In addition, 
measurement of MAA in urine may be useful as an indicator of the potential for adverse 
reproductive effects.
5.4.6 Methods for Analyzing Urinary EAA and MAA
A variety of methods have been developed for the analysis of EAA and MAA in human 
urine. Gas chromatographic procedures are based on either fluoranhydride derivatization 
following the extraction of the acid tetrabutylammonium ion-pair [Smallwood et al. 1984, 
1988] or diazomethane derivatization following lyophilization of the urine [Groeseneken et 
al. 1986a]. Groeseneken etal. [1989b] developed a method that combined the best attributes 
of the two basic existing models. Detailed descriptions of the above methods are presented 
in Appendix H.
5.4.7 Summary
EGEE, EGME, and their acetates are metabolized to their respective alkoxyacetic acid 
metabolites, EAA and MAA, which are excreted in the urine. EAA and MAA have produced 
reproductive and hematotoxic effects noted for glycol ethers. These glycol ethers can also 
be absorbed through the skin. In fact, the major route of exposure to EGME and EGEE may 
be through the skin [Johanson 1988]. Thus, monitoring of these acids may serve not only 
as a measure of exposure or uptake, but also as a measure of potential adverse health effects.
The alkoxyacetic acid metabolites may be analyzed by a variety of sensitive and specific 
methods. The recently developed method of Groeseneken et al. [1989b] has sufficient 
sensitivity to monitor excretion of these metabolites at the recommended RELs.
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Results from human laboratory inhalation exposure studies indicated that EAA in urine 
could be used to monitor uptake of EGEE and EGEEA [Groeseneken et al. 1986c, 1987b]. 
The total amount of urinary EAA was related to EGEE and EGEEA uptake, and was 
influenced by pulmonary ventilation and the concentration of EGEE and EGEEA in 
inspired air. EAA excretion in urine peaked about 4 hr after cessation of exposure and was 
eliminated in the urine with a half-life of 42 hr [Groeseneken et al. 1988].
Investigations of occupational exposure also revealed a correlation between urinary EAA 
excretion and repeated daily inhalation exposure of workers to a mixture of EGEE and 
EGEEA [Veulemans et al. 1987a]. Data showed the accumulation of EAA following repeated 
daily exposures to EGEE and EGEEA. The estimated elimination half-life of EAA was 48 hr.
Two other worksite investigations of occupational exposure to EGEE demonstrated the 
utility of EAA in urine to assess uptake of EGEE regardless of the route of exposure [Ratcliffe 
et al. 1986; Clapp et al. 1987; Lowry 1987; McManus et al. 1989; Sparer et al. 1988; Welch et 
al. 1988].
Experimental studies were conducted in which humans were exposed to EGME. Results of 
these studies indicated that measurement of urinary MAA could be used to assess uptake of 
EGME. The concentration of MAA peaked several hr after exposure ended, and MAA was 
eliminated with a half-life of 77 hr. Examination of the elimination kinetics showed that 
MAA would accumulate following repeated daily exposures, and could also accumulate 
over extended exposure periods.
Insufficient information is available at present to construct a dose-response plot that would 
provide statistically sound guidelines for the concentration of alkoxyacetic acid metabolites 
in urine that would correspond to an airborne exposure to glycol ethers. Table 5-11 presents 
a summary of the laboratory and occupational dose-response data.
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Table 5-11.—Summary of EGEE, EGEEA, and EGME exposure studies
Glycol
ether
Type
of
exposure
No. of 
subjects 
and sex
Concen­
tration
(ppm)
Workload
(W)
Time
(hr)
Total 
glycol ether 
uptake 
(mg)
Total 
metabolite 
excretion 
(m g/g creatinine) Reference
EGEE Face mask 10 males 2.7 0 4 16.7 ± 4.2 1.12 ±0.34* Groeseneken
inhalation 5.4 0 4 3 5 .l t  7.6 2.61 ±0.50 et al. 1986c
10.8 0 4 64.1 + 14.5 4.54 ±1.36
5.4 0 4 33.3 ± 8.3 2.61 ±0.50
5.4 30 4 57.0 ±11.8 6.26±1.92
5.4 60 4 94.4 ±13.9 8.64 ±3.05
EGEEA Face mask 10 males 2.6 0 4 23.3 ± 2.1 1.81±0.60+ Groeseneken
inhalation 5.2 0 4 44.9 ± 1.3 2.12 ±0.20 et al. 1987b
9.3 0 4 85.1 ± 5.5 4.15 ±0.52
5.2 0 4 37.1 ± 2.4 2.12 ±0.20
5.2 30 4 84.4 ± 2.5 5.32 ±0.62
5.2 60 4 121.5 ± 5.4 7.78 ±1.21
EG EE / Occupational 5 females 3.9 60 8* — 42 Veulemans
EGEEA 3.9 60 1 week® — 106 et al. 1987a
EGM E“ Face mask 7 males 5.1 0 4 19.4 ± 2.1 --- Groeseneken
inhalation et al. 1989a
Urine EAA data are from 18 hr postexposure (before next shift).
*Urine EAA data are from 18 hr postexposure (before next shift).
*Data represent 8-hr exposure to EG EB and EGEEA by female silk screen workers on the first day following 12 days without exposure. Workloads 
were estimated. Urine EAA data were estimated from samples collected before the shift on the second day of exposure following 12 days without 
exposure.
^Data represent 1-week exposure to EGEE and EG EEA after regular weekly exposure in previous weeks. Urine EAA data were stated by the author 
as the average end-of-the-week concentrations.
Urine MAA (2.4 /xg/min) was estimated from the plot in the cited reference and represents a urine sample collected 18 hr after the end of exposure.
6 OTHER STANDARDS AND RECOMMENDATIONS
In 1971, OSHA adopted the current Federal standards for worker exposure to EGME, 
EGMEA, EGEE, and EGEEA, which are based on the American Conference of Governmen­
tal Industrial Hygienists (ACGEH) 1968 Threshold Limit Values (TLVs®). These TLVs® 
were based on the hematotoxic and neurotoxic effects and exposure concentrations reported 
in the early case reports of human health effects [Donley 1936; Parsons and Parsons 1938; 
Greenburg et al. 1938]. The OSHA PELs include a “skin’’ notation, indicating the potential 
for skin absorption of toxic amounts of these glycol ethers.
The OSHA PELs for occupational exposure to the glycol ethers are as follows: 25 ppm 
(80 mg/m3) for EGME, 25 ppm for EGMEA (120 mg/m3), 200 ppm (740 mg/m3) for EGEE, 
100 ppm (540 mg/m3) for EGEEA, as TWAs for an 8 -hr workshift [29 CFR 1910.1000]. 
OSHA is considering a revision of these PELs.
NIOSH has previously recommended that EGME and EGEE be regarded in the workplace 
as having the potential to cause adverse reproductive effects in male and female workers 
and embryotoxic effects, including teratogenesis, in the offspring of the exposed pregnant 
female, and that occupational exposure to them should be reduced to the lowest extent 
possible [NIOSH 1983a]. These recommendations were based on the results of animal 
studies that demonstrated dose-related embryotoxicity and other reproductive effects in 
several species of animals exposed by different routes of administration [Stenger et al. 1971; 
Nagano etal. 1979; Nagano etal. 1981; Andrew etal. 1981; Miller etal. 1981,1983a; Nelson 
et al. 1981,1984b; Hardin et al. 1982; McGregor et al. 1983; Rao et al. 1983; Hanley et al. 
1984a].
In 1946, ACGIH established maximum allowable concentrations (m.a.c.s) of 100 ppm for 
EGME, EGMEA, and EGEEA, and 200 ppm for EGEE [ACGIH 1984], In 1947, the m.a.c.s 
for EGME and EGMEA were lowered to 25 ppm because of the Greenburg et al. [1938] 
study in which neurologic and hematologic changes were observed in men exposed to 
EGME at concentrations estimated to be as low as 25 ppm. The m.a.c. for EGMEA was 
lowered because the toxic effects caused by it were likely to be similar to those caused by 
EGME as a result of EGMEA’s metabolism to EGME and then to the active metabolite 
[ACGIH 1962,1984]. Although the values remained unchanged, the term “threshold limit 
value” was substituted for m.a.c. in 1948.
In 1968, the notation “skin” (indicating the potential for skin absorption of toxic amounts 
of a compound) was added to the TLVs® for EGME, EGEE, EGMEA, and EGEEA. In 
1971, ACGIH lowered the TLV® for EGEE from 200 to 100 ppm to prevent irritation of 
the nose and eyes [ACGIH 1980]. In 1981, the ACGIH adopted TLVs® of 50 ppm for
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EGEE and EGEEA, each with a short-term exposure limit (STEL) of 100 ppm; in 1987-88, 
the STELs were deleted [ACGIH 1991]. The TLVs® were lowered because of adverse 
hematologic effects observed in laboratory animals [Carpenter et al. 1956]. Changes in rat 
erythrocyte fragility were produced by 125 ppm EGEE but not by 62 ppm. ACGIH deemed 
it prudent to maintain chemical exposures below levels found to cause blood changes in 
experimental animals. Because the TLV® of 100 ppm for EGEEA was based on analogy 
with EGEE, it was logical to establish a similar TLV® of 50 ppm for its acetate [ACGIH
1980].
Reports of adverse testicular effects in experimental animals treated with EGME, EGEE, 
and their acetatesJNagano et al. 1979] led ACGIH to lower the TLVs® for these compounds. 
The 5-ppm TLV for EGME, EGMEA, EGEE, and EGEEA as an 8-hr TWA was adopted 
in 1984, and the “skin” notation was retained.
Table 6 -1 presents a compilation of occupational exposure limits of various countries for 
these glycol ethers.
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Table 6-1.—Occupational exposure lim its for EGME, EGEE, and their acetates in various countries**
EGME EGMEA EGEE EGEEA
Country
Type
of standard ppm m g/m 3 ppm m g/m 3 ppm m g/m 3 ppm m g/m 3
USA
OSHA PEL TWA 25* 80 25* 120 200* 740 100* 540
[skin]
ACGIH TLV*-TWA 5 16 5 24 5 19 5 27
Belgium
[skin]
25 80 __ 50 185 25 135
GRF (Germany) mak [skin] 5 15 5 25 20 75 20 110
Denmark 25 80 25 120 100 370 50 270
Finland 25 80 25 120
50*
100
185*
370
50
25
270
135
Holland mac
5
5*
16
15*
5 24 5
5*
19
19*
5 27
Italy — — -- -- — -- — —
Japan 25 80 25 120 100 370 — —
Norway [skin] 25 80 -- — 50 185 — --
Sweden^ LLV [skin] 5 16 5 25 5 19 5 30
STV [skin] 10 30 10 50 10 40 10 50
Switzerland mak [skin] 5* 15* — — 20* 75* 100 540
United kingdom TW A [skin] 25 (5* ) 80(15*) 120(25 ) 100(10 ) 370(37*’) 10* 55*
STEL [skin] 35(15 ) 120(45 ) 35(15 ) 170(75 ) 150(30 ) 560(115 ') 30* 175*
’Data from ECETOC [1985].
^Abbreviations: PEL = Permissible exposure limit; STEL = Short term exposure limit; LLV = Level limit value;
STV = Short term value; TW A = Time weighted average; mak, mac = Maximum allowable concentration. 
*Value is subject to be changed.
JN B O S H  [1989],
Intended change.
7 ASSESSMENT OF EFFECTS
The principal health effects documented in humans exposed to EGEE, EGME, and their 
acetates involve the blood, central nervous and hematopoietic systems, liver, and kidneys. 
These effects include headache, drowsiness, dizziness, forgetfulness, personality change, 
loss of appetite, tremors, hearing loss, slurred speech, hematuria, hemoglobinuria, anemia, 
and leukopenia.
Only limited direct evidence indicates that exposure to EGEE, EGME, or their acetates 
causes adverse reproductive effects in humans. However, experimental studies in animals 
provide strong evidence of adverse reproductive and developmental effects related to these 
exposures. Summaries of the developmental and reproductive toxicity of EGEE, EGEEA, 
and EGME are presented in Tables 7-1 through 7-3. Because humans and the animal 
species studied metabolize these glycol ethers in the same way, the animal data are 
considered to be highly predictive of the hazard for humans.
7.1 CORRELATION OF EXPOSURE AND EFFECTS
7.1.1 EGEE
7.1.1.1 Studies in Humans
No epidemiologic studies describe the effects of EGEE in humans, and only one case report 
exists. A 44-year-old woman who mistakenly drank 40 ml of EGEE (Section 4.1.1) 
experienced chest pains and vertigo, and lost consciousness shortly after the ingestion [Fucik 
1969]. Upon hospitalization, the following signs and symptoms were observed: restless­
ness, cyanosis, tachycardia, swelling of the lungs, tonoclonic spasms, and breath smelling 
of acetone. The urine tested positive for protein, acetone, and RBCs; the liver became 
enlarged and jaundice developed. After 44 days, the woman’s condition improved, but 
insomnia, fatigue, and paresthesia of the extremities persisted for 1 year.
Several cases of anemia were reported in shipyard workers exposed to EGEE and EGME, 
and all cases were suspected to have been caused by the exposure [Welch and Cullen 1988]. 
A detailed description of this study is provided in Chapter 4.
Few data are available on the reproductive effects of EGEE in humans. Ratcliffe et al. [1986] 
concluded that EGEE may have affected the semen quality by lowering the sperm counts 
of male workers exposed to this chemical during the preparation of ceramic shells for casting
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Table 7-1.—Reproductive and developmental toxicity of EGEE
Study Sex Route of Male Maternal Developmental
type and and administration -----------------------------  ---------------------------- -----------------------------
reference species and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Reproductive, 
Nagano et al. 
[1979]
Male Oral;
mice 500, 1,000, 2,000,
or 4,000 m g/kg  
per day,
5 days/wk for 
5 wk
1,000 
m g/kg  
per day
500
m g/kg  
per day
Testicular atrophy
Reproductive, 
Foster et al. 
[1983]
Reproductive, 
Oudiz et al. 
11984]
Male
rats
Reproductive, Male 
Creasy and rats 
Foster [1984]
Male
rats
Oral;
250, 500, or
1.000 m g/kg  
per day for 
11 days
Oral;
250, 500, or
1.000 m g/kg  
per day for 
11 days
Oral;
936, 1,872, or 
2,808 m g/kg  
per day for 
5 days
500 250
mg/kg m g/kg  
per day per day
500
m g/kg  
per day
936 
m g/kg  
per day
250
m g/kg  
per day
Decreased testis weight 
and spermatocyte 
depletion and 
degeneration
Microscopic testicular 
lesions
Decreased sperm count, 
increased abnormal 
sperm forms, and 
decreased epididymal 
weights
(Continued)
VOUt Abbreviations: g.d. = gestation day; LOAEL = lowest observable adverse effect level; NOAEL = no observable adverse effect level.
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VOo\ Table 7-1 (Continued).—Reproductive and developmental toxicity of EGEE
Study Sex Route of Male Maternal Developmental
type and and administration -----------------------------  ----------------------------  -----------------------------
reference species and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Reproductive; Male Inhalation; 400 ppm —  —  —  —  —  Decreased testis weight
Barbee et al. rabbits 25, 100, or and microscopic
[1984], Terrill 400 ppm, testicular lesions
and Daly 6 hr/day,
[1983a,b] 5 days/wk
for 13 wk
Male Inhalation; ----- ----- ----- ----- ----  ----  No biologically
rats 25, 100, or significant effects
400 ppm,
6 hr/day,
5 days/wk 
for 13 wk
Developmental Female Oral; —  —  —  —  93 mg/kg 46.5 m g/kg Skeletal defects
and rats 11.5,23,46.5, per day per day
reproductive, 93, 186, or
Stenger 372 m g/kg ^ per
et al. [1971] day on g.d.
1-21
Male Oral; 186 m g/kg —    —  —  —  Microscopic testicular
rats 46.5,93, or per day lesions
186 m g/kg per 
day for 13 wk
EGM
E, EGEE, and 
Their Acetates
Developmental, 
Andrew et al. 
[1981], Hardin 
et al. [1981]
Developmental, 
Doe [1984a]
Developmental, 
Nelson et al. 
[1981]
Female Inhalation;     160 ppm
rabbits 160 or 615 ppm,
7 hr/day on 
g.d. 1-18
Female Inhalation; —  —  765 ppm
rats 150 or 650 ppm,
7 hr/day, 5 days/wk 
for 3 wk before 
breeding; then 
200 or 765 ppm,
7 hr/day 
on g.d. 1-19
Female Inhalation; —  ----- ■—
rats 10, 50, or 250 ppm,
6 hr/day on g.d.
6-15
Female Inhalation; —  ----- —
rabbits 10, 50, or 175 ppm,
6 hr/day on g.d.
6-18
Female Inhalation; —    100 ppm
rats 100 ppm on g.d.
7-13 and 14-20
VO
160 ppm ----- Decreased maternal food
consumption; 22% 
fetolethality and renal, 
cardiovascular, and 
ventral body wall 
defects
200 ppm —  Slight maternal toxicity;
retarded fetal growth 
and fetal cardiovascular 
and skeletal defects
250 ppm 50 ppm Retarded fetal growth, 
decreased ossification, 
and increased skeletal 
variations
175 ppm 50 ppm Fetal skeletal variations
  —  Extended gestation time
(0.7 day)
100 ppm —  Altered behavioral
tests and brain 
neurochemical 
concentrations in 
offspring
(Continued)
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00 Table 7-1 (Continued).—Reproductive and developmental toxicity of EGEE
Study Sex 
type and and 
reference species
Route of Male Maternal Developmental
administration 
and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Developmental, Female 
Hardin et al. rats 
[1982]
Dermal; ----- —
4 applications 
of 0.25 or 0.5 ml
on g.d. 7-16 —  —
4x0.5 ml -----
4x0.25 ml -----
Decreased maternal body 
weight gain and ataxia
Fetotoxicity, 75% 
fetolethality and 
malformations
EGM
E, EGEE, and 
Their Acetates
Table 7-2.—Reproductive and developmental toxicity of EGEEA
Study Sex Route of Male Maternal Developmental
type and and administration -----------------------------  ----------------------------  -----------------------------
reference species and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Reproductive, 
Nagano et al. 
[1979]
Male Oral; 
mice 500,1,000, 2,000, 
or 4,000 m g/kg  
per day,
5 days/wk 
for 5 wk
1,000 
m g/kg  
per day
500
mg/kg 
per day
  —  —  —  Testicular atrophy
Reproductive, Male Oral; 726
Foster ct al. rats 726 m g/kg per m g/kg  
[1984) day for 11 days per day
Developmental, 
Nelson et al. 
[1984b]
Developmental, 
Doe [1984a]
Female
rabbits
Female
rabbits
Inhalation; 
130, 390, or 
600 ppm,
6 hr/day on 
g.d. 7-15
Inhalation;
25, 100, or 
400 ppm,
6 hr/day 
on g.d. 6-18
130 ppm
—  100 ppm —
  —  400 ppm 100 ppm ----- -----
\o'O
Testicular atrophy and 
spermatocyte depletion
Decreased fetal weights 
and visceral 
malformations
Reduced fetal body 
weight and retarded 
fetal ossification
Decreased maternal body 
weight gain and food 
consumption
(Continued)
Abbreviations: g.d. = gestation day; LOAEL = lowest observable adverse effect level; NOAEL = no observable adverse effect level.
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Table 7-2 (Continued).—Reproductive and developmental toxicity of EGEEA
Study Sex Route of Male Maternal Developmental
type and and administration -----------------------------  ----------------------------  -----------------------------
reference species and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Developmental, Female 
Tyl et al. rabbits
[1988]
Developmental, Female 
Tyl et al. rats
(1988]
Developmental, Female 
Hardin rats
et al. [1984]
Inhalation;
50, 100, 200, 
or 300 ppm, 
6 hr/day on 
g.d. 6-18
Inhalation;
50, 100, 200, 
or 300 ppm, 
6 hr/day 
on g.d. 6-15
Dermal;
1.4 ml/day 
on g.d. 7-16
  100 ppm 50 ppm
      100 ppm 50 ppm
  100 ppm 50 ppm ----- -----
      100 ppm 50 ppm
—  —    14 ml/day —
Maternal toxicity 
(increased liver weight, 
decreased gravid uterine 
weight)
Fetotoxidty
Maternal toxicity 
(reduced weight gain 
and food consumption)
Fetotoxicity
Visceral malformations 
and skeletal variations
Table 7-3.—Reproductive and developmental toxicity of EGME
Study 
type and 
reference
Sex
and
species
Route of 
administration 
and dose
Male Maternal Developmental
LOAEL* NOAEL* LOAEL NOAEL LOAEL NOAEL Observed effects
Reproductive, 
Nagano et al. 
[1979]
Male
mice
Oral;
62.5, 125, 250, 
500, 1,000, or 
2,000 m g/kg per 
day, 5 days/wk 
for 5 wk
250
mg/kg
per day
125 
m g/kg  
per day
Testicular atrophy
Reproductive, 
Foster et al. 
[1983]
Male
rats
Oral;
50, 100, 250, 
or 500 m g/kg  
per day for 
11 days
100 
m g/kg  
per day
50 
m g/kg  
per day
Lesions in primary 
spermatocytes and 
partial depletion 
and degeneration of 
spermatids and 
spermatocytes
Reproductive, 
Chapin et al. 
[1985a]
Male
rats
Oral;
50, 100, or 
200 m g/kg
50
m g/kg  
per day
Decreased sperm counts
per day for 
5 days
(Continued)
Abbreviations: g.d. = gestation day, LOAEL = lowest observable adverse effect level; NOAEL = no observable adverse effect level.
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Table 7-3 (Continued).—Reproductive and developmental toxicity of EGME
Study Sex Route of Male Maternal Developmental
type and and administration -----------------------------  ----------------------------  -----------------------------
reference species and dose LOAEL NOAEL LOAEL NOAEL LOAEL NOAEL Observed effects
Reproductive, Male Oral; 50 —  —    —  —  Abnormal sperm
Chapin et al. rats 50, 100, or m g/kg morphology at week 4
[1985b] 200 m g/kg per day
per day for
5 days
Reproductive, Male Inhalation; 300 ppm 100 ppm —  —    —  Decreased male fertility
Rao et al. and 30, 100, or 300
[1983] female ppm, 6 hr/day, No effect on reproductive
rats 5 days/wk performance
for 13 wk
Reproductive Female Inhalation;   —  100 ppm —  —  —  Increased gestation time
and rats 100 or 300 ppm,
developmental, 6 hr/day on   —  —    100 ppm —  Decreased numbers of
Doe et al. g.d. 6-17 live pups
[1983]
Male Inhalation; 300 ppm 100 ppm —  —    —  Testicular atrophy
rats 100 or 300 ppm,
6 hr/day for 
10 days
Reproductive, 
Miller et al. 
[1983a]
Reproductive, 
McGregor 
et al. [1983]
Developmental, 
Nagano et al. 
[1981]
Developmental, 
Toraason 
et al. [1985]
Male Inhalation; 300 ppm 100 ppm
rats 30, 100, or 
300 ppm,
6 hr/day,
5 days/wk 
for 13 wk
Male Inhalation; 100 ppm -
rabbits 30, 100, or 
300 ppm,
6 hr/day,
5 days/wk
for 13 wk —— 30 ppm
Male Inhalation; 500 ppm 25 ppm
rats 25 or 500 ppm,
7 hr/day for 
5 days
Female Oral; —  —
mice 31.25, 62.5, 125
250, 500, or
1,000 m g/kg per 
day on g.d. 7-14
Female Oral (gavage); —  —
rats 25 or 50 mg in
10 ml water/kg  
per day for
11 days
ou>
Microscopic testicular 
lesions and decreased 
testis weights
3 1 .2 5
m g/kg  
per day
25 mg
Slight microscopic 
changes in testicular 
tissue in 1 of 5 rabbits
Microscopic testicular 
lesions and decreased 
testis weights
Decreased fertility during 
weeks 3-8
Bifurca ted or split 
cervical vertebrae
Increased number of 
fetuses with abnormal 
QRS complexes
(Continued)
7 
Assessm
ent of 
Effects
104 Table 7-3 (Continued).—Reproductive and developmental toxicity of EGME
Study 
type and 
reference
Sex
and
species
Route of 
administration 
and dose
Male Maternal
LOAEI, NOAEL LOAEL NOAEL
Developmental
LOAEL NOAEL Observed effects
Developmental, Female Oral;
Scott ct al. monkeys 12, 24, or 36
[1989] m g/kg on 
g.d. 20-45
Developmental, Female Inhalation;
Hanley et al. rats 3, 10, or 50 ppm, 
[1984a] 6 hr/day on
g.d. 6-15
Female Inhalation; 
rabbits 3, 10, or 50 ppm, 
6 hr/day on 
g.d. 6-18
      12 mg ----
  —  50 ppm 10 ppm   —
—  —  —  —  50 ppm 10 ppm
50 ppm 10 ppm ----- -----
50 ppm 10 ppm
23% embryonic death (3 
of 13 pregnancies ended 
in death)
Decreased maternal body 
weight gain
Increased incidence of 
lumbar spurs and 
delayed ossification
Decreased maternal body 
weight gain
Increased resorption rate, 
decreased mean fetal 
body weights, and 
increased incidence of 
malformations of all 
organ systems
EGM
E, EGEE, and 
Their Acetates
Female Inhalation; —  —  50 ppm
mice 10 or 50 ppm,
6 hr/day on 
g.d. 6-15
Developmental, Male 
Nelson et al. rats 
{1984a]
Inhalation;
25 ppm, 7 hr/day, 
7 days/wk for 
6 wk
Female Inhalation; 
rats 25 ppm,
7 hr/day on g.d.
7-13 or 14-20
Developmental, Female 
Wickramaratne rats 
[1986]
Developmental, Female 
Feuston et al. rats 
[1990]
Dermal;
3%, 10%, 30%, 
or 100% solutions
Dermal;
250, 500, 1,000, 
or 2,000 m g/kg on 
g.d. 12, or
2,000 mg/kg on 
g.d. 10, 11, 12,
13, or 14
—  100%
500
mgAg
o
10 ppm
250
mg/kg
50 ppm
25 ppm
25 ppm
10%
500 
mg/kg
—  Minimally decreased
maternal body weight 
gains
10 ppm Increased incidence of
extra lumbar ribs and 
unilateral testicular 
hypoplasia
—  Neurochemical deviations
in offspring
Significant differences in 
avoidance conditioning 
of offspring from 
mothers exposed on g.d, 
7-13; neurochemical 
deviations in offspring
100% maternal death
Reduced litter sizes
Decrease in mean body 
weight gain
250 Increases in external,
mg/kg visceral, and skeletal
malformations
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metal parts. Lowered sperm counts were also demonstrated in shipyard painters exposed to 
airborne EGEE ranging from nondetectable concentrations to 22 ppm [Welch et al. 1988]. 
The potential also existed for skin absorption. In addition, the shipyard painters had been 
exposed to EGME, lead, and epichlorohydrin, all of which have been reported to affect 
semen quality. Airborne concentrations of lead were well below those known to depress 
sperm count. Most blood lead concentrations were below 20 pg%, with the highest single 
concentration being 40 ¿¿g%. Epichlorohydrin was not detected in the air sampling during 
the study [Sparer et al. 1988].
7.1.1.2 Studies In Animals
Studies in animals have provided evidence of adverse reproductive and developmental 
effects from EGEE exposure (see Appendix B). The LOAELs and the NOAELs of the 
following studies were used in determining the REL for EGEE.
Testicular atrophy occurred in mice given oral doses of EGEE (1,000 mg/kg of body weight 
per day or more), for 5 days/wk during a 5-wk period. The NOAEL noted in this study was 
500 mg EG EE/kg per day [Nagano et al. 1979], Decreased testis weight, spermatocyte 
depletion and degeneration, and microscopic testicular lesions were observed in rats treated 
with 500 or 1,000 mg EGEE/kg per day for 11 days [Foster et al. 1983; Creasy and Foster 
1984]; no effects were observed at 250 mg/kg. Decreased sperm counts, abnormal sperm 
morphology, and decreased epididymal weights were found in rats given oral doses of 936, 
1,872, or 2,808 mg EGEE/kg per day for 5 days [Oudiz et al. 1984]. A no-effect level was 
not included in this study. Stenger et al. [1971] treated male rats orally with 46.5, 93, or 
186 mg EGEE/kg per day for 13 wk. Microscopic testicular lesions were found only at 
doses of 186 mg EGEE/kg per day.
Rats and rabbits of both sexes were exposed to 0,25,100, or 400 ppm EGEE for 6 hr/day, 
5 days/wk over a 13-wk period [Terrill and Daly 1983a,b; Barbee et al. 1984]. At the highest 
exposures (400 ppm EGEE), reduced testicular weights and microscopic testicular lesions 
were observed in rabbits, and reduced pituitary weights were observed in male rats. Reduced 
body weights were observed in male and female rabbits at 25 and 400 ppm EGEE, and 
reduced spleen weights were found in nonpregnant female rats at 100 and 400 ppm EGEE.
Studies have demonstrated adverse effects on the dam and the developing fetus. Stenger 
et al. [1971] treated rats orally with 11.5, 23,46.5,93, 186, or 372 mg EGEE/kg per day on 
g.d. 1 through 21. Decreased fetal body weights and skeletal defects were demonstrated at 
93, 186, and 372 mg/kg per day. No effects were noted at 11.5, 23, or 46.5 mg/kg per day.
In rabbits exposed to EGEE for 7 hr/day on g.d. 1 through 18, maternal toxicity and 
embryolethality were observed at 615 ppm, and embryolethality (22%), skeletal variations, 
renal and cardiovascular defects, and decreased maternal food consumption were observed 
at 160 ppm [Andrew et al. 1981; Hardin et al. 1981]. No effects were apparent on fertility 
or pregnancy outcome when female rats were exposed to 150 or 650 ppm EGEE for 7 hr/day, 
5 days/wk during the 3 wk before breeding. Toxic signs were noted in female rats exposed 
at 650 ppm, but none were observed at 150 ppm. However, when pregnant rats were exposed
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to 765 ppm EGEE for 7 hr/day on g.d. 1 through 19, 100% intrauterine death occurred. 
Similar exposure at 200 ppm EGEE significantly increased fetal cardiovascular and skeletal 
defects. These effects on development were not influenced by exposures to filtered air or 
EGEE before pregnancy [Andrew et al. 1981; Hardin et al. 1981].
In rats exposed 6  hr/day to 250 ppm EGEE on g.d. 6  through 15, investigators observed 
increased postimplantation loss, retarded fetal growth, decreased ossification, and increased 
skeletal variations; they found no effects on fetuses at 50 or 10 ppm EGEE [Doe 1984a], 
Fetal skeletal variations were found in rabbits exposed 6  hr/day to 175 ppm EGEE on g.d. 6 
through 18; no effects were found in fetuses at 10 or 50 ppm EGEE [Doe 1984a].
Exposure of pregnant rats to 100 ppm EGEE on g.d. 14 through 20 caused extended gestation 
(0.7 day), and exposure to 100 ppm EGEE on g.d. 7 through 13 or 14 through 20 caused 
altered behavioral responses and altered brain neurochemical concentrations in offspring 
[Nelson etal. 1981].
Effects on the fetus were also demonstrated in a dermal application study of EGEE [Hardin 
et al. 1982]. Four daily doses of 0.25 or 0.50 ml EGEE were applied to rats on g.d. 7 through 
16. The higher dose resulted in decreased maternal body weight gain, ataxia, and 100% 
fetolethality; the lower dose produced fetotoxicity, 75% fetolethality, and malformations.
7.1.1.3 Basis for Selecting the No Observable Adverse Effect Level (NOA EL)
Acute toxicity data for EGEE (Table 4-2) indicate that CNS and kidney effects occurred at 
higher EGEE concentrations than adverse reproductive and developmental effects. Smyth 
et al. [1941] reported narcosis, digestive tract irritation, and kidney damage in guinea pigs 
and rats exposed to 1,400 or 3,000 mg EGEE/kg. Dyspnea» damaged lungs, and toxic effects 
on WBCs were reported in mice exposed to 1,130 to 6,000 ppm EGEE [Werner et al. 1943c], 
and the LC50 was 1,820 ppm EGEE.
Adverse effects on the blood and hematopoietic system also occurred at higher EGEE 
concentrations than adverse reproductive and developmental effects. Data in Table 4-9 
indicate that EGEE adversely affects the blood and hematopoietic system at concentrations 
of 125 to 2,000 ppm. These effects include decreased Hb, Hct, RBCs, WBCs, and increased 
osmotic fragility of erythrocytes [Werner et al. 1943a,b; Stenger et al. 1971; Carpenter et al. 
1956; Nagano et al. 1979; Terrill and Daly 1983a,b; Barber et al. 1984; Doe 1984a].
Limited human data correlate adverse reproductive effects with EGEE exposure [Ratcliffe 
et al. 1986; Welch et al. 1988].
Table 7-1 presents the reproductive and developmental effects resulting from exposure to 
EGEE. In rabbits, the LOAEL for male reproductive effects was 400 ppm [Barbee et al. 
1984; Terrill and Daly 1983a]. This concentration caused decreased testis weight and micro­
scopic testicular lesions, but 100 ppm and 25 ppm had no effect on the male reproductive 
system. In the male rat, the LOAEL (500 mg/kg) caused decreased testis weight and micro­
scopic testicular lesions [Foster et al. 1983; Creasy and Foster 1984]; the NOAEL was250mg/kg.
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Adverse developmental effects (behavioral and neurochemical alterations) were observed 
in rats exposed at 100 ppm EGEE in a study that did not demonstrate an NOAEL for these 
effects [Nelson et al. 1981]. The NOAEL for structural malformations in rats and rabbits 
was 50 ppm EGEE [Doe 1984a]. Carpenter et al. [1956] had previously established a 
62-ppm NOAEL for osmotic fragility.
Adverse developmental effects occur at lower EGEE concentrations than reproductive, 
hematotoxic, CNS, and kidney effects. Thus, limiting exposures to control adverse develop­
mental effects will also control reproductive, hematotoxic, CNS, and kidney effects.
The LOAELs and NOAELs in Table 7-1 indicate that 50 ppm is the highest NOAEL [Doe 
1984a] in rats that is also lower than the lowest LOAEL in rats [Nelson et al. 1981]. Because 
of the lack of human data and because the rat is the species most sensitive to EGEE, it is 
reasonable to use the rat NOAEL to extrapolate an equivalent dose for humans. NIOSH 
therefore deems it appropriate to use 50 ppm as the NOAEL for EGEE and to use the body 
freights of rats [Doe 1984a] for calculating their daily NOAEL and extrapolating an 
equivalent dose for humans.
7.1.2 EGEEA
No information is available about the toxic effects of EGEEA in humans.
7.1.2.1 Studies fn Animais
In mice administered EGEEA orally 5 days/wk for 5 wk, testicular atrophy occurred at 1,000, 
2,000, and 4,000 mg/kg per day, and depletion and degeneration of spermatocytes occurred 
at 4,000 mg/kg per day [Nagano et al. 1979], When doses were expressed as mmoles/kg 
per day, the dose-response relationships of EGEE and EGEEA were equivalent. No effects 
appeared at 500 mg EGEEA/kg per day. Testicular atrophy and spermatocyte depletion 
developed in rats fed 726 mg EGEEA/kg per day for 11 days [Foster et al. 1984].
Nelson et al. [1984b] examined the effects of EGEEA on rat embryo-fetal development by 
exposing pregnant rats to 130,390, or 600 ppm EGEEA for 7 hr/day on g.d. 7 through 15. 
The highest concentration (600 ppm) caused 100% fetolethality. A 56% increase in 
resorptions occurred at 390 ppm EGEEA, and fetal weights were significantly reduced at 
130 and 390 ppm EGEEA. Visceral malformations of the heart and umbilicus occurred in 
fetuses at 390 ppm, and one fetus from dams exposed to 130 ppm EGEEA had a heart defect.
In another study, rabbits were exposed to 25, 100, or 400 ppm EGEEA on g.d. 6  through 
18 [Doe 1984a]. Adverse effects on the fetus included decreased fetal body weights and 
retarded ossification at 100 ppm EGEEA, and vertebral column malformations at 400 ppm 
EGEEA. Decreased maternal body weight gain and food consumption, and increased 
resorptions also occurred at 400 ppm EGEEA. No adverse maternal effects developed at 
25 or 100 ppm EGEEA, and no adverse effects on the fetus appeared at 25 ppm EGEEA.
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These studies in animals provide ample evidence of adverse reproductive and developmental 
effects from EGEEA exposure. The following studies, including the LOAEL and the 
NOAEL of each, were used in determining the REL for EGEEA.
Tyl et al. [1988] found evidence of maternal toxicity and fetotoxicity in rabbits exposed by 
inhalation to 100, 200, and 300 ppm EGEEA for 6  hr/day on g.d. 6 through 18. A 100% 
incidence of malformations occurred at 300 ppm EGEEA, and external, visceral, and skeletal 
malformations increased significantly at 200 ppm EGEEA. No effects were observed on 
dams or fetuses at 50 ppm EGEEA.
Tyl et al. [1988] found evidence of maternal toxicity (i.e., decreased body weight gain and 
food consumption, and increased liver weight) in rats exposed by inhalation to 100 , 2 0 0 , 
and 300 ppm EGEEA for 6 hr/day on g.d. 6  through 15. Fetotoxicity was also found at 100, 
200, and 300 ppm EGEEA, with an increased incidence of visceral, skeletal, and external 
malformations at 200 and 300 ppm EGEEA. Dams and fetuses showed no effects at 50 ppm 
EGEEA.
Dermal treatment of pregnant rats on g.d. 7 through 16 with 1.4 ml EGEEA/day caused 
decreased maternal body weights and adverse developmental effects in offspring, including 
visceral malformations and skeletal variations [Hardin et al. 1984],
7A .2.2 Basis for Selecting the No Observable Adverse Effect Level (NOAEL)
Reports in the literature indicate that EGEEA exerts adverse hematologic effects in ex­
perimental animals at 62 to 4,000 ppm [von Oettingen and Jirouch 1931; Carpenter et al. 
1956; Doe 1984a; Tyl et al. 1988; Truhaut et al. 1979; Nagano et al. 1979]. These effects 
include hemolysis, reduced RBC and WBC counts, and a reduction in Hb, Hct, and MCV.
Acute toxicity data for EGEEA (Table 4-2) indicate that CNS and kidney effects occur at 
higher EGEEA concentrations than adverse reproductive and developmental effects. Smyth 
et al. [1941] reported narcosis and damaged kidneys in guinea pigs and rats treated with 
1,910 or 5,100 mg EGEEA/kg. Hemoglobinuria, hematuria, and renal lesions were reported 
in rats treated with 2,900 to 3,900 mg EGEEA/kg [Truhart et al. 1979], and transient 
hemoglobinuria and/or hematuria were reported in rabbits exposed to 2,000 ppm EGEEA 
for 4 hr.
Adverse reproductive and developmental effects generally occur at lower concentrations 
than hematotoxic, CNS, and kidney effects. Thus, limiting exposures to prevent adverse 
reproductive and developmental effects will also prevent hematotoxic, CNS, and kidney 
effects.
Table 7-2 presents reproductive and developmental effects resulting from exposure to 
EGEEA. These data include the LOAEL for mice (1,000 mg/kg), rats (130 ppm), and rabbits 
(100 ppm). In the study by Tyl et al. [1988], 50 ppm EGEEA caused no effects in rabbits. 
The LOAELs and NOAELs presented in Table 7-2 indicate that 50 ppm is the highest
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NOAEL in rabbits that is also lower than the lowest LOAEL in rabbits [Tyl et al. 1988]. 
Because human data are lacking and because the rabbit is the animal species most sensitive 
to EGEEA, it is reasonable to use the rabbit NOAEL to extrapolate an equivalent dose for 
humans. NIOSH therefore deems it appropriate to use 50 ppm as the NOAEL for EGEEA 
and to use the body weights of rabbits studied by Tyl et al. [1988] for calculating their daily 
NOAEL and extrapolating an equivalent dose for humans.
7.1.3 EGME
7.1.3.1 Studies in Humans
As reported in Chapter 4 (Section 4.3), adverse CNS effects (headache, forgetfulness, 
fatigue, personality change, nausea, and neurologic abnormalities) and hematotoxic effects 
(anemia and lymphopenia) were observed in workers exposed to EGME-containing solvents 
in shirt factories [Donley 1936; Parsons and Parsons 1938]. Greenburg et al. [1938] studied 
workers fusing shirt collars at the same factory as Parsons and Parsons [1938] and observed 
similar effects (i.e., anemia, neurologic abnormalities, drowsiness, and fatigue). Industrial 
hygiene measurements taken after the report of adverse health effects in workers indicated 
that the airborne concentration of EGME was about 25 ppm with windows open and 75 ppm 
with windows partially closed. Greenburg et al. [1938] stated that worker exposures to 
EGME had been higher than the measured concentrations because improvements had been 
made to exhaust and ventilation systems after the report of adverse health effects in workers.
Severe anemia [Zavon 1963; Cohen 1984], major encephalopathy, and bone marrow 
depression [Ohi and Wegman 1978; Cohen 1984] were observed in workers exposed to 
EGME dermally and by inhalation in the printing and microfilm industries. In one study 
[Zavon 1963], EGME was used as a cleaning agent and as a solvent, but the workers seldom 
wore gloves. No means were available to measure possible dermal absorption. Workers 
were exposed to 60 to 3,960 ppm EGME during the various cleaning operations, but after 
airborne EGME concentrations were reduced to the order of 20 ppm EGME, no further ill 
effects were noted. No mention was made about preventing skin exposure.
Nitter-Hauge [1970] reported general weakness, disorientation, nausea, and vomiting in two 
men who had each ingested about 0.1 liter of pure EGME, believing it to be ethyl alcohol. 
Upon admittance to the hospital, the men were suffering from cerebral confusion, pronounced 
hyperventilation, and profound metabolic acidosis. After i.v. treatment with sodium bicar­
bonate and ethyl alcohol, both patients made an uneventful recovery over a 4-wk period.
Limited evidence shows the adverse effects of EGME on the male reproductive system. 
Data suggest that testicle size may have been reduced in male workers with potential 
exposure to EGME (see Section 4.1.2.2) [Cook et al. 1982]. Welch et al. [1988] noted 
lowered sperm counts in shipyard painters exposed to EGME and EGEE; airborne EGME 
ranged from nondetectable concentrations to 5.6 ppm. Details of this study, which are 
presented in Chapter 4, indicated that lead and epichlorohydrin (also present in the work 
environment) had no effect on semen quality.
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When hematologic parameters were studied in the same group of shipyard painters [Welch 
and Cullen 1988], several cases of anemia were reported. Exposure to EGME and EGEE 
was suspected as the cause of the hematologic disorders, but no dose - response relationship 
was established.
7.1.3.2 Studies In Animals
Chapter 4 summarizes experimental studies demonstrating reproductive and developmental 
toxicity resulting from EGME exposure (see Appendix B for the complete studies). Doses 
of 62.5, 125, 250, 500, 1,000, or 2,000 mg EGME/kg per day were administered to mice 
5 days/wk for 5 wk [Nagano et al. 1979]. Testicular atrophy was found at 250, 500,1,000, 
and 2,000 mg EGME/kg per day, but not at lower doses.
In a study to determine temporal development and the site of the testicular lesion, rats were 
treated orally with 50,100,250, or 500 mg EGME/kg per day for up to 11 days [Foster et al. 
1983]. Testis weights were significantly reduced after 2 days at 500 mg/kg per day and after 
7 days at 250 mg/kg per day. The lesion appeared localized in the primary spermatocyte 
24 hr after a single dose of 100 mg/kg. Partial depletion and degeneration of spermatids 
and spermatocytes were also observed in rats treated with 100 mg EGME/kg per day for 
11 days. No effects were noted over the 11-day treatment period at 50 mg EGME/kg per day.
Treatment of rats with 50 mg EGME/kg per day for 5 days in another study caused a 
reduction in epididymal sperm counts [Chapin et al. 1985a] and the appearance of abnormal 
sperm morphology at wk 4, followed by recovery at wk 8 [Chapin et al. 1985b].
Adverse reproductive effects were noted in male rats exposed to >100 ppm EGME by 
inhalation for 6  hr/day, 5 days/wk during a 10-day to 13-wk period [Miller et al. 1983a; Rao 
et al. 1983; Doe et al. 1983]. At 300 ppm, rats showed decreased male fertility [Rao et al. 
1983], testicular atrophy [Doe et al. 1983], microscopic testicular lesions, and decreased 
testis weights [Miller et al. 1983a]; at 100 ppm, male rats showed no effects. Miller et al. 
[1983a] observed testicular effects in rabbits exposed to 100 or 300 ppm EGME and slight 
microscopic changes in testicular tissue in 1 of 5 rabbits exposed to 30 ppm EGME. These 
investigators considered 30 ppm to be the NOAEL in rabbits.
The effects of EGME on rat reproductive performance were studied by exposing males or 
females to 30, 100, or 300 ppm EGME for 6  hr/day, 5 days/wk for 13 wk before mating 
with unexposed animals [Rao etal. 1983]. At 300 ppm, EGME completely suppressed male 
fertility for 2 wk after exposure; fertility was partially restored 13 to 19 wk after exposure 
ended. No effects were observed on female reproductive performance at any concentration 
of EGME, or on male reproductive performance at 30 or 100 ppm. No neonatal effects were 
found in this study at any EGME concentration.
Nagano et al. [1981] administered doses of 31.25, 62.5, 125, 250, 500, or 1,000 mg 
EGME/kg per day to rats on g.d. 7 through 14. Skeletal variations consisting of bifurcated 
and split cervical vertebrae were observed at the lowest dose, and increased malformations 
(spina bifida occulta) occurred at 62.5 mg EGME/kg per day.
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Heart function was also evaluated in rat fetuses from dams treated orally on g.d. 7 through 
13 with 25 or 50 mg EGME/kg per day [Toraason et al. 1985]. At 25 mg/kg per day, EGME 
caused a significant increase in the number of fetuses with abnormal QRS wave complexes; 
and at 50 mg/kg per day, it caused an increase in cardiovascular defects.
Oral treatment of nonhuman primates with 36 mg EGME/kg during gestation resulted in 
one embryo that was missing a digit on each forelimb [Scott et al. 1989], Three of thirteen 
pregnancies (23%) at the 12-mg/kg dose ended in embryonic death.
Rats and rabbits were exposed by inhalation to 3,10, or 50 ppm EGME for 6  hr/day on g.d. 6 
through 15 (rats) or 6  through 18 (rabbits) [Hanley et al. 1984a]. Maternal toxicity 
(decreased body weight) in dams of both species was noted at 50 ppm EGME. A significant 
increase in the resorption rate was also noted in pregnant rabbits exposed to 50 ppm EGME. 
Significant increases in the incidence of two minor skeletal variations (i.e., lumbar spurs 
and delayed ossification) indicated slight fetotoxicity in rat fetuses from dams exposed to 
50 ppm EGME. Rabbit fetuses from dams exposed to 50 ppm EGME exhibited a significant 
increase in the incidence of malformations of all organ systems and a significant decrease 
in the mean body weight. No effects were noted in either species for dams and fetuses at 3 
or 10 ppm EGME.
Hanley et al. [1984a] found minimally decreased body weight gains in mice exposed to 
50 ppm EGME 6  hr/day on g.d. 6  through 15. Examination of fetuses from dams exposed 
to 50 ppm EGME revealed statistically significant increases in the incidence of extra lumbar 
ribs and of unilateral testicular hypoplasia. No adverse effects were noted in dams or fetuses 
at 10 ppm EGME.
In another study, pregnant rats were exposed to 100 or 300 ppm EGME for 6  hr/day on g.d. 6 
through 17, and males were exposed to 100 or 300 ppm EGME for 6  hr/day during a 10-day 
period [Doe et al. 1983]. At 100 ppm, EGME increased gestation time and decreased the 
number of pups and live pups. At 300 ppm, EGME decreased maternal body weight and 
produced 100% fetolethality. Male rats showed testicular effects after 10 exposures to 
300 ppm, but not after exposures to 100 ppm EGME.
In a dominant lethal study, male rats were exposed by inhalation to 25 or 500 ppm EGME 
for 6  hr/day over 5 days [McGregor et al. 1983]. Rats exposed to 500 ppm showed decreased 
fertility during wk 3 through 8 , and rats exposed to 25 ppm EGME showed no adverse effects 
on fertility.
Nelson et al. [1984a] exposed male rats to 25 ppm EGME for 7 hr/day, 7 days/wk during a 
6 -wk period. These rats were then mated with untreated females that were allowed to deliver 
and rear their young. In the same study, pregnant females were exposed to EGME for 
7 hr/day on g.d. 7 through 13 or 14 through 20 and allowed to deliver and rear their young. 
Significant differences in avoidance conditioning were observed in offspring of dams 
exposed on g.d. 7 through 13, but not in offspring of dams exposed on g.d. 14 through 20. 
Brain neurochemical deviations were noted in offspring from the paternally exposed group 
and in offspring from both maternally exposed groups.
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In a dermal exposure study, female rats were exposed to solutions of 3%, 10%, 30%, or 
100% EGME (10 ml/kg) in physiological saline [Wickramaratne 1986], Reduced litter sizes 
were observed at the 10% concentration, 100% fetolethality occurred at the 30% concentra­
tion, and 100% maternal death was observed at the 1 00% concentration.
A single dermal application of 500, 1,000, or 2,000 mg EGME/kg on g.d. 12 caused 
statistically significant increases (P<0.05) in external, visceral, and skeletal malformations 
[Feuston et al. 1990]. In the same study, dermal exposure of female rats to EGME 
(1,000  mg/kg on g.d. 12 or 2 ,0 0 0  mg/kg on g.d. 10 and 12) caused a statistically significant 
decrease in fetal body weights (P<0.05). The investigators determined 250 mg EGME/kg 
to be the NOAEL for adverse developmental effects.
7.1.3.3 Basis for Selection o f No Observable Adverse Effect Level (NOAEL)
Adverse CNS effects (encephalopathy) and hematotoxic effects (bone marrow depression, 
anemia, and leukopenia) were observed in workers exposed to EGME [Donley 1936; 
Parsons and Parsons 1938; Greenburg et al. 1938; Zavon 1963; Ohi and Wegman 1978; 
Cohen 1984]. However, there is limited evidence of an adverse effect on the male 
reproductive system as a result of EGME exposure [Welch et al. 1988].
Acute toxicity data for EGME (Table 4-2) indicate that CNS, liver, and kidney effects occur 
at higher EGME concentrations than adverse reproductive and developmental effects. 
Wiley et al. [1938] reported tissue damage to the kidneys and liver in dogs and rabbits 
exposed to 2,130 mg EGME/kg. Narcosis, lung, and kidney damage were reported in rats 
(3,250 to 3,400 mg/kg), rabbits (890 mg/kg), and guinea pigs (950 mg/kg) [Carpenter et al. 
1956], and digestive tract irritation and damaged kidneys were reported in rats and guinea 
pigs exposed to 246 and 950 mg EGME/kg, respectively.
Adverse effects on the blood and hematopoietic system also occurred at higher EGME 
concentrations than adverse reproductive or developmental effects. Data in Table 4-9 
indicate that 32 to 2,000 ppm EGME adversely affects the blood and hematopoietic system. 
These effects include increased osmotic fragility, decreased Hb, Hct, RBC and WBC counts 
[Carpenter et al. 1956; Nagano et al. 1979; Grant et al. 1985; Wemer et al. 1943a,b; Miller 
et al. 1981; Miller et al. 1983a].
Table 7-3 presents the reproductive and developmental effects caused by exposure to 
EGME. In rats, the LOAEL of 50 mg EGME/kg per day caused decreased sperm counts 
and abnormal sperm morphology in two separate studies that did not demonstrate a NOAEL 
[Chapin et al. 1985a,b], In rabbits, the LOAEL (100 ppm EGME) caused microscopic 
testicular lesions and decreased testis weights, and the NOAEL was 30 ppm EGME [Miller 
et al. 1983a]. In mice, the LOAEL (250 mg/kg per day) caused testicular atrophy, and the 
NOAEL was 125 mg/kg per day [Nagano et al. 1979].
Behavioral defects and neurochemical deviations were observed in the offspring of rats 
exposed to 25 ppm EGME [Nelson et al. 1984a]. Retarded fetal ossification was observed
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in the offspring of mice treated with 31.25 mg EGME/kg per day (LOAEL) [Nagano et al.
1981]. Adverse developmental effects were observed in the offspring of rats, rabbits, and 
mice exposed to an LOAEL of 50 ppm EGME [Hanley et al. 1984a]; the NOAEL for these 
species was 10 ppm EGME. In the same study, the NOAEL for maternal effects in these 
species was 10 ppm EGME.
Feuston et al. [1990] observed an increase (P<0.05) in external, visceral, and skeletal 
malformations in the fetuses of rats exposed to single dermal applications of 500,1,000, or
2,000 mg EGME/kg on g.d. 12. The authors determined 250 mg EGME/kg to be the NOAEL 
for adverse developmental effects in this study.
Adverse developmental effects occur at lower EGME concentrations than reproductive, 
hematotoxic, CNS, liver, and kidney effects. Thus, limiting exposure to control adverse 
developmental effects will also control reproductive, hematotoxic, CNS, liver, and kidney 
effects.
The data that demonstrate reproductive and developmental toxicity, and the LOAELs and 
NOAELs presented in Table 7-3 indicate that in several species (rats, rabbits, and mice), 
10 ppm is the highest NOAEL that is also lower than the lowest LOAEL [Hanley et al. 
1984a]. Because of the lack of human data, it is reasonable to use the NOAEL of 10 ppm 
[Hanley et al. 1984a] to extrapolate an equivalent dose for humans.
7.1.4 EGMEA
Few data are available on the toxicity of EGMEA. Bolt and Golka [1990] reported the 
occurrence of hypospadias at birth in two boys whose mother had been exposed to EGMEA 
during her pregnancies. The authors concluded that the hypospadias were caused by 
exposure to EGMEA. Testicular atrophy was observed in mice exposed orally for 5 days/wk 
during a 5-wk period to 500,1,000, or 2,000 mg EGMEA/kg per day; no reproductive effects 
were noted at 62.5, 125, or 250 mg EGMEA/kg per day [Nagano et al. 1979]. When doses 
were expressed as mmol/kg per day, the dose-response relationships of EGMEA and EGME 
were almost identical. The toxic effects caused by EGMEA are likely to be similar to those 
caused by EGME because EGMEA is metabolized to EGME and then to the active 
metabolite (see Section 4.2). Therefore, it is reasonable to use the NOAELs for EGME to 
extrapolate NOAELs for EGMEA. On the basis of the Hanley et al. [1984a] study, a NOAEL 
of 10 ppm was used for EGMEA.
7.2 BASIS FOR RECOMMENDED STANDARDS FOR EGEE, EGME, AND 
THEIR ACETATES
7.2.1 Data Available from Studies in Humans and Animals
Toxic effects of human exposure to EGEE and EGME include personality change, memory 
loss, drowsiness, blurred vision, hearing loss, anemia, and leukopenia. However, data are
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limited on possible adverse reproductive and developmental effects of worker exposure to 
EGEE, EGME, and EGMEA, and no human data are available on EGEEA exposure. Cook 
et aL [1982] suggested that testicle size in males may have been reduced because of EGME 
exposure. Welch et al. [1988] concluded that exposure to EGEE and EGME caused 
functional impairment in males by lowering sperm counts. The occurrence of hypospadias 
in two boys at birth was attributed to the mother’s exposure to EGMEA during her 
pregnancies [Bolt and Golka 1990].
Ballew and Hattis [1989] performed a quantitative risk analysis under contract to NIOSH 
to determine the risk of developmental effects in the offspring of pregnant women exposed 
to EGEE and EGME. Table 7-4 summarizes the concentrations of EGEE and EGME that 
the authors associated with developmental risks in humans at a frequency of 1 per 1 million 
or 1 per 10,000. Because the estimates presented in this table are based on a series of 
assumptions and carry considerable uncertainty, and because this was an exploratory 
analysis, NIOSH does not deem it appropriate to base RELs for EGEE, EGME, or their 
acetates on this risk analysis.
Although data for humans are limited, ample evidence from studies in animals indicates that 
EGEE, EGME, and their acetates adversely affect reproduction and development. In the 
absence of sufficient human data, NIOSH deems it appropriate to base the RELs for EGEE, 
EGME, and their acetates on animal data. The following procedure was therefore used to 
calculate equivalent human doses from animal data.
7.2.2 Procedure for Calculating Equivalent Human Doses from Animal Data
No mechanistic models exist to describe the relationship of reproductive and developmental 
toxicity to exposure; only empirical models are available to use in a quantitative risk 
assessment (QRA). Because a threshold is assumed to exist for reproductive and develop­
mental toxicity, a QRA model is inappropriate since these models assume a no-threshold 
effect. Therefore, the following method was used to determine the RELs for EGEE, EGME, 
and their acetates.
Both humans and animals were assumed to retain 100% of inhaled EGEE, EGME, or their 
acetates. The retained dose for animals exposed at the NOAEL was calculated as follows 
by using the inhalation rate and the average body weights of the animals (see Table 7-5):
Retained dose for animals ■ NOAEL (mg/m3) x inhaja^ onrate (m /day) x q 2 5  ¿ay (1 )
animal body weight
That dose was converted to an equivalent exposure for humans by assuming a 70-kg body weight 
and an inhalation rate of 10 m3 in an 8-hr workday [45 Fed. Reg. 79318 (1980); EPA 1987]:
t, . , . „ , retained dose for animals (mg/kg per day) x 70 kgEquivalent exposure for humans  -----------------\ a -a r j-l---- e. (2)
1 0  m  /day
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Table 7-4.—Concentrations of EGME and EGEE associated with developmental 
risks in humans at a frequency of 1 per 1 million or 1 per 10,000
(ppm)
EGEE EGME
Developmental effect Lower limit* Best estimate* Lower limitf Best estimate*
Concentrations associated with projected risk of 1 per 1 million for each effect
Miscarriages
Minor skeletal defects
External malformations
Digit or limb malformations
Total malformations
Infant mortality* (projected 
from fetal weight changes)
0.00056 0.53 
0.0000044 0.022 
0.0011 1.1
0.069
0.00026 0.067
0.00013 0.15 
0.000046 0.042
0.0085
Concentrations associatedwith projected risk of I per 10,000 for each effect
Miscarriages 0.0061 1.8 0.0029 0.22
Minor skeletal defects 0.000048 0.073 — ----
External malformations 0.012 3.5 — -----------
Digit or limb malformations — — 0.0014 0.48
Total malformations — — 0.0005 0.14
Infant mortality* (projected 
from fetal weight changes) — 6.8 — 0.84
Adapted from Ballew and Hattis [1989].
^Concentrations of EGEE or EGME associated with the indicated effect under a more pessimistic 
assumption about the degree of interindividual variability in susceptibility of the human population (log 
probit slope of 1).
1 Bast-estimate assumption of the degree of interindividual variability in susceptibility for the quantal 
developmental effects (log probit slope of 2).
sDeath in the first year after birth. In the case of this hypothesized effect, only best estimates have 
been made.
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Table 7-5.—Data for inhalation studies
Glycol ether 
and
species studied
NOAEL 
ppm mg/mJ Exposure duration
Average body 
weight 
(kg) Inhalation rate*
EGEE:*
Rat 50 184.25 6 hr/day on g.d. 6-15 0.240 0.184 m3/day
Rabbit 50 184.25 6 hr/day on g.d. 6-18 2.25 1.23 m3/day
EGEEA:*
Rabbit 50 270 6 hr/day on g.d. 6-18 3.25 1.61 mg/m3
EGME:*
Rabbit 10 31.12 6 hr/day on g.d. 6-18 4.17 1.94 mg/m3
Rat 10 31.12 6 hr/day on g.d. 6-15 0.22 0.172 mg/m3
Mouse 10 31.12 6 hi/day on g.d. 6-15 0.0499 0.07 mg/m3
Data from Guyton [1947] and Adolph [1949],
*Data from Doc [1984a].
*Data from Tyl et al. [1988].
^Data from Hanley et al. [1984a].
To allow for potential interspecies variability, an uncertainty factor of 10 was applied to the 
equivalent exposure for humans. An additional uncertainty factor of 10 was then applied 
to allow for potential intraspecies variability. The resulting concentration was converted 
to parts per million:
Equivalent exposure for humans __________ 24.45__________ _
100 mol wt of particular glycol ether
7.2.2.1 REL fo r EGEE and EGEEA
Although limited data in humans have shown adverse reproductive or developmental effects 
from exposure to EGEE [Ratcliffe et al. 1986; Welch et al. 1988], sufficient data have 
demonstrated these effects in animals exposed to EGEE [Nagano et al. 1979; Stenger et al. 
1971; Andrew et al. 1981; Hardin et al. 1981, 1982; Nelson et al. 1981; Terrill and Daly 
1983a; Foster et al. 1983; Doe 1984a; Barbee et al. 1984; Oudiz et al. 1984] and EGEEA 
[Nagano et al. 1979; Doe 1984a; Foster et al. 1984; Nelson et al. 1984b; Tyl et al. 1988]. 
These animal data provide the basis for determining the RELs for worker exposure to EGEE 
and EGEEA and for instituting controls to reduce worker exposure. On the basis of the 
calculations presented in Equations 4 through 12, NIOSH recommends that occupational
117
EGME, EGEE, and Their Acetates
exposure to EGEE and EGEEA be limited to 0.5 ppm as a TWA for up to a 10-hr workshift 
during a 40-hr workweek. Because both EGEE and EGEEA can be absorbed percutaneously 
[Dugard et al. 1984], dermal contact is prohibited. The data in Table 7-5 were used in 
Equations 4 through 12 to calculate the human equivalents to the daily animal NOAELs for 
EGEE and EGEEA as follows:
Daily rat NOAEL for EGEE - 184.25 mg/m3 * “ 35.3 mg/kg per day (4)
Human equivalent to daily rat NOAEL for EGEE « 3^ .3 mg/kg per day * 70 kg , 2 4 7 mg/in3 (5)
10 m  /day
247 mg/m 
100
24.45
90.1
! 0.67 ppm (6)
2
Daily rabbit NOAEL for EGEE = 184.25 mg/m3 * /dy xO^Sday) * 25.18 mg/kg per day (7)
L.ÙO Kg
Human equivalent to daily rabbit NOAEL for EGEE - I25-1? Pf day x 70 kg = ll616 m^ m 3 /g)
10 m /day
176.26 24.45 ___
-JÒQ- * “ 0-^ 78 ppm = 0.5 ppm (9)
Daily rabbit NOAEL for EGEEA - 270 mg/m3 * i1-^ 1 m / 0 25 <**?) , 334 mg/kg perday ( j Q)
Human equivalent to daily rabbit NOAEL for EGEEA =■ ^ 3.4 mg/kg per day * 70kg _ 2 3 4 nig/m3 ( 1 1)
10 m /day
234 24.45 „ _
165* ialii'=0‘43ppm (12)
7.2.2.2 REL for EGME and EGME A
Case reports and clinical studies demonstrated adverse CNS and hematotoxic effects on 
workers exposed to EGME [Donley 1936; Parsons and Parsons 1938; Greenburg et al. 1938; 
Zavon 1963; Ohi and Wegman 1978; Cohen 1984], but data demonstrating adverse 
reproductive and developmental effects in offspring of EGME-exposed workers are limited 
[Welch etal. 1988]. Bolt and Golka[1990] reported hypospadias at birth in two boys whose 
mother was exposed to EGMEA during her pregnancies.
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Sufficient evidence in animal studies indicates that EGME exerts adverse reproductive and 
developmental effects [Nagano et al. 1979; Nagano et al. 1981; Doe et al. 1983; Foster et al. 
1983; McGregor etal. 1983; Miller etal. 1983a; Raoetal. 1983; Hanley etal. 1984a; Nelson 
etal. 1984a; Chapin et al. 1985a; Chapin etal. 1985b; Toraason et al. 1985; Scott et al. 1989; 
Wickramaratne 1986]. EGMEA was also shown to have such effects by Nagano et al. 
[1979], who found that this glycol ether caused testicular atrophy in mice. Data from these 
animal studies warrant concern that EGME and EGMEA are capable of inducing similar 
adverse effects in exposed workers.
Based on information presented in Table 7-3, a 10-ppm NOAEL was determined for EGME 
in rats, rabbits, and mice [Hanley et al. 1984a]. Any effects that EGMEA might cause would 
be likely to occur through the initial conversion of EGMEA to EGME (see Section 4.2). 
Therefore, it is reasonable to propose the same REL for both compounds. An equivalent 
human dose was determined for EGME using the information presented in the study by 
Hanley et al. [1984a], On the basis of the calculations presented in Equations 13 through 
21, NIOSH recommends that occupational exposure to EGME and EGMEA be limited to
0.1 ppm as a TWA for up to a 10-hr workday during a 40-hr workweek. Because EGME 
and EGMEA can be absorbed percutaneously [Dugard et al. 1984], dermal contact is 
prohibited. The data in Table 7-5 were used in Equations 13 through 21 to calculate the 
human equivalents to the daily animal NOAELs for EGME and EGMEA as follows:
Daily rabbit NOAEL for EGME -3 1 .1 2  mg/m3 * ^Q-25 ^ y )  ,  362 mg/kg per day (13 )
H* L / Kg
Human equivalent to daily rabbit NOAEL for EGME - 3 6 2 m S/kS P^^ay * . 7 0 kg «25.34 mg/m3 (14)
10 m 3/day
25.34 mg/m3 24.45 , /1
 — *^gj-«0.08ppm-0.lppm (15)
Daily rat NOAEL for EGME - 31.12 mg/m3 * (0 ! 7 2 m V<ky * °- 2 5 «ty) _ 6 0 8 mg/kg perday (16)
U.22 Kg
Human equivalent to daily rat NOAEL for EGME - 6.08 mg/kg per day x 70 kg _ ^  5 5 mg/m3 (17)
10 m3/day
42.56 mg/m3
100 76.1 * 0.137 ppm * 0.14 ppm (18)
Daily mouse NOAEL for EGME - 31.12 mg/m3 x - 10.9 mg/kg perday (19)
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Human equivalent to daily mouse NOAEL for EGME “ *0.9 m^ c£ P^ r 437— 70 kg ^  -yg j mg/m3 (20)
10 m3/day
76.3 mg/m3 24.45 ___
100 0.245 ppm  (21)
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8 METHODS FOR WORKER PROTECTION
8.1 INFORMING WORKERS OF HAZARDS
On November 21, 1983, OSHA promulgated an occupational safety and health standard 
entitled “Hazard Communication.” Under the provisions of this standard (29 CFR 
1910.1200), employers in the manufacturing sector (i.e., SIC Codes 20 through 39) must 
establish a comprehensive hazard communication program that includes, at a minimum, 
container labeling, material safety data sheets (MSDSs), and a worker training program. 
The hazard communication program is to be written and made available to workers and their 
designated representatives.
Chemical manufacturers, importers, and distributors are required to ensure that containers 
of hazardous chemicals leaving their workplaces are labeled, tagged, or marked to show the 
identity of the chemical, appropriate hazard warnings, and the name and address of the 
manufacturer or other responsible party. Employers must ensure that labels on incoming 
containers of hazardous chemicals are not removed or defaced unless they are immediately 
replaced with other labels containing the required information.
Each container in the workplace must be prominently labeled, tagged, or marked to show 
the identity of any hazardous chemical it contains and the hazard warnings appropriate for 
worker protection. If a work area has a number of stationary containers that have similar 
contents and hazards, the employer may post hazard signs or placards rather than label each 
container. Employers may use various types of standard operating procedures, process 
sheets, batch tickets, or other written materials as substitutes for individual container labels 
on stationary process equipment. However, these written materials must contain the same 
information that is required on the labels and must be readily accessible to workers in the 
work areas. Pipes or piping systems are exempted altogether from the OSHA labeling 
requirements, although NIOSH recommends that filler ports and outlets be labeled. In 
addition, NIOSH recommends that a system be set up to ensure that pipes containing 
hazardous materials are identified to avoid accidental cutting and discharge of their contents.
Employers are not required to label portable containers holding hazardous chemicals that 
have been transferred from labeled containers and that are intended only for the immediate 
use of the worker who performs the transfer. According to the OSHA definition of 
“immediate use,” the container must be under the control of the worker performing the 
transfer and must be used only during the workshift in which the chemicals are transferred.
The OSHA Hazard Communication standard requires chemical manufacturers and importers 
to develop an MSDS for each hazardous chemical they produce or import. Employers in
121
EG ME, EGEE, and Their Acetates
the manufacturing sector (which includes paint and allied coating products) are required to 
obtain or develop an MSDS for each hazardous chemical used in the workplace. The MSDS 
is required to provide information such as the chemical and common names for the hazardous 
chemical. For hazardous chemical mixtures, the MSDS must list each hazardous component 
that constitutes 1 % or more of the mixture. NIOSH suggests that any potential occupational 
carcinogen be listed. Ingredients present in concentrations of less than 1 % must also be 
listed if there is evidence that the PEL may be exceeded or that the ingredients could present 
a health hazard in those concentrations. Additional information on the MSDS must include 
the physical and chemical characteristics of the hazardous chemical, known acute and 
chronic health effects, precautionary measures, and emergency and first aid procedures. The 
NIOSH publication entitled A Recommended Standard—An Identification System for Oc­
cupationally Hazardous Materials [NIOSH 1974] can be used as a guide when preparing 
the MSDS. Required information can be recorded on the MSDS shown in Appendix B or 
on a similar form.
Employers should establish a training program for all workers exposed to hazardous 
chemicals. Training should be provided whenever a new job is assigned and whenever a 
new chemical hazard is introduced into the work area. Workers should be informed about
(1) any hazardous chemicals in their work areas, and (2) the availability of information about 
individual chemicals in the MSDS.
Workers should also be trained in methods for detecting the presence or release of hazardous 
chemicals (e.g., monitoring conducted by the employer, continuous monitoring devices, 
visual appearance or odor of hazardous chemicals when released, etc.). Training should 
include information about measures workers can take to protect themselves from exposure 
to hazardous chemicals (e.g., the use of appropriate work practices, emergency procedures, 
and personal protective equipment).
8.2 WORK PRACTICES
8.2.1 Worker Isolation
If feasible, workers should be isolated from direct contact with the work environment by 
the use of automated equipment operated from a closed control booth or room. The control 
room should be maintained at a positive pressure so that air flows out of rather than into the 
room. However, when workers must perform process checks, adjustments, maintenance, 
or other related operations in work areas where EGME, EGEE, or their acetates are present, 
personal protective clothing and equipment may be necessary, depending on exposure 
concentrations and the potential for dermal contact.
8.2.2 Storage and Handling
Containers of EGME, EGEE or their acetates should be stored in a cool, dry, well ventilated 
location away from any area containing a fire hazard. Outside or detached storage is 
preferred. These glycol ethers should be isolated from materials with which they are
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incompatible; contact with strong oxidizing agents may cause fires and explosions. Con­
tainers of solvents, including those that contain EGME, EGEE, or their acetates, should be 
tightly covered at all times except when material is transferred. Working amounts of these 
solvents should be stored in containers that (1) hold no more than 5 gal, (2) have spring- 
closing lids and spout covers, and (3) are designed to safely relieve internal pressure in case 
of fire. Because small amounts of residue may remain and present a fire hazard, containers 
that have held solvents should be thoroughly cleaned with steam and then drained and dried 
before reuse. Fittings should not be struck with tools or other hard objects that may cause 
sparks. Special spark-resistant tools of nonferrous materials should be used where flam­
mable gases, highly volatile liquids, or other explosive substances are used or stored [NSC 
1980]. In addition, all sources of ignition such as smoking and open heaters should be 
prohibited except in specified areas. Fire hazards around tank trucks and cars can be reduced 
by keeping motors turned off during loading or unloading operations.
Specific OS HA requirements for the storage and handling of flammable and combustible 
liquids are given in 29 CFR 1910.106.
8.2.3 Sanitation and Hygiene
The preparation, storage, or consumption of food should not be permitted in areas where 
there is exposure to EGME, EGEE or their acetates. The employer should make handwash­
ing facilities available and encourage the workers to use them before eating, smoking, using 
the toilet, or leaving the worksite. Tools and protective clothing and equipment should be 
cleaned as needed to maintain sanitary conditions. Toxic wastes should be collected and 
disposed of in a manner that is not hazardous to workers or the environment. Vacuum pickup 
or wet mopping should be used to clean the work area at the end of each workshift or more 
frequently if needed to maintain good housekeeping practices. Collected wastes should be 
placed in sealed containers that are labeled as to their contents. Cleanup and disposal should 
be conducted in a manner that enables workers to avoid contact with the waste.
Tobacco products should not be smoked, chewed, or carried uncovered in work areas. 
Workers should be provided with and advised to use facilities for showering and changing 
clothes at the end of each workshift. Work areas should be kept free of flammable debris. 
Flammable work materials (rags, solvents, etc.) should be stored in approved safety cans.
8.2.4 Spills and Waste Disposal
Procedures for decontamination and waste disposal should be established for materials or 
equipment contaminated with EGME, EGEE, or their acetates. The following procedures 
are recommended in the event of a spill of these glycol ethers [NIOSH 1981; DOT 1984; 
Canadian Center for Occupational Safety and Health 1988]:
•  Exclude persons not wearing protective clothing and equipment from areas of spills 
or leaks until cleanup has been completed.
•  Remove all ignition sources.
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•  Ventilate the area of a spill or leak.
•  Absorb small spills on paper towels. Allow the vapors to evaporate in a suitable 
place such as a fume hood, allowing sufficient time for them to clear the hood 
ductwork. Bum the paper towels in a suitable location away from combustible 
materials.
•  Absorb large quantities with sand or other noncombustible absorbent material and 
atomize the contaminated material in a suitable combustion chamber.
•  Collect contaminated waste and place in sealed containers for disposal in accord­
ance with existing regulations of the U.S. Environmental Protection Agency and 
the U.S. Department of Transportation. State and local regulations may supersede 
Federal regulations if they are more restrictive.
8.3 LABELING AND POSTING
In accordance with 29 CFR 1910.1200 (Hazard Communication), workers must be informed 
of chemical exposure hazards, of their potential adverse health effects, and of methods to 
protect themselves. Labels and signs also provide an initial warning to other workers who 
may not normally work near processes involving hazardous chemicals such as EGME, 
EGEE, or their acetates. Depending on the process, warning signs should state a need to 
wear eye protection or a respirator, or they may be used to limit entry to an area without 
protective equipment. For transient nonproduction work, it may be necessary to display 
warning signs at the worksite to inform other workers of the potential hazards.
All labels and warning signs should be printed in both English and the predominant language 
of workers who do not read English. Workers who cannot read labels or posted signs should 
be identified so that they may receive information about hazardous areas and be informed 
of the instructions printed on labels and signs.
8.4 EMERGENCIES
The employer should formulate a set of written procedures covering fire, explosion, 
asphyxiation, and any other foreseeable emergency that may arise during the use of materials 
that may contain EGME or EGEE, or their acetates. All potentially affected workers should 
receive training in evacuation procedures to be used in the event of fire or explosion. All 
workers who are using materials containing these glycol ethers should be thoroughly trained 
in proper work practices that reduce the potential for starting fires and causing explosions. 
Selected workers should be given specific training in first aid, cardiopulmonary resuscita­
tion, and fire control. Procedures should include prearranged plans for transportation of 
injured workers and provision for emergency medical care. At least two trained persons in 
every work area should have received extensive emergency training. Necessary emergency
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equipment, including appropriate respirators and other personal protective equipment, 
should be stored in readily accessible locations.
8.5 ENGINEERING CONTROLS
Engineering controls should be the principal method for minimizing exposure to airborne 
EGME, EGEE, or their acetates in the workplace. To achieve and maintain reduced airborne 
concentrations of these glycol ethers, adequate engineering controls are necessary (e.g., 
properly constructed and maintained closed-system operations and ventilation). Control 
technology applicable to spray painting is discussed in a NIOSH document [O’Brien and 
Hurley 1981],
Airborne concentrations of these glycol ethers can be most effectively controlled at the 
source of contamination by enclosure of the operation and use of local exhaust ventilation. 
Enclosures, exhaust hoods, and ductwork should be kept in good repair so that designed 
airflows are maintained. Measurements of variables such as capture velocity, duct velocity, 
or static pressure should be made at least semiannually, and preferably monthly, to 
demonstrate the effectiveness of the mechanical ventilation system. The use of continuous 
airflow indicators (such as water or oil manometers marked to indicate acceptable airflow) 
is recommended. The effectiveness of the system should also be made as soon as possible 
after any change in production, process, or control that may result in any increase in airborne 
contaminants.
It is essential that any scheme for exhausting air from a work area also provide a positive 
means of bringing in at least an equal volume of air from the outside, conditioning it, and 
evenly distributing it throughout the exhausted area. The ventilation system should be 
designed and operated to prevent the accumulation or recirculation of airborne contaminants 
in the workplace. Technical criteria to ensure this are discussed in the NIOSH publication, 
The Recirculation o f Industrial Exhaust Air [NIOSH 1978].
Principles for design and operation of ventilation systems are presented in Industrial 
Ventilation—A Manual o f Recommended Practices, published by the American Conference 
of Governmental Industrial Hygienists [ACGIH 1988a]; American National Standard: 
Fundamentals Governing the Design and Operation o f Local Exhaust Systems, Z9.2( 1971), 
published by the American National Standards Institute [ANSI 1979]; and Recommended 
Industrial Ventilation Guidelinest published by NIOSH [Hagopian and Bastress 1976].
8.6 PERSONAL PROTECTIVE EQUIPMENT (PPE)
8.6.1 Protective Clothing and Equipment
Workers should use appropriate personal protective clothing and equipment that must be 
carefully selected, used, and maintained to be effective in preventing skin contact with 
EGME, EGEE or their acetates. The PPE ensemble is dictated by the worker’s potential
125
EG ME, EGEE, and Their Acetates
exposure to these glycol ethers and ranges from gloves to encapsulating suits. The following 
materials have good but varied resistance to the chemicals indicated below [Forsberg and 
Mandorf 1989]:
Breakthrough time
Chemical PPE material (hr)
EGEE Butyl rubber, Saranex® >8
PE/EVAL laminate >4
Neoprene, nitrile 1 -4
EGME Butyl rubber >8
To evaluate the use of these materials with EGMEA or EGEEA, users should consult the 
best available performance data and manufacturer’s recommendations. Significant differen­
ces have been demonstrated in the chemical resistance of generically similar PPE 
materials (e.g., butyl) produced by different manufacturers [Mickelsen and Hall 1987]. In 
addition, the chemical resistance of a mixture may be significantly different from that of any 
of its neat components [Mickelsen et al. 1986]. Users should therefore test the candidate 
material with the chemicals to be used.
The worker should be trained in the proper use and care of the chemical protective clothing. 
After this clothing is in routine use, it should be examined along with the workplace to ensure 
that nothing has occurred to invalidate the effectiveness of these materials. The NIOSH 
publication A Guide for Evaluating the Performance of Chemical Protective Clothing 
[Roder 1990] may be helpful. Safety showers and eye wash stations should be located close 
to operations that involve EGME, EGEE, or their acetates.
Splash-proof chemical safety goggles or face shields (20 to 30 cm minimum) should be worn 
during any operation in which a solvent, caustic, or other toxic substance may be splashed 
into the eyes.
In addition to the possible need for wearing protective outer apparel (e.g., aprons, encap­
sulating suits), workers should wear work uniforms, coveralls, or similar full-body coverings 
that are laundered each day. Employers should provide lockers or other closed areas to store 
work and street clothing separately. Employers should collect work clothing at the end of 
each workshift and provide for its laundering. Laundry personnel should be informed about 
the potential hazards of handling contaminated clothing and instructed about measures to 
minimize their health risk.
Employers should ensure that protective clothing is inspected and maintained to preserve 
its effectiveness. Clothing should be kept reasonably free of oil or grease.
Workers and persons responsible for worker health and safety should be informed that 
protective clothing may interfere with the body’s heat dissipation, especially during hot 
weather or in hot industries or work situations (e.g., confined spaces). Additional monitoring
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is required to prevent heat-related illness when protective clothing is worn under these 
conditions.
8.6.2 Respiratory Protection
Engineering controls should be the primary method used to control exposure to airborne 
contaminants. Respiratory protection should be used by workers only in the following 
circumstances:
•  During the development, installation, or testing of required engineering controls
•  When engineering controls are not feasible to control exposure to airborne con­
taminants during short-duration operations such as maintenance and repair
•  During emergencies
Respiratory protection is the least preferred method of controlling worker exposures and 
should not be used routinely to prevent or minimize exposures. When respirators are used, 
employers should institute a complete respiratory protection program that includes worker 
training at regular intervals in the use and limitations of respirators, routine air monitoring, 
and maintenance, inspection, cleaning, and evaluation of the respirator. Any respiratory 
protection program must, at a minimum, meet the requirements of 29 CFR 1910.134. 
Respirators should be used in accordance with the manufacturer’s instructions. Each 
respirator user should be fit-tested and, if possible, receive a quantitative, on-the-job 
evaluation of his or her respiratory protection factor to confirm the protection factor assumed 
for that class of respirator. For additional information on the use of respiratory protection, 
refer to the NIOSH Guide to Industrial Respiratory Protection [NIOSH 1987a] and NIOSH 
Respirator Decision Logic [NIOSH 1987b].
Selection of the appropriate respirator depends on the types of glycol ethers and their 
concentrations in the worker’s breathing zone. Before a respirator can be selected, an 
assessment of the work environment is necessary to determine the concentrations of EGME, 
EGEE, EGMEA, EGEEA and other contaminants that may be present. Respirator types 
should be selected in accordance with the most recent edition of the NIOSH Respirator 
Decision Logic [NIOSH 1987b].
The actual respirator selection should be made by a qualified individual, taking into account 
specific use conditions, including the interaction of contaminants with the filter medium, 
space restrictions caused by the work location, and the use of any required face and eye 
protective devices. Respirator selection tables are presented in Chapter 1.
8.7 CHEMICAL SUBSTITUTION
The substitution of less hazardous materials can be an important measure for reducing 
worker exposure to hazardous materials.
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8.8 EXPOSURE MONITORING
An occupational health program designed to protect workers from adverse effects caused 
by exposure to EGME, EGEE, or their acetates should include the means for thoroughly 
identifying all potential hazards. Routine environmental sampling as an indicator of worker 
exposure is an important part of this program, as it provides a means of assessing the 
effectiveness of work practices, engineering controls, personal protective clothing and 
equipment, etc.
Prior knowledge of the presence of certain types of inteifering compounds in the sampled 
environment will greatly help the analyst in the selection of the appropriate analytical 
conditions for sample analysis. This list of compounds can be compiled from the material 
safety data sheets for the compounds that are used in or around the process where the 
sampling will take place.
Initial and routine worker exposure surveys should be made by competent industrial hygiene 
and engineering personnel. These surveys are necessary to characterize worker exposures 
and to ensure that controls already in place are operational and effective. Each worker’s 
exposure should be estimated, whether or not it is measured by a personal sampler. 
Therefore, the sampling strategy should allow reasonable estimates of each worker’s 
exposure. The NIOSH publication Occupational Exposure Sampling Strategy Manual may 
be helpful in developing efficient programs to monitor worker exposure [Leidel et al. 1977].
In work areas where airborne exposures to EGME, EGEE or their acetates may occur, an 
initial survey should be done to determine the extent of worker exposure. In general, TWA 
exposures should be determined by collecting samples over a full shift. Measurements to 
determine worker exposure should be taken so that the average 8-hr exposure is based on a 
single 8-hr sample or on two 4-hr samples. Several short-term interval samples (up to 
30 min) may also be used to determine the average exposure concentration.
When the potential for exposure to these glycol ethers is periodic, short-term samples may 
be needed to replace or supplement full-shift sampling. Personal sampling (i.e., samples 
collected in the worker’s breathing zone) is preferred over area sampling. If personal 
sampling is not feasible, area sampling can be substituted only if the results can be used to 
approximate worker exposure. Sampling should be used to identify the sources of emissions 
so that effective engineering controls or work practices can be instituted.
If a worker is found to be exposed to EGME, EGEE, or their acetates at concentrations 
below the REL but at or above one-half the REL, the exposure of that worker should be 
monitored at least once every 6  months or as otherwise indicated by a professional industrial 
hygienist
When the work environment contains concentrations exceeding the respective RELs for 
these glycol ethers, workers must wear respirators for protection until adequate engineering 
controls or work practices are instituted; exposure monitoring is recommended at 1-wk 
intervals. Such monitoring should continue until consecutive determinations at least 1 wk 
apart indicate that the workers’ exposure no longer exceeds the REL.
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When workers’ exposures are greater than one-half the REL but less than the REL, sampling 
should be conducted after 6  months; if the concentrations of these glycol ethers are lower 
than one-half the REL after two consecutive biannual surveys, sampling can then be 
conducted annually. Exposure monitoring should be conducted whenever changes in 
production, process, controls, work practices, or weather conditions may result in a change 
in exposure conditions.
8.9 MEDICAL MONITORING
8.9.1 General Requirements
Workers exposed to EGME, EGEE, or their acetates are at risk of suffering adverse health 
effects. Medical monitoring as described below should be made available to all workers. 
The employer should provide the following information to the physician responsible for the 
medical monitoring program:
• Any requirements of the applicable OSHA standard or NIOSH recommended 
standard
• Identification of and extent of exposure to physical and chemical agents that may 
be encountered by the worker
• Any available workplace sampling results that characterize exposures for job 
categories previously and currently held by the worker
•  A description of any protective devices or equipment the worker may be required 
to use
•  The frequency and nature of any reported illness or injury of a worker
•  The results of any monitoring of urinary MAA or EAA for any worker exposed to 
unknown concentrations of EGME or EGMEA during a spill or emergency (see 
Appendix G).
8.9.2. Medical Examinations
The objectives of a medical monitoring program are to augment the primary preventive 
measures, which include industrial hygiene monitoring of the workplace, the implementa­
tion of engineering controls, and the use of proper work practices and personal protective 
equipment. Medical monitoring data may also be used for epidemiologic analysis within 
large plants and on an industrywide basis; they should be compared with exposure data from 
industrial hygiene monitoring.
Medical examinations are conducted before job placement and periodically thereafter. The 
preplacement medical examination allows the physician to assess the applicant’s functional
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capacity and inform him or her of how it relates to the physical demands and risks of the 
job. Furthermore, such an examination provides baseline medical data that can be compared 
with subsequent health changes. The preplacement examination should also provide 
information about prior occupational exposures. Periodic medical examinations after job 
placement are intended to detect work-related changes in health at an early stage.
The following factors should be considered during the preplacement medical examination 
and any periodic medical examinations of the worker: (a) exposure to chemical and physical 
agents that may produce interdependent or interactive adverse effects on the worker’s health 
(including exacerbation of pre-existing health problems and nonoccupational risk factors 
such as tobacco use), and (b) potentially hazardous characteristics of the worksite (e.g., 
confined spaces, heat, and proximity to hazards such as explosive atmospheres and toxic 
chemicals). The type of information that should be gathered is discussed in the following 
subsections.
8.9.2.1 Preplacement medical examination
8.9.2.1.1 Medical history
The medical history should contain information about occupational history, including the 
number of years worked in each job. Special attention should be given to any history of 
occupational exposure to hazardous chemical and physical agents [Guidotti et al. 1983].
8.9.2.1.2 Clinical examination
The preplacement clinical examination should determine the fitness of the worker to perform 
the intended job assignment. Appropriate pulmonary and musculoskeletal evaluation 
should be done for workers whose jobs may require extremes of physical exertion or stamina 
(e.g., heavy lifting), especially these who must wear personal respiratory protection. 
Because the standard 12-lead electrocardiogram is of little practical value in monitoring for 
asymptomatic cardiovascular disease, it is not recommended. More valuable diagnostic 
information is provided by physician interviews of workers that elicit reports of the 
occurrence and work-relatedness of angina, breathlessness, and other symptoms of chest 
illnesses. Special attention should also be given to workers who require the use of 
eyeglasses. These workers must be able to wear simultaneously any equipment needed for 
respiratory protection, eye protection, and visual acuity, and they must be able to maintain 
their concurrent use during work activities.
The worker’s duties may be performed near unrelated operations that generate potentially 
harmful exposures (e.g., asbestos or cleaning or degreasing solvents). The physician must 
be aware of these potential exposures to evaluate possible hazards to the individual worker.
$.9.2.2 Periodic medical examination
A periodic medical examination should be conducted annually or more frequently, depend­
ing on age, health status at the time of a prior examination, and reported signs or symptoms
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associated with exposure to EGME, EGEE, or their acetates. The physician should note 
any trends in health changes revealed by epidemiologic analyses of examination results. 
The occurrence of an occupationally related disease or other work-related adverse health 
effects should prompt an immediate evaluation of industrial hygiene control measures and 
an assessment of the workplace to determine the presence of a previously unrecognized 
hazard.
The physician’s interview with the worker is an essential part of a periodic medical 
examination. The interview gives the physician the opportunity to leam of (1) changes in 
the work setting (e.g., confined spaces), and (2 ) potentially hazardous workplace exposures 
that are in the vicinity of the worker but are not related to the worker’s job activities.
During the periodic medical examination, the physician should re-examine organ systems 
at risk to note changes from the previous examination.
8.10 BIOLOGICAL MONITORING
Urinary concentrations of the metabolites of EGME, EGEE, and their acetates may be useful 
biological indicators of worker exposure to these glycol ethers. Biological monitoring 
accounts not only for environmental concentrations and actual respiratory uptake, but 
also for absorption through the skin. Information about biological monitoring appears in 
Section S.4 of this document and guidelines for biological monitoring are given in Appendix G.
Biological monitoring is suggested when the potential exists for (1) airborne exposure 
to EGME, EGEE, or their acetates at or above their respective RELs, or (2) skin contact 
as a result of accidental exposure or breakdown of chemical protective clothing (see 
Section 8 .6 .1). Monitoring of urinary MAA or EAA (see Appendix G) should be made 
available to any worker exposed to unknown concentrations of EGME, EGEE, or their 
acetates during a spill or other emergency. In the absence of skin exposure, a urinary 
MAA concentration of 0.8 mg/g creatinine or an EAA concentration of 5 mg/g creatinine 
approximates the concentration that would result from exposure to the REL for EGME 
(0.1 ppm) or EGEE (0.5 ppm) during an 8 -hr workshift. If a worker’s urinary MAA or 
EAA suggests exposure to EGME, EGEE, or their acetates above their respective RELs, 
an effort should be made to ascertain the cause (e.g., failure of engineering controls, 
poor work practices, or nonoccupational exposures).
8.11 RECORDKEEPING
Medical records as well as exposure and biological monitoring results must be maintained 
for workers as specified in Section 1.9 of this document. Such records must be kept for at 
least 30 years after termination of employment. Copies of environmental exposure records 
for each worker must be included with the medical records. These records must be made 
available to the past or present workers or to anyone having the specific written consent of 
a worker, as specified in Section 1.9.4 of this document.
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The following research is needed to further reduce the risk of adverse developmental and 
reproductive effects from occupational exposure to EGME, EGEE, or their acetates:
•  Investigations should be conducted in the workplace to relate glycol ether exposure 
to concentrations of metabolites in urine and toxic effects such as reduction in testis 
size, semen quality, etc.
•  Additional studies are needed to define more accurately the human reproductive 
hazards posed by EGME, EGEE, and their acetates.
•  Evaluations of exposed populations are needed to correlate dermal absorption of 
EGME, EGEE, and their acetates with concentrations of metabolites in urine.
•  Additional data should be collected to quantify airborne and dermal exposures to 
EGME, EGEE, and their acetates under actual conditions of use in the workplace.
•  Other glycol ethers should be evaluated to identify any that have effects similar to 
those of EGME, EGEE, and their acetates (see Appendix E for a list of glycol 
ethers).
•  Physiologically based pharmacokinetic models for EGME, EGEE, and their 
acetates need to be developed and validated in both human beings and the animal 
species in which NOAELs were determined.
•  Methods are needed for quantitative monitoring of dermal exposure.
•  Epidemiologic studies are needed to determine the effects of occupational exposure 
to EGME, EGEE, and their acetates.
•  The method of Groeseneken et al. [1989b] should be validated.
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METHODS FOR SAMPLING AND ANALYSIS OF 
EGME, EGEE, EGMEA, AND EGEEA IN AIR*
A.1 General Requirements for Sampling
Air samples are collected that represent the air a worker breathes while performing each job
or specific operation. It is advisable to maintain records of the date, time, rate, duration,
volume, and location of sampling.
A.2 Collection and Shipping of Samples
1. Immediately before sampling, break the ends of the sampling tube to provide an opening 
at least one-half the internal diameter of the tube (2 mm).
2. Attach the sampling tube to the sampling pump with flexible tubing. The smaller section 
of charcoal is used as a backup and should be positioned nearest the sampling pump.
3. The charcoal tube should be placed in a vertical direction during sampling to minimize 
channeling through the charcoal.
4. Air being sampled should not be passed through any hose or tubing before entering the 
charcoal tube.
5. The flow rate of sampling should be known with an accuracy of at least +5 %. Calibrate 
each sampling pump with a representative charcoal tube in line.
6 . The temperature, relative humidity, and pressure of the atmosphere being sampled 
should be recorded. If a pressure reading is not available, record the elevation.
7. The charcoal tubes should be capped with the supplied plastic caps immediately after 
sampling. Under no circumstances should rubber caps be used.
8 . One tube should be handled in the same manner as the sample tube (break, seal, and 
transport), except that no air is sampled through this tube. This tube should be labeled 
as a blank.
*This appendix was reprinted from NIOSH [1984].
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9. Capped charcoal tubes should be packed tightly and padded before they are shipped to 
minimize tube breakage during shipping.
10. A sample of the bulk material should be submitted to the laboratory in a glass container 
with a Teflon-lined cap. This sample should not be transported in the same container 
as the charcoal tubes.
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2-METHOXYETHANOL (METHYL CELLOSOLVE, 2ME) 
2-METHOXYETHYL ACETATE (METHYL CELLOSOLVE ACETATE, 2MEA) 
2-ETHOXYETHANOL (CELLOSOLVE, 2EE) 
2-ETHOXYETHYL ACETATE (CELLOSOLVE ACETATE, 2EEA)
OSHA METHOD NO. 79 FOR EGME, EGMEA, EGEE, AND EGEEA [OSHA 1990]v
Method no.:
Matrix:
Procedure:
Recommended air volume 
and sampling rate:
79
Air
Samples are collected by drawing air through 
standard size coconut shell charcoal tubes. 
Samples are desorbed with 95/5 (v/v) methylene 
chloride/methanol and analyzed by gas chroma­
tography using a flame ionization detector.
48 liters at 0.1 liters/min for TWA samples 
15 liters at 1.0 liters/min for STEL samples
Target conc.: ppm (mg/m3)
Reliable quantitation 
limit: ppb (jig/m3)
Standard error of estimate at target 
concentration:
(Section 4.7)
Special requirements:
Status of method:
Date: January, 1990
2ME 2MEA 2EE 2EEA
0.1 (0.3) 0.1 (0.5) 0.5 (1.8) 0.5 (2.7)
6.7 (21) 1.7 (8.4) 2.1 (7.8) 1.2 (6.5)
6 .0 % 5.7% 6 .2 % 5.7%
As indicated in OSHA Method 53 (Ref. 5.1), 
samples for 2MEA and 2EEA should be refrig­
erated upon receipt by the laboratory to minimize 
hydrolysis.
Evaluated method. This method has been sub­
jected to the established evaluation procedures of 
the Organic Methods Evaluation Branch.
Chemist: Carl J. Elskamp
Organic Methods Evaluation Branch 
OSHA Analytical Laboratory 
Salt Lake City, Utah
This method was reprinted from OSHA [1990].
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1 General Discussion
1.1 Background
1.1.1 History of procedure
An air sampling and analytical procedure for 2ME, 2MEA, 2EE, and 2EE A 
(OSHA Method 53) was previously evaluated by the Organic Methods 
Evaluation Branch of the OSHA Analytical Laboratory (Ref. 5.1). The 
target concentration for all four analytes in that method was 5 ppm. OSHA 
is now in the process of 6 (b) rulemaking to consider reducing occupational 
exposure to these glycol ethers. Because the proposed exposure limits may 
be significantly lower than the target concentrations in Method 53, the 
methodology was re-evaluated at lower levels.
A number of changes were made to Method 53 to accommodate the lower 
target concentrations.
(1) The recommended air volume for TWA samples was increased from 
10 liters to 48 liters. This allows for lower detection limits and increases 
the TWA sampling time to a more convenient 480 min (8 hr) when 
sampling at 0.1 liter/m in.
(2) A capillary GC column was substituted for a packed column to attain 
higher resolution. This was especially helpful in achieving better separa­
tion of 2ME and methylene chloride, a major component of the desorption 
solvent.
(3) It was found that the desorption efficiency from wet charcoal was 
significantly lower for 2ME, and to a lesser extent for 2EE, at these lower 
concentrations. This problem was overcome by adding about 125 mg of 
anhydrous magnesium sulfate to each desorption vial to remove the 
desorbed water. Because charcoal will always collect some water from 
sampled air, all 2ME and 2EE air samples must be treated in this manner.
Utilizing these three major modifications of Method 53, a successful 
evaluation was performed for these glycol ethers at the lower target 
concentrations. Also, a minor modification was made in the determination 
of desorption efficiencies. Aqueous instead of methanolic stock solutions 
were used to determine the desorption efficiencies for 2MEA and 2EEA. 
It was found that at these lower levels, when stock methanolic solutions 
are spiked on dry Lot 120 charcoal, part of the 2MEA and 2EEA react with 
the methanol to form methyl acetate and 2ME and 2EE, respectively. The 
reaction, which is analogous to hydrolysis, is called transesterification 
(alcoholysis) and is catalyzed by acid or base. The surface of dry Lot 120 
charcoal is basic and the reaction was verified to occur by quantitatively
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determining methyl acetate and the corresponding alcohol (2ME for 2MEA 
samples, 2EE for 2EEA samples) from spiked samples. Transestérification 
was not observed when methanolic stock solutions were spiked onto wet 
charcoal. Therefore, transestérification is not expected to occur for 
samples collected from workplace air containing methanol as well as 
2MEA or 2EEA because workplace atmospheres are seldom completely 
dry.
Because of the number of modifications and the extensive amount of data 
generated in this evaluation, the findings are presented as a separate method 
instead of a revision of Method 53. This method supercedes Method 53, 
although Method 53 is still valid at the higher analyte concentrations. 
Although hydrolysis of 2MEA and 2EEA does not appear to be a problem 
at lower concentrations, as a precautionary measure, the special require­
ment that 2MEA and 2EEA samples should be refrigerated upon receipt 
by the laboratory was retained from Method 53.
1.1.2 Toxic effects (This section is for information only and should not be taken 
as the basis of OSHA policy.)
As reported in the Documentation of Threshold Limit Values (Refs. 5.2 to 
5.5), all four analytes were investigated by Nagano et al. (Ref. 5.6) in terms 
of potency for testicular effects. They concluded that on an equimolar 
basis, the respective acetate esters were about as potent as 2ME and 2EE 
in producing testicular atrophy and leukopenia (an abnormally low number 
of white blood cells) in mice. Based on this study and because 2MEA and 
2EEA hydrolyze to 2ME and 2EE respectively in the body, ACGEH 
suggests lowering the time-weighted TLVs for all four analytes to 5 ppm.
The following is quoted from NIOSH Current Intelligence Bulletin 39 (Ref. 
5.7).
The National Institute for Occupational Safety and Health 
(NIOSH) recommends that 2-methoxyethanol (2ME) and 
2-ethoxyethanol (2EE) be regarded in the workplace as having 
the potential to cause adverse reproductive effects in male and 
female workers. These recommendations are based on the 
results of several recent studies that have demonstrated dose- 
related embryotoxicity and other reproductive effects in several 
species of animals exposed by different routes of administra­
tion. Of particular concern are those studies in which exposure 
of pregnant animals to concentrations of 2ME or 2EE at or 
below their respective Occupational Safety and Health Ad­
ministration (OSHA) Permissible Exposure Limits (PELs) led 
to increased incidences of embryonic death, teratogenesis, or 
growth retardation. Exposure of male animals resulted in
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testicular atrophy and sterility. In each case the animals had 
been exposed to 2ME or 2EE at concentrations at or below their 
respective OSHA PELs. Therefore, appropriate controls 
should be instituted to minimize worker exposure to both 
compounds.
On May 20,1986, EPA referred these four analytes to OSHA in accordance 
with the Toxic Substances Control Act (TSCA). On April 2,1987, OSHA 
issued an Advanced Notice of Proposed Rulemaking (ANPR) which 
summarized the information currently available to OSHA concerning the 
uses, health effects, estimates of employee exposure and risk determina­
tions for these glycol ethers. OSHA invited comments from interested 
parties and, based on the gathered information, will decide on appropriate 
action (Ref. 5.8).
1.1.3 Workplace exposure
2ME—It is used as a solvent for many purposes: cellulose esters, dyes, 
resins, lacquers, varnishes, and stains; and as a perfume fixative and jet fuel 
deicing additive (Ref. 5.2).
2MEA—It is used in photographic films, lacquers, textile printing, and as 
a solvent for waxes, oils, various gums and resins, cellulose acetate, and 
nitrocellulose (Ref. 5.3).
2EE—It is used as a solvent for nitrocellulose, natural and synthetic resins, 
and as a mutual solvent for the formulation of soluble oils. It is also used 
in lacquers, in the dyeing and printing of textiles, in varnish removers, in 
cleaning solutions, in products for the treatment of leather, and as an 
anti-icing additive for aviation fuels (Ref. 5.4).
2EEA—It is used as a blush retardant in lacquers; as a solvent for nitrocel­
lulose, oils and resins; in wood stains, varnish removers; and in products 
for the treatment of textiles and leathers (Ref. 5.5).
1.1.4 Physical properties (Refs. 5.2-S.5)
Chemical formulae:
2ME- CH3OCH2CH2OH 2MEA- CH3OCH2CH2OOCCH3
2EE- CH3CH20CH2CH20H 2EEA- CH3CH2OCH2CH2OOCCH3
Synonyms: (Ref. 5.9)
2ME—Methyl Cellosolve; glycol monomethyl ether; ethylene glycol 
monomethyl ether; methyl oxitol; Ektasolve; Jeffersol EM
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2MEA—Methyl Cellosolve acetate; glycol monomethyl ether acetate; 
ethylene glycol monomethyl ether acetate
2EE—Cellosolve solvent; ethylene glycol monoethyl ether
2EEA—Cellosolve acetate; glycol monoethyl ether acetate; ethylene 
glycol monoethyl ether acetate
Analyte 2ME 2MEA 2EE 2EEA
CAS no. 109-86-4 110-49-6* 110-80-5 111-15-9
mol wt 76.09 118.13 90.11 132.16
bp(°C) 124.5 145 135.6 156.4
Color all are colorless liquids
spgr 0.9663 1.005 0.931 0.975
vp [kPa (mm Hg)
at 20°C] 0 .8(6) 0.3(2) 0.49(3.7) 0.3(2)
Flash pt.
(°C, closed cup) 43 49 40 49
Odor mild, mild, sweetish mild,
(Ref. 5.9) non­ ether­ non­
residual like residual
Explosive
limits, %
(Ref. 5.9):
Lower 2.5 1.1 1.8 1.7
Upper 19.8 8.2 14 ?
The analyte air concentrations throughout this method are based on the recommended 
TWA-sampling and analytical parameters. Air concentrations listed in ppm and ppb are 
referenced to 25°C and 101.3 kPa (760 mm Hg).
1.2 Limit-defining parameters
1.2.1 Detection limit of the analytical procedure
The detection limits of the analytical procedure arc 0.10,0.04, 0.04, and 
0.03 ng per injection (1.0-^iL injection with a 10:1 split) for 2ME, 2MEA, 
2EE, and 2EEA respectively. These are the amounts of each analyte that 
will give peaks with heights approximately 5 times the height of baseline 
noise (Section 4.1).
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1.2.2 Detection limit of the overall procedure
The detection limits of the overall procedure are 1.0,0.40,0.37, and 0.31 fig 
per sample for 2ME, 2MEA, 2EE, and 2EEA respectively. These are the 
amounts of each analyte spiked on the sampling device that allow recovery 
of amounts of each analyte equivalent to the detection limits of the 
analytical procedure. These detection limits correspond to air concentra­
tions of 6.7 ppb (21 jig/m3), 1.7 ppb (8.4 jig/m3), 2.1 ppb (7.8 fig/m3), 
and 1.2 ppb (6.5 jig/m ) for 2ME, 2MEA, 2EE, and 2EEA respectively 
(Section 4.2).
1.2.3 Reliable quantitation limit
The reliable quantitation limits are the same as the detection limits of the 
overall procedure because the desorption efficiencies are essentially 100% 
at these levels. These are the smallest amounts of each analyte that can be 
quantitated within the requirements of recoveries of at least 75% and 
precisions (±1.96 SD) of ±25% or better (Section 4.3).
The reliable quantitation limits and detection limits reported in the method 
are based upon optimization of the GC for the smallest possible amounts 
of each analyte. When the target concentration of an analyte is exception­
ally higher than these limits, they may not be attainable at the routine 
operating parameters unless one optimizes parameters of instruments.
1.2.4 Instrument response to the analyte
The instrument response over the concentration ranges of 0.5 to 2 times 
the target concentrations is linear for all four analytes (Section 4.4).
1.2.5 Recovery
The recovery of 2ME, 2MEA, 2EE, and 2EEA from samples used in a 
15-day storage test remained above 84, 87, 84, and 85% respectively 
when the samples were stored at ambient temperatures. The recovery of 
analyte from the collection medium after storage must be 75% or greater. 
(Section 4.5, from regression lines shown in Figures 4.5.1.2, 4.5.2.2, 
4.5.3.2, and 4.5.4.2)
1.2.6 Precision (analytical procedure)
The pooled coefficients of variation obtained from replicate determinations 
of analytical standards at 0.5, 1, and 2 times the target concentrations are 
0.022,0.004,0.002, and 0.002 for 2ME, 2MEA, 2EE, and 2EEA respec­
tively (Section 4.6).
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1.2.7 Precision (overall procedure)
The precisions at the 95% confidence level for the ambient temperature 
15-day storage tests are ±11.7, ±11.1, ±12.3, and ±11.2% for 2ME, 2MEA, 
2EE, and 2EEA respectively. These include an additional ±5% for sam­
pling error. The overall procedure must provide results at the target concen­
tration that are ±25% or better at the 95% confidence level (Section 4.7).
1.2.8 Reproducibility
Six samples for each analyte collected from controlled test atmospheres 
and a draft copy of this procedure were given to a chemist unassociated 
with this evaluation. The samples were analyzed after 12 days of 
refrigerated storage. No individual sample result deviated from its theoreti­
cal value by more than the precision reported in Section 1.2.7 (Section 4.8).
1.3 Advantages
1.3.1 Charcoal tubes provide a convenient method for sampling.
1.3.2 The analysis is rapid, sensitive, and precise.
1.4 Disadvantage
It may not be possible to analyze co-collected solvents using this method. Most
of the other common solvents which are collected on charcoal are analyzed after
desorption with carbon disulfide.
2 Sampling Procedure
2.1 Apparatus
2.1.1 Samples are collected using a personal sampling pump calibrated to within 
±5% of the recommended flow rate with a sampling tube in line.
2.1.2 Samples are collected with solid sorbent sampling tubes containing 
coconut shell charcoal. Each tube consists of two sections of charcoal 
separated by a urethane foam plug. The front section contains 100 mg of 
charcoal and the back section, 50 mg. The sections are held in place with 
glass wool plugs in a glass tube 4-mm i.d. * 70-mm length. For this 
evaluation, SKC Inc. charcoal tubes (catalog number 226-01, Lot 120) 
were used.
2.2 Reagents
None required
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2.3 Technique
2.3.1 Immediately before sampling, break off the ends of the charcoal tube. All 
tubes should be from the same lot.
2.3.2 Connect the sampling tube to the sampling pump with flexible tubing. 
Position the tube so that sampled air first passes through the 100-mg 
section.
2.3.3 Air being sampled should not pass through any hose or tubing before 
entering the sampling tube.
2.3.4 Place the sampling tube vertically (to avoid channeling) in the employee’s 
breathing zone.
2.3.5 After sampling, seal the tub« immediately with plastic caps and wrap 
lengthwise with OSHA Form 21.
2.3.6 Submit at least one blank sampling tube with each sample set. Blanks 
should be handled in the same manner as samples, except no air is drawn 
through them.
2.3.7 Record sample volumes (in liters of air) for each sample, along with any 
potential interferences.
2.3.8 Ship any bulk sample(s) in a container separate from the air samples.
2.4 Sampler capacity
2.4.1 Sampler capacity is determined by measuring how much air can be sampled 
before breakthrough of analyte occurs (i.e., the sampler capacity is ex­
ceeded). Individual breakthrough studies were performed on each of the 
four analytes by monitoring the effluent from sampling tubes containing 
only the 100-mg section of charcoal while sampling at 0 .2  liters/min from 
atmospheres containing 10 ppm analyte. The atmospheres were at ap­
proximately 80% relative humidity and 20-25°C. No breakthrough was 
detected in any of the studies after sampling for at least 6  hr (>70 liters). 
(These data were collected in the evaluation of OSHA Method 53, Ref. 5.1.)
2.4.2 A similar study as in 2.4.1 was done while sampling an atmosphere 
containing 10 ppm of all four analytes. The atmosphere was sampled for 
more than 5 hr (>60 liters) with no breakthrough detected. (These data 
were collected in the evaluation of OSHA Method 53, Ref. 5.1.)
2.5 Desorption efficiency
2.5.1 The average desorption efficiencies of 2ME, 2MEA, 2EE, and 2EEA from 
Lot 120 charcoal are 95.8, 97.9, 96.5, and 98.3% respectively over the
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range of 0.5 to 2 times the target concentrations. Desorption samples for 
2MEA and 2EEA must not be determined by using methanolic stock 
solutions since a transesterification reaction can occur (Section 4.9).
2.5.2 Desorbed samples remain stable for at least 24 hr (Section 4.10).
2.6 Recommended air volume and sampling rate
2.6.1 For TWA samples, the recommended air volume is 48 liters collected at 
0.1  liters/min (8-hr samples).
2.6.2 For short-term samples, the recommended air volume is 15 liters collected 
at 1.0 liter/min (15-min samples).
2.6.3 When short-term samples are required, the reliable quantitation limits be­
come larger. For example, the reliable quantitation limit is 21 ppb (67 jig/m3) 
for 2ME when 15 liters is sampled.
2.7 Interferences (sampling)
2.7.1 It is not known if any compound(s) will severely interfere with the 
collection of any of the four analytes on charcoal. In general, the presence 
of other contaminant vapors in the air will reduce the capacity of charcoal 
to collect the analytes.
2.7.2 Suspected interferences should be reported to the laboratory with submitted 
samples.
2.8 Safety precautions (sampling)
2.8.1 Attach the sampling equipment to the employee so that it will not interfere 
with work performance or safety.
2.8.2 Wear eye protection when breaking the ends of the charcoal tubes.
2.8.3 Follow all safety procedures that apply to the work area being sampled.
3 Analytical Procedure
3.1 Apparatus
3.1.1 A GC equipped with a flame ionization detector. For this evaluation, a 
Hewlett-Packard 5890 Series II Gas Chromatograph equipped with a 
7673A Automatic Sampler was used.
3.1.2 A GC column capable of separating the analyte of interest from the 
desorption solvent, internal standard, and any interferences. A thick film, 
60-m x 0.32-mm i.d., fused silica RTx-Volaiiles column (Cat. no. 10904, 
Restek Corp., Bellefonte, PA) was used in this evaluation.
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3.1.3 An electronic integrator or some other suitable means of measuring peak 
areas or heights. A Hewlett-Packard 18652A A/D converter interfaced to 
a Hewlett-Packard 3357 Lab Automation Data System was used in this 
evaluation.
3.1.4 Two-milliliter vials with Teflon-lined caps.
3.1.5 A dispenser capable of delivering 1.0 mL to prepare standards and samples. 
If a dispenser is not available, a 1.0-mL volumetric pipet may be used.
3.1.6 Syringes of various sizes for preparation of standards.
3.1.7 Volumetric flasks and pipets to dilute the pure analytes in preparation of 
standards.
3.2 Reagents
3.2.1 2-Methoxy ethanol, 2-methoxyethyl acetate, 2-ethoxyethanoI, and 
2-ethoxyethyl acetate, reagent grade. Aldrich Lot HB062777 2ME, 
Eastman Lot 701-2 2MEA, Aldrich Lot DB040177 2EE, and Aldrich Lot 
04916HP 2EEA were used in this evaluation.
3.2.2 Anhydrous magnesium sulfate, reagent grade. Chempure Lot M172 
KDHM was used in this evaluation.
3.2.3 Methylene chloride, chromatographic grade. American Burdick and Jack­
son Lot AQ098 was used in this evaluation.
3.2.4 Methanol, chromatographic grade. American Burdick and Jackson Lot 
AT015 was used in this evaluation.
3.2.5 A suitable internal standard, reagent grade. “Quant Grade” 3-methyI-3- 
pentanol from Polyscience Corporation was used in this evaluation.
3.2.6 The desorption solvent consists of methylene chloride/methanol, 95/5 (v/v) 
containing an internal standard at a concentration of 20 pL/liter.
3.2.7 GC grade nitrogen, air, and hydrogen.
3.3 Standard preparation
3.3.1 Prepare concentrated stock standards by diluting the pure analytes with 
methanol. Prepare working standards by injecting microliter amounts of 
concentrated stock standards into vials containing 1.0 mL of desorption solvent 
delivered from the same dispenser used to desorb samples. For example, to 
prepare a stock standard of 2ME, dilute 195 pL of pure 2ME (sp gr = 0.9663) 
to 50.0 mL with methanol. This stock solution would contain 3.769 fig/jiL. 
A working standard of 15.08 jig/sample is prepared by injecting 4.0 jjL of 
this stock into a vial containing 1.0 mL of desorption solvent.
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3.3.2 Bracket sample concentrations with working standard concentrations. If 
samples fall outside of the concentration range of prepared standards, 
prepare and analyze additional standards to ascertain the linearity of 
response.
3.4 Sample preparation
3.4.1 Transfer each section of the samples to separate vials. Discard the glass 
tubes and plugs.
3.4.2 For 2ME and 2EE samples, add about 125 mg of magnesium sulfate to 
each vial.
3.4.3 Add 1.0 mL of desorption solvent to each vial using the same dispenser as 
used for preparation of standards.
3.4.4 Immediately cap the vials and shake them periodically for about 30 min.
3.5 Analysis
column—80°C for 4 min
10°C/minto 125°C 
125°C for 4 min 
injector— 150°C 
detector—200°C
hydrogen (carrier)—2.5 (80 kPa head pressure) 
nitrogen (makeup)—20 
hydrogen (flame)—65 
air—400
1.0 (with a 10:1 split)
60-m x 0.32-mm i.d. fused silica, 
RTx-Volatiles, thick film
retention times (min): 2M E-5.0
2M EA-10.0
2EE-6.7
2EEA-11.9
(3-methyl-3-pentanol-7.5)
chromatograms: Section 4.11
3.5.2 Peak areas (or heights) are measured by an integrator or other suitable 
means.
3.5.1 GC conditions
zone temperatures:
gas flows (mL/min):
injection volume: 
column:
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3.5.3 An internal standard (1STD) calibration method is used. Calibration curves 
are prepared by plotting micrograms of analyte per sample versus ISTD- 
corrected response o f standard injections. Sample concentrations must be 
bracketed by standards.
3.6 Interferences (analytical)
3.6.1 Any compound that responds on a flame ionization detector and has the 
same general retention time of the analyte or internal standard is a potential 
interference. Possible interferences should be reported to the laboratory 
with submitted samples by the industrial hygienist. These interferences 
should be considered before samples are desorbed.
3.6.2 GC parameters (i.e., column and column temperature) may be changed to 
possibly circumvent interferences.
3.6.3 Retention time on a single column is not considered proof of chemical 
identity. Analyte identity should be confirmed by GQmass spectrometer 
if possible.
3.7 Calculations
The analyte concentration for samples is obtained from the appropriate calibration 
curve in terms o f micrograms per sample, uncorrected for desorption efficiency. 
The air concentration is calculated using the following formulae. The back 
(50-mg) section is analyzed primarily to determine if  there was any breakthrough 
from the front (100-mg) section during sampling. If a significant amount of 
analyte is found on the back section (e.g., greater than 25% o f the amount found 
on the front section), this fact should be reported with sample results. If any analyte 
is found on the back section, it is added to the amount found on the front section. 
This total amount is then corrected by subtracting the total amount (if any) found 
on the blank.
mgAn3 = (micrograms of analyte per sample)
(liters o f air sampled) (desorption efficiency)
where desorption efficiency * 0.958 for 2ME, 0.979 for 2MEA
0.965 for 2EE, 0.983 for 2EEA
ppm ,   f o g/m3) (24.46)_____
(molecular weight o f analyte)
where 24.46 ” molar volume (liters) at 25°C and 101.3 kPa (760 mm Hg) 
molecular weight ” 76.09 for 2ME, 118.13 for 2MEA 
90.11 for 2EE, 132.16 for 2EEA
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3.8.1 Avoid skin contact and inhalation o f all chemicals.
3.8.2 Restrict the use of all chemicals to a fume hood when passible.
3.8.3 Wear safety glasses and a lab coat at all times while in the lab area.
3.8 Safety precautions (analytical)
4 Backup Data
4.1 Detection limit o f the analytical procedure
The injection size listed in the analytical procedure (1.0 ¿iL with a 10:1 split) was 
used in the determination o f the detection limits of the analytical procedure. The 
detection limits of 0.10, 0.04, 0.04, and 0.03 ng were determined by making 
injections o f 1.00,0.40, 0.37, and 0.31 ng/pL standards for 2ME, 2MEA, 2EE, 
and 2EEA respectively. These amounts were judged to produce peaks with heights 
approximately 5 times the baseline noise. Chromatograms o f such injections are 
shown in Figures 4.1.1 and 4.1.2.
4.2 Detection limit o f the overall procedure
Six samples for each analyte were prepared by injecting (from dilute aqueous 
standards) 1.00 jig of 2ME, 0.40 pg of 2MEA, 0.37 jig o f 2EE, and 0.31 fig of 
2EEA into the 100-mg section of charcoal tubes. The samples were stored at room 
temperature and analyzed the next day. The detection limits o f the overall 
procedure correspond to air concentrations o f 6.7 ppb (21 pg/m 3), 1.7 ppb 
(8.4  pg/m 3), 2.1 ppb (7.8 pg/m3),and 1.2ppb (6.5 pg/m ) for2M E, 2MEA, 2EE, 
and 2EEA respectively. The results are given in Tables 4.2.1 to 4.2.4.
Table 4.2.1
Detection Limit of Overall Procedure for 2ME
Sample no. pg spiked pg recovered
1 1.00 0.908
2 1.00 0.945
3 1.00 0.957
4 1.00 0.982
5 1.00 1.067
6 1.00 0.969
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Table 4X2
Detection Limit of Overall Procedure for 2MEA
Sample no. fig spiked jig recovered
1 0.40 0.382
2 0.40 0.392
3 0.40 0.385
4 0.40 0.402
5 0.40 0.402
6 0.40 0.408
Table 4.23
Detection Limit of Overall Procedure for 2EE
Sample no. jig spiked jig recovered
1 0.37 0.347
2 0.37 0.352
3 0.37 0.347
4 0.37 0.388
5 0.37 0.370
6  0.37 0.361
Table 4.2.4
Detection Limit of Overall Procedure for 2EEA
Sample no. fig spiked jig recovered
1 0.31 0.301
2 0.31 0.319
3 0.31 0.304
4 0.31 0.322
5 0.31 0.328
6 0.31 0.328
4.3 Reliable quantitation limit
The reliable quantitation limits were determined by analyzing charcoal tubes 
spiked with loadings equivalent to the detection limits o f the analytical procedure. 
Samples were prepared by injecting 1.0 pg of 2ME, 0.40 jig of 2MEA, 0.37 jig of
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2EE, and 0.31 jig o f 2EEA into the 100-mg section o f charcoal tubes. These 
amounts correspond to air concentrations of 6.7 ppb (21 yg/m3), 1.7 ppb (8.4 jjg/m3),
2.1 ppb (7.8 jig/m3), and 1.2 ppb (6.5 fig/m3) for 2ME, 2MEA, 2EE, and 2EEA 
respectively. The results are given in Tables 4.3.1 to 4.3.4.
Table 43.1 
Reliable Quantitation Limit for 2ME 
(Based on samples and data of Table 4-2.1)
Sample d o . Percent recovered Statistics
1 90.8 X - 97.1
2 94.5
3 95.7
4 98.2 SD - 5.3
5 106.7 Precision - (1.96)(±5.3)
6 96.9 - ±10.4
Table 4.3.2 
Reliable Quantitation Limit for 2MEA 
(Based on samples and data of Table 4.2.2)
Sample no. Percent recovered Statistics
1 95.5 X - 98.8
2 98.0
3 96.2
4 100.5 SD - 2.6
5 100.5 Precision - (1.96)(±2.6)
6 1 0 2 . 0 - ±5.1
Table 4.3.3 
Reliable Quantitation Limit for 2EE 
(Based on samples and data of Table 4.2.3)
Sample no. Percent recovered Statistics
1 93.8 X - 97.5
2 95.1
3 93.8
4 104.9 SD - 4.3
5 1 0 0 . 0 Precision - (1.96)(±4.3)
6 97.6 - ±8.4
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Table 4 3A 
Reliable Quantitation Limit for 2EEA 
(Based on samples and data of Table 4-2 >1)
Sample no. Percent recovered Statistics
I 97.1 X - 102.3
2 102.9
3 98.1
4 103.9 SD - 3.8
5 105.8 Precision - (1.96)(±3.8)
6 105.$ - ±7.4
4.4 Instrument response to the analyte
The instrument response to the analytes over the range o f 0.5 to 2 times the target 
concentrations was determined from multiple injections o f analytical standards. 
These data are given in Tables 4.4.1 to 4.4.4 and Figures 4.4.1 and 4.4.2. The 
response is linear for all four analytes with slopes (in ISTD-corrected area counts 
per micrograms of analyte per sample) o f 980, 1040, 1300, and 1330 for 2ME, 
2MEA, 2EE, and 2EEA respectively.
4.5 Storage test
Storage samples are normally generated by sampling the recommended air 
volume at the recommended sampling rate from test atmospheres at 80% 
relative humidity containing the analyte at the target concentration. Because 
this would require generation o f 8-hr samples, in the interest o f time, samples 
were generated by sampling from atmospheres containing the analytes at about 
4 times the target concentrations for 60 min at 0.2 liters/min (12-liter samples). 
(Note: To test the performance o f the sampler for 48-liter volum es and to show  
the validity o f collecting 12-liter samples at 4 times the target concentrations 
instead o f 48-liter samples at the target concentrations, a set o f six 48-liter 
samples at the target concentration for each analyte was individually generated 
and compared to the corresponding Day 0 samples. A ll samples agreed within 
the precisions o f the method.) 2ME and 2EE were generated in the same 
atmosphere, and 2MEA and 2EEA were generated together in another atmos­
phere. For each set o f 36 samples, 6 samples were analyzed immediately after 
generation, 15 were stored in a refrigerator at 0°C and 15 were stored in a 
closed drawer at ambient temperatures o f 20-25°C. Six samples, three from 
refrigerated and three from ambient storage, were analyzed in 3-day intervals 
over a period o f 15 days. The results are given in Tables 4.5.1 to 4.5.4 and 
shown graphically in Figures 4 .5 .1 .1 ,4 .5 .1 .2 ,4 .5 .2 .1 ,4 .5 .2 .2 ,4 .5 .3 .1 ,4 .5 .3 .2 , 
4.5.4.1, and 4.5.4.2.
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Table 4.4.1 
Instrument Response to 2ME
x target cone.
Hg/sample
ppm
0.5*
7.537
0.050
lx
15.07
0 . 1 0 1
2 *
30.15
0 . 2 0 2
area counts 6930.6 14033 29007
6832.1 14219 28908
6771.4 14139 28920
6655.9 14133 28691
6202.5 14165 28834
6786.0 14176 28887
X 6696.4 14144 28874
Table A A 2  
Instrument Response to 2MEA
x target conc. OJx lx 2 x
mg/sample 1 1 . 6 6 23.32 46.63
ppm 0.050 0 . 1 0 1 0 . 2 0 1
area counts 11946 24182 48262
11772 24108 48302
11987 24124 48160
1 2 0 0 2 24230 48281
11954 24168 48116
11888 24111 48250
X 11925 24154 48228
Table 4.4.3 
Instrument Response to 2EE
x target conc. 0 ^x lx 2 x
jig/sample 44.69 89.38 178.8
ppm 0.253 0.505 1 . 0 1
area counts 54351 112883 229836
54263 113321 229797
53870 113357 229284
54239 113320 229292
54102 113176 228496
54292 113418 229250
X 54186 113246 229326
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Table AAA 
Instrument Response to 2EEA
x target conc.
pg/sample
ppm
0.5*
6135
0.248
lx
128.7
0.496
2 x
257.4
0.992
area counts 84793 171546 342651
84896 171239 343419
84718 171727 341665
84795 171787 342505
84446 171303 341122
84612 171138 342812
X 84710 171457 342362
Table 4.5.1 
Storage Data for 2ME
Storage time 
(days)
% recovery
(refrigerated) (ambient)
0 97.8 1 0 2 . 0 96.3 97.8 1 0 2 . 0 96.3
0 99.9 104.2 94.8 99.9 104.2 94.8
3 96.8 99.5 95.9 93.7 91.7 94.2
6 96.3 96.6 93.3 92.8 91.4 92.8
9 91.4 8 8 . 8 91.4 8 6 . 1 8 8 . 8 87.5
1 289.9 89.8 88.7 91.3 93.1 86.9
1 587.4 8 8 . 8 84.4 87.8 79.8 80.7
Table 4.5.2 
Storage Data for 2ME
Storage time % recovery
(days) (refrigerated) (ambient)
0 101.2 103.5 1 0 1 . 8 1 0 1 . 2 103.5 1 0 1 . 8
0 102.0 105.0 103.8 1 0 2 . 0 105.0 103.8
3 96.8 99.2 99.4 94.1 95.0 93.7
6 94.2 93.1 95.9 92.6 93.3 92.0
9 96.9 99.7 98.7 92.0 90.8 90.2
1 2 95.1 96.2 95.5 8 8 . 6 90.5 87.1
15 94.0 95.9 96.1 89.3 89.4 89.8
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Table 4.5.3
Storage Data for 2EE
Storage time 
(days)
% recovery
(refrigerated) (ambient)
0 96.4 101.4 95.8 96.4 101.4 95.8
0 99.8 1 0 0 . 2 93.9 99.8 1 0 0 . 2 93.9
3 93.9 100.5 98.3 93.9 95.7 96.2
6 96.4 96.9 96.7 93.4 96.8 94.0
9 92.1 8 8 . 2 91.5 81.6 87.9 8 8 . 0
1 2 89.2 89.6 89.1 92.6 92.3 8 6 . 1
15 8 8 . 6 88.4 84.1 90.1 80.4 80.0
Table 4.5.4
Storage Data for 2EEÀ
Storage time % recovery
(day) (refrigerated) (ambient)
0 99.7 101.7 1 0 1 . 8 99.7 101.7 1 0 1 . 8
0 100.9 104.1 1 0 2 . 2 100.9 104.1 1 0 2 . 2
3 94.5 96.7 103.6 92.8 94.2 91.6
6 92.7 92.2 95.7 91.4 91.5 90.8
9 96.2 98.7 98.0 90.3 88.9 8 8 . 8
1 2 93.5 94.6 94.7 87.0 8 8 . 8 84.9
15 92.9 95.0 95.2 87.6 87.6 87.6
4.6 Precision (analytical procedure)
The precision of the analytical procedure for each analyte is the pooled coefficient 
of variation determined from replicate injections of standards.
The precision of the analytical procedure for each analyte is given in Tables 4.6.1 
to 4.6.4. These tables are based on the data presented in Section 4.4.
Table 4.6.1
Precision of the Analytical Procedure for 2ME 
(Based on Table 4.4.1)
x target cone, 
jjg/sample
ppm
0.5*
44.6»
0.253
lx
8938
0.505
2 x
178.8
1 . 0 1
SD (area counts) 257.9 62.5 106.0
CV 0.0385 0.0044 0.0037
CV -0.022
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Table 4.6 J2 
Precision of the Analytical for 2MEA 
(Based on Table 4.4.2)
x target conc. 
pg/s ample 
ppm
0.5*
1 1 . 6 6
0.050
1 *
2332
0 . 1 0 1
2 x
46.63
0 . 2 0 1
SD (area counts) 84.7 48.2 73.6
CV 0.0071 0 . 0 0 2 0 0.0015
CV -0.004
Table 4.63 
Precision of the Analytical for 2EE 
(Based on Table 4.43)
x target conc.
fig/sample
ppm
0.5*
44.6»
0.253
Ix
8938
0.505
2 *
178.8
1 . 0 1
SD (area counts) 175.6 194.8 485.7
CV 0.0032 0.0017 0 . 0 0 2 1
CV -0.002
Table 4.6.4 
Precision of the Analytical for 2EEA 
(Based on Table 4.4.4)
x target conc.
)jg/sample
ppm
0-5*
6435
0.248
lx
128.7
0.496
2 x
257A  
0392
SD (area counts) 160.0 269,3 830.3
CV 0.0019 0.0016 0.0024
CV -0.002
4.7 Precision (overall procedure)
The precision of the overall procedure is determined from the storage data. The 
determination of the standard error of estimate (SEE) for a regression line plotted 
through the graphed storage data allows the inclusion of storage time as one of the 
factors affecting overall precision. The SEE is similar to the standard deviation,
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except it is a measure of dispersion of data about a regression line instead o f about 
a mean. It is determined with the following equation:
An additional 5% for pump error is added to the SEE by the addition o f variances. 
The SEEs are 6.0%, 5.7%, 6.2%, and 5.7% for 2ME, 2MEA, 2EE, and 2EEA 
respectively. The precision of the overall procedure is the precision at the 95% 
confidence level, which is obtained by multiplying the SEE (with pump error 
included) by 1.96 (the z-statistic from the standard normal distribution at the 95% 
confidence level). The 95% confidence intervals are drawn about their respective 
regression lines in the storage graphs. The precisions of the overall procedure are 
± 11.7%, ± 11.1 %, ± 12.3%, and ± 11.2% for 2ME, 2MEA, 2EE, and 2EEA respec­
tively. The SEE and precision of the overall procedure for each analyte were 
obtained from Figures 4.5.1.2,4.5 .2 .2 ,4.5.3.2, and 4.5.4.2 for 2ME, 2MEA, 2EE, 
and 2EEA respectively.
4.8 Reproducibility
Six samples for each analyte, collected from controlled test atmospheres (at about 
80% R.H., 20-26X1,86-88 kPa) containing the analytes at about 4 times the target 
concentrations, were analyzed by chemists unassociated with this evaluation. The 
samples were generated by drawing the test atmospheres through sampling tubes for 
60 min at approximately 0.2 liters/min. The samples were stored in a refrigerator 
for 12 days before being analyzed. The results are presented in Tables 4.8.1 to 4.8.4.
SEE = ^ Yobs ~ y<r5*)2 Vi
n -  k
where
n * total no. of data points
k = 2 for linear regression
k = 3 for quadratic regression
Yobs = observed % recovery at a given time
Yest -  estimated % recovery from the
regression line at the same given time
Table 4.8.1 
Reproducibility for 2ME
Sample no. found pg expected % found % deviation
1
2
3
4
5
6
14.90
15.21
15.06
15.42
15.41
15.88
14.59
15.36
14.93
15.38
15.07
15.54
102.1
99.0
100.9
100.3
102.3 
102.2
+2.1
- 1.0
+0.9
+0.3
+2.3
+2.2
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Table 4.8.2
Reproducibility for 2 M E A
Sample no. jig found fig expected % found % deviation
1 21.61 23.35 92.5 *7.5
2 20.33 22.77 89.3 *10.7
3 21.47 23.12 92.9 -7.1
4 21.51 22.84 94.2 -5.8
5 22.44 23.87 94.0 -6 . 0
6 22.48 24.01 93.6 -6.4
Table 4.83 
Reproducibility for 2EE
Sample no. fig found fig expected % found % deviation
1 83.47 85.55 97.6 -2.4
2 8 8 . 2 2 90.07 97.9 -2 . 1
3 84.10 87.57 96.0 -4.0
4 86.57 90.20 96.0 -4.0
5 84.79 88.40 95.9 -4.1
6 88.90 91.16 97.5 -2.5
Table 4.8.4 
Reproducibility for 2EEA
Sample no. fig found fig expected % found % deviation
1 117.3 129.9 90.3 -9.7
2 118.1 126.7 93.2 -6 . 8
3 117.5 128.6 91.4 -8 . 6
4 117.4 127.1 92.4 -7.6
5 1 2 2 . 8 132.8 92.5 -7.5
6 121.9 133.6 91.2 -8 . 8
4.9 Desorption efficiency
The desorption efficiency for each analyte was determined by injecting microliter 
amounts of aqueous stock standards onto the front section of charcoal tubes. 
Aqueous standards were used because it was found that when methanolic standards 
were injected onto dry charcoal, part of the 2MEA and 2EEA reacted with the 
methanol via transestérification (alcoholysis). The reaction was presumably 
catalyzed by the basic surface of the charcoal. Eighteen samples were prepared,
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six samples for each concentration level listed in the following tables. The samples 
were stored in a refrigerator and analyzed the next day.
Table 4.9.1
Desorption Efficiency Data for 2ME and 2MEA
Analyte 2EE 2EEA
x target conc. 0.5* 1 * 2 * 0.5* 1 * 2 *
jjg/sample 7.537 15.07 30.15 1 1 . 6 6 23.32 46.63
ppm 0.050 0 . 1 0 1 0 . 2 0 2 0.050 0 . 1 0 1 0 . 2 0 1
Desorption 92.8 94.5 96.2 97.6 97.6 96.7
efficiency, % 96.8 97.7 97.0 98.8 98.0 98.3
93.0 94.0 98.0 97.4 98.3 98.0
97.1 96.4 97.6 97.5 99.6 96.9
95.8 94.9 96.2 97.9 99.1 96.7
90.7 97.9 97.3 98.1 98.4 96.9
X 94.4 95.9 97.0 97.9 98.5 97.2
X 95.8 97.9
Table 4.9.2
Desorption Efficiency Data for 2EE and 2EEA
Analyte 
* target conc. 
pg/sample 
ppm
0.5*
2EE
1 * 2 * 0.5x
2EEA
lx 2 x
44.69
0.2530
89.38 
0305
178.8
1 . 0 1
6435
0.248
128.7
0.496
257.4
0.992
Desorption 94.9 95.4 96.9 97.7 98.5 97.1
efficiency, % 95.3 97.3 97.7 99,1 98.8 98.4
93.1 94.9 98.4 98.6 98.8 98.2
97.3 97.2 98.3 98.3 1 0 0 . 2 97.5
95.4 97.7 96.9 98.5 99.5 96.8
93.0 98.8 98.1 97.9 98.9 97.3
X 94.8 96.9 97.7 98.4 99.1 97.6
X 96.5 98.3
4.10 Stability of desorbed samples
The stability of desorbed samples was checked by reanalyzing the target concentra­
tion samples from Section 4.9 one day later using fresh standards. The sample
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vials were resealed with new septa after the original analyses and were allowed to 
stand at room temperature until reanalyzed. The results are given in Table 4.10.
Table 4.10 
Stability o f Desorbed Samples 
at the Target Concentration
Sample no.
% desorption after 24 h
2ME 2MEA 2EE 2EEA
1 95.0 100.9 98.9 101.6
2 97.7 99.4 99.0 101.0
3 98.5 101.3 99.3 101.6
4 98.4 101.8 99.0 101.9
5 99.7 101.2 100.2 101.4
6 98.5 101.2 100.2 101.7
X 98.0 101.0 99.4 101.5
4.11 Chromatograms
A chromatogram of the four analytes is shown in Figure 4.11. The chromatogram 
is from an injection o f a standard equivalent to a 48-liter air sample at the target 
concentrations.
Figure 4.1.1 Detection limit chromatogram for 2ME.
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Figure 4.1.2 Detection limit chromatogram for 2MEA, 2EE, and 2EEA.
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Figure 4.4.1 Instrument response to 2ME and 2MEA.
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Figure 4.4.2 Instrument response to 2EE and 2EEA.
Figure 4.5.1.1 2ME refrigerated storage samples.
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Figure 4,5.1.2 2ME ambient storage samples.
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Figure 4.5.3.1 2EE refrigerated storage samples.
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Figure 4.S.4.2 2EEA ambient storage samples.
0.00 l .s e  3.12 4.88 a .25 7.81 9.37 10.83 12. BO
E l u t i o n  T i m e  ( m i n u t e s )
Figure4.11 Chromatogram o f a standard at the target concentrations. Key: (1)2M E , 
(2) 2EE, (3) 3-methyl-3-pentanol, (4) 2MEA, (5) 2EEA. Other peaks: (A) methyl alcohol, 
(B) methylene chloride, (C) chloroform (impurity in methylene chloride), (D) cyclohexene 
(preservative in methylene chloride).
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UNION CARBIDE METHOD OF AIR MONITORING FOR GLYCOL ETHERS: 
DETERMINATION OF GLYCOL ETHERS IN AIR BY ADSORPTION ON 
ACTIVATED CHARCOAL AND PASSIVE DOSIMETERS WITH SUBSEQUENT 
ANALYSIS BY GAS CHROMATOGRAPHY1
INTRODUCTION
This bulletin details the air monitoring and analytical procedures used by Union Carbide 
Corporation in obtaining personal air samples to determine the degree of exposure, if  any,
* Reprinted from an unpublished bulletin of the Union Carbide Corporation, Tarrytown, NY 10591.
5 REFERENCES
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of its employees to glycol ethers and glycol ether acetates. New information has been 
included in this booklet concerning the use of PASSIVE MONITORS as an alternate method 
to evaluate employee exposure. These PASSIVE MONITORS have become very popular 
recently because they are small, light-weight badges that are worn by the employee and do 
not require sampling pumps or other forms of calibration.
It is the intention of this bulletin to provide those who use glycol ethers or glycol ether 
acetates with all of the information available within Union Carbide in detecting and defining 
personal exposure to the chemicals. You are strongly urged to make use of this information 
to determine the degree of such exposure of your employees to these chemicals. This bulletin 
is designed as an aid to you in establishing and implementing your exposure limitation and 
reduction program.
METHOD
The method featured in this booklet can be used to measure several glycol ethers in the work 
environment. Union Carbide has confirmed the validity of the charcoal tube sampling 
method for:
Methyl CELLOSOLVE®
Methyl CELLOSOLVE® Acetate 
CELLOSOLVE® Solvent 
CELLOSOLVE® Acetate
while the Passive Dosimeter part of the method can be used for sampling:
Methyl CELLOSOLVE®
Methyl CELLOSOLVE® Acetate 
CELLOSOLVE® Solvent
1. Principle
The sample is collected by drawing air through a glass tube containing activated charcoal 
(SKC-226-01) or by using a passive dosimeter (3M #3500 Organic Vapor Monitor) 
containing petroleum based carbon. The adsorbed glycol ethers and/or glycol ether acetates 
are then desorbed from the adsorbent with a 5% (v/v) methanol in methylene chloride 
solution and analyzed by gas chromatography with a flame ionization detector.
2. Range, Stability and Interference
This method has been validated for sampling air concentrations of the stated glycol ethers 
and their acetates from 2 to 25 ppm by volume in air. The method can be used for higher 
concentrations; however, the higher range has not been validated by Union Carbide.
Because some o f the compounds may become hydrolyzed when sampled in high humidity 
atmospheres, the analysis of the charcoal tube samples must be completed within 24 hours
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of the sampling. However, in the case of CELLOSOLVE solvent, samples can be stored 
for up to 14 days in a refrigerator but should be analyzed within 90 minutes after desorption.
In the case of passive dosimeters, the sample may be refrigerated for up to five days prior 
to analysis without any significant less.
The presence of other glycol ether vapor with similar molecular weights and vapor pressure 
may result in interference.
3. Instrument Parameters
Chromatograph
Detector
Column
Alternate column
Temperatures
Column
Detector
Injection Port
Carrier gas and flow rate
Air flow rate
Hydrogen flow rate
Sample size
Approximate retention
time
Recorder
Hewlett-Packard 5830A or equivalent 
Flame ionization
3.05 m x 3.2 mm (10-ft x 1/8-inch) stainless 
steel packed with 5% FFAP on 80/100 mesh, acid 
washed DMCS 
Chromosorb W
Same as above except 10% FAPP loading
100°C
250°C
250°C
nitrogen at 30 cc per minute 
250 cc per minute 
20 cc per minute 
2 fiL, solvent flush technique
Methyl CELLOSOLVE®: 2.45 min.
Methyl CELLOSOLVE® acetate: 3.25 min. 
CELLOSOLVE® Solvent: 5.6 min. 
CELLOSOLVE® Acetate: 3.0 min.
0-1 mV recorder or electronic integration
4. Apparatus
a) Personal sampling pump. MSA Model S, Sipin SP-2, SK C-222-3 or equivalent.
b) Charcoal tube. Coconut-Base, 150 mg. SKC Catalog, No. 226-01, SKC Inc. RD1, 
395 Valley View Road, Eighty Four, PA 15330.
c) 3M Organic Vapor Monitor, #3500 3M Occupational Health and Safety Products 
Division, P.O. Box 33155, St. Paul, MN 55101.
d) Syringes, 1 0 ,2 5 ,100-fiL Hamilton, or equivalent.
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e) Pipets, I and 2-tnL graduated, 1, 2, and 5-mL (Repipef dispenser may be used to 
add desorption solvent to vials. Cat. No. 13-687-54, Fisher Scientific Co., or 
equivalent).
f) Balston DFU Grade B filter. Balston, Inc., P.O. Box C, 703 Massachusetts Ave., 
Lexington, MA 02173. The same filter is also available from DuPont Company, 
Applied Technology Division, Room B1275, Wilmington, DE 19898, Part No. 
P101.
g) Vials, 4.0-mL screw-capped septum, Cat., No. 2-2954, Supelco, Inc., Bellefonte, 
PA 16823 or equivalent.
h) Flasks, 10 and 100-mL, volumetric.
i) Rotameter, calibrated to measure flows in the 1000 cc per minute range or equivalent.
j) File, 3-comer for scoring sample tubes.
k) Wire, small diameter with hook formed at end to remove charcoal retainers from 
sample tube.
1) Sample tube holder, Size A, SKC Cat. No. 222-31, SKC, Inc., Eighty Four, PA or 
equivalent.
m) Soap film flow meter, 0-250 mL and 0-1000 mL to calibrate pumps and rotameter.
n) Developing vibrator, SKC Cat., No. 226-D -03-115, SKC, Inc., Eighty Four, PA or 
equivalent.
o) Sample tube opener. Tape a 4 * 6-inch piece of 1/2-inch plywood (or equivalent) to 
the top o f a 6 * 6 x 6-inch cardboard box and drill a 7-mm hole through the plywood 
into the box.
p) 3M Organic Vapor Monitor Badge Sampling Chamber. Available from 3M, Oc­
cupational Health and Safety Division, P.O. Box 33155, St. Paul, MN 55101.
5. Reagents
a) Methanol, ACS Grade
b) Methylene Chloride ACS Grade
c) Methyl CELLOSOLVE®
d) Methyl CELLOSOLVE® Acetate
168
Appendix A
e) CELLOSOLVE® Solvent
f) CELLOSOLVE® Acetate
g) Nitrogen, high purity
h) Hydrogen, high purity
i) Compressed air-filtered
6. Sampling Procedure With Charcoal Tubes
a) Calibration of personal pumps: Each pump must be calibrated with a representative 
sample tube in line. This will minimize errors associated with uncertainties in the 
sample volume collected. Use soap film flowmeter to determine the sampling pump 
flow rate.
b) Immediately before sampling, break the tips o f each tube to be used to provide 
openings of at least 2mm.
c) Attach the tube to a portable pump with the back-up section next to the pump by 
means o f a piece of Tygon tubing of the desired length.
d) Long-term sampling: Set the air flow rate through the charcoal tube for 50 to 200 cc 
per minute. Collect 15 to 30 liters volume.
e) If a personal sample is to be taken, put the tube in an appropriate holder to protect 
the individual from the glass tube.
f) Record the stroke count, if using pump with counter, time, temperature, relative 
humidity, and barometric pressure when the air sampling is started.
g) At the end of the sample time stop the pump, seal the ends o f the sample tube, record 
the stroke count, if required, and the time, temperature, relative humidity, and 
barometric pressure. Return the tube to the laboratory for analysis.
h) Short-term sampling. Flow rates of up to one liter per minute can be used to collect 
a sufficient quantity o f the analyte to measure quantitatively. Use a MSA Model S 
personal pump or equivalent to obtain the flow rates.
i) Determine the actual flow rate through the charcoal tube by means o f a soap film  
meter or a calibrated rotameter.
j) Record the flow rate, time, temperature, relative humidity and barometric pressure, 
when sampling is started.
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k) At the end o f the sampling period, recheck and record the flow rate, seal the ends of 
the tube, record the time, temperature, relative humidity, and barometric pressure 
and return the tube to the laboratory for analysis.
1) Sample tubes must be analyzed within 24 hours if stored at room temperature.
m) Break the tips from a tube at the same time the sample tubes are opened to be used 
as a blank. Cap, and return to the laboratory with the sample tubes.
7. Sampling Procedure with 3M Organic Vapor Monitors
a) Remove from protective pouch and clip monitor to lapel of worker near the breathing 
zone.
b) Record the time, temperature, relative humidity, and barometric pressure when the 
air sampling has started.
c) At the end of the sample time, remove the white face and retaining ring and snap on 
the elutriation cap. Firmly close both ports. Record the time, temperature, relative 
humidity, and barometric pressure.
d) Place monitor back in original package and seal.
e) Samples may be stored up to 5 days refrigerated before laboratory analysis.
f) Remove a monitor from the pouch at the same time the sample monitors are removed 
to be used as a blank. Reseal immediately and return to the laboratory with the 
sample monitors.
8. Analytical Procedure For Charcoal Adsorption Tubes
a) Wash all glassware with hot soapy water and rinse with distilled water followed by 
acetone. Air- or oven-dry to remove all traces of acetone.
b) Score the sample tube between the end and the primary section retainer and break 
off the end of the tube in the tube opener (care must be exercised to prevent loss of 
the bent wire retainer and possible loss of the glass wood and charcoal).
c) Make a small hook at the end o f a piece o f wire and remove the glass wool retainer 
plug and discard. Make sure no charcoal particles adhere to the glass wool plug.
d) Transfer the charcoal from the primary section and back-up section o f the tube into 
separate Supelco desorption vials. Cool in wet ice 5 minutes while capped.
e) Pi pet 5 mL o f methanol into 95 mL o f methylene chloride and mix w ell. Pipet
1.0 mL o f this solvent into each desorption vial and cap securely.
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f) Shake or vibrate gently for 30 minutes.
g) Solvent flush injection technique. This injection technique is designed to eliminate 
difficulties arising from blow-back or distillation within the needle o f the microliter 
syringe.
h) Flush a 10-^L syringe with the methanol-methylene chloride desorption solution 
several times to wet the barrel and plunger.
i) Draw a 1 ¿iL of methanol-methylene chloride solution into the syringe and remove 
the tip o f the needle from the solution. Withdraw the plunger and additional 0.5 jjL 
to separate the methanol-methylene chloride from the sample with a pocket of air.
j) Dip the needle into the sample solution in the desorption vial and withdraw the 
plunger until the air bubble between the solvent and the sample has passed the 3-jjL 
mark on the syringe.
k) Remove the top of the needle from the sample solution and adjust the volume in the 
syringe until the meniscus of the air bubble rests on the 3-yL mark. Remove the 
excess sample solution from the tip o f the needle.
1) Pull the plunger back an additional 0.5 jiL to prevent the sample solution from 
evaporating from the tip of the needle.
m) Inject the entire contents of the syringe into the chromatograph.
n) Measure the peak area or height and determine the organic content from a previously 
prepared calibration curve.
o) Analyze the backup (small) section of charcoal tube in the same manner as the 
primary.
p) Analyze the blank tube in the same manner as the sample tube.
9. Analytical Procedure For 3M Organic Vapor Monitors
a) Open the center élutriation port and inject 1.5 mL of 5fi MeOH as CH2CI2 with a 
syringe.
b) Close the center port and allow to elutriate for 1/2 hour with occasional gentle 
agitation. Be sure to not let any desorption solvent get on the élutriation cap.
c) Solvent flush injection technique. This injection technique is designed to eliminate 
difficulties arising from blow-back or distillation within the needle of the microliter 
syringe.
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d) Flush a 10-pL syringe with the methanol-methylene chloride desorption solution 
several times to wet the barrel and plunger.
e) Draw 1 pL o f methanol-methylene chloride solution into the syringe and remove the 
tip o f the needle from the solution. Withdraw the plunger an additional pL to 
separate the methanol-methylene chloride from the sample with a pocket o f air.
f) Dip the needle into the center elutriation port and withdraw the plunger until the air 
bubble between the solvent and sample has passed the 2-pL mark on the syringe.
g) Remove the top o f the needle from the sample solution and adjust the volume in the 
syringe until the meniscus o f the air bubble rests on the 3-fiL mark. Remove the 
excess sample solution from the tip o f the needle.
h) Pull the plunger back an additional 0.5 jjL to prevent the sample solution from 
evaporating from the tip o f the needle.
i) Inject the entire contents of the syringe into the chromatograph.
j) Measure the peak area or height and determine the organic content from a previously 
prepared calibration curve.
k) Analyze the blank monitor in the same manner as the sample monitor.
10. Calibration Curve
a) Determine quantities of analyte required to prepare standards in desired range based 
on a 15 liter sample by referring to Table A.
b) Inject standards in the chromatograph using the solvent flush procedure described 
in the analytical procedure.
c) Plot peak height or area versus micrograms o f analyte per mL.
11. Desorption Efficiency
a) Desorption efficiency (percentage o f adsorbed analyte desorbed from the charcoal 
by the desorbing solution) can vary from one laboratory to another and from one 
batch o f charcoal to another.
b) Make up an analyte (glycol ether or acetate sampled) standard in the desorption 
solvent that will allow injection of 2 to 10 microliters of standard to cover the range 
desired. Use a 10 mL syringe to inject the standard in the charcoal and 3M Organic 
Vapor Monitor.
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c) Calculate the microliters o f analyte (glycol ether or acetate sampled) standard to be 
added to the adsorption tube based on a 15 liter sample of 0 .5 ,1 .0  and 2.0 times the 
TLV-TWA or the expected concentration using the following equation:
TLV or TWA * V x MW
G x 24.450 s
A s * pL of analyte to be added to the selected
volume of solvent to produce a solution of the 
desired ppmv
G “ specific gravity of analyte at temperature being
measured (specific gravity at 20/20°C ± A sp. 
gr. /  A T x temperature difference)
MW = molecular weight o f analyte
TLV or TWA m threshold limit value - time weighted average
in ppm
V “ volume of air sample in liters
24.450 ” molar volume (mL per mole) at 25°C and
101.3 kPa (760 mm o f Hg)
d) The recommended number o f tubes at each level is six plus three blanks for a total 
of twenty-one tubes. Tubes used for the desorption efficiency study must be of the 
same lot that will be used for monitoring the work place. If practical, analyte should 
be added to the front of the primary section of charcoal in the tube and humidified 
air (to approximate work place air) pulled across the tube to total twenty liters at 
flow rates up to 500 cc per minute by personal pumps or a vacuum manifold. Air 
can be humidified by passing cylinder air through three bubblers in series containing 
distilled water and directing the eluent into a sampling chamber. Total flow in the 
chamber must be more than that being withdrawn through the tubes. If this proves 
impractical, 100 mg of charcoal from the tubes may be transferred to each of a 
sufficient number o f desorption vials (twenty-one), the analyte added, the vials 
capped and allowed to stand overnight to allow the analyte to permeate the charcoal. 
Analysis is accomplished using the procedure in Section 10.
e) The recommended number of 3M Organic Vapor Monitors at each level is six plus 
three blanks for a total of 21 monitors. The monitors used for the desorption 
efficiency study must be of the same lot that will be used for monitoring the work 
place. If practical, analyte should be added to the monitor through the white face 
onto the charcoal pad. Humidified air (to approximate work place air) is pulled 
across the monitor to total fifteen liters at flow rates up to 500 cc per minute by a 
3M Organic Vapor Monitor Badge Sampling Device. Air can be humidified by 
passing cylinder air through three bubblers in series containing distilled water and 
directing the eluent into a sampling chamber. Total flow into the chamber must be 
more than that being withdrawn through the monitors. Analysis is accomplished 
using the procedure in Section 11.
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f) Calculation o f the desorption efficiency
A i B  = d e
A = average peak area or peak height o f sample 
B = average peak area or peak height of blank 
DE *= desorption efficiency 
S ” average peak area or peak height o f standard
Plot the description efficiency versus the pg/mL found.
12. Calculations
a) Read the weight in pg/mL corresponding to each peak area or height from the 
calibration curve and convert to total micrograms by multiplying the fig/mL by the 
desorbant volume in milliliters.
b) Correct each sample weight for the blank, 
fig sample - jig blank “ fig sample, corrected
fig sample ” jig found in front section o f sample tube 
jig blank * pg found in front section o f blank tube
c) Follow a similar procedure for the back-up section.
d) Add the amounts present in front and back-up sections to determine the total weight 
in the sample.
e) Read the desorption efficiency (DE) from the DEC curve for the amount found in 
the sample tube. Divide the total weight by the DE to obtain the corrected pg/sample.
Total Weight ,g— = corrected pg/sample
DE ~ desorption efficiency 
Total Weight “ fig o f analyte found in the front section o f the sample 
tube - pg found in the front section o f the blank tube 
+ pg of analyte found in the backup section o f the 
sample tube.
f) Correct the volume of air sampled to standard conditions o f 25°C and 760 mm of 
pressure.
V x P x 298
760 * (T+273) = vo u^me sample hi liters at 25° C and 760 mm o f pressure
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P = barometric pressure in mm of mercury 
T ” temperature (°C) of air sampled 
V * volume o f air sample in liters as measured 
760 = standard pressure in mm o f mercury 
298 = standard temperature (°K)
NOTE: The sampling rate for the 3M Organic Vapor Monitors has been determined 
by 3M as being 36.3 cc/min for methyl CELLOSOLVE®, 29.0 cc/min for methyl 
CELLOSOLVE® acetate, and 32.2 cc/min for CELLOSOLVE® Solvent.
g) The concentration o f the analyte in the air sampled can be expressed in milligrams 
per cubic meter.
Corrected micrograms _ . 3
Air volume samples (liters)
h) Another way of expressing concentration is ppmv.
mg/m3 x 24.45
 ^  = ppmv
MW = molecular weight (g/mole) o f the analyte 
24.45 ” molar volume (liters/mole) at 25° C and 760 mm of pressure
13. Other Relevant Information
The National Institute for Occupational Safety and Health has published other sampling and 
analytical methods for glycol ethers. The recently consolidated NIOSH Manual of Analyti­
cal Methods, Vol. 1 contains Method #1403, which can be used for Methyl CELLOSOLVE® 
and CELLOSOLVE® Solvent while Method #1450 can be used for CELLOSOLVE® 
Acetate. It is also stated in this manual that NIOSH intends to revise their previously 
published method for Methyl CELLOSOLVE® Acetate (S39).
In addition to the 3M #3500 Organic Vapor Monitoring Badge, passive dosimeter badges 
from other manufacturers, such as Dupont’s Pro-Tek® Organic Badge, may also be used for 
monitoring glycol ethers. Please contact the manufacturer for information concerning the 
suitability of their monitors for specific glycol ethers or glycol ether acetates.
Some firms are also known to provide analytical services for these monitors for specific 
chemicals, including glycol ethers. This may be useful for some of the smaller locations 
which do not have air sampling equipment and/or on-site analytical capabilities o f their own. 
Further information about the NIOSH methods or passive monitors may be obtained from 
the NIOSH regional office or equipment manufacturer.
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Further information on this subject or the Union Carbide method may be obtained from
Union Carbide Corporation 
Saw Mill River Road 
Route 100 C 
Tarrytown, NY 10591 
(914)789-2232
TABLEA  
Calibration Curve Standards
Analyte
Molecular
weight
Specific 
gravity 
at 25°C
Microliters 
for 10 mL
solvent
Micrograms 
per mL
Air con c. (ppm), 
15-liter sample
CELLOSOLVE® 132.16 0.9708 1.4 136 1.7
Acetate
42 408 5.0
8.4 815 10.0
21.0 2,039 25.1
CELLOSOLVE® 90.12 0.9269 1.0 93 1.7
Solvent
3.0 278 5.0
6.0 556 10.1
15.0 1,390 25.1
Methyl 76.10 0.9617 0.8 77 1.6
CELLOSOLVE®
2.4 231 4.9
4.8 462 9.9
12.2 1,173 25.1
Methyl 118.13 1.0012 12 120 1.7
CELLOSOLVE®
Acetate
3.6 360 5.0
12 721 9.9
18.0 1,802 24.9
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GLYCOL ETHER TOXICITY IN ANIMALS
B.1 MALE REPRODUCTIVE EFFECTS 
B.1.1 EGEE and EGEEA
B.1.1.1 Subcutaneous and Intravenous Administration
Reports in the literature indicate that EGEE and EGEEA exert adverse effects on the male 
reproductive system. Histopathological testicular changes were reported in rats treated 
subcutaneously (s.c.) with varying doses of EGEE (93, 186, 372, or 744 mg/kg per day) 
[Stenger et al. 1971 ]. Treatment of five rats/group for 4 wk with 372 mg EGEE/kg per day 
caused testicular damage. The interstitium of the testes was edematously disintegrated; 
parent spermatophores were found in the tubuli between typical Sertoli cells, and in some 
instances, powdery spermatophores and spermatocytes were found in several layers. In most 
instances, there were no additional maturation stages; polynuclear cells were found oc­
casionally. Limited changes in the liver and kidneys were also observed. Subcutaneous 
administration o f 744 mg EGEE/kg per day caused occasional edema and hemorrhaging at 
the injection site. The histopathological changes described in the 372 mg EGEE/kg per day 
group were more pronounced in the 744 mg EGEE/kg per day group. Stenger et al. [ 1971] 
also noted that treating dogs (two per group) i.v. for 22 days with 93 mg EGEE/kg per day 
resulted in inflammation at the injection site, and treatment with 465 mg EGEE/kg per day 
caused pronounced thrombophlebitis.
B.1.1.2 Oral Administration
Twenty male albino rats were fed 1.45% EGEE in their basic diet for 2 yr [Morris et al. 
1942]. Upon histological examination, testicular enlargement and edema and tubular 
atrophy were observed in two-thirds o f the animals that had received EGEE. These changes 
were not seen in untreated controls. The testicular lesions were more often bilateral than 
unilateral and consisted of marked interstitial edema.
Oral administration o f 46.5 or 93 mg EGEE/kg per day for 13 weeks to male dogs (three 
per group) had no adverse effect [Stenger et al. 1971 ]. On the other hand, oral administration 
of 186 mg EGEE/kg per day for 13 wk caused degenerative changes in the testes o f all
*References for Appendix B can be found beginning on page 262.
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three animals. In one dog, the lumen o f the tubuli appeared to be expanded, and the last 
maturation stages of the seminal epithelium clearly were absent in many o f the tubuli. 
In the second dog, tubuli were constricted, and parent and powdery spermatophores had 
been retained. In the third dog, there was a conspicuous flattening o f germinal 
epithelium with complete absence o f upper layers; the parent epithelium was, in some 
cases, absent in these tubuli. Slight kidney changes were observed in two o f the three 
dogs; the lumen in the region o f the tubuli contorti was expanded, and the epithelium  
was flattened.
In another set o f experiments by Stenger et al. [1971], groups o f five rats per dosage level 
were orally administered 46.5 or 93 mg EGEE/kg per day for 13 wk or 93 mg EGEE/kg per 
day for 59 days followed by an oral dose of 372 mg EGEE/kg per day for the remainder of 
the 13-wk period. No adverse effects were observed at these doses. Following oral 
administration of 186 mg EGEE/kg per day for 13 wk, the testicular interstitium was 
occasionally broken down edematously, and there was a lack o f mature cells in the canals. 
The oral administration of 186 mg EGEE/kg per day for 59 days, followed by oral 
administration o f 744 mg EGEE/kg per day for the 32 days remaining in the 13-wk period, 
also caused testicular changes that corresponded to findings following a 4-w ks.c. application 
of 744 mg EGEE/kg per day. The diameters o f tubuli were also reduced.
Nagano et al. [1979] treated groups of five male JCL-ICR mice orally with various doses 
(500, 1,000, 2,000, or 4,000 mg/kg per day) o f EGEE or EGEEA 5 days/wk for 5 wk. 
Testicular atrophy was observed and assessed in terms of testicular weight, both absolute 
and relative to body weight. Statistically significant decreases in the testicular weights of 
exposed animals in comparison to control animals were noted in those given doses of at least
1.000 mg/kg per day of either EGEE or EGEEA (P<0.05). Histologically, varying dosage- 
related degrees o f seminiferous tubule atrophy were observed. In the 2,000 mg EGEE/kg 
per day and the 4,000 mg EGEEA/kg per day groupe, the diameter of the seminiferous 
tubules decreased, spermatozoa and spermatids completely vanished, and spermatocytes 
existed in extremely small numbers in only some o f the tubules; interstitial tissue also 
increased. When expressed as moles/kg per day, EGEE and EGEEA exerted the same 
degree of testicular toxicity [Nagano et al. 1979].
Foster et al. [1983] administered EGEE (250, 500, or 1,000 mg/kg per day) or EGEEA at 
727 mg/kg per day (equimolar to 500 mg EGEE/kg per day) orally foi 11 days to 36 male 
Sprague-Dawley ratsi/group. Animals treated with equivalent volumes o f the water vehicle 
served as controls. A statistically significant decrease in testes weights was noted on day 
11 in the 500 (P<0.01) and 1,000 mg (P<0.Q5) EGEE/kg per day groups. Although the 
degree of spermatocyte degeneration and depletion was similar for both dosage groups, the 
onset of degeneration was more rapid with the 500 mg EGEE/kg per day dose than with
1.000 mg/kg per day. Testicular degeneration was restricted to the later stages of primary 
spermatocyte development and secondary spermatocytes. Partial maturation depletion o f 
early stage spermatids occurred, whereas Sertoli cells, Leydig cells, spermatogonia, and 
pre-pachytene spermatocytes were unaffected. Animals treated with EGEEA at a dose 
equimolar to 500 mg EGEE/kg per day showed a similar pattern o f testicular damage 
[Foster et al. 1983]. These findings were confirmed in a similar set o f experiments using
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EGEE in which testicular lesions were examined at sequentially timed intervals (1/4, 1 ,2 , 
4, 7, and 11 days) during the dosing period of 11 days [Creasy and Foster 1984]. EGEE 
exerted no adverse testicular effect at 250 mg/kg per day, but it did at doses o f 500 and
1,000 mg/kg per day. Although no testicular abnormalities were observed in any of the 
groups 6 hr after dosing, degenerative spermatocytes were frequently seen 24 hr after dosing 
with EGEE. Dose levels o f500 and 1,000 mg EGEE/kg per day produced degeneration of 
the dividing and early-pachytene spermatocytes but had no effect cm the middle and late 
stage o f pachytene development. Although the 500 mg EGEE/kg per day induced a more 
extensive lesion than did 1,000 mg EGEE/kg per day after 48 hr of dosing, this trend was 
reversed with prolonged dosing. The authors concluded that primary spermatocytes under­
going pachytene development constitute the initial and major site of morphological damage 
[Creasy and Foster 1984].
Ethoxyacetic acid (EAA) and its glycine conjugate are known metabolites o f EGEE [Jonsson 
et al. 1982; Cheever et al. 1984]. Foster et al. [1987] undertook the following study to 
support the contention that the testicular toxicity o f EGEE [Foster et al. 1983] is due to the 
toxicity exerted by EAA. Foster et al. [1987] exposed groups o f six male Alpk/AP 
(Wistar-derived) rats to a single coal dose of EAA (137, 342, or 684 mg/kg) to determine 
the initial target for testicular toxicity. Rats were sacrificed at 1, 2, 4, and 14 days 
post-treatment. Histological examination revealed that dosing with EAA induced testicular 
damage at the highest dose level only; diplotene, diakinetic, secondary, and early pachytene 
spermatocytes were affected at 24 hr, with effects on round spermatids seen at day 14. The 
pachytene spermatocytes had previously been identified [Fester et al. 1983] as the target o f 
EGEE toxicity.
In a 2-yr study, groups of 50 Fischer 344/N rats and 50 B6C3Fj mice of both sexes were 
administered EGEE by gavage at dose levels of 0, 500, 1,000, and 2,000 mg/kg per day 
[Melnick 1984]. Repeated administration of EGEE at the 2,000 mg/kg dose level was lethal 
to rats and mice, and death appeared to result from stomach ulcers. As a consequence of 
the high mortality rate, the high dose (2,000 mg/kg per day) group was terminated at wk 17 
to 18. Gross and microscopic examinations at the end of the study revealed testicular atrophy 
in male rats and mice at all doses o f EGEE.
The effect of EGEE on spermatogenesis was studied by Oudiz et al. [1984]. Groups o f 16 
Long-Evans hooded male rats were treated by gavage on 5 consecutive days with 0 ,936 , 
1,872, or2,808 mg EGEE/kg per day. The animals were then mated weekly for the following 
14 wk with ovariectomized females, and ejaculated semen samples recovered from females 
immediately following copulation were analyzed al selected timepoints over a 16-wk 
period. The males were killed at wk 16, and the testes and epididymides were submitted 
for histological examination. Exposure to 936 mg EGEE/kg per day impaired testicular 
function as reflected in an increased percent of abnormal sperm forms as well as in decreased 
sperm count; azoospermia and oligozoospermia were observed in the higher-dose groups 
(1,872 and 2,808 mg EGEE/kg per day). Although there appeared to be no effect on motility, 
a significant decline in sperm count, relative to that of the controls, occurred as early 
as wk 4 post-exposure in the groups receiving 1,872 mg EGEE/kg per day (P<0.001) 
and 2,808 mg EGEE/kg per day (P50.01). The most dramatic effects were noted at wk 7
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postexposure; at this time, the Iow-dose group (936 mg EGEE/kg per day) also exhibited 
significantly decreased (P50.01) sperm counts and increased (PS0.05) abnormal forms 
in the semen. Partial recovery of sperm count was evident in semen samples collected at 
wk 14 in the group receiving doses of 1,872 mg EGEE/kg per day where sperm counts were 
40% of the baseline value o f 58.8 * IO6 sperm/ml of recovery fluid. Animals in the group 
receiving the high dose (2,808 mg EGEE/kg per day) manifested total recovery of sperm 
counts by wk 14. Insult resulting from EGEE treatment also occurred on the epididymis. 
Epididymal weights in the group receiving 1,872 mg EGEE/kg per day were significantly 
lower than those o f the controls (P<,0.05), whereas differences between the high-dose 
(2,808 mg EGEE/kg per day) and control groups only approached significance 
(P<0.10).
In a later study by Oudiz and Zenick [1986], the time course of effects on rat sperm 
parameters was examined. Male rats were treated orally with 936 mg EGEE/kg per day, 
5 days/wk for 6 wk. Semen samples were collected on a weekly basis during the 
exposure period from ovariectomized, hormonally primed females 15 min after mating. 
The samples were analyzed for sperm count, sperm morphology, and sperm motility. 
All males were sacrificed 3 days after cessation o f treatment. The weights o f testes, 
epididymides, vas deferens, prostates, and seminal vesicles were recorded at termina­
tion. The EGEE-treated males had significantly decreased sperm counts at wk 5 and 6 
when compared with those o f the controls (P<0.001). A 30% to 40% decline in sperm 
counts was noted at wk 5, and by wk 6, 3 of the 10 EGEE-treated males were azoo- 
spermic. The remaining rats had severely reduced sperm counts ranging from 5 to 30 
m illion compared with counts o f 70 to 78 million sperm in the unexposed group. At 
wk 5 and 6, there were significant increases in abnormal sperm morphology for the 
EGEE-treated males (P<0.01), and at wk 6, a significant decrease in percent sperm 
motility (P<0.01) was seen in the EGEE-treated males. There were also significant 
decreases in the weights o f testes and epididymides (P<0.01), although there was no 
effect on the weights o f vas deferens [Oudiz and Zenick 1986].
0.7.7.3 inhalation
In two separate reports o f a single study, Terrill and Daly [1983a,b] and Barbee et al. [1984] 
exposed Sprague-Dawley CD rats (15 per group) and New Zealand white rabbits (10 per 
group) o f both sexes to EGEE vapor at 0 ,2 5 , 100, or 400 ppm for 6 hr/day, 5 days/wk for 
13 wk. The only significant alterations noted in the rats were decreased pituitary weights 
in males exposed to 400 ppm (P<0.05) and reduced spleen weights in females exposed to 
100 or 400 ppm EGEE (P<0.01). The rabbit was more sensitive to EGEE exposure. Mean 
body w eights decreased for low  (25 ppm EGEE, P<0.05) and high exposure groups 
(400 ppm EGEE, P<0.01), whereas animals in the middle (100 ppm EGEE) group showed 
no change. However, pathological changes supportive of these organ weight changes were 
not observed. The testis weights of rabbits were decreased significantly at 400 ppm EGEE 
(P<0.01). Microscopic examination of testes in this group revealed slight focal seminiferous 
tubule degeneration in 3 o f 10 rabbits. The authors concluded that no biologically significant 
effects were observed in rats exposed at 400 ppm EGEE and in rabbits exposed at 100 ppm 
EGEE.
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Toxicity of EGME on the male reproductive system was first demonstrated in rabbits by 
Wiley et al. [1938]. Two male rabbits received two or three injections o f unspecified doses 
of EGME; both animals developed degeneration o f the germinal epithelium.
B.1,2 EGME and EGMEA
B.1.2.1 Oral Administration
Nagano et al. [ 1979] treated groups o f five male JCL-ICR m ice by gastric intubation 
5 days/wk for 5 wk with EGME or EGMEA (6 2 .5 ,125 ,250 ,500 ,1,000s, and 2,000 mg/kg). 
Testicular atrophy was assessed in terms of testicular weight, both absolute and relative to 
body weight. Statistically significant decreases (P<0.01) in testes weights were seen in 
animals given doses of 250 mg EGME/kg per day or greater or 500 mg EGMEA/kg per day 
or greater when compared with controls. Graphs o f testes body weight ratios per dose were 
almost identical for EGME and EGMEA when doses were expressed as mmoles per kg body 
weight. Dose-related seminiferous tubular atrophy was observed in the mice with decreased 
testicular weight, with the 1,000 mg EGME/kg per day and 2,000 mg EGMEA/kg per day 
groups having no germ cells present. Histologically, varying dosage-related degrees of 
testicular seminiferous tubule atrophy were noted. At 250 mg o f EGME and 500 mg of 
EGMEA, spermatozoa and spermatids were seen in small numbers in some of the tubules 
and spermatocyte numbers were reduced. At 500 mg EGME/kg and 1,000 mg EGMEA/kg, 
the diameter of the seminiferous tubules decreased and spermatozoa and spermatids com­
pletely vanished although extremely small numbers of spermatocytes existed in some of the 
tubules; interstitial tissue also increased.
The relationship between oral administration of EGME and testicular damage was also 
investigated by Foster et al. [1983]. Groups of 36 male Sprague-Dawley rats received 
EGME orally at dosages of 0 ,5 0 ,1 0 0 ,2 5 0 , or 500 mg/kg per day. Six animals from each 
group were sacrificed at 6 and 24 hr, and at 2, 4 ,7 , and 11 days. Significant decreases in 
testicular weight (P<0.05) were evident at day 2 in the 500 mg EGME/kg per day group and 
became more pronounced (P<0.01) with increasing total dose (day 4 ,7 , and 11). At days
7 and 11, statistically significant decreases in testicular weight (P<0.01) were also seen in 
the 250 mg EGME/kg per day group.
Foster et al. [1983] also conducted a recovery study in which groups of male Sprague- 
Dawley rats received 500 mg EGME/kg per day orally for 4 days. After cessation of 
treatment, six animals from treated and control groups were sacrificed at 0  (the day after the 
last treatment), 2, 4, and 8 wk. A statistically significant decrease (P<0.001) in relative 
testicular weights was noted at 0 ,2 , and 4 wk, with testes weights returning to control values
8 wk following treatment. Seminal vesicle weights were significantly increased (P<0.05) 
at wk 8; the authors suggested this might have been due to increased testosterone levels 
[Foster etal. 1983].
Histological examination of testes from rats exposed to EGME at 100,250, and 500 mg/kg 
per day revealed degeneration of pachytene spermatocytes as early as 24 hr after a single
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dose, whereas dosing with 50 mg EGME/kg per day for 11 days produced no testicular 
abnormalities (no-effect level) [Foster et al. 1983]. The proportion of the spermatocyte 
population affected at 24 hr was related to dose. Progressive depletion o f spermatocytes 
and maturation depletion of early spermatids were observed with continued dosing. 
Degenerative changes (cellular shrinkage, increased eosinophilia, and nuclear pyknosis) 
were restricted to secondary spermatocytes and to pachytene, diplotene, diakinetic, and 
dividing stages o f primary spermatocyte development. Preleptotene, leptotene, and 
zygotene spermatocytes were unaffected. After 4 days of treatment with 500 mg EGME/kg 
per day and 7 days o f treatment with 250 mg EGME/kg per day, degenerative changes 
(chromatin margination) were evident in the spermatid population. After 11 days of 
treatment with 250 and 500 mg EGME/kg per day, spermatid and late spermatocyte 
populations were absent, and zygotene spermatocytes showed an increase in number; these 
events were indicative o f maturation arrest. Treatment for 11 days with 100 mg EGME/kg 
per day produced partial depletion and continued degeneration of spermatocytes and partial 
maturation depletion o f early spermatids. Ultrastructural examination of testes 24 hr after 
a single dose o f 100 mg EGME/kg per day showed spermatocytes with mitochondrial 
swelling and disruption, cytoplasmic vacuolation, and early condensation o f nuclear 
chromatin [Foster et al. 1983].
In the recovery study, the animals sacrificed 2 wk after 4 days o f dosing with 500 mg 
EGME/kg per day showed maturation depletion o f middle and late stage spermatids and 
maturation arrest of pachytene spermatocytes. At 4 wk after exposure, recovery was evident 
by the presence o f maturation phase spermatids, and by 8 wk, full spermatogenesis was 
present in the majority o f tubules from all animals [Foster et al. 1983]. The authors, in a 
separate publication [Creasy and Foster 1984], concluded that the data demonstrated a 
defined order of spermatocyte sensitivity: dividing spermatocytes (Stage 14) > early 
pachytene spermatocytes (Stages 1 through 3) > late pachytene spermatocytes (Stages 9 
through 13) > mid-pachytene spermatocytes (Stages 4 through 8) > leptotene/zygotene 
spermatocytes (Stages 9 through 14).
Similar studies were conducted by Chapin and Lamb [1984] using a different age and strain 
of rat. Forty adult male F344 rats were treated orally with 150 mg EGME/kg per day 
for 5 days/wk for up to 10 days. Controls received daily doses o f distilled water. Animals 
were killed on days 1 ,2 ,4 ,7 , and 10 after the start of dosing. As previously observed [Foster 
et al. 1983], degeneration o f spermatocytes appeared in treated animals 24 hr after a single 
dose o f EGME. Subsequently, a more consistent, progressive degeneration of sper­
matocytes and epithelial disruption were accompanied by a statistically significant reduction 
(P<0.05) in testicular weight. In contrast to the work o f Foster et al. [1983], a broader range 
of spermatocytes was affected, including leptotene and zygotene stages as well as pachytene 
stage spermatocytes and spermatids. An additional purpose o f this research was to correlate 
histologic changes with androgen binding protein (ABP), a Sertoli cell secretion, found in 
fluid collected at the rete testis after ligation o f the efferent testicular ducts. Six animals 
were treated with EGME as previously described and were sacrificed on days 2 ,4 , 7, and
10. No significant difference in production of testis fluid was observed between the ligated 
animals from treated and control groups; total protein and ABP activity in this fluid were 
unchanged by EGME treatment. The authors concluded that early and late spermatocytes
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are targets for EGME in the testes and that Sertoli cell functions, as measured by ABP levels, 
fluid production, and total protein profile, were unaffected [Chapin and Lamb 1984].
The following study was undertaken to assess possible effects of EGME on late stage and 
epididymal spermatids and on spermatogonia [Chapin et al. 1985a], Male F344 rats (20 per 
group) were treated orally with EGME at 0, 50,100, or 200 mg/kg per day for 5 days and 
then allowed to mate with two female F344 rats/week for 8 wk. At the end o f the 8-wk 
period, the male rats were housed singly for an additional 8 wk, and then allowed to mate 
again for 5 days. The percentage pregnancies decreased significantly (P<0.05) during 
wk 4 for females mated to high-dose males (200 mg EGME/kg per day) and remained 
significantly lower than controls for the duration of the study. At the 100 mg EGME/kg per 
day dosage, males demonstrated significantly reduced fertility at week 5 only (P<0.05). The 
fertility rate of males dosed with 50 mg EGME/kg per day was not affected by treatment. 
The mean number of live fetuses per pregnant female was significantly decreased (P<0.05) 
in the high-dose animals during wk 4 through 16 when compared with controls. Mid-dose 
(100 mg EGME/kg per day) males sired significantly fewer pups (P<0.05) at wk 5 only, 
whereas the number of live young sired by the 50 mg EGME/kg per day males was not 
significantly different from that of the controls. Statistically significant increases (P<0.05) 
in resorptions in females were found only in the high-dose group at wk 5 and 6. The 
high-dose group also demonstrated significantly increased (£*<0.05) preimplantation losses 
during wk 3 through 16. A significant increase (P<0.05) in preimplantation loss was also 
seen in the 100 mg EGME/kg per day group during wk 2 and 5 [Chapin et al. 1985a],
In addition to the above mating studies, Chapin et al. [1985a] also conducted sperm 
assessments in the same investigation using groups of 96 male F344 rats treated orally with 
EGME at the same doses as above. At weekly intervals for 8 wk, bilateral efferent duct 
ligation was performed on nine animals/group and the following day each was sacrificed. 
A dose and time-dependent change in the number of sperm/gram cauda epididymis was seen 
in the 100 and 200 mg EGME/kg per day groups. Both groups had significantly fewer 
(P<0.05) sperm/gram cauda at wk 2, and sperm counts remained significantly lower than 
did those o f the controls for the 8-wk study. High-dose animals had lower sperm counts 
than mid-dose animals. Rats treated with 50 mg EGME/kg per day had lower sperm counts 
at wk 5 only. Sperm motility was also significantly decreased (P<0.05) for high- and 
mid-dose animals: high-dose (200 mg EGME/kg per day) rats were significantly affected 
from wk 3 through 8, and sperm of mid-dose (100 mg EGME/kg per day) rats showed 
decreased motility from wk 4 through 8. Motility depression for both groups reached a 
maximum at wk 5 and 6, and then began to recover. The percentage of morphologically 
abnormal sperm was significant (P<0.05) at wk 3 for the high-dose group and at wk 5 for 
the mid-dose group, and remained significantly high for both throughout the study, reaching 
a maximum at wk 6 (mean 80% + 10%, high-dose group) and falling thereafter.
The authors [Chapin et al. 1985a] concluded that the fertility decline from wk 4 through 
wk 8 in the high-dose group suggested an effect of EGME on elongating testicular 
spermatids and cells at least as immature as intermediate or B spermatogonia. At 16 wk, 
fertility in these males was 70% that o f controls, indicating a relatively prolonged recovery 
process. This slow recovery demonstrates that A spermatogonia were also affected by
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EGME treatment at 200 mg/kg per day. They also concluded that, as the dose was increased, 
the number of types o f affected cells increased and that EGME was a very weak inducer o f 
dominant lethal mutations [Chapin et al. 1985a].
In a separate study, Chapin et al. [1985b] attempted to correlate the above noted fertility 
ind ie« with changes in testicular histology, the activity o f cell specific enzymes, and protein 
in fluid collected from the ligated rete testis. Adult F344 rats were treated orally with 0 ,5 0 , 
100, or 200 mg EGME/kg per day for 5 days. Three days later (wk 1), and at weekly intervals 
for the next 7 wk, nine rats/group were subjected to bilateral efferent duct ligation and 
sacrificed 16 hr later. In the 50 mg EGME/kg per day group, no change in the morphology 
of the testes was seen until wk 4, when condensed spermatids lacking tails were seen close 
to the basement membrane o f some tubules in some rats. At wk 5 through 7,20%  to 40% 
of stage 9 or 10 tubules contained these condensed spermatid nuclei near the basement 
membrane. By wk 8, none of the animals sacrificed had treatment-related lesions.
In the 100 mg EGME/kg per day group, numerous spermatid heads were seen near the 
basement membrane and pachytene spermatocyte death was frequent in stages 10 to 12 at 
wk 1. By wk 3, 100% o f the tubules were affected by early and late stage spermatid and 
pachytene spermatocyte loss, delayed spermiation, or numerous spermatid heads near the 
basement membrane. These effects persisted through wk 6, and by wk 8,50%  of stage 1 to 
5 tubules and some tubules of each stage were unaffected; delayed spermiation was less 
prominent [Chapin et al. 1985b].
All animals dosed with 200 mg EGME/kg per day showed severe testicular effects at wk 1. 
By wk 5, 10% to 30% of the tubules were indistinguishable from controls. Fifty percent 
appeared normal by wk 7; the remaining 50% were severely depopulated with delayed 
spermiation, and basally located spermatid heads were common in 50% to 80% of stage 9 
to 11 tubules [Chapin et al. 1985b],
The effects o f EGME on the epididymis were limited to tubular contents: high- and 
mid-dose groups had fewer sperm and many more immature germ cells than did the controls, 
whereas low-dose rats showed only a transient mild increase in the number o f immature 
germ cells and decreased sperm density at wk 2. The amount o f protein in rete testis fluid 
was elevated in the high-dose group at wk 2 through 5 and in the mid-dose group at wk 4 
and 6.
The authors [Chapin et al. 1985b] concluded that although the low dose o f EGME was 
designed to be a no-effect level, there were slight, previously noted [Chapin et al. 1985a] 
changes in epididymal sperm concentration and morphology, that is, a delay in spermiation 
and the presence o f tailless, basally located spermatid heads. In the 100 mg EGME/kg per 
day group, the observed histologic effects tended to be more severe and to diminish with 
increased time after dosing, until many tubules appeared normal by wk 8. Previous fertility 
data [Chapin et al. 1985a] showed that the pregnancy rate and number o f live pups were 
similar for the 100 mg EGME/kg per day group and controls at wk 8 also. The most 
widespread and persistent testicular damage was produced by 200 mg EGME/kg per day. 
Chapin et al. [1985b] also concluded that the elevation o f fluid protein levels suggests first
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that the ability o f the testes to secrete protein is not inhibited by EGME and second that the 
lack o f germ cells that normally take up this protein may have contributed to the elevated 
protein levels.
Anderson et al. [1987] investigated the stage-specific effect of EGME on spermatogenesis. 
Adult male CD rats and C D -1 mice were given single oral doses of EGME at 0 ,500, 750, 
1,000, or 1,500 mg/kg. Groups of 10 rats and 10 mice were sacrificed at weekly intervals, 
after dosing for a period o f 8 wk, for analysis of epididymal sperm counts and morphology 
or testicular histology; additional groups o f 10 EGME-treated animals were sequentially 
mated to pairs o f virgin females to test for dominant lethality or gross fetal malformations 
in the Fj generation (F1 abnormalities). In the rat, a reduction in testes weights was observed 
at all dose levels at wk 3, 4, and 5, but this effect disappeared in all but the 1,500 mg 
EGME/kg group by wk 6. At wk 4 ,5 ,6 , and 7, the sperm counts were significantly lower 
(P<0.001) in the EGME-treated groups compared with those o f the controls. A dose- 
dependent increase in abnormal sperm morphology was noted at all dose levels (P<0.01). 
In the EGME-treated mice, the mean testes weights were significantly lower than those of 
the control group® at wk 2 to 5, and apjp>eared to increase again towards the end of the study 
(statistics not given); there was also a tendency towards a dose-response relationship in the 
incidence o f abnormal sperm (statistics not given).
In the rat dominant lethal study, the total implant numbers among females mated at wk 5 to 
EGME-dosed rats were reduced in a dose-dependent manner (P 0 .0 0 1 ). Although there 
was a rise in preimplantation loss rate, there was no statistically significant evidence for the 
induction of dominant lethality. All rats were infertile at wk 6 after dosing except for those 
given the lowest dose (500 mg EGME/kg). No induction o f gross abnormalities in the 
offspring was noted (data not given). The histological study in the rats revealed a dose-de­
pendent response to EGME-treatment. One day after treatment with 500 mg EGME/kg, 
primary spermatocytes undergoing pachytene development were either degenerate or ab­
sent. Other stages of spermatocytes, including those in midpachytene, zygotene, and 
leptotene, were affected with increasing doses of EGME. Depletion o f early pachytene 
spermatocytes 2 and 4 wk after dosing with 1,000 or 1,500 mg EGME/kg suggested early 
spermatogonial damage. In the mouse, however, the sensitive cells were the late sper­
matocytes and spermatids [Anderson et al. 1987].
B.1.2.2 Inhalation
Inhalation exposure to EGME has also caused testicular damage [Miller et al. 1981 ]. Groups 
of five male Fischer 344 rats and five male B6C3Fj mice were exposed to EGME (0,100, 
300, or 1,000 ppm) 6 hr/day for 9 days in an 11-day interval. EGME at concentrations of 
100 or 300 ppm exerted no adverse effects on rat or mouse testes. At 1,000 ppm, however, 
EGME exerted statistically significant decreases (P<0.05) in testes weights when compared 
with controls. Histopathologic changes in this group included severe degeneration of the 
testicular germinal epithelium with necrosis of all sp>ermatogenic elements.
Miller et al. [1983a] continued their investigation of the inhalation toxicity o f EGME by 
exposing groups o f 10 male Sprague-Dawley rats and 5 male New Zealand white rabbits to
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0, 30,100, or 300 ppm EGME 6 hr/day, 5 days/wk, for a total o f 13 wk. The mean testes 
weights o f the rats and rabbits in the 300-ppm group were significantly reduced (P<0.05). 
Testes weights o f rabbits in the 100-ppm group were also decreased when compared with 
these of the controls, but not in a statistically significant manner. Gross pathology showed 
small, flaccid testes in the males of both species at 300 ppm. Microscopic lesions were 
found in rats only at the 300-ppm EGME-exposure level; these lesions included bilateral, 
diffuse, and moderate-to-severe degeneration of the tubular germinal epithelium and 
reduced numbers of spermatozoa or degenerating spermatozoa. Rabbits demonstrated a 
dose-related increase in the incidence and severity of the testicular degeneration. In the three 
surviving rabbits at 300 ppm EGME, severe degeneration affected every tubule, with only 
Sertoli cells and occasional spermatogonia remaining. At 100 ppm EGME, three o f five 
rabbits had some normal tubules and some tubules contained no germinal elements. Two 
animals from this group had normal testes. Microscopic degenerative changes were seen in 
one rabbit from the 30-ppm group. The authors concluded that rabbits were apparently more 
sensitive than rats to EGME [Miller et al. 1983a].
In reproductive and dominant lethal studies, Rao et al. [1983] exposed Sprague-Dawley rats 
to EGME vapor. Male rats were exposed to EGME (30 per group at 0 and 30 ppm; 20 per 
group at 100 and 300 ppm) 6 hr/day, 5 days/wk for 13 consecutive wk. Immediately after 
the 13-wk exposure period, the males were paired with unexposed female rats for breeding. 
The fertility index (number of fertile males per number housed with unexposed females) 
was significantly decreased (P<0.05) only in males exposed to 300 ppm EGME. To assess 
the recovery of reproductive function in males exposed to 300 ppm EGME, additional 
breedings were conducted at 13 and 19 wk after the termination of exposure. A continued 
significant decrease (P<0.05) in the fertility index was found (50% o f males were infertile), 
although it was not as great as that found in this group immediately after exposure (when 
80% of males were infertile). Data suggested that the decreased reproductive function 
induced by EGME was partially reversible [Rao et al. 1983], Reproductive parameters 
examined were normal for males exposed to 30 or 100 ppm EGME; male rats exposed to 
300 ppm EGME failed to sire any litters. No dominant lethal effects were found in male 
rats exposed to 30 or 100 ppm EGME for 13 wk. It was not possible to assess dominant 
lethality in male rats exposed to 300 ppm due to the complete infertility of these animals. 
All implantations from the 20% fertile group were nonviable. There was no indication o f 
an increased incidence of resorptions when males exposed to 300 ppm EGME were bred 
again with unexposed virgin females 26 wk and 32 wk post-exposure after fertility had 
partially recovered. The authors concluded that the no-adverse-effect level of EGME for 
fertility and reproduction was 100 ppm in male rats [Rao et al. 1983].
Doe et al. [1983] reported the same 100 ppm EGME no-adverse-effect level for male rats. 
Groups of 10 male Wistar-derived, Alderly Park strain rats were exposed to 0, 100, or 300 
ppm EGME 6 hr/day for 10 consecutive days. The testes of the 300 ppm group were flaccid, 
reduced in size, and lighter than controls, whereas testes of rats exposed to 100 ppm EGME 
did not differ from controls. Histological examination of the testes revealed pronounced 
tubular atrophy in all the rats exposed to 300 ppm EGME, with 70% to 100% o f the tubules 
affected. In contrast, the testes o f rats exposed to 100 ppm EGME could not be distinguished 
from those of controls.
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The same laboratory also investigated the effects o f a single inhalation exposure of EGME 
in male rats [Samuels et al. 1984]. Groups o f 20 SPF Alpk/AP male albino rats were exposed 
to 150,300,625,1 ,250,2 ,500, or 5,000 ppm EGME for 4 hr. The control group consisted 
of 40 rats. Following the single exposure, they were returned to their cages for 13 days and 
were sacrificed on day 14. Statistically significant reductions (P<0.01) in testes weights 
were seen in the 1,250-, 2,500-, and 5,000-ppm exposure groups when compared with 
controls. Histological examination revealed severe bilateral tubular atrophy with disordered 
spermatogenesis in the 5,000-ppm group. Many tubules showed only stem cells and Sertoli 
cells. Similar but less marked changes were seen in the 2,500- and 1,250-ppm exposure 
groups, and at 625 ppm, testes weights were not reduced but maturing spermatids showed 
unspecified evidence of damage.
Samuels et al. [1984] conducted a second study in which groups o f 90 SPF Alpk/AP male 
albino rats were exposed to 0,1,000, or 2,500 ppm EGME for a single 4-hr period. Ten rats 
per group were sacrificed on each of days 1 ,2 ,3 ,4 ,5 ,8 ,1 0 ,1 5 , and 19 following exposure. 
Forty-eight hours following exposure, testes weight reduction was observed in both exposed 
groups. Damage to the germinal epithelium was observed 24 hr postexposure with primary 
spermatocytes the target cells for EGME. At day 19, recovery was not evident in the 
2,500-ppm EGME group and the germinal epithelium remained disordered. Cytoplas­
mic retraction and swollen mitochondria in Sertoli cells were observed 4 days following 
exposure using electron microscopy. The authors concluded that even a relatively brief 
exposure to EGME vapor can cause marked testicular atrophy [Samuels et al. 1984].
B. 1.2.3 Dermal Exposure
EGME has been shown to penetrate human skin in vitro [Dugard et al. 1984]. To determine 
if EGME produced toxicity following subchronic dermal exposure, six male Hartley guinea 
pigs were dermally dosed with 1 g EGME/kg per day, 5 days/wk for 13 wk [Hobson et al. 
1986]. EGME was applied to 2 * 2 cm gauze patches that were affixed to the shaved 
backs of the guinea pigs and held in place for 6 hr with a stockinette bandage. At the end 
of 13 wk, the mean and relative testicular weights were significantly decreased (P<0.01) 
when compared with those o f the controls. All animals had severe testicular atrophy, with 
moderate to severe segmental degeneration o f the seminiferous tubules characterized by 
complete loss of spermatogenic cells. Sertoli cells and Leydig cells remained largely 
unaffected.
B.2 EFFECTS ON THE FEMALE REPRODUCTIVE SYSTEM AND THE 
DEVELOPING EMBRYO 
B.2.1 EGEE and EGEEA
B.2.1.1 Subcutaneous Administration
The effects of EGEE-treatment on pregnant rats, mice, and rabbits were examined in a study 
by Stenger et al. [1971]. Groups of 20 pregnant rats were treated s.c. with varying
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concentrations o f EGEE (0 ,2 3 ,4 6 .5 ,9 3  mg/kg per day) on gestation days (g.d.) 1 through 
21; pregnant mice (20 per group) were treated s.c. on g.d. 1 through 18 with 0, 46.5, or 
93 mg/kg per day; and rabbits (15 per group) were treated s.c. on g.d. 7 through 16 with 0 
or 23 mg/kg per day. At the highest doses used, no adverse effects were noted in mice 
(93 mg EGEE/kg per day) and rabbits (23 mg EGEE/kg per day), but fetal skeletal defects 
were observed in rats treated s.c. with 93 mg EGEE/kg per day.
B.2.1.2 Oral Administration
In the Stenger et al. study [1971], groups of 20 pregnant rats were treated orally with EGEE 
(0 ,11 ,2 3 ,4 6 .5 ,9 3 ,1 8 6 , or 372 mg/kg per day) on g.d. 1 through 21. A significant increase 
in embryonic and fetal deaths occurred in rats treated orally with doses of 46.5 mg EGEE/kg 
per day and higher, at oral doses o f 93 to 372 mg EGEE/kg per day, the incidence of skeletal 
aberrations increased in a dose related pattern (no statistical treatment given).
Using an in vivo mouse screening bioassay, a group of 10 pregnant C D -1 mice was treated 
orally with 3,600 mg EGEE/kg per day on g.d. 7 through 14. Results indicated 10% maternal 
mortality and no viable litters [Schuler et al. 1984].
The in vitro culture system o f Yonemoto et al. [1984] was used by Rawlings et al. [1985] 
to demonstrate the fetotoxicity o f EAA, the alkoxy acid metabolite o f EGEE [Jonsson et al. 
1982; Cheever et al. 1984]. Conceptuses were explanted from pregnant Wistar-Porton rats 
at embryonic age 9.5 days and cultured for 48 hr with 2 mM or 5 mM EAA. At the end of 
the culture period, crown-rump length, head length, and yolk sac diameter were measured, 
and the degree o f differentiation and development was evaluated by a morphological scoring 
system. EAA at the 5 mM concentration had an adverse effect on fetal development. 
EAA-exposed embryos had statistically significant reductions (P<0.01) in morphological 
score, crown-rump length, head length, and yolk sac diameter. Additionally, EAA produced 
statistically significant reductions (P<0.01) in somite number and in protein content o f the 
embryo. No statistically significant reductions in growth parameters were seen at the 2-mM 
level. Irregularity of the neural suture line was found in 100% of the EAA-exposed embryos. 
Other abnormalities seen in the EAA groups were abnormal otic and somite development, 
turning failure, open cranial folds, and abnormal yolk sac [Rawlings et al. 1985].
B.2.1.3 Inhalation
In inhalation studies [Andrew et al. 1981; Hardin et al. 1981], pregnant New Zealand white 
rabbits were exposed 7 hr/day on g.d. 1 through 18 to 0, 160, or 615 ppm of EGEE. Five 
of 29 rabbits died at the high dose (615 ppm); the other 24 suffered severe anorexia and 
weight loss. Maternal toxicity was mild in rabbits exposed at 160 ppm; a statistically 
significant reduction in food consumption and body weight gain and increased maternal 
liver weight was noted (P<0.05). In the 615-ppm group, all litters were totally resorbed, 
and in the 160-ppm group, the number o f live fetuses was significantly reduced and 
resorptions were increased (P<0.001). Fetal morphological examinations revealed a sig­
nificantly increased incidence (P<0.05) of renal, cardiovascular, and ventral body wall
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defects in fetuses from the 160-ppm exposure group; there were also increases in certain 
minor skeletal variations.
In the same studies [Andrew et al. 1981 ; Hardin et al. 1981], female Wistar rats were exposed 
to 0 ,150, or 650 ppm EGEE for 7 hr/day, 5 days/wk for 3 wk before breeding, and then for 
7 hr/day on g.d. 1 through 19 to 0 ,200, or 765 ppm EGEE. Exposure to EGEE under these 
conditions exerted no effect on fertility (i.e., mating success or the establishment o f 
pregnancy). A statistically significant (P<0.05) reduction in maternal liver weight and an 
increase in lung and kidney weight (P<0.05) occurred with the higher EGEE-exposure 
regimen (i.e., 650 ppm before breeding followed by 765 ppm on g.d. 1 through 19), and no 
maternal toxicity occurred at the lower EGEE-exposure regimen (i.e., 150 ppm before 
breeding followed by 200 ppm on g.d. 1 through 19). Although the incidence of resorptions 
was not significantly increased in the lower exposure group, all the litters were totally 
resorbed in the higher exposure group. Fetal toxicity was evident in the lower exposure 
group as a significarti reduction (PS0.05) in fetal body weight and crown-rump length. 
Morphological examinations of fetuses from the lower EGEE-exposure group revealed a 
significantly increased incidence (P<0.05) in cardiovascular and skeletal defects.
Nelson et al. [1981] also conducted an inhalation study in which EGEE was evaluated for 
possible functional effects in the offspring of Sprague-Dawley rats allowed to deliver litters 
following exposures during gestation to 0, 100, 200, or 900 ppm. The pilot dose-finding 
study revealed complete resorption o f litters in dams exposed to 900 ppm EGEE for 7 hr/day 
during g.d. 7 through 13, and no live pups in litters of dams exposed on g.d. 14 through 20. 
There was 34% mortality of pups after exposure of dams to 200ppm EGEE on g.d. 7 through 
13 or 14 through 20. Exposure to 900 ppm EGEE during days 14 through 20 of gestation 
also produced a consistent pattern of a 48-hr extended gestation period. The only maternal 
effect observed in rats exposed to 100 ppm EGEE for 7 hr/day on g.d. 7 through 13 and 14 
through 20 was a slightly prolonged gestation period (0.7 day, P<0.001) in the rats exposed 
on g.d. 14 through 20. Six behavioral tests were selected to assess central nervous system 
functions in the control group (filtered air) and in the 100-ppm EGEE-treated groups: 
neuromuscular ability (ascent and rotorod tests), exploratory activity (open field test), 
circadian activity (activity wheel test), aversive learning (avoidance conditioning test), and 
operant conditioning (appetitively motivated test of learning). Behavioral testing o f off­
spring from dams exposed on days 7 through 13 o f gestation revealed: (1) impaired 
performance on a rotorod test (P-0.002); (2) prolonged latency of leaving the start of an 
open field (P-0.009); and (3) marginal superiority in avoidance conditioning begun on day 
34 o f age (not significant, P-0.061). Offspring from dams exposed on g.d. 14 through 20 
were less active than were controls in a running wheel (not significant, P=0.32); they also 
received an increased number and duration of shocks in avoidance conditioning begun on 
day 60 of age (P=0.004).
Neurochemical alterations also occurred in newborn and 21 -day-old rats from dams exposed 
prenatally to 100 ppm EGEE. Levels of norepinephrine in offspring from both exposure 
periods (g.d. 7 through 13 and 14 through 20) were decreased significantly (P<0.01). In 
21 -day-old offspring of dams exposed to 100 ppm EGEE on g.d. 7 through 13, the cerebrum 
had significant elevations in acetylcholine (P<0.01), norepinephrine (P<0.01), and
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dopamine (P<0.05); the cerebellum had nearly a threefold increase in acetylcholine 
(P<0.01); the brainstem had an increase in norepinephrine (P<0.01); and the midbrain had 
excesses of acetylcholine (P<0.01), norepinephrine (P<0.05) and protein (P<0.05). In 
21 -day-old offspring from dams exposed on g.d. 14 through 20, the cerebrum had significant 
elevations in acetylcholine, dopamine, and 5-hydroxytryptamine (P<0.05) [Nelson et al. 
1981].
Neuromotor ability of offspring, assessed by ascent and rotorod tests, was reduced (P<0.05) 
when pregnant Sprague-Dawley rats were exposed by inhalation to 200 ppm EGEE 7 hr/day 
on g.d. 7 through 13; the 200 ppm treatment group was also less active than controls in 
exploratory activity in the open field and in the shuttle box [Nelson et al. 1982a]. Exposure 
of pregnant Sprague-Dawley rats to 200 ppm EGEE 7 hr/day on g.d. 7 through 13 altered 
neurochemical transmitter levels in all brain regions except for the brainstem of 21-day-old 
offspring. Dopamine levels increased significantly in the cerebrum and midbrain (P<0.01 
and P<0.05, respectively). Norepinephrine levels increased significantly (P<0.01) in the 
cerebrum and cerebellum [Nelson et al. 1982b].
Female Dutch rabbits were exposed to 0, 50,150, or 400 ppm EGEE on g.d. 6 through 18 
[Tinston 1983]. On g.d. 21, animals were sacrificed and necropsied. Although maternal, 
mean body-weight gain and food consumption o f the 400 ppm EGEE-exposure group were 
markedly lower than those of the controls, they were not statistically different. At 400 ppm 
EGEE, the group mean number of live fetuses (P<0.01), gravid uterus weight (P<0.01), and 
litter weight (P<0.01) were statistically lower than they were in the control group. The group 
mean percentage post implantation loss (P<0.01), percentage o f early fetal deaths (P<0.01), 
and percentage of late deaths (P<0.05) were statistically higher in the 400 ppm EGEE- 
exposure group compared with controls. No adverse effects were observed in the groups 
exposed to either 50 or 150 ppm EGEE. No macroscopic pathological abnormalities or 
external fetal abnormalities could be attributed to EGEE exposure.
EGEE and EGEEA were examined in an inhalation study [Doe 1984a] in which groups o f 
24 pregnant Alpk/AP rats were exposed to 0 ,1 0 ,5 0 , or 250 ppm EGEE 6 hr/day on g.d. 6 
through 15, and groups o f 24 pregnant Dutch rabbits were exposed either to 0, 10, 50, or 
175 ppm EGEE or to 0 ,2 5 ,1 0 0 , or 400 ppm EGEEA on g.d. 6 through 18. Animals were 
sacrificed on g.d. 21 (rats) or 29 (rabbits), and fetuses were examined for external, visceral, 
and skeletal malformations. In the rat study, the only sign o f maternal toxicity was an effect 
on the hematopoietic system; reductions in Hb, Hct, and MCV were observed in the group 
exposed to 250 ppm and are reported in Chapter 4, Section 4.3.4.1. Although there was a 
higher incidence of preimplantation losses in all exposure groups, this was statistically 
significant only in the 10- and 50-ppm groups (P<0.05). Fetal weights were significantly 
reduced (P<0.05) in the 250-ppm group. In addition, reduced ossification and an increased 
incidence o f skeletal variants (P<0.05) were observed in this exposure group. A small and 
statistically insignificant number o f these changes (unossified cervical centra, partial os­
sification o f the second stemebra, extra ribs) also occurred at 50 ppm EGEE. No statistically 
significant increase in visceral malformations was observed. Data indicated that although 
EGEE was not teratogenic in rats at the concentrations tested, it was fetotoxic in rats at 250 
ppm (98% of fetuses affected) and slightly fetotoxic (51% of fetuses affected) at 50 ppm
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(P<0.05). Exposure of rabbits to 10, 50, or 175 ppm EGEE resulted in no evidence of 
maternal toxicity. The incidence of skeletal defects and variants at the 175-ppm dose was 
statistically greater than in the control group (P<0.05). This was a result o f retarded skeletal 
ossification, an increased incidence o f presacral vertebrae, and an increased number of 
fetuses with extra ribs, both of short and of normal length.
Exposure of rabbits to 400 ppm EGEEA in the same study [Doe 1984a] caused reduced 
maternal weight gain and food consumption, whereas no adverse maternal effects were noted 
in the groups exposed to 25 or 100 ppm EGEEA. At 400 ppm EGEEA, there was an increase 
in resorptions and a reduction in fetal body weight per litter (P<0,05). Reduced fetal body 
weight also occurred at 100 ppm EGEEA (P<0.05). There was no effect on fetal number 
or weight at 25 ppm EGEEA. Retarded ossification was seen at 400 (P<0.05) and 100 ppm 
(P<0.05) but not at 25 ppm EGEEA. Major malformations of the vertebral column were 
noted at 400 ppm EGEEA, and the incidence of minor defects and variants was elevated at 
both 400 and 100 ppm EGEEA (P<0.05). The investigator concluded that EGEEA was 
teratogenic in rabbits exposed at 400 ppm, slightly fetotoxic at 100 ppm, and exerted no 
effect at 25 ppm [Doe 1984a].
In another series o f experiments, groups o f 15 pregnant Sprague-Dawley rats were exposed 
7 hr/day to 0, 130, 390, or 600 ppm EGEEA on g.d. 7 through 15 and sacrificed on g.d. 20 
[Nelson et al. 1984b]. All implantations from dams exposed to 600 ppm EGEEA were 
resorbed, and there was a 56% increase in resorptions at 390 ppm. At 390 and 130 ppm 
EGEEA, fetal weights were significantly reduced compared with those o f the controls 
(P<0.05). Visceral malformations o f the heart and umbilicus occurred in fetuses o f the 
390 ppm group (P<0.01). One fetus from the 130 ppm group had a heart defect. The authors 
concluded that both 130 ppm and 390 ppm EGEEA were teratogenic in the rat [Nelson et 
al. 1984b].
Tyl et al. [1988] evaluated the teratogenic potential of EGEEA. Pregnant Fischer 344 rats 
(30 per group) and New Zealand white rabbits (24 per group) were exposed to EGEEA vapor 
by inhalation 6 hr/day on g.d. 6 through 15 (rats) or 6 through 18 (rabbits) at concentrations 
of 0, 50, 100, 200, or 300 ppm; the animals were then sacrificed on g.d. 21 (rats) or 29 
(rabbits). This study indicated that exposure of rabbits to EGEEA during organogenesis 
resulted in maternal toxicity at 100 to 300 ppm. Signs of this included significantly 
decreased weight gain and reduced gravid uterine weight (P<0.001) and elevated absolute 
liver weight (P<0.05). In rats, significantly (P<0.001) reduced weight gain and reduced 
food consumption were noted at 200 and 300 ppm EGEEA; significantly elevated relative 
liver weights were noted at 100,200, and 300 ppm EGEEA (no statistics given). In rabbits, 
an increased incidence of totally resorbed litters at 200 ppm (P<0.05) and 300 ppm 
(P<0.001), an increase in nonviable fetuses at 300 ppm (P<0.05), and a decrease in viable 
fetuses per litter at 200 ppm and 300 ppm EGEEA (P<0.05) were observed. Fetotoxicity 
(reduced ossification) was observed at 100, 200, and 300 ppm EGEEA. The incidence of 
external visceral and skeletal malformations was increased at 200 ppm and 300 ppm 
(P<0.05). In rats, embryo/fetotoxicity was observed at 100,200, and 300 ppm EGEEA. 
Observations included increased nonviable implantations/litter at 300 ppm (P<0.05), 
reduced fetal body weight/litter at 200 and 300 ppm (P<0.05), and increased incidence
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(P<0.05) of external variations at 300 ppm and visceral and skeletal variations at 100, 200, 
and 300 ppm. There was no evidence of maternal, embryonic, or fetal toxicity (including 
teratogenicity) at 50 ppm EGEEA in either species. Tyl et al. [1988J concluded that 50 ppm 
EGEEA was the no observable effect level.
B.2.1.4 Dermal Exposure
The effects of dermal exposure to EGEE on pregnant Sprague-Dawley rats have been 
investigated by Hardin et al. [1982]. Applications of EGEE (0.25 mL or 0.5 mL) were made 
4 times per day on g.d. 7 through 16 to the shaved interscapular region o f pregnant rats (20 
per group); control rats were treated similarly with water. The only signs of maternal toxicity 
were ataxia and significantly reduced body weight gain in the last half of gestation following 
treatment with 0.5 mL EGEE (P<0.001). All litters were completely resorbed in the high 
exposure group, and the incidence of resorptions (76%) was significantly increased in the 
low exposure group (P<0.001). There was a significant reduction in fetal body weight 
(P<0.001), and both cardiovascular malformations (ventricular septal defects) and skeletal 
variations were significantly increased (P<0.05) in the litters treated with 0.25 mL EGEE.
Using the preceding experimental design, equimolar volumes o f EGEE (0.25 mL) and 
EGEEA (0.35 mL) were applied cutaneously to pregnant rats [Hardin et al. 1984]. Data 
demonstrated that EGEE and EGEEA treatment reduced maternal body weight gain, and at 
days 17 and 21, body weight gain in the EGEEA group was significantly lower than that in 
the controls (P<0.001). Gravid uterus weights were also significantly reduced in both 
treatment groups compared with those of the controls (P<0.001). Although extragestational 
body weights did not differ significantly (P<0.1), extragestational body weight gain was 
significantly reduced (P<0.05) in the treated group«. A reduction in body weight, which 
was associated with completely resorbed litters and significantly fewer live fetuses per litter 
(P<0.01), was noted in EGEE- and EGEEA-treated rats relative to that o f the controls. Fetal 
body weights were also significantly decreased (P<0.001). Cardiovascular malformations 
and skeletal variations were significantly increased compared with untreated controls 
(P 0 .0 0 1 ) in both EGEE- and EGEEA-treated groups.
B.2.2 EGME and EGMEA
B.2.2.1 Oral Administration
Female JCL-ICR mice were mated with males o f the same strain and assigned to experimen­
tal and control groups o f 21 to 24 animals [Nagano et al. 1981]. EGME was administered 
by gavage on g.d. 7 through 14 at doses o f 0, 31.25, 62.5, 125, 250,500, or 1,000 mg/kg 
per day, and the animals were sacrificed on g.d. 18. The incidence o f dead fetuses was 
significantly increased at 250, 500, and 1,000 mg EGME/kg per day (P<0.01). Only one 
fetus survived in the 500 mg EGME/kg per day group, and none survived in the 1,000 mg 
EGME/kg per day group. Fetal weights were significantly reduced at the 125 and 250 mg 
EGME/kg per day doses (P<0.01). The incidence o f gross anomalies in the 250 mg 
EGME/kg per day exposure group was significantly increased when compared with the 
controls and included exencephaly, abnormal digits, and umbilical hernia (P<0.01). The
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one live fetus from the 500 mg EGME/kg per day group also had exencephaly and abnormal 
digits. The incidence of skeletal malformations was also significantly higher (P<0.01) in 
the 250 mg EGME/kg per day group than in the control group. All fetuses examined in this 
group had skeletal malformations, including fusion and/or agenesis (nondevelopment) o f 
vertebrae or ribs, spina bifida occulta, syndactyly (fusion of digits), oligodactyly (fewer than 
five digits), and polydactyly (more than five digits). A significant increase (P<0.01) in 
skeletal malformations was seen also in the 125 mg EGME/kg per day exposure group (fused 
ribs, fusion and/or agenesis of vertebrae, and spina bifida occulta) and the 62.5 mg EGME/kg 
per day exposure group (spina bifida occulta). Bifurcated or split cervical vertebrae 
(P<0.05) were observed in the 31.25 mg EGME/kg per day exposure group. The ossification 
of fetuses was significantly retarded (P<0.05) in all treatment groups when compared with 
the controls, as indicated by decreased numbers of proximal and middle phalanges of fore 
and hind limbs. The authors concluded that the severity and frequency of the malformations 
noted following administration of EGME at doses greater than 31.25 mg/kg per day were 
dose dependent [Nagano et al. 1981].
Pregnant C D -I mice dosed by gavage with 1,400 mg EGME kg/day on days 7 to 14 of 
gestation produced no viable litters. EGME caused 14% maternal mortality [Schuler et al.
1984].
The developmental phase-specific and dose-related embryotoxic effects of EGME were 
investigated by Horton et al. [1985]. Initially, 250 mg EGME/kg per day was administered 
orally on g.d. 7 through 14 to 10 pregnant CD-I strain micc, which were subsequently 
sacrificed on g.d. 18. This group demonstrated gross malformations (exencephaly and paw 
lesions) similar to these reported by Nagano et al. [1981]. The treatment period was then 
reduced to 250 mg/kg on g.d. 7 through 9 ,8  through 10,9 through 11, or 250 mg/kg on g.d. 
7 and 8 ,9  and 10,10 and 11, or 500 mg EGME/kg on g.d. 9 ,1 0 ,1 1 , 12, or 13 to define the 
developmental phase specificity of the embryotoxic effects observed. M ultiple doses 
o f 250 mg EGME/kg per day cm* single doses of 500 mg EGME/kg significantly reduced 
fetal weights in all dose groups (P<0.05) and significantly increased embryolethality 
(percentage o f implantations resorbed) in all groups except the single 500 mg EGME/kg 
exposure on g.d. 12 or 13 (P<0.05).
Studies with mice dosed during different gestational stages also demonstrated phase-specific 
teratogenic effects [Horton et al. 1985]. Groups o f 9 or 10 pregnant mice treated on g.d. 7 
through 9 or 8 through 10 with 250 mg EGME/kg per day had significantly more exen- 
cephalic fetuses than did the controls (P<0.05). Exposure during later stages of development 
did not result in excess exencephaly. The incidence of digit malformations (syndactyly, 
oligodactyly, and polydactyly) increased significantly after three doses on days 8 through
10, or 9 through 11, as well as with two doses on days 10 and 11 (P<0.05).
A single oral administration o f 500 mg EGME/kg to groups of 9 to 12 mice on g.d. 9, 10,
11, or 12 produced significant increases in paw malformations (P<0.05) [Horton et al. 1985]. 
Peak susceptibility to paw malformations occurred on g.d. 11 and 12 and included syndac­
tyly and oligodactyly. Treatment with EGME on g.d. 9 ,10 , or 11 produced a prevalence of 
forepaw anomalies; treatment on g.d. 12 shifted the higher incidence to hind paw syndactyly.
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Horton et ai. [1985] also investigated the dose dependence o f digit anomalies in groups 
o f 9 to 11 m ice orally dosed with 100, 175, 250, 300, 350, 400, or 450 mg EGME/kg 
on g.d. 11. Exposure to 100 mg EGME/kg did not induce digit anomalies. Digit anomalies 
occurred at 175 mg EGME/kg (not statistically significant), and their frequency increased 
in a statistically significant dose-related manner (P<0.05) to a maximum incidence at 
350 mg EGME/kg, with intermediate responses at 250 and 300 mg EGME/kg. The authors 
concluded a no observed effect level of 100 mg EGME/kg for digit malformations after a 
single oral dose o f EGME [Horton et al. 1985].
The role o f cytotoxicity in digital maldevelopment in C D -I mouse embryos was 
examined following oral treatment o f dams with 100,250, or 350 mg EGME/kg on g.d. 11 
[Greene et al. 1987]. Pregnant mice were sacrificed 6 or 24 hr later. The embryos were 
removed and incubated for 15 min in N ile blue A stain. The right forelimb buds o f 
EGME-treated embryos were compared with the right forelimb buds from control 
embryos o f the same gestational age. Right forelimbs were examined for the pattern o f 
cell death as determined by uptake o f the dye into the tissue, and the overall shape and 
conformation were recorded by photography and drawings. None o f the treatment 
regimens produced maternal toxicity. Forelimb buds collected 6 or 24 hr after ad­
ministration o f EGME showed marked cytotoxic responses, which were dose related. 
Cell death was induced in the mesenchymal tissue and to some extent in the limb bud 
ectoderm. Forelimb buds from the dams treated with 350 mg EGME were consistently 
malformed in the preaxial region; virtually all o f the limb buds examined were extremely 
altered in appearance. Necrosis was evident in forelimb buds from the dams treated 
with 250 mg EGME, but the lesions were less severe. In the embryos from the dams 
treated with 100 mg EGME only slight increases in cell death were noted in approxi­
mately 50% o f the limb buds from embryos collected 24 hr after EGME treatment 
[Greene et al. 1987].
Pregnant mice that had been treated with 350 mg EGME/kg on g.d. 11 were sacrificed 2 ,6 , 
24, or 48 hr later [Greene et al. 1987]; a single untreated mouse was included for each time 
point. Forelimb buds from at least five embryos/dam were excised and prepared for 
examination by light or electron microscopy. Microscopic evaluations o f forelimb buds 
revealed the presence of phagocytic vacuoles and condensed, fragmented cytoplasm, 
indicative o f cytotoxicity, as early as 2 hr after EGME treatment. The maximum effect 
was observed 6 hr after EGME treatment, and the severity o f the effect appeared to be 
dose-related.
In the same study [Greene et al. 1987], pregnant mice were given a single oral dose o f 
EGME (100, 175, 250, 300, 350, 400, 450, or 500 mg) on g.d. 11 and were sacrificed 
on g.d. 18. Near-term fetuses were removed and examined for digit malformations. 
Although digital malformations were not detected in near-term fetuses following 
treatment with 100 mg EGME, they were induced in all other treatment groups in a 
dose-dependent manner (statistics not given). The percentage o f fetuses with paw 
malformations ranged from 12% to 93%. The primary anomalies observed were 
preaxial syndactyly (fusion o f digits o f No. 2 and No. 3) and ectrodactyly (absence o f 
digit No. 1).
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Hardin and Eisermann [1987] studied the potency o f dimethyl-substituted ethylene 
glycol ethers relative to EGME in inducing paw malformations. EGME, ethylene glycol 
dim ethyl ether (EGdiM E), diethylene g lycol dim ethyl ether (diEGdiM E), and 
triethylene glycol dimethyl ether (triEGdiME) were administered orally in single 
equimolar doses (304, 361, 537, and 713 mg/kg, respectively) to CD mice on g.d, 11. 
On g.d. 18, fetuses were collected, weighed, and examined for gross external malfor­
mations. None o f the treatment regimens produced maternal toxicity. In the fetuses, 
only paw malformations were observed; they occurred with significantly increased 
frequency (P<0,05) in litters o f mice treated with EGME, EGdiME, diEGdiME, but not 
in litters o f triEGdiME-treated dams. The average percent o f fetuses affected per litter 
was 69% (EGME), 34% (EGdiME), and 40% (diEGdiME). Only in litters o f dams 
treated with EGME was polydactyly observed with significantly increased frequency 
(P<0.05) in forepaws. Syndactyly appeared in increased frequency (P<0.05) in 
hindpaws o f EGME, EGdiME, and diEGdiME litters. The frequency o f short digits was 
significantly increased (P<0.05) in both forepaws and hindpaws o f EGME litters but 
only in hindpaws o f diEGdiME-treated litters. Oligodactyly appeared in both forepaws 
and hindpaws o f EGME litters, forepaws of EGdiME litters, and hindpaws o f diEGdiME 
litters more often (P<0.01) than in controls. It was suggested by Hardin and Eisenmann 
[1987] that these paw malformations were attributable to in vivo conversion o f these 
glycol ethers to a common teratogen, MAA.
Toraason et al. [1985] studied the effect of EGME on the developing cardiovascular system  
using electrocardiography. Pregnant Sprague Dawley rats were treated by gavage with 0, 
25 ,50 , or 100 mg EGME/kg per day on g.d. 7 through 13. All fetuses from the eight rats 
treated with 100 mg EGME/kg per day were resorbed. There was a dose-dependent increase 
in cardiovascular defects in fetuses exposed to EGME, including ventricular septal defects 
and right ductus arteriosus in the 50 mg EGME/kg per day exposure group. No cardiovas­
cular malformations were seen in control fetuses. Significantly more litters in the 25 and 
50 mg EGME/kg per day exposure groups had fetuses with aberrant heart QRS intervals 
than did the controls (P<0.05). The mcst prevalent abnormality was a prolonged QRS 
complex, which the authors suggest indicated the presence of an mtraventricular conduction 
delay. There was no association between abnormal electrocardiograms (EKGs) and any 
morphological defect.
To assess the risk for women of childbearing age exposed to EGME, Scott et al. [1989] 
exposed nonhuman primates, Macaco fasicularìs females, orally to 12, 24, or 36 mg 
EGME/kg on g.d. 20 through 45 (8 ,11 , and 13 animals/group, respectively). The fetuses 
were collected by Caesarean section at day 100. Two groups o f three monkeys served as 
controls. One of the control groups was treated orally on g.d. 20 through 45 with 15 mL of 
ethanol. Although no statistics were presented, the data indicated that EGME caused a 
dose-related loss o f maternal body weight. This was accompanied by anorexia, the severity 
of which was dose-related.
Because the loss of appetite was so severe at times, especially in the high-dose animals, the 
investigators administered gruel and/or electrolytes by gavage to prevent serious physical 
deterioration o f the adult animals. After the cessation o f treatment at g.d. 45, the animals
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regained their appetites, and body weights were similar to control body weights at the tíme 
of Caesarean section on g.d. 100 [Scott et al. 1989].
Hematologic analysis o f the EGME-treated monkeys did not reveal any dose-related effects. 
Embryotoxicity o f EGME in these monkeys was manifest mainly in the form o f embryonic 
death. At the 36 mg/kg dose, all eight pregnancies ended in death. One of these dead 
embryos, judged to have been about 40 days old at the time of death, was missing one digit 
on each forelimb. This malformation has never been seen in macaque pregnancies, and 
EGME has caused the same type of defect in mice [Horton et al. 1985], rats [Ritter et al.
1985], and rabbits [Hanley et al. 1984a]. The authors [Scott et al. 1989] therefore attributed 
this malformation to EGME treatment. Three o f 10 pregnancies (30%) at the 24-mg/kg dose 
and 3 o f 13 pregnancies (23%) at the 12-mg/kg dose ended in embryonic death. An 
additional pregnancy in each o f the 12- and 24-mg/kg groups was lost to abortion, but both 
were thought to be spontaneous (spontaneous abortions occur in 10% to 20% o f untreated 
macaque pregnancies). All surviving fetuses were free from malformation. Despite the 
maternal toxicity associated with the higher doses of EGME, the authors concluded that 
EGME acted directly on the embryo to cause its demise [Scott et al. 1989].
B.2.2.2 Inhalation
A rapid assessment o f the effect of inhaled EGME on the developing embryo was conducted 
by Doe et al. [1983]. Groups of 20 pregnant female Wistar-derived, Alderly Park strain rats 
were exposed to 0 ,100, or 300 ppm EGME for 6 hr/day on g.d. 6 through 17. The rats were 
allowed to deliver their litters, which were observed for 3 days. Maternal body weight gain 
was significantly reduced in the 300 ppm group (P<0.05), and none o f these rats produced 
litters. The gestation period was significantly increased for the nine rats producing litters 
in the 100 ppm EGME group when compared with that of the controls (23.6 vs. 22 days, 
P<0.05). This group also showed a significant reduction in the total number o f pups 
(P<0.001), the proportion of live pups at birth (P<0.01), and the proportion surviving to 3 
days (P<0.01). All the pups were normal externally [Doe et al. 1983].
Hanley et al. [1984a] conducted a study to compare the teratogenic potential o f exposure to 
low vapor concentrations of EGME in F344 rats, C F-1 mice, and New Zealand white rabbits. 
Groups of 24 to 32 pregnant mice, rats, and rabbits were exposed to EGME via inhalation 
for 6 hr/day on g.d. 6 through 15 (rats and mice) or g.d. 6 through 18 (rabbits). Exposure 
concentrations were 0, 3, 10, or 50 ppm EGME for rats and rabbits, and 0, 10, or 50 ppm 
EGME for mice. Mice were sacrificed on g.d. 18, rats on g.d. 21, and rabbits on g.d. 29. 
Statistically significant increases (P<0.05) in lumbar spurs and delayed ossification of the 
ventral centra (minor skeletal variations) were seen in rats at 50 ppm. Maternal effects found 
in rats were minimal. At 50 ppm, a slight transient decrease in body weight gain was 
observed, and decreases in mean Hb, packed cell volume (PCV), and RBC values were 
found. Hanley et al. [1984a] concluded that these decreases were o f no toxicologic 
significance. The mice demonstrated a pattern o f effects similar to that observed in rats. 
The only maternal effect was a statistically lower (P<0.05) body weight gain on g.d. 12 
through 15. There was a significant increase (P<0.05) in the incidence of extra ribs, and the
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incidence of unilateral testicular hypoplasia in animals exposed to 50 ppm indicated slight 
fetotoxicity [Hanley et al. 1984a].
Rabbits demonstrated a greater sensitivity to EGME at these concentrations than did rats or 
mice [Hanley et al. 1984a]. At 50 ppm EGME, significant decreases in maternal body weight 
gain during exposure (P<0.05) and significant increases in the absolute weights of the liver 
(P<0.05) occurred. Changes in reproductive and developmental parameters in the 50 ppm 
EGME group included a significant increase in the resorption rate (P<0.05) and a significant 
decrease in the mean fetal body weights (P<0.05) when compared with those of the controls. 
Examination of fetuses revealed a statistically significant increase (P<0.05) in the total 
incidence of malformations in the 50 ppm group. External malformations involved the 
extremities and included persistent joint contracture (arthrogryposis) and digit anomalies 
such as absence o f nails (anonychia), shortness o f digits (brachydactyly), and absence of 
digits (ectrodactyly). Visceral examination o f rabbit fetuses revealed ventricular septal 
defects and coarctation (segmental constriction) of the aortic arch, splenic hypoplasia, and 
severe dilation of the renal pelvis. Malformations seen at skeletal examination o f the 
50-ppm EGME exposure group included missing bones of the paws and a variety of rib 
malformations. Numerous minor variations considered evidence o f fetotoxicity at 50 ppm 
EGME included patent ductus arteriosus (delayed development), pale spleen, and con­
voluted or dilated ureters. Other variations were delayed ossification of the hyoid, tarsals, 
and stemebrae and an irregularity in the pattern o f the palatine rugae. At 3 or 10 ppm EGME, 
there were no differences among fetal rabbits suggesting any adverse developmental effect. 
Hanley et al. [1984a] concluded that these results established no observed cffect levels of 
10 ppm EGME in these three species.
Nelson et al. [1984a] determined how offspring were affected when male or fem ale rats 
were exposed at 25 ppm EGME. Pregnant female Sprague-Dawley rats were exposed 
either on g.d. 7 through 13 or 14 through 20 and then allowed to deliver their young. 
Males were exposed to EGME 7 hr/day, 7 days/wk for 6 wk and then mated with unexposed 
females. Six behavioral tests were selected to evaluate CNS functions in offspring: ascent 
on a wire mesh, rotorod, open field, activity wheel, avoidance conditioning, and operant 
conditioning. Offspring from the group exposed on g.d. 7 through 13 showed significant 
differences (P<0.05) in performance o f avoidance conditioning (aversive learning) 
when compared with the control animals. No other significant behavioral differences 
were seen.
Chemical analyses were performed on whole brain samples from newborns o f each group, 
and on cerebrum, cerebellum, brain stem, and midbrain samples from 21-day-old animals. 
Concentrations o f total brain protein and four neurotransmitters (acetylcholine [Ach], 
dopamine [DA], norepinephrine [NE], and 5-hydroxytryptamine [5-HT]) were measured. 
Significant differences in concentrations o f Ach, DA, NE, and 5-H T  were apparent in 
21-day-old rats from all three exposed groups when compared with the controls (P<0.05). 
Protein levels were significantly (P<0.05) different only in 21-day-old offspring exposed 
from day 14 through 20 o f gestation. In whole brain samples from newborns, increases were 
found in Ach and 5-HT for the offspring o f exposed males, but no other differences were 
significant when compared with the controls [Nelson et al. 1984a],
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B.2.2.3 Dermal Exposure
The teratogenic potential of dermal exposure to EGME was estimated using the Chemoff 
and Kavlock in vivo assay. Groups of 10 pregnant Alpk/AP (Wistar derived) rats were 
exposed to 3%, 10%, 30%, or 100% EGME in physiological saline at 10 mL/kg [Wick- 
ramaratne 1986]. The test compound was applied for 6 hr (occluded exposure) on g.d. 6 
through 17. Rats were then allowed to deliver litters normally and rear their litters until day 
5 post-partum. The application o f 100% EGME was lethal to all dams and 30% was lethal 
to all developing fetuses. At 10% EGME, the litter size was reduced by 26% as was survival 
at day 5 (neither statistically significant). No adverse effects were seen in the 3% group. 
The results were evaluated using “rules” generated from the Chemoff and Kavlock in vivo 
teratology screen assay. The authors concluded that the data demonstrated a clear dose- 
response and that a 10% solution o f EGME is likely to be a rat teratogen [Wickramaratne
1986].
Feuston et al. [1990] studied the effect of a single dermal application o f EGME as a function 
of both gestation day administered and dose level. Pregnant Sprague-Dawley rats (8 to 10 
rats/group) received a single dermal application o f0,250,500,1,000, or 2,000 mg EGME/kg 
on g.d. 12. In the other part o f the study, pregnant Sprague-Dawley rats (8 to 10 rats/group) 
received a single dermal application o f 2,000 mg EGME/kg on g.d. 10, 11, 12, 13, or 14. 
The control group was sham treated on g.d. 10 through 14 to correspond to all o f the days 
of 2,000 mg EGME/kg exposure. Dose levels were based on a pilot study at this facility 
(data not presented). Each female rat was observed daily; body weights were measured on 
g.d. 0 ,6 ,1 0  through 15, and 20. On g.d. 20, each female rat was necropsied and the fetuses 
were examined for normal development.
Maternal toxicity consisted o f a statistically significant (P<0.05) decrease in mean body 
weight gain for female rats on the day following their exposure. This occurred at all EGME 
exposure concentrations on g.d. 10 through 14, except for animals exposed to 250 mg 
EGME/kg on g.d. 12. This weight less was transient.
Adverse reproductive effects were noted in the female rats who had received 2000 mg 
EGME/kg (Mi g.d. 10. These effects included a statistically significant increase (P<0.05) in 
both the mean number of resorptions and the mean percentage resorptions. The number of 
dams in this group with resorptions was also higher than the number of dams with resorptions 
in the untreated group.
There was a statistically significant decrease (P<0.05) in fetal body weights in the female 
tats exposed to 1,000 mg EGME/kg on g.d. 12 or 2,000 mg EGME/kg on g.d. 10 and 12. 
In general, female fetuses were more affected than were male fetuses.
Application o f 500,1,000, or 2,000 mg EGME/kg on g.d. 12 caused statistically significant 
(P<0.05) increases in external, visceral, and skeletal malformations. Cardiovascular and 
urinary system defects were the prominent visceral malformations. The most frequently 
observed skeletal defects were limb (primarily of the digits) and vertebral column (primarily 
of the tail) defects. The application o f250 mg EGME/kg caused no adverse developmental
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effects and was considered to be the no observable adverse effect level (NOAEL) by the 
investigators [Feuston et al. 1990]. Examination of the effects on the various days of 
exposure indicated that application of 2,000 mg EGME/kg on g.d. 11, 12, or 13 produced 
the highest incidence and greatest variety o f fetal visceral malformations. The application 
of EGME on g.d. 12 or 13 resulted in a predominance of external and skeletal malformations. 
Exposure to EGME on g.d. 14 produced minimal developmental effects.
B.3 HEMATOLOGY 
B.3.1 EGEE and EGEEA
An early report [von Oettingen and Jirouche 1931] indicated that adding 1 cc o f EGEE or 
EGEEA to 5 cc suspensions of dog or beef red blood cells in Ringer solution caused 
hemolysis. The investigators noted that hemolysis was more marked with EGEEA than with 
EGEE.
B.3.1.1 Ora! Administration
In a study by Stenger et al. [1971], EGEE administered orally 7 days/wk for 13 wk to dogs 
(186 mg/kg per day) and rabbits (186,372, or 744 mg/kg per day) decreased the Hb and Hct 
values. No statistical analysis was presented. Hemosiderin accumulation and isolated 
hematopoietic foci were observed in the spleens of all dogs and rabbits treated with EGEE.
In a study by Nagano et al. [1979], oral administration to mice o f 2,000 mg EGEE or 
EGEEA/kg per day, 5 days/wk for 5 wk significantly reduced WBC counts compared with 
control values (P<0.05). No disturbances of erythrocytic parameters were observed follow­
ing administration of 500, 1,000, or 2,000 mg EGEE/kg per day. However, administration 
of 4,000 mg EGEEA/kg per day, reduced the MCV (P<0.01).
B.3.1.2 Inhalation
When rats were exposed to 370 ppm EGEE 7 hr/day, 5 days/wk for 5 wk, an adverse effect 
on both the RBC and WBC populations was evident from (1) the increase in the hemosiderin 
content and the decrease in myeloid cells in the spleen, (2) fat replacement in the bone 
marrow, and (3) an increase in the proportion of circulating immature granulocytes [Werner 
et al. 1943a]. Hemosiderin was still present in the 3-wk interval following termination of 
EGEE exposure. Exposure of dogs 7 hr/day, 5 days/wk for 12 wk to 840 ppm EGEE also 
increased the numbers of circulating immature granulocytes [Werner et al. 1943b]. Al­
though the hemosiderin content in the spleen was increased, RBC counts, Hb concentration, 
and MCV were only marginally reduced in the exposed dogs. These blood changes occurred 
at exposure concentrations not sufficiently severe to cause overt signs of toxicity. These 
studies demonstrated hematologic changes from EGEE exposure that were not severe and 
were reversible.
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In a study by Carpenter et al. [1956], a single 4-hr inhalation exposure o f rats to either EGEE 
or EGEEA increased erythrocyte osmotic fragility. The lowest concentrations causing 
osmotic fragility were 125 ppm EGEE and 62 ppm EGEEA. In another study, a single 4-hr 
exposure o f rats and rabbits to 2,000 ppm EGEEA caused transient hematuria and/or 
hemoglobinuria only in rabbits [Truhaut et al. 1979]. In the same study [Truhaut et al. 1979], 
exposure o f rats and rabbits o f both sexes to 200 ppm EGEEA 4 hr/day, 5 days/wk for 
10 months caused no effect on RBC or Hb levels.
Adverse effects on hematologic parameters were observed in rats and rabbits exposed to 0, 
25,100, or 400 ppm EGEE 6 hr/day, 5 days/wk for 13 wk [Terrill and Daly 1983a,b; Barbee 
et al. 1984]. In the rabbit study, Hct and Hb levels and erythrocyte counts were reduced 
significantly in males (P<0.05, P<0.01, P<0.05, respectively) and females (P<0.05) exposed 
to 400 ppm EGEE. No hematologic changes were observed in either sex at lower concentra­
tions. In the rat study, WBC counts were significantly reduced (P<0.05) in females exposed 
to 400 ppm EGEE; no effects were observed in male rats.
Exposure o f pregnant rats and rabbits during gestation to EGEE or EGEEA also affected 
hematologic parameters [Doe 1984a]. Pregnant Alpk/AP rats were exposed to 0 ,1 0 , 50, or 
250 ppm EGEE 6 hr/day on g.d. 6 through 15. In the 250 ppm EGEE-exposure group, there 
were reductions in Hb, Hct, and MCV in erythrocytes. There were no effects at either 50 
or 10 ppm EGEE in rats. No hematologic effects were observed in pregnant Dutch rabbits 
exposed to 0, 10, 50, or 175 ppm EGEE 6 hr/day on g.d. 6 through 18. In the same study, 
pregnant rabbits were exposed to 0 ,25 ,100 , or 400 ppm EGEEA 6 hr/day on g.d. 6 through 
18. Doe [1984a] concluded that a significant reduction in Hb concentration and a slight 
reduction in the associated RBC parameters were seen in the 400 ppm EGEEA-exposure 
group but provided no specific statistical data. No effects were observed in rabbits at the 
lower exposure concentrations.
Exposure o f New Zealand white rabbits and Fischer 344 rats to 0 ,50 ,100 ,200 , or 300 ppm 
EGEEA 6 hr/day on g.d. 6 through 18 (rabbits) and 6 through 15 (rats) resulted in adverse 
hematologic parameters in both species [Tyl et al. 1988]. In rabbits, there was evidence of 
enlarged erythrocytes (elevated MCV) at 300 ppm EGEEA (P<0.01) and significant 
dose-related decreases in the number of platelets at 100 (P<0.05), 200 (P<0.01) and 300 
ppm EGEEA (P<0.001). In rats, the WBC count was significantly increased (P<0.001) at 
200 and 300 ppm EGEEA. Statistically significant reductions in rat RBC count (P<0.0), 
Hb level (P<0.01), and Hct and RBC volume (0.05) were seen at the three highest exposures 
(100, 200, and 300 ppm EGEEA). Platelet counts were also significantly reduced at 
200 ppm (P<0.001) and 300 ppm EGEEA (P<0.01) in the rat.
B.3.1.3 Dermal Exposure
In a study by Truhaut et al. [1979], rabbits were exposed to a single 24-hr dermal application 
(10,500 mg/kg) o f EGEEA; death followed between 1 and 4 days after application. The 
reduction in RBC count did not exceed 15% to 20% and blood Hb levels showed little 
variation; however, a 50% to 70% decrease in WBC count was noted.
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B.3.2 EGME and EGMEA
B.3.2.1 Oral Administration
Oral administration of EGME and EGMEA has induced hematologic changes in laboratory 
animals. Nagano et al. [1979] found a statistically significant decrease (P<0.01) in WBC 
counts following oral administration o f 500 mg EGME/kg or 1,000 mg EGME A/kg to male 
JCL-ICR mice 5 times/wk for 5 wk. Statistically significant decreases were also observed 
in RBC and Hb values for the 1,000 mg EGME/kg group (P<0.01) and in Hb values for the
2,000 mg EGMEA/kg group (P<0.01). Treatment o f female JCL-ICR mice with 1,000 mg 
EGME/kg on g.d. 7 through 14 also significantly decreased the leukocyte counts (P<0.01) 
[Nagano et al. 1981].
Grant et al. [1985] investigated the effects o f subchronic oral exposure to EGME on the 
hematopoietic system of rats and the reversibility o f such effects. Groups o f 24 male F344 
rats were orally dosed with EGME at 0, 100, or 500 mg/kg per day for 4 consecutive days. 
Six animals from each group were then sacrificed 1 ,4 ,8 , and 22 days after the last treatment. 
Rats in the high-dose group displayed severely hemorrhagic femoral bone marrow with 
major loss o f the normal nucleated tissue and damage o f sinus endothelial cells on day 1. 
The normal architecture o f the marrow was restored by day 4 post-treatment. Treatment 
with 500 mg EGME/kg for 4 days abolished extramedullary hemopoiesis (EMH) in the 
spleen; partial recovery was seen on day 4, followed by marked improvement on day 8, and 
a return to control values by day 22. The high-dose group also showed mild anemia 
characterized by reductions o f the Hct and Hb values at day 4 (P<0.05 and P<0.001, 
respectively), and RBC, Hct, and Hb values at day 8 (P<0.05, P<0.05, and P<0.01, respec­
tively). Leukocyte counts (neutrophils and lymphocytes) were significantly reduced in this 
group on day 1 (P<0.001) and did not return to control values by the end of the recovery 
period. Low dose (100 mg EGME/kg per day) rats also had reduced leukocyte counts on 
day 1 (P<0.05). The authors [Grant et al. 1985] concluded that the major hematological 
effect o f EGME was leukopenia characterized by reductions in lymphocytes and neutrophils. 
Changes in the circulating blood together with reduced splenic EMH and bone marrow 
toxicity suggested an inhibitory action on erythropoiesis.
B.3.2.2 Inhalation
Hematologic effects from exposure to EGME were first reported by Wemer et al. [1943b] 
who exposed two dogs by inhalation to 750 ppm EGME for 7 hr/day, 5 days/wk for 12 wk. 
This exposure to EGME resulted in microcytic anemia as indicated by depressed erythrocyte 
and Hb values, which appeared at 4 to 6 wk of exposure; these values remained depressed 
throughout the exposure period. Recovery, as measured by Hb and Hct values, was gradual 
in proportion to the severity of the anemia. RBC were found to have increased osmotic 
fragility at the end o f 11 and 12 wk of exposure. When Wemer et al. [1943a] exposed Wistar 
rats to 310 ppm EGME 7 hr/day, 5 days/wk for 5 wk, increased levels of hemosiderin and 
immature granulocytes were observed; this indicated destruction o f blood cell populations.
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In a study by Carpenter et al. [1956], hemolytic effects in the rat erythrocyte were 
demonstrated by a single 4-hr inhalation exposure of six female rats to EGME or EGMEA. 
The lowest concentrations causing significant osmotic fragility were 2,000 ppm EGME and 
32 ppm EGMEA.
In a study by Miller et al. [1981], Fischer 344 rats and B6C3F1 mice were exposed by 
inhalation to 0, 100, 300, or 1,000 ppm EGME 6 hr/day for a total o f 9 days in an 11-day 
period. WBC counts o f both rats and mice exposed to 1,000 ppm EGME were statistically 
lower than those of the controls (P<0.05). MCV, RBC counts, and Hb levels o f male and 
female rats and male mice in the 1,000 ppm EGME-exposure group were also statistically 
depressed (£*<0.05). At 300 ppm EGME, similar but less severe effects were seen in rats; 
statistically lower (P<0.05) WBC counts in both sexes and Hb and RBC counts in females 
were noted. Hematologic parameters in mice exposed at 300 ppm EGME were stated to be 
similarly affected, but data were not presented. Histopathology was performed on rats only, 
revealing reduced bone marrow cellularity, lymphoid depletion in the cortex of the thymus, 
and reduced numbers of lymphoid cells in the spleen and in the mesenteric lymph nodes in 
the 1,000-ppm EGME group. Both myeloid and erythroid elements of the bone marrow 
were markedly reduced in all rats exposed to 1,000 ppm EGME, and megakaryocytes were 
present in decreased numbers and were smaller than those o f controls. The entire thymic 
cortical lymphoid population was depleted, with less dramatic reductions in the lymph nodes 
and spleen. Lymphoid organ toxicity persisted at 300 ppm EGME, but to a much lesser 
extent. In addition, serum total protein, albumin (males only), and globulin values in the
1,000 ppm EGME-exposure group (rats) were significantly reduced (P<0.05).
In a longer inhalation study, Miller et al. [1983a] exposed Sprague-Dawley rats and New 
Zealand white rabbits to 0, 30, 100, or 300 ppm EGME 6 hr/day, 5 days/wk for 13 wk. 
Hematologic analyses were performed after 4 or 12 wk of exposure. After 12 wk, both rats 
and rabbits from the 300 ppm EGME-exposure groups had significantly decreased mean 
WBC counts, platelet counts, MCV, and Hb concentrations (P<0.05); RBC counts were 
significantly reduced only in the 300 ppm EGME-exposed rabbits. These same hematologic 
changes were also seen after 4 wk (data not given). Mean values for total protein, albumin, 
and globulins were significantly lower than those of the controls in rats exposed to 300 ppm 
EGME (PcO.OS) but were normal in rabbits. Microscopic lesions in rats occurred in the 
300-ppm group only as a decrease in cortical lymphocytes indicating thymic atrophy. No 
histopathologic changes were seen in bone marrow. In rabbits, microscopic lesions 
were also present at 300 ppm EGME, includ ing  lymphoid atrophy of the thymus and 
gut-associated lymphoid organs and a decrease in the size o f hepatocytes [Miller et al. 
1983a].
B.3.2.3 Dermal Exposure
Subchronic dermal exposure o f male guinea pigs to EGME demonstrated adverse 
hematologic effects [Hobson et al. 1986]. Six male Hartley guinea pigs were exposed to
1,000 mg EGME/kg per day, 5 days/wk for 13 wk. EGME was applied to gauze patches 
affixed to the shaved backs o f the guinea pigs and held in place with a stockinette bandage
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6 hr/day, 5 days/wk for 13 wk. Statistically significant decreases in RBC counts and 
increases in MCV were noted when compared with the control values (P<0.05). Differential 
white cell counts demonstrated significant (P<0.05) lymphopenia with neutrophilia. Addi­
tionally, significantly increased serum creatinine kinase (CK) and lactate dehydrogenase 
(LDH) activity were noted in this group (P<0.01).
B.4 METABOLISM, UPTAKE, AND ELIMINATION 
B.4.1 EGEE/EGEEA
Jonsson et al. [1982] investigated the biotransformation of EGEE in albino rats exposed 
either to 10 ppm EGEE via inhalation for 1 hr or to single doses o f 9.3 or 93 mg EGEE by 
gastric intubation. Ethoxyacetic acid (EAA) and N-ethoxyacetyl glycine were the two major 
metabolites present in the urine o f animals dosed by either route. In the oral-dosing study, 
urine was collected after dosing for 48 hr, in 24-hr portions. The combined excretion of the 
two metabolites amounted to 30% of the administered oral dose for both dose groups. No 
recovery was given for the animals dosed by inhalation.
The biotransformation and excretion of EGEE was studied by Cheever et al. [1984] in 
Sprague-Dawley rats. The animals received a single oral dose of 230 mg/kg of EGEE 
[ethanol or ethoxy labeled ^C]. The animals were sacrificed for assay of tissue radioactivity 
at the end of a 96-hr experimental period. Rats treated with the ethanol-labeled material 
excreted 81 % of the radioactive dose in urine over a 96-hr period, whereas rats treated with 
the ethoxy-labeled compound excreted 76% o f the dose in urine. Within the first 24 hr, 72 % 
of the ethanol label and 70% o f the ethoxy label were excreted in urine. The major urinary 
metabolites were EAA and N-ethoxyacetyl glycine, which accounted for 73% to 76% of the 
administered radioactivity. Results of this study confirmed previous work by Jonsson et al. 
[1982] and indicated that, in the rat, metabolism o f EGEE proceeds primarily through 
oxidation via alcohol dehydrogenase to EAA, with some subsequent conjugation of the acid 
metabolite with glycine. It is noteworthy that in this study, 2 hr after administration of 
EGEE, EAA was found in the rat testes; these data suggest that adverse testicular effects of 
EGEE may be due to EAA [Cheever et al. 1984].
Absorption and elimination of EGEEA were studied by Guest et al. [1984] in beagle dogs 
following inhalation, intravenous (i.v.), or dermal exposure. EGEEA was rapidly absorbed 
through the lungs during exposure to 50 ppm EGEEA for 5 hr. After 10 min o f exposure, 
the concentration of EGEEA in expired breath was 9 ppm (80% absorption), and it reached 
the plateau value of 16 ppm at 3 hr, indicating that 68% o f the inhaled compound was 
absorbed. The breath concentration of EGEEA decreased to 2 ppm at 3 hr post-exposure. 
Following single i.v. dosing with 1 mg/kg, 20% and 61% o f the dose appeared in urine in 
4 and 24 hr, respectively. The blood elimination half-life was 7.9 hr. Estimated over a 
60-min period, the percutaneous absorption rate of EGEEA following dermal application to 
the dog’s thorax was 110 mM/cm2 per min. The rate of absorption of EGEEA through dog 
skin in vitro was 292 nmol/cm2 per hr (2.3 mg/cm2 per hr).
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Groeseneken et al. [1986a] developed a method for measuring urinary EAA. Five healthy 
male volunteers were exposed at rest via face mask to air containing 5.4 ppm EGEE during 
four 50-min periods. Experimental conditions are described in Groeseneken et al. [1986b]. 
Urinary EAA concentration rose significantly 1 hr after the exposure period. Urinary EAA 
concentration rose from 0.07 mg/liter before exposure to 2.39 ±  1.03 mg/liter 1 hr after the 
exposure period (P<0.005). One o f the subjects showed measurable levels of EAA before 
exposure. Questioning o f the subject indicated that he may have had occupational exposure 
to EGEE some days before the experiment. Preliminary results o f the excretion of EAA in 
urine suggested that measurement of EAA could be a specific and sensitive parameter for 
monitoring worker exposure to EGEE.
Groeseneken et al. [1986b] next investigated the respiratory uptake and elimination of EGEE 
in 10 male volunteers under controlled experimental conditions o f exposure concentration 
and physical workload. The subjects were divided into two groups, five subjects per group, 
and were exposed to EGEE for 4 hr, the equivalent of half a workshift. At the end of each 
50 min during exposure, a short break o f 10 min was inserted. All subjects participated in 
three experiments according to their group assignment. Experimental conditions are 
presented in Table B -l.
Table B -l.—Experimental conditions for Groeseneken et ah [1986b]
Exposure concentration Workload
Group ppm
3
mg/m (W)
I 2.7 10 0
5.4 20 0
10.8 40 0
n 5.4 20 0
5.4 20 30
5.4 20 60
This study showed that in man, EGEE is rapidly absorbed through the lungs. About 64% 
of the inhaled vapor was retained at rest, and retention increased as physical exercise was 
performed during exposure. The absorbed dose was apparently proportional to the inhaled 
concentration, and a linear relation was observed between uptake rate and exposure 
concentration. The rate o f uptake increased when physical exercise was performed during 
exposure. The rate o f uptake was higher as exposure concentration, or pulmonary ventilation 
rate, or both increased. Individual uptake rates seemed dependent only on transport 
mechanisms (pulmonary ventilation, or cardiac output, or both) and not on anthropometric 
data or body fat content. Respiratory elimination of unchanged EGEE accounted for ¿0.4% 
of the total body uptake and occurred rapidly after cessation of exposure, followed by a 
much slower decrease. This slow decrease indicated that two pharmacological compart­
ments were involved.
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Groeseneken et al. [1986c] also studied the urinary excretion o f EAA in the 10 male 
volunteers who inhaled various concentrations o f EGEE for 4 hr both at test and during 
physical exercise in the previously described study [Groesenken et al. 1986b]. The subjects, 
divided into two groups of five, were either exposed at rest to concentrations of 2 .7 ,5 .4 , or
10.8 ppm EGEE (10,20, or 40 mg/m3, respectively) or were exposed to 5.4 ppm EGEE at 
rest and during physical exercises (see Table B -2). Urine samples were collected at hourly 
intervals during exposure and up to 4 hr after exposure ended. Additional urine samples 
were collected at 2-hr intervals for the rest of the day; four 8-hr samples were collected 
during the next 2 days. Urine samples were analyzed for EAA using the method of 
Groeseneken et al. [1986a]. During both experimental protocols, the rate of excretion of 
EAA increased and continued to do so to a maximum level 3 to 4 hr after the end o f the 
exposure period. After attaining the maximum level, a slow decrease began with a biological 
half-life between 21 and 24 hr. In both the resting condition under increasing EGEE 
concentrations and during physical exercise at a constant EGEE concentration, the rate of 
urinary excretion o f EAA increased (P<0.001 and P<0,005, respectively) and appeared to 
be related to the rate o f uptake of EGEE. The rate of uptake increased under both 
experimental conditions in a statistically significant manner (P<0.001).
The total amount of EAA excreted within 42 hr was significantly related (P<0.001) to the 
EGEE concentration in inspired air, uptake rate, pulmonary ventilation rate, oxygen con­
sumption during exposure, and heart rate during and after exposure. EAA was negatively 
related (P<0.05) to height, body weight, and lean body mass. Multiple linear regression 
analysis revealed that only the relations between EAA excretion and EGEE uptake rate 
(P<0.001), heart rate (P<0.001), oxygen consumption during exposure (P<0.05), and height 
(P<0.001) were significant Respiratory frequency was a contributing factor to EAA 
excretion. On the average, 23% of inhaled EGEE was recovered as EAA within 42 hr in 
both experiments at rest and during physical work. The authors concluded that good 
correlations between EAA excretion and EGEE uptake were found following the exposure 
period. Although biological monitoring o f exposed workers is usually based on urinary 
metabolite levels in samples taken immediately after the end of a workshift, a maximal 
excretion rate o f EAA may be reached several hours later. In addition, as a result of the long 
biological half-life of EAA, EAA will not be cleared from the urine the next morning, and 
accumulation can be expected through repetitive exposures [Groeseneken et al. 1986c].
The urinary excretion of EAA was studied in a group of five female silk-screen printing 
operators during repeated daily inhalation exposure to a mixture o f EGEE and EGEEA 
[Veulemans et al. 1987]. The subjects worked in weekly, alternating morning and evening 
shifts. They agreed to wear rubber gloves at all times to avoid occasional skin contact with 
inks and thinners. Air and urine samples were collected each day during 5 days of normal 
production and 7 days after a 12-day production stop. Urine samples were collected 
immediately before and after work; air samples were collected as individual half-shift 
samples. Urinary EAA excretion increased during the workweek, and elimination proved 
to be far from complete over the weekends. In the last observation period, urinary EAA 
values on Monday morning still attained about half the urinary concentration on Friday 
evening (30 mg EAA/g creatinine versus 64 mg EAA/g creatinine). Even after a prolonged 
nonexposure period of 12 days, traces of the metabolite (1.2 to 2.6 mg EAA/g creatinine)
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were still detectable. On a number of days, the preshift EAA concentrations were even 
higher than the immediate postshift values on the preceding and same day. For this reason, 
and because of the more constant exposure profiles, an estimation of the maximum EAA 
levels after prolonged daily exposure was made on the basis o f the results of the first exposure 
period. A linear correlation (r-0.92) was found between average exposure to EGEE and 
EGEEA over the 5 exposure days and EAA excretion at the end of the 5-day workweek. 
EAA estimate of 150 mg ±  35 mg/g creatinine was found to correspond with repeated 5-day 
full-shift exposures to 5 ppm of EGEE or 5 ppm of EGEEA.
Groeseneken et al. [1988] compared urinary EAA excretion in man and the rat after 
experimental exposure to EGEE. The human data were drawn from the previously men­
tioned inhalation study [Groeseneken et al. 1986c] in which five subjects had been exposed 
to 2.7 ppm, 5.4 ppm, or 10.8 ppm EGEE. Urine samples collected at short intervals were 
pooled into 12-hr groups for comparison with rat data. Groups of five male Wistar rats were 
treated by oral intubation with 0.5, 1 ,5 , 10, 50, or 100 mg EGEE/kg. Rat urine samples 
were collected before EGEE exposure and then at 12-hr intervals up to 60 hr after the dosing. 
The maximal excretion rate of EAA in human and rat urine was found within 12 hr after 
exposure or dosing. Afterwards, the decline of urinary EAA was much slower in man than 
in the rat. In man, the half-life o f EAA was on average 42.0 + 4.7 hr, a longer half-life than 
reported in the original study (21 to 24 hr) [Groeseneken et al. 1986c]. The author attributes 
the longer half-life to the use o f 12-hr pooled urine specimens in this study [Groeseneken 
et al. 1988] rather than to specimens collected at 1- to 2-hr intervals in the previous study 
[Groeseneken et al. 1986c]. In the previous study, half-lives were calculated from the peak 
exposure time (8 hr after the start o f exposure). Examination of the excretion curves from 
the previous paper showed that elimination between 8 and 12 hr was more rapid than at 
longer time intervals, leading to a shorter calculated elimination half-life [Groeseneken 
et al. 1986c]. The authors concluded that the longer elimination half-life was more 
consistent with half-lives seen in occupational exposure, which were as high as 48 hr 
[Groeseneken et al. 1988; Veulemans et al. 1987]. The recovery o f EAA in human urine 
after 48 hr averaged 23%. Based on the half-life of EAA elimination of 42 hr, the authors 
estimated total recovery of EAA as 30% to 35% of the absorbed dose.
In the rat, the half-life of EAA was 7.20 ± 1.54 hr. On the average, 27.6% + 6.1 % of urinary 
EAA in rats was present as the glycine conjugate, with the extent of conjugation being 
independent o f the dose. The extent of conjugation demonstrated a diumal variation; the 
lowest extent of conjugation was found during the night EAA glycine conjugates were 
absent in human urine. In man, the recovery of EAA was higher than in the rat for equivalent 
low doses of EGEE (0.5 and 1 mg/kg). When urinary excretion data for the lower dose 
range were normalized for body weight in both species, rats excreted EAA at a higher rate 
than did man for equivalent doses. The authors concluded, that although nonlinear kinetics 
had been observed in some animal studies at high doses, the elimination kinetics seen at low 
doses in this study were not dose-dependent in either rats or humans [Groeseneken et al. 
1988].
Groeseneken et al. [1987a] studied the pulmonary absorption and elimination o f EGEEA in 
10 male subjects under various conditions of exposure and physical workload; subjects were
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assigned into two group«, 5 per group. Exposures were by mask for 50 min/hr. Experimental 
conditions are presented in Table B-2.
Table B -2.—Experimental conditions for Groeseneken et al. [1987a]
Exposure concentration Workload
Group ppm mg/m (W)
I 2.6 14 0
5.2 28 0
9.3 50 0
n 5.2 28 0
5.2 28 30
5.2 28 60
All subjects performed three experiments according to their group assignment. The subjects 
remained unexposed for at least 1 wk between experimental sessions. The pharmacokinetics 
of respiratory uptake are more complicated for EGEEA than for EGEE. Retention, atmos­
pheric clearance, and uptake rate decreased with time and reached steady-state levels at 3 
to 4 hr; retention increased with exposure and workload. Retention at steady state for the 
three exposure concentrations was 53%, 57%, and 62%, respectively. Although retention 
of EGEEA increased proportional to the workload, no further increase was noticed for EGEE 
after 30 w [Groeseneken 1986b]. Individual uptake o f EGEEA was determined by pul­
monary ventilation, cardiac output, height, and fat content, whereas uptake of EGEE seemed 
mainly determined by the cardiopulmonary transport parameters alone [Groeseneken 
1986b]. The hypothesis that EGEEA is first converted to EGEE by plasma esterases was 
confirmed by the observation of partial respiratory elimination of EGEE. The amount of 
EGEE expired during steady state conditions correlated with the uptake rate o f EGEEA 
rather than with EGEEA exposure concentrations. Respiratory elimination of unmetabol- 
ized EGEEA accounted for 50.5% of total body uptake. This slow decrease could be 
represented as a regression equation with two exponential terms, indicating at least two 
pharmacologic compartments were involved. The author speculated that the complex 
pulmonary kinetics may be due to metabolic competition in the conversion o f EGEEA to 
EGEE and to possible redistribution into the fat soluble compartment.
Groeseneken et al. [1987b] examined urinary EAA excretion in the experimental groups 
exposed to EGEEA in the previous study [Groeseneken et al. 1987a]. Urine samples were 
taken at the beginning o f the exposure period and at every hour until the fourth hour after 
exposure. Then three 2-hr samples followed by four 8-hr samples were collected. Urine 
samples were analyzed for EAA by the method of Groeseneken et al. [1986a]. EAA levels 
appeared with a half-life o f 2.3 + 0.1 hr during the 4-hr EGEEA exposure period. Maximal 
EAA excretion rate was attained 3 to 4 hr after the exposure period. The half-life was
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23.6± 1.8 hr. However, 3hrafterthe first peak EAA excretion, a second maximum excretion 
of EAA was observed; this second peak was especially pronounced after exposure during 
physical exercise. Redistribution of EGEEA, or EAA, or both from a peripheral to central 
compartment could explain this phenomenon. Urinary EAA excretion was dependent on 
the EGEEA uptake rate, as a consequence of higher exposure (.PO.OOl), and on the uptake 
rate of EGEEA at constant exposure, as a consequence o f physical workload (P<0.001). On 
average, 22.2% ±  0.9% of the absorbed EGEEA was metabolized and excreted in the urine 
as EAA within 42 hr. The total excretion of EAA in 42 hr was related both to total uptake 
from increasing concentrations of EGEEA (P<0.001) and to total uptake, at constant 
exposure, with increasing workload (P<0.001). Total EAA excretion was correlated to 
EGEEA concentration, uptake rate, and transport mechanisms (pulmonary ventilation, 
oxygen consumption, respiratory rate, etc.). In addition, EAA excretion was correlated to 
body fat (r=0.40, /*<0.001). Groeseneken et al. [1987b] concluded that the metabolism of 
EGEEA proceeded through EGEE via esterases and then continued through the same 
excretion pathway as EGEE. Indeed, the kinetics of EAA excretion after exposure to 
EGEEA were very similar to these found after exposure to EGEE [Groeseneken et al. 1987a].
Workers from a shipyard painting operation who applied paint containing EGEE were 
evaluated for EGEE exposure [Lowry 1987]. Work conditions and practices varied consid­
erably between brush and spray painters. Some workers were in confined spaces below 
deck, whereas others were in the open. The study was conducted in the winter, and the 
temperatures varied greatly depending on the painters’ work areas. Information on work 
practices such as the number of hours spent painting, the type of paint used, the work area 
locations, and the use of personal protective equipment was gathered from questionnaires.
Environmental breathing zone samples were collected for each worker for 3 days. Urine 
samples were collected every day for 1 wk, at the beginning and end o f each workday, and 
EAA levels were measured. A wide range of EAA levels was noted in workers using 
EGEE-containing paints; this was probably due to variation in work assignments, work 
areas, and use of personal protective equipment. This study has not gone through extensive 
evaluation to determine the importance of the many variables on the levels o f EAA in urine. 
The author could only conclude that there appeared to be a relationship between urinary 
EAA excretion and the use of paints containing EGEE [Lowry 1987].
Clapp et al. [1987] investigated EGEE exposure o f workers engaged in casting precision 
metal parts. The 8-hr TWAs of EGEE ranged from nondetectable to 23.8 ppm. EGEE was 
not detected in any of the blood samples from the EGEE-exposed workers, but exposed 
workers were found to have measurable levels of EAA in urine (163 mg/g creatinine). EAA 
was not detected in the urine of unexposed control subjects.
B.4.2 EGME and EGMEA
EGME has been shown to be a possible substrate for alcohol dehydrogenase (ADH) [Tsai 1968; 
Blair and Vallee 1966], and thus oxidation of EGME via ADH and aldehyde dehydrogenase 
to methoxyacetic acid (MAA) is a potential route o f  metabolism [Miller et al. 1982].
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The toxicity o f MAA will be discussed next to evaluate the importance of metabolism 
as a detoxification or bioactivation mechanism for EGME. In a study by Miller et al. 
[1982], groups o f five male F344 rats were given daily doses o f 0, 30 ,100 , or 300 mg 
MAA/kg per day orally on 8 days out of 10 and were then sacrificed 24 hr after the final 
dose. Rats given the high dose had significantly lower body weights on the fifth day 
and again when recorded on the tenth day (P<0.05). Absolute and relative weights of 
spleen, thymus, and testes were also significantly reduced in the 300 mg MAA/kg per 
day exposure group (P<0.05). In the 100 mg MAA/kg per day exposure group, relative 
thymus weight was significantly reduced (P<0.05). Hematology revealed significantly 
lower RBC, Hb concentration, MCV, and WBC in the group dosed with 300 mg 
MAA/kg per day (P<0.05). Significant but less pronounced reductions in RBC, Hb, 
and MCV were seen in those receiving 100 mg MAA/kg per day (P<0.05). Testicular 
atrophy and a decrease in the size o f the thymus were seen in the 300 mg MAA/kg per 
day group; thymus size was decreased in the 100 mg MAA/kg per day group also. 
Histological evaluation revealed diffuse, severe depletion of cortical lymphoid elements 
in the thymus of all rats treated with 300 mg MAA/kg per day and a slight reduction in 
the same cell population in all rats treated with 100 mg MAA/kg per day. All rats treated 
with 300 mg MAA/kg per day had severe degenerative changes in the germinal 
epithelium of the seminiferous tubules, and slight degenerative changes were observed 
in the rats treated with 100 mg MAA/kg per day [Miller et al. 1982].
Miller et al. [1983b] used radiolabeled EGME to isolate and identify urinary metabolites 
in rats. Groups of three male F-344 rats were given a single oral dose of approximately 
76.1 mg/kg or 660 mg/kg of 14C EGME; animals were sacrificed 48 hr after dosing. Urine 
was the major route of elimination (50% to 60% of 14C) at both dose levels, with 
approximately 18% and 12% of the radioactivity remaining in the carcasses of low- and 
high-dose animals, respectively. Target organs of EGME such as testes, thymus, and spleen 
did not show an accumulation of EGME or its metabolites. Blood had the greatest amount 
of C per gram of tissue at 48 hr postexposure. The profile of radioactivity in a composite 
sample of urine collected during the 0 to 12 hr interval for both high- and low-dose groups 
was very similar. The majority of the I4C (83% to 95%) was found in one major peak 
identified as MAA. The authors [Miller et al. 1983b] proposed that oxidation to MAA is a 
major route for elimination of EGME and occurs via ADH to methoxyaldehyde and, 
thereafter, via aldehyde dehydrogenase to MAA.
Foster et. al. [1983] exposed six male Sprague-Dawley rats orally to 592 mg MAA/kg per 
day (equimolar to 500 mg EGME/kg per day) for 4 days. Significant decreases in actual 
and relative liver and testes weights were seen (P<0.01). The severity and nature of testicular 
changes were essentially similar to those of the corresponding dosage of EGME given for 
the same period [Foster et al. 1983].
Foster et al. [1987] exposed groups o f six male Alpk/AP (Wistar-derived) rats to a single 
oral dose of MAA to determine the initial target for testicular toxicity. Dose levels were 
administered equimolar with 100, 250, or 500 mg EGME/kg (i.e., 118, 296, or 592 mg 
MAA/kg). Rats were sacrificed at 1,2,4, and 14 days post-treatment. A significant decrease 
in testes weight relative to body weight was seen only in the high dose MAA group at days
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4 and 14 (P<0.05). Histological examination of testes revealed damage 24 hr after dosing 
in all groups treated with MAA. Pyknosis and nuclear condensation were seen in late 
pachytene, diplotene, diakinetic, and secondary spermatocytes in high-dose rats at 24 hr. At 
2 days, these effects were more extensive and included the loss of early and late pachytene, 
diplotene, and secondary spermatocytes; some signs o f degeneration to zygotene sper­
matocytes (precursor cells to pachytene spermatocytes); and partial loss o f the succeeding 
generation o f early round spermatids. By day 4, the lesion had progressed to midpachytene 
spermatocytes, although by day 14, resolution of the damage had begun.
Degeneration seen in the mid-dose MAA-exposed rats included fewer stages of sper­
matogenesis with some Ices of affected cells and early round spermatids at day 2. Low-dose 
MAA-exposed rats demonstrated minimal effects in diplotene secondary spermatocytes and 
early pachytene spermatocytes [Foster et al. 1987].
Wistar-Porton rats were given single injections o f 224 mg MAA/kg on g.d. 8,10, 12, or 14, 
and then sacrificed on g.d. 20 to study the teratogenicity of MAA [Brown et al. 1984]. 
Embryotoxicity was indicated by increased embryo-fetal death, structural malformations, 
and decreased fetal weight (no statistical treatment given). Embryo-fetal mortality was 
greatest after MAA administration on g.d. 8 (93%), decreasing to 3 % for g.d. 14. The highest 
incidence of fetal malformations followed exposure on g.d. 12, although malformations were 
induced on each day of treatment. Defects included skeletal malformations, hydrocephalus, 
and urogenital abnormalities [Brown et al. 1984].
The teratogenicity of MAA compared with that of EGME was further studied in pregnant 
Wistar rats (six, seven, or eight per group). The rats received single oral doses of 186 or 
373 mg MAA/kg or 158 or 315 mg EGME/kg on g.d. 12 [Ritter et al. 1985]. Pregnancy 
was terminated on g.d. 20, and total embryotoxicity was calculated as the sum of dead, 
resorbed, and malformed fetuses as percent of total implantations. MAA demonstrated a 
dose response at 186 mg MAA/kg (58% total embryotoxicity) and at 373 mg MAA/kg (99%); 
these responses were not significantly different from that produced by EGME doses of 158 
(54%) and 315 mg EGME/kg (100%). The authors noted that between 80% and 96% of the 
total defects found in any of the treatment groups were classified as hydronephrosis and 
heart, tail, and limb defects. These defects included dilated ductus arteriosus, dilated aortic 
arch, and ventral polydactyly; the authors report these are rarely seen with any other 
teratogenic agent.
The role o f metabolism in EGME-induced testicular toxicity was investigated by Moss 
et al. [1985] using groups of nine male Sprague-Dawley rats pretreated i.p. with 400 mg 
pyrazole/kg, an alcohol dehydrogenase (ADH) inhibitor, or pretreated with 300 mg disul- 
firam/kg, an aldehyde dehydrogenase inhibitor. One hr after pretreatment with pyrazole or 
24 hr after pretreatment with disulfiram, animals were injected i.p. with 250 mg of labeled 
EGME/kg. Controls with no pretreatment also received 250 mg(14C) EGME/kg i.p. 
Urinary excretion was the major route of elimination o f EGME metabolites after 24 hr 
(40.4% ±  3.6% of dose) and 48 hr (14.8% ±  0.6% of dose) in controls. High performance 
liquid chromatography (HPLC) analysis identified MAA as the major urinary metabolite at 
0 to 24 hr (63% of the radioactivity) and at 24 to 48 hr (50% of the radioactivity). The
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second major urinary metabolite was identified as methoxyacetylglycine (approximately 
20% of radioactivity). Analysis o f radioactivity in the plasma demonstrated rapid disap­
pearance (tl/2 = 0.56 hr) o f EGME between 0 and 4 hr after dosing with a corresponding 
appearance of MAA. Radioactivity clearance from plasma (tl/2) was estimated to be 
19.7 hr.
In the rats pretreated with pyrazole, the metabolism of EGME to MAA was inhibited. 
Analysis of radioactivity in plasma showed a slower disappearance o f EGME (tl/2 “ 42.6 
± 5 .6  hr) and radioactivity clearance from plasma (tl/2 -  51.0 + 7.8 hr) than in the controls. 
The percentage o f the dose found in urine after 24 hr (9.8% ±  2.4%) and 48 hr (7.9% + 2.2%) 
showed urinary excretion not to be the major route o f elimination. MAA was not a major 
urinary component, and methoxyacetylglycine was not found in urine from these rats. 
Pretreatment with the aldehyde dehydrogenase inhibitor disulfiram had no significant 
effect on plasma or urinary metabolic profiles. Administration o f EGME by i.p. injection 
demonstrated extensive degeneration and necrosis o f rat primary spermatocytes in the early 
and late pachytene stages of development. Pretreatment with pyrazole appeared to protect 
against spermatocyte damage, whereas pretreatment with disulfiram had no effect on the 
degree of spermatocyte damage observed [Moss et al. 1985].
Ritter et al. [1985] investigated the effect o f an ADH inhibitor, 4-methylpyrazole (4-MP), 
on EGME-induced teratogenicity in pregnant Wistar rats. Groups of seven animals were 
administered 315 mg EGME/kg i.p. on g.d. 12 with or without a concurrent dose o f 100 mg 
4-MP/kg. Pregnancy was terminated on g.d. 20. Coadministration of EGME and 4-M P  
resulted in significantly decreased total embryotoxicity: 16.8% compared with 100% with 
EGME alone (¿><0.05). Ritter et al. [1985] stated that 4-MP inhibits ADH and might 
interfere with the metabolism of EGME to MAA and consequently prevent the 
embryotoxicity or teratogenicity dependent on the production of MAA.
Sleet et al. [1988] conducted a series o f experiments on the role o f EGME metabolism in 
the induction of paw malformations in CD-I mice. Pregnant dams were dosed on g.d. 11 
and sacrificed on g.d. 18. A comparison was made o f dose-dependent digit anomalies 
produced by oral exposure to a single dose of EGME (99 to 463 mg/kg) or of MAA (99 to 
693 mg/kg). MAA and EGME were equipotent in producing digit anomalies (syndactyly, 
oligodactyly, and polydactyly) as expressed on the basis o f percent o f litters affected and 
percent o f fetuses affected. Fetal body weights and incidence of resorbed implants were not 
significantly different between EGME- and MAA-exposed animals.
The effects o f gavage and i.v. injection on the teratogenicity of MAA were also compared 
by Sleet et al, [1988]. MAA was administered to pregnant mice on g.d. 11 by gavage or tail 
vein injection at doses o f 261 mg/kg or 342 mg/kg. The incidence of digit malformations 
in both i.v. groups was statistically lower than that o f the corresponding gavage group 
(P<0.05). These results are expected since gavage and i.v. routes o f administration differ 
with respect to the metabolic fate o f MAA [Sleet et al. 1988].
Sleet et al. [1988] administered EGME (251 or 350 mg/kg) orally to pregnant CD-I mice 
on g.d. 11 in combination with ethanol (2,901 mg/kg) to investigate competition for
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oxidation by ADH to teratogenic metabolites o f EGME. Three experimental conditions 
were used: (1) ethanol concomitantly with EGME (251 and 350 mg/kg) and again 5 hr and 
10 hr later; (2) ethanol 5 hr and 10 hr after 251 mg EGME/kg; and (3) single doses of ethanol 
concomitantly with 251 mg EGME/kg or 5 hr later. Single and multiple dosings o f ethanol 
attenuated EGME teratogenicity as expressed by digit malformations. Experimental con­
dition No. 1 provided the greatest reductions in incidences o f total anomalies (P<0.05) when 
compared with controls exposed to EGME only. At 251 and 350 mg EGME/kg, ethanol 
administration decreased the incidence from 47% to 6% and 94% to 36%, respectively. The 
single dose of ethanol at 0 hr (condition No. 3) significantly decreased, from 47% to 23%, 
the occurrence of digit anomalies caused by 251 mg/kg of EGME (P<0.05). Reduction of 
paw malformations decreased when ethanol was administered following EGME exposure. 
Condition No. 2 lowered paw malformations from 47% to 35% (P<0.05), but condition 
No. 3 of a single dose of ethanol 5 hr after EGME treatment had no protective effect.
Levels of EGME, MAA, and (14C) in maternal and conceptus compartments were quan­
titated by isotope dilution analysis for up to 6 hr after oral administration o f (*4C) EGME 
(251 mg/kg) and ethanol (2,901 mg/kg) [Sleet et al. 1987]. HPLC measurements 
demonstrated that ethanol caused only a transient delay in EGME metabolism to MAA and 
embryonal accumulation of 14C MAA. Using (14C) EGME only, approximately 90% of 
the radioactivity in the maternal plasma and in the embryo was (14C) MAA at 1 hr and 100% 
at 6 hr after treatment. Additionally, the (14C) level of the embryo was greater than that of 
maternal blood at both times. Concomitant dosing with ethanol reduced the proportion of 
( C) MAA in maternal plasma and embryo. At 1 hr, MAA represented 17% of radioactivity 
in both compartments, and at 2 hr, it increased to 40% in plasma and 32% in the embryo. 
At 3 hr, plasma levels of EGME and MAA were equivalent to the 1-hr levels following 
EGME administration alone; 80% of the total radioactivity in the embryo was MAA.
In light of the previous results, Sleet et al, [1988] investigated the possibility that further 
metabolism of MAA was necessary for expression of embryotoxicity by coadministering 
metabolic intermediates common to alcohol oxidation with EGME (251 mg or 350 mg/kg) 
on g.d. 11 and sacrificing the dams on g.d. 18. The incidence of paw malformations induced 
by EGME at either dosage was significantly lowered (P<0.05) by coadministration of 
sodium acetate (43 mmol/kg), formic acid (4.3 mmol/kg), or glycine (43 mmol/kg). The 
authors concluded that the marked decline in the incidence of digit malformations 
demonstrated that EGME teratogenicity is dependent on events subsequent to the formation 
of MAA [Sleet et al. 1988].
Yonemoto et al. [1984] used an in vitro culture system [New 1978] to determine the effects 
of EGME and MAA on the development of post-implantation rat embryos. On g.d. 9, 
conceptuses were removed from the dams (Wistar-Porton strain) and placed in pairs in 
bottles that contained 3 mL of heat-inactivated male rat serum and 1 mL of test compound. 
Ten to 15 conceptuses per group were cultured for 48 hr in 381 mg EGME or in 90, 180, 
270, or 450 mg MAA and then examined under a stereoscopic dissecting microscope. 
EGME had no significant effects on embryonic growth and development when compared 
with that of the controls. MAA, however, produced statistically significant reductions in 
morphological development, crown-rump length, head length, number of somites, and yolk
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sac diameter when compared with those o f the controls (P<0.001). These effects 
demonstrated a dose response, as all were seen at 450 mg MAA; all but yolk sac diameters 
were affected at 270 mg, and only head length and morphological development were affected 
at 180 mg. No significant effects were seen at 90 mg MAA. The predominant abnormalities 
seen in affected conceptuses were irregular fusion of the neural tube (wavy or open neural 
suture line) and irregular segmentation of the somites. The authors [Yonemoto et al. 1984] 
concluded that the data demonstrated that MAA or its metabolites are the proximal toxins 
in vivo and that, at the organogenesis stage, the rat fetus in vitro lacks alcohol dehydrogenase 
activity.
The in vitro culture system used by Yonemoto et al. [1984] was used by Rawlings et al. 
[1985] to study the mechanism of teratogenicity o f EGME. Conceptuses were explanted 
from pregnant Wistar-Porton rats at embryonic age 9.5 days and cultured for 48 hr with 2 
or 5 mM MAA. At the end of the culture period, crown-rump length, head length, and yolk 
sac diameter were measured, and the degree of differentiation and development was 
evaluated by a morphological scoring system. MAA at the 5 mM concentration had an 
adverse effect on fetal development. MAA-exposed embryos had statistically significant 
reductions (P<0.01) in morphological score, crown-rump length, head length, and yolk sac 
diameter compared with those of the controls. MAA also produced statistically significant 
reductions (P<0.05) in the protein content of the embryo. No statistically significant 
reductions in growth parameters were seen at the 2 mM level. However, irregularity of the 
neural suture line was seen in 100% of the MAA-exposed embryos. Other abnormalities 
observed in the MAA-exposed groups included abnormal otic and somite development, 
turning failure, open cranial folds, and abnormal yolk sac [Rawlings et al. 1985].
As has been demonstrated, the induction of paw malformations following in utero [Brown 
et al. 1984; Ritter et al. 1985] as well as in vitro [Yonemoto et al. 1984] exposure to EGME 
appears to depend on the oxidation of EGME to MAA. Sleet et al. [1988] investigated the 
relationship between the induction of paw malformations and the disposition of EGME in 
the maternal and embryonal compartments. Pregnant C D -1 mice were dosed by gavage on 
g.d. 11 with either EGME (1.3 to 6.6 mmol/kg, 100 to 500 mg/kg, or 5.2 fil/g) or MAA (1.1 
to 7.7 mmol/kg, 100 to 693 mg/kg, or 4.9 pl/g) and were sacrificed on g.d. 18. Fetuses were 
delivered by laparotomy and weighed before external examination for paw defects. The 
embryotoxic potencies o f EGME and MAA were determined by comparing the dose- 
dependent incidence o f digit anomalies. EGME and MAA were equipotent in causing digit 
malformations. The ADH inhibitor 4-methylpyrazole administered orally 1 hr before 
EGME reduced the incidence of malformations 60% to 100%, depending on the dosing 
regimen. Oxidation of EGME to MAA was nearly complete after 1 hr when approximately 
90% of (I4C) in maternal compartment and conceptus coeluted with authentic (14C)-MAA 
on HPLC. Embryonic (14C)-MAA levels were 1.2 times those in plasma 1 hr and 6 hr after 
dosing; by 6 hr, however, concentrations in the embryo had declined to approximately 50% 
of 1-hr values. Dams treated i.v. with (14C) MAA had higher (14C) blood levels than did 
dams treated orally, but the offspring of the former had fewer digit malformations. The 
authors concluded that peak and steady-state plasma levels of MAA, as well as embryonic 
MAA levels, do not appear to determine the embryotoxic outcome whereas further metabo­
lism of MAA does [Sleet et al. 1988].
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EGME uptake and urinary MAA excretion were examined in seven male subjects exposed 
at rest to 5.1 ppm EGME (16 mg/m3) by mask for four 50-min periods [Groeseneken et al. 
1989a]. There was a short 10-min break at the end of each 50-min period to allow for urine 
collection. Urine samples were collected immediately before the beginning of the experi­
ment and at hourly intervals until the fourth hour after exposure. Collections were taken 
until the morning of the fifth day after the exposure period (four 2-hr collections, one 8-hr 
collection, and eight 12-hr collections). Urinary MAA was then measured by the method 
of Groeseneken et al. [1989b]. Retention o f EGME was 76% during the 4-hr exposure 
period. The uptake rate showed no significant variation because of constant pulmonary 
ventilation and a fixed exposure concentration. On average, 19.4 ± 2 .1  mg EGME was 
inhaled during the 4-hr exposure period. MAA was detected in the urine during and up to 
120 hr after exposure. The elimination half-life averaged 77.1 ±  9.5 hr. On average, 54.9 % 
±  4.5% of inhaled EGME was excreted within 120 hr o f the start o f exposure; half of this 
amount was excreted within 48 hr. By extrapolation, the total amount of MAA was 
estimated at 85.5% ±  4.9% of inhaled EGME.
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OCCUPATIONAL EXPOSURES TO THE GLYCOL ETHERS BY WORKSITE OR PROCESS
Table C-X.—Occupational exposures by worksite or process
Number
Concentration
Glycol
ether Worksite or process Reference*
and type 
of samples
Range
(ppm)
Average
(ppm)
EGEE Leather dyeing Gill 1977 1 B 2 f ND* ND
Spray painting Lee 1982 2 BZ both 25 25
Painting (brush 
and spray)
Love and Donohue 
1983 
Sparer et al. 1988
8 BZ  
90 BZ
N D -128
0-21.5
22
2.6
Manufacture of solid 
state circuits
Gunter 1985 6 BZ N D -96 17
Hospital housekeeping A pol and Cone 1983 3 BZ <0.2 <0.2
(Continued)
See footnotes at end of table.
Table C -l (Continued).—Occupational exposures by worksite or process
Concentration
Number
Glycol
ether Worksite or process Reference
and type 
of samples
Range
(ppm)
Average
(ppm)
EGEE Construction of Crandall and Hartle 7 BZ 0.2-1.1 1.1
(Cont’d) plastic and wood boats 1983
Printing Burroughs 1979 16 BZ <2.4-<49 <14
5 area® < 3.0-< 17 <5.9
Ceramic shell production Ratcliffe et al. 1986 10 BZ N D -24 Not presented
8 area 10-17 Not presented
EGEEA Painting, molding. Gunter and Lucas 1974 21 BZ <0.4-20 2.4
inspection
Spray painting Hervin and Thoburn 22 BZ 13-4,657 543
1975 20 area 11-1,262 191
Gunter et al. 1980 6 B Z ND ND
1 area ND ND
Hartle 1980 3 BZ 5.7-14 8.8
6 area 0 3 -3 .4 2.2
Apol 1976 8 BZ N D -5 1.3
2  area ND ND
Chrostek and Levine 8  BZ 0.5-8.1 3.3
1981
Paint compounding 
and mixing
Degreasing
Manufacture of solid 
state circuits
Mixing and application 
of epoxy-type paint
Graphic arts department
Sill:-screening
Construction of 
plastic and wood boats
Coatings processes
Johnson and Boxer 
1983
Gunter 1985
Cohen and Maier 1973
McLouth and Gorman 
1980
Boiano 1983
Crandall and Hartle 
1983
Bryant 1978
Gilles 1977
Spray painting and 
curing operations
McQuilken 1980
24 BZ ND-1.0 0.11
4 area ND N D
2 BZ Trace Trace
2 area Trace Trace
14 BZ N D-1.3 0.2
15 BZ 0.83-98 27
5 area ND ND
7 BZ 1.2-3.8 2.3
6  BZ 0.5-4.0 2.6
7  BZ 0.4-2.7 1.1
4  area N D-0.6 0.2
6  BZ N D-1.6 0.5
6  area ND N D
2 BZ 4.Ó-8.9 6.8
1 area 24 24
(Continued)
Table C -l (Continued).—Occupational exposures by worksite or process
Glycol
ether Worksite or process Reference
Number 
and type 
of samples
Concentration
Range Average 
(ppm) (ppm)
EGM E Degreasing and paint 
stripping
Hervin et al. 1974 24 BZ ND ND
Painting, molding, 
inspection
Gunter and Lucas 
1974
35 BZ <0.8-5 1.4
Painting (brush and 
spray)
Love and Donohue 
1983
1 BZ 15 15
Sparer et al. 1988 81 BZ 0-5.6 0.8
Coating of paper and 
fabric with resin
Ramos and Lucas 1973 9 BZ  
8 area
N D-11
0.7-9.0
4.1
5.0
Press room and reel room Markel and Moody 
1982
5 BZ
3 area
N D -0.5
N D -0.4
0.4
0.2
EGM EA Photo etching Levy 1976 1 BZ 37 37
See References beginning on page 262. 
"^Breathing zone sample.
*Not detectable.
^Immediate work area sample(s).
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Table C-2.—Long-term sampling results for 2-methoxyethanol (2-ME), 
2-ethoxyethanoI (2-EE), and 2-ethoxyethyl acetate (2-EEA)
Industry
Glycol
ether(s)
sampled
No. of 
samples
Samples 
below limit 
of detection 
No. Percent
Concentration
range
(ppm)T
Aerospace 2-ME 8 8 100 all ¿0.27*
2-EE 5 5 100 all ¿0.22*
2-EEA 15 15 100 all ¿0.23*
Electronics 2-EEA 8 8 100 all ¿0.02*
Airlines 2-EEA 13 0 0 0.29-2.69
Coating mfg. 2-EEA 6 0 0 0.07**-0.35
Automotive 2-EEA 12 10 80 ¿0.02*-0.05**
Fuel distribution 2-ME 10 3 34 ¿0.03*-0.34
Paperboard mfg. 2-ME 9 6 66 ¿0.04*-1.06
Glycol ether mfg. 2-EEA 31 25 81 ¿0.02^-0.44
Summary 2-ME 27 17 63 ¿0.02*-1.06
2-EE 5 5 100 all ¿0.22*
2-EEA 85 58 68 ¿0.02*-2.69
Total 117 80 60 ¿0.02*-2.69
* Adapted from Piacitelli et al. [1989],
^Samples were not time-weighted to 8-hr concentrations.
* Laboratory analysis was below limit o f detection (0.03 mg/sample). 
^Laboratory analysis was below limit of detection (0.01 mg/sample).
Laboratory analysis was below limit o f quantitation (0.03 mg/sample).
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Table C-3.—Distribution of ethylene glycol ethers among the various industrial 
operations as detected in air samples
Operation
Number of 
air samples
Number o f glycol ethers detected
EGME EGMEA EGEE EGEEA
Printing 94 0 2 76 61
Painting 81 4 0 19 66
Car repair 20 10 1 0 9
Various 67 0 12 11 38
Total 262 14 15 106 174
Table taken from Veulemans et ai. [1987b],
Table C-4.—Concentration (ppm) of ethylene glycol ethers used in 
various industrial operations*
Operation EGME EGMEA EGEE EGEEA
Printing g .m .t ___ 0.9 2.6 3.04
Range ----- 0.8-0.9 0.18-47.9 0.06-34.6
Painting G.M. 9.8 ___ 2.5 1.8
Range 1.75-42.8 ----- 0.37-55.3 0.22-14.6
Car repair G.M. 2.47 0.48 . . . 1.7
Range 1.8-5.0 — ----- 0.28-7.8
Various G.M. . . . 2.4 4.5 1.8
Range ---- 0.08-29.9 0.82-332 0.11-151.8
*
Table adapted from Veulemans et al. [1987]. 
*Data are geometric means.
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MATERIAL SAFETY DATA SHEET
The following sections describe the information that must be supplied for each product or 
material in the appropriate blocks of the Material Safety Data Sheet (MSDS).
To facilitate filing and retrieval, insert the product designation in the block in the upper left 
comer of the first page. Print in upper case letters as large as possible. The MSDS should 
be printed to read upright with the sheet turned sideways. For the product designation, use 
the name or code that appears on the label or the name by which the product is sold or known 
by workers. The relative numerical hazard ratings and key statements are those determined 
by the rules in Chapter V, Part B, of the NIOSH publication entitled A Recommended 
Standard: An Identification System for Occupationally Hazardous Materials [NIOSH 1974b]. 
The company identification may be printed in the upper right comer if desired.
D.1 SECTION I. PRODUCTION IDENTIFICATION
Insert the manufacturer’s name, address, and regular and emergency telephone numbers 
(including area code) in the appropriate blocks of Section I. The company listed should be 
a source of detailed backup information on the hazards of the materials) covered by the 
MSDS. The listing of suppliers or wholesale distributors is discouraged. The trade name 
should be the product designation or common name associated with the material. The 
synonyms are those commonly used for the product, especially formal chemical nomencla­
ture. Every known chemical designation or competitor’s trade name need not be listed.
D.2 SECTION II, HAZARDOUS INGREDIENTS
The “materials” listed in Section II shall be those substances that are part of the hazardous 
product covered by the MSDS and that individually meet any of the criteria defining a 
hazardous material. Thus, one component of a multicomponent product might be listed 
because of its toxicity, another component because of its flammability, and a third com­
ponent for both its toxicity and its reactivity. Note that a MSDS for a single component 
product must have the name of the material repeated in this section to avoid giving the 
impression that there are no hazardous ingredients.
List chemical substances according to their complete name derived from a recognized system 
of nomenclature. Where possible, avoid using common names and general class names such
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as “aromatic amine,” “safety solvent,” or “aliphatic hydrocarbon” when the specific name 
is known.
The “ % ” may be the approximate percentage by weight or volume (indicate basis) that each 
hazardous ingredient o f the mixture bears to the whole mixture. This may be indicated as 
a range or maximum amount (i.e., 10% to 40% vol. or 10% max. wt.) to avoid disclosure 
of trade secrets.
State toxic hazard data in terms of concentration» mode of exposure or test, and animal used 
(e.g., 100 ppm LC50-rat, 25 mg/kg LD50-skin-rabbit, 75 ppm LC man, permissible 
exposure from 29 CFR 1910.1000) or, if  not available, from other sources such as NIOSH 
RELs and publications of the American Conference of Governmental Industrial Hygienists 
(ACGIH) or the American National Standards Institute, Inc. (ANSI). Flashpoint, shock 
sensitivity, or similar descriptive data may be used to indicate flammability, reactivity, or 
similar hazardous properties of the material.
D.3 SECTION III. PHYSICAL DATA
The data in Section III should be for the total mixture. Include the boiling point and melting 
point in degrees Fahrenheit (Celsius in parenthesis); vapor pressure, in conventional millimeters 
of mercury (mm Hg); vapor (tensity of gas or vapor (air “ 1); solubility in water, in parts/hundred 
parts of water by weight; specific gravity (water = 1); percent volátiles (indicated if by weight or 
volume) at 70°F (21.1°C); evaporation rate for liquids or sublimable solids, relative to butyl 
acetate; and appearance and odor. These data are useful for the control of toxic substances. 
Boiling point, vapor density, percent volátiles, vapor pressure, and evaporation are useful for 
designing proper ventilation equipment This information is also useful for designing and 
deploying adequate fire and spill containment equipment The appearance and odor may facilitate 
identification of substances stored in improperly marked containers or spilled substances.
D.4 SECTION IV. FIRE AND EXPLOSION DATA
Section IV should contain complete fire and explosion data for the product. Include flashpoint 
and autoignition temperature in degrees Fahrenheit (Celsius in parentheses), flammable limits 
in percent by volume in air, suitable extinguishing media or materials, special fire-fighting 
procedures, and unusual fire and explosion hazard information. If the product presents no fire 
hazard, insert “NO FIRE HAZARD” on the line labeled “Extinguishing Media.”
D.5 SECTION V. HEALTH HAZARD INFORMATION
For the “Health Hazard Data” line, use a combined estimate of the hazard of the total product. 
This can be expressed as a TWA concentration, as a permissible exposure, or by some other 
indication of an acceptable standard. Other data are acceptable, such as lowest LD50 if  
multiple components are involved.
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Under “Routes of Exposure,” comments in each category should reflect the potential hazard 
from absorption by the route in question. Indicate the severity of the effect and the basis 
for the statement, if possible. The basis might be animal studies, analogy with similar 
products, or human experiences. Comments such as “yes” or “possible” are not helpful. 
Typical comments might be:
Skin Contact—single short contact, no adverse effects likely; prolonged or repeated 
contact, possibly mild irritation.
Eye Contact—some pain and mild transient irritation; no comeal scarring.
Write “Emergency and First Aid Procedures” in lay language. The procedure should 
primarily represent first-aid treatment that could be provided by paramedical personnel or 
individuals trained in first aid.
Include in the “Notes to Physician” section any special medical information of assistance to 
an attending physician, e.g, required or recommended preplacement and periodic medical 
examinations, diagnostic procedures, and medical management o f overexposed workers.
D.6 SECTION VI. REACTIVITY DATA
The comments in Section VI relate to safe storage and handling of hazardous, unstable 
substances. Be sure to highlight instability or incompatibility to common substances or 
circumstances, such as water, direct sunlight, steel or copper piping, acids, alkalies, etc. 
Include in “Hazardous Decomposition Products” those products released under fire condi­
tions. Also include dangerous products produced by aging, such as peroxides in the case of 
some ethers. Where applicable, indicate shelf life.
D.7 SECTION VII. SPILL OR LEAK PROCEDURES
List detailed procedures for cleanup and disposal; place emphasis on precautions to be taken 
to protect workers assigned to cleanup detail. Describe specific neutralizing chemicals or 
procedures in detail. Disposal methods should be explicit including proper labeling of 
containers holding residues and ultimate disposal methods such as “sanitary landfill” or 
“incineration.” Warnings such as “comply with local, State and Federal antipollution 
ordinances” are proper but not sufficient. Identify specific procedures.
D.8 SECTION VIII. SPECIAL PROTECTIONS INFORMATION
Section VIII requires specific information concerning ventilation requirements and personal 
protective equipment. Statements such as “yes,” “no,” or “if necessary" are not informative. 
Specify the type and preferred methods of ventilation. Specify the type and NIOSH or Mine 
Safety and Health Administration approval class (e.g., supplied air or organic vapor canister 
for respirators). Specify the type and materials of construction for protective equipment.
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D.9 SECTION IX. SPECIAL PRECAUTIONS
“Precautionary Statements” shall consist of the label statements selected for use on the 
container or placard. Insert in this section additional information on any aspect of safety or 
health not covered in other sections. The lower block can contain references to published 
guides or in-house procedures for handling and storage. Department of Transportation 
markings and classifications and other freight, handling, or storage requirements and 
environmental controls can be noted.
D.10 SIGNATURE AND FILING
Finally, enter the name and address o f the responsible person who completed the MSDS and 
the date of completion. This will facilitate correcting errors and identifying a source of 
additional information.
File the MSDS in a location readily accessible to workers exposed to the hazardous 
substance. The MSDS can be used as a training aid and as the basis for discussion during 
safety meetings and training of new workers. Its purpose is to assist management by 
directing attention to the need for specific control engineering, work practices, and protective 
measures that will ensure safe handling and use of the material. The MSDS will aid the 
safety and health staff in planning a safe and healthful work environment and in suggesting 
appropriate emergency procedures and sources of help in the event of harmful exposure of 
workers.
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MATERIAL SAFETY DATA SHEET 
Sections I -  III
MATERIAL SAFETY DATA SHEET
1 PRODUCT IDENTIFICATION
M A N U F A C T U R E R  S NAME
REG O LAR TÉLÉPHONÉ NO 
EMERGENCY TELEPHONE NO
AOOftESS
TRADE NAME
SYNONYMS
II HAZARDOUS INGREDIENTS
M A T E R IA L  OR COMPONENT % H A Z A R D  O ATA
lit PHYSICAL DATA
» O IU N G  POINT 760 M M  « 0 M ELTIN G  PO*NT
Sp e c if i c  g r a v i t y  i h j û - i i VAPOR frA€S$UR€
V A FO rt O EN S 'TV  ! jU R M > S O LU B IL IT Y  IN  M jQ  S 0Ÿ WT
% V O t-A T lL £ S a v  VO L € V A P O flA T lO N  RATE t f tu T Y i AC ETATE 1»
a p p e a r a n c e  a n o  o d o r
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MATERIAL SAFETY DATA SHEET (Continued) 
Sections IV -  V
IV FIRE AND EXPLOSION DATA
FLASK POINT
ÍTCSTMÉTWOO i
AUTOlGNlTlON
TEM PERATURA
FLAMMASLE LIMITS IN AIR , »  0Y VOL LOWER UP*E*
EXTINGUISH INC 
MEDIA
S ^fC iA L  F IRC
FIGHTING
PftOCEOURES
UNUSUAL f  tR€ 
AND EXPLOSION 
HAZARD
V HEALTH HAZARD INFORMATION
HEALTH HAZARD DATA
ROUTES OF EXPOSURE
i n h a l a t io n
SKIN CONTACT
SKIN ABSORPTION
EYE CONTACT
INGESTION
EFFECTS O f  OVEREXPOSURE 
ACUTE ÔVCREXPOSUR€
CHRONIC OVEREXPOSURE
EMERGENCY ANO FIRST AID  PROCEDURES 
EYES
$KIN
INHALATION:
INGESTION
NOTES TO PHYSICIAN
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MATERIAL SAFETY DATA SHEET (Continued) 
Sections V I-V IH  
VI REACTIVITY DATA
CONDITIONS CONTRIBUTING TO INSTABILITY 
INCOMPATIBILITY
HAZARDOUS DECOMPOSITION PRODUCTS
CONDITIONS CONTRIBUTING TO HAZARDOUS POLYMERIZATION
VII SPILL OR LEAK PROCEDURES
STEPS TO BE TAKEN IF M ATERIAL «S AELE ASEO OR SPILLED
NEUTRALIZING CHEMICALS 
WASTE DISPOSAL METHOD
_____________VIII SPECIAL PROTECTION INFORMATION
VENTILATION REQUIREMENTS
SPECIFIC PERSONAL PROTECTIVE EQUIPMENT 
RESPIRATORY : SPICI F Y IN DETAIL!
IVI
O lO V tl
OTHER CLOTHING ANO IOU1FMINT
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MATERIAL SAFETY DATA SHEET (Continued) 
Section IX
IX SPECIAL PRECAUTIONS
PRECAUTION*«*
S T A T E M E N TS
O T H f *  H A N D L IN G  ANO 
STORAGE R £ Q U iR £ M E N T $
PREPARED SY
a d d r e s s
DATE
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OTHER GLYCOL ETHERS
Table E - l .—Methyl-based glycol ethers, amides, etc.
CAS number Name
3610-27-3
3121-61-7
24493-59-2
45103-58-0
6976-93-8
68133-26-6
68133-25-5
16501-01-2
117-82-8
106-00-3
140-05-6
111-10-4
111-07-9
70703-47-8
6522-67-4
51248-73-8
49744-35-6
Methoxytriethylene glycol acetate 
2-Methoxy -ethanol acrylate 
Methoxytriethylene glycol methacrylate 
2-(2 Methoxyethoxy) ethyl methacrylate 
2-Methoxy ethyl methacrylate
N -(5 -Amino -2-methoxypheny l)-beta-alanine, 2-methoxyethyl ester 
N-(2-Methoxy-5-nitrophenyI)-beta-alamne, 2-methoxyethyl ester
1.2-BenzenedicarboxyIic acid, mono (2-methoxyethyl) ester
1.2-BenzenedicarboxyIic acid, bis (2-methoxyethyl) ester 
Hexanedioic acid, bis (2-methoxyethyl) ester 
Ethylene glycol monomethyl ether acetylricinoleate 
Ethylene glycol monomethyl ether oleate 
Hexadecanoic acid, 2-methoxyethyl ester
Acetylated ethylene glycol monomethylether hydroxystearate
N-[5-(AcetyIamrao)-4-[(2-bromo^,6-dmi£rophenyl)azo]-2 methoxypheny!] - 
beta-alanine, 2-methoxyethyl ester
N-[4-[2-Chloro-4-nitrophenyl)azo]-3-(acetylamino)phenylI-N-(2-cyanoethyl)- 
beta-alanine, 2-methoxyethyl ester
Aminobenzoic acid, 2-(2-methoxyethoxy) ethyl ester
(Continued)
Adapted from TSCA [1977] and SANSS/CIS [1988].
^Chemical Abstracts Service.
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Table E-l (Continued).— Methyl-based glycol ethers, amides, etc.
CAS number Name
49744-26-5 4-I5-Cyano-l-ethyl-l,6-dihydro-2-hydroxy-4-methyl-6-oxy-3'pyridinyl)azo] 
benzoic acid, (2-methoxyethoxy) ethyl ester
42861-47-2 N-Ethyl-N(4-(2-bromo-4,6-dinitrophenyl)azo)-5-(acetylaniino)- 
2-methoxyphenyl)-beta-a!anine, 2-methoxyethyl ester
42228-65-9 N-[5-(Acetylamino)-2-methoxyphenyl]-N-ethyI-beta-alanine, 2-methoxyethyl 
ester
18016-42-7 Cholesteryl 2-(2-methoxy ethoxy) ethyl carbonate
40228-74-8 Cholesteryl methoxy ethyl carbonate
68479-79-8 N,N'-(4,8-Dihydn>xy-9,I0-dioxo-I,5-anthracenediyl) bis [beta-alanine], 
bis(2-metfaoxyethyl) ester
1616-88-2 Carbamic acid, 2 -methoxyethyl ester
10143-22-3 Carbamic acid, bis(hydroxymethyl)-, 2-methoxyethyI ester
50883-78 8 Carbamic acid, dimethyl-, 2-methoxy ethyl ester
16672-66-5 2-Methoxy ethyl methylocarbamate
14983-42-7 Boric acid, tris (2-methoxyethyl) ester
6163-73-1 Phosphoric acid, methoxyethyl ester
42372-33-8 1 -Naphthalenesulfonic acid, 6-diazo-5,6-dihydro-5-oxo-, 2-methoxyethyI ester
17178-10-8 2-Methoxyethyl p-toluenesul fonate
71550-36-2 1-Naphthalenesulfonic acid, 6-diazo-5,6-dihydro-5-oxo-, 2-(2-methoxyethoxy) 
ethyl ester
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Table E-2.— Butyl-based glycol ether esters, amides, etc.*
CAS* num ber Name
124-17-4 Butoxyethoxyethyl acetate
112-07-2 Butoxyethyl acetate
7251-90-3 Acrylic acid, 2-butoxyetboxy ester
5330-17-6 2-Butoxy ethyl chloroacetate
27447-53-6 2-ButoxyethyI mercaptoacetate
68797-46-6 Propanic acid, 2-chloro-, 2-butoxyethyl ester
20442-06-2 2-ButoxyethyI butanoate
20442-11-9 2-Butoxyethyl pelargonate
109-37-5 Ethylene glycol monobutyl ether laurate
109-38-6 Butoxyglycol stearate
109-39-7 Ethylene glycol monobutyl ether oleate
65520-45-8 Butanedioic acid, di-2-I2-(2-butoxyethoxy) ethoxy] ethyl ester
65520-42-5 Pentanedioic acid, di-2-[2-(-2-butoxy ethoiy) ethoxyl ethyl ester
65520-46-9 Hexanedioic acid, di-2-[2-(2-butoxyethoxy) ethoxy] ethyl ester
141-18-4 Adipic acid, bis (ethylene glycol monobutyl ether) ester
141-17-3 Adipic acid, bis (diethylene glycol monobutyl ether) ester
63021-23-8 Nonanedioic acid, bis (2-butyoxyetbyl) ester
70900-47-9 Nonanedioic acid, bis [2-(2-butoxyethoxy) ethyl] ester
70900-46-8 Decanedioic acid, bis [2-(2-butoxy ethoxy) ethyll ester
141-19-5 Decanedioic acid, bis (2-butoxyethyl) ester
117-83-9 1,2-BenzenedicarboxyIic acid, bis (2-butoxyethyl) ester
16672-39-2 Phthalic acid, bis [2-(2-butoxyethoxy) ethyl] ester
70900-48-0 1,2,4-Benzenetricarboxylic acid, tris [2-(2-butoxyethoxy) ethyll ester
62778-23 8 Cholest-5-en-3-ol (3-beta)-, 2-butoxyethyl carbonate
5451-76-3 Benzoic acid, 2-butoxyethyl ester
(Continued)
’Adapted fromTSCA [1977] and SANS S/CIS [19881.
^Chemical Abstracts Service.
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Table E-2 (Continued).— Butyl-based glycol ether esters, amides, etc.
CAS number Name
6661-54-7 Ethanol, 2-butoxy-, 4-methylbenzesuIfonate
53404-31-2 2-(2,4-Dichlorophenoxy) propionic acid, butoxyethanol ester
19480-43-4 Acetic acid, (4-chIoro-2-methylpbenoxy)-, 2-butoxyethyI ester
30387-70-3 2,4,5-Trichlorophenoxypropiooic acid n-butylglycol ester
32357-46-3 2,4-Dichlorophenoxybutyric acid, butoxyethyl ester
72152-95-5 Carbamic acid, [5-isocyanato-1,3,3 -trimethy Icyclobexy 1) methyl]-, 
2-butoxyethyI ester
78-51-3 Butoxyethyl phosphate
7332-46-9 2-(2-Butoxyethoxy) ethanol phosphate
64051-22-5 2-Butoxyethanol, hydrogen phosphate, diethy lamine salt
14260-97-0 Dibutoxyethyl phosphate
64051-23-6 2-Butoxyethanol, dihydrogen phosphate, bis(diethylamine) salt
68133-43-7 Ethanol, 2-butoxy-, dihydrogen phosphate, dipotassium salt
14260-98-1 Butoxyethylphosphate
Table E-3.— Branched glycol ether estere, carbamates, etc.
CAS* number Name
68413-83-2 N,N-I>imethylol isopropoxyethyl carbamate
67952-46-9 Isopropoxyethyl carbamate
67952-44-7 Carbamic acid, (hydroxymethyl)-, 2-(l-methylethoxy) ethyl ester
16006-09-0 Carbamic acid, (2-isobutoxyethyl) ester
16005-83-7 Carbamic acid, bis (hydroxymethyl)-, 2-isobutoxyethyl ester
1464-69-3 2-MethyI-2-propenoic acid, 2-(ethenyloxy ethyl ether))
16839-48-8 Methacrylic acid, 2-(aIIyloxy) ethyl ester
‘Adapted from TSCA [1977] and SANSS/CIS [1988].
^Chemical Abstracts Service.
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Table E-4.— Longer chain (butyl) glycol ether esters, phosphates, etc.
CAS number Name
20207-36-7
3538-36-1
64051-25-8
64051-24-7
63294-54-2
68757-58-4
3694-74-4
56049-85-5
55901-67-2
61894-66-4
14858-61-8
14858-54-9
13150-00-0
15826-16-1
25446-80-4
25446-78-0
3088-31-1
67923-90-4
66104-67-4
65138-77-4
65087-01-6
57119-83-2
57119-69-4
Laurie acid, 2-(hexyloxy) ethyl ester 
Ethanol, 2-(hexyloxy)-, hydrogen phosphate
Ethanol, 2-(hexyloxy)-, dihydrogen phosphate, cmpd. with N-ethylethanamine 
(1:2)
Ethanol, 2-(hexyIoxy)-, hydrogen phosphate, cmpd. with N-ethylethanamine 
(1:1)
Ethanol, 2-(hexyIoxy)-, dihydrogen phosphate 
Propanoic acid, 2,2-dimethyl-, 2-(hexyloxy) ethyl ester 
Ethanol, 2-{tetradecy loxy)-, hydrogen sulfate, sodium salt 
Triethylene glycol monohexadecyi ether sulfate ammonium salt 
2 -Decy loxyethy I sodium sulfate 
2 -Decy loxyethy I hydrogen sulfate 
2 -(Octadecyloxy) ethyl sodium sulfate 
2 -(Hexadecyloxy) ethyl sodium sulfate
Ethanol, 2-[2-[2-(dodecyloxy) ethoxy] ethoxy]-, hydrogen sulfate sodium salt
Ethylene glycol monododecyl ether sulfate sodium salt
Triethylene glycol monomyristyl ether sodium sulfate
Sodium tridecyl tri(oxy ethyl) sulfate
Diethylene glycol monododecyl ether sodium sulfate
Ethanol, 2 - [2- [2*(decy loxy )ethoxy Jethoxy]-, hydrogen sulfate, ammonium salt
2-Butenedioic acid (2)-, mono[2-[2-(dodecy!oxy) ethoxy] ethoxy] ethyl]ester
Ethanol, 2-[20(tridecyIoxy) ethoxy]-, dihydrogen phosphate
Ethanol, 2-[2-(tridecyloxy) ethoxy]-, hydrogen phosphate
2-I2-[r4-[(2-Bromo-4,6-dinitiophenyl)azo]-l-naphthyl]ammo] ethoxy] ethanol, 
acetate (ester)
EthanoL, 2 - [2 - [[4- [(2 -chloro -4,6 -dinitropheny I)azo] -1 -naphthaleny I ] 
amino]ethoxy]-, acetate (ester)
(Continued)
Adapted from TSCA [1977] and SANSS/CIS [1988].
* Chemical Abstracts Service.
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Table E-4 (Continued).—Longer chain (butyl) glycol ether esters, phosphates, etc.
CAS number Name
21116-11-0 Ethanol,2-[p-[[4-[(p-hydroxyphenyl)azo]-o-toIyI]azo] phenoxy]-, 1-(hydrogen 
sulfate), monosodium salt
65993-31-5 Dicyclopentyloxyethyl acrylate
66710-97-2 2-Propenoic acid, ( 1 -methylethylidene) bis [(2,6-dibn>mo-4,l-phenyIene) 
oxy-2,1-ethanediyl] ester
68400-37-3 7-Amino-4-hydroxy-3-[[4-[2-(suIfooxy)ethoxy]pbenyI]azo]-2-napthaIenesul- 
fonic acid
68586-19-6 2-Propenoic acid, 2-methyl-, 2-[[2,3,3a,4,7,7a (or 3a,4,5,6,7,7a)-hexahydro- 
4,7 -methano-1 H-indenyl ]oxy ] ethyl ester
70865-23-5 3-[[4-[2-(Sulfoxy)ethoxy ]pheny ] ]azo] [1,1'-bipheny 1] -4 -ol, monosodium salt
71701-31-0 2-NaphthalenesuIfonic acid, 4-hy droxy-3-[ [4 - [2-(sul fooxy )ethoxy ]pheny I ]azo] 
-7 - [(2,5,6-tricUoro- 4-pyrimidinyl)amino]-, disodium salt
Table E-5.— Phenoxy ethanol-based glycol esters, maleates, etc.
CAS* number Name
68141-05-0 Benzenoctadecanoic acid, 2 -phenoxyethyl ester
103-60-6 Ethanol, 2-phenoxy-, isobutyrate
10534-77-7 Di(phenoxyethyl)maIeate
46841-90-1 Mono(phenoxyethy I)maleate
48145-04-6 Ethanol, 2-phenoxy-, acrylate
58214-96-3 Butanoic acid, 3-methyl-, 2-phenoxyethyl ester
10595-06-9 2-Propenoic acid, 2-methyl-, 2-phenoxyethyl ester
23495-12-7 Propionic acid, 2-phenoxyethyl ester
23495-13-8 Pentanoic acid, 2-phenoxyethyl ester
23511-70-8 Butanoic acid, 2 -phenoxyethyl ester
67845-81-2 Ethanol, 2-(2-phenoxyethoxy)-, benzoate
65379-23-9 Ethanol, 2-phenoxy-, dihydrogen phosphate, dipotassium salt
* Adapted from TSCA [ 1977] and SANSS/CIS 11988],
^Chemical Abstracts Service.
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Table E -6.—Substituted phenoxy ethanol glycol esters, acetates, etc.
CAS* number Name
6807-11-0 Ethanol, 2-(4-methyIphenoxy)-, acetate
63217-11-8 Ethanol, 2 -[2-(4-dodecyl phenoxy) ethoxy]-dihydrogen phosphate
52368-50-0 Decanoic acid, 2-[2-(nonylphenoxy) ethoxy] ethyl ester
7347-19-5 2-(2,4,6-Tribromophenoxy) ethyl acrylate
40184-38-1 2-(4'-Aminophenoxy) ethyl hydrogen sulfate
68140-43-2 m-(2-Acetoxyethoxy) phenol
56744-60-6 2-Propenoic acid, 2-melhyl-, (1-methylethylidene) bis (4,I-phenyleneoxy-2, 
1 -ethanediyloxy-2,1 -ethanediyl) ester
56361-55-8 2-Propetioic acid, (1-methylethylidene) bis (4,l-phenyleneoxy-2, 
1-ethanediyloxy-2,1-ethanediyI) ester
24447-78-7 2-Propenoic acid, (1-methylethylidene) bis (4,l-phenyIeneoxy-2,l-ethanediyl) 
ester
65133-66-6 2-Propenoic acid, 2-methyl-, 2-[4-[l-methyl-1-[4-[2-[2-[(2-methyl-l-oxo- 
2-propenyI)oxy] ethoxy]ethoxy] pheny I ]ethy 1 [phenoxy J ethyl ester
‘Adapted from TSCA 11977] and SANSS/CIS [1988]. 
^Chemical Abstracts Service.
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Table E-7.—Glycol ether acetals
CAS* number Name
5405-88-9 Diethylene glycol monomethyl ether formai
71563-31-0 Propionaldehyde, bis (2-methoxyethyl acetal)
71808-63-4 Butyraldehyde, bis (2-methoxyethyl acetal)
71808-62-3 Isovaleraldehyde, bis (2-methoxyethyl acetal)
71808-60-1 3,3-di (beta-Methoxyethoxy)-2-butanone
71808-59-8 Isobutyraldebyde, bis(2-methoxyethyl acetal)
* Adapted from TSCA [1977] and SANSS/CIS [1988],
Chemical Abstracts Service.
Table E-8.— Alkyl glycol ethers (methyl)
CAS* number Name
52788-79-1 Diethylene glycol methyl tert-butyl ether
112-49-2 1,2 bis(2 -Methoxy ethoxy )™ethane (GIyme-3)
111-96-6 bis(2-Methoxyethyl) ether
110-71-4 Dimethoxyethane
7382-32-3 2-Butoxyethyl 2-methoxymethyl ether
19685-21-3 Methyl triethylene glycol allyl ether
66728-50-5 1 -tert-Butoxy-2-methox y ethane
54303-31-0 3-(2-Methoxy ethoxy)-propan enitrile
52808-36-3 2 -(2-Methoxyethoxy) ethyl chloride
3970-21-6 2-Methoxyethoxymethyl chloride
* Adapted fromTSCA [1977] and SANSS/CIS [1988]. 
^Chemical Abstracts Service.
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Table E-9.—Phenoxy-based glycol ethers
CAS* number Name
68385-79-5 N-[3-Ammo-4-(2-methoxyethoxy) phenyl] acetamide
67674-33-3 1 - [(2 -Methoxy )ethoxy]-2,4-dinitrobenze
63810-51-5 2 -(2-Methoxy ethoxy) -4-nitrobenzenamine
63810-54-8 2-{2-Methoxyethoxy) -5 -nitrobenzenamme
68703-73-1 N-[3-(DiethyIammo)-4-(2-methoxyethoxy)phenyI] propanamide
68703-72-0 N-[3-(Diethylamino) -4-(2-methoxyethoxy )pheny 1] propionamide
68703-71-9 N-[3-(Diethylamino)-4-(2-methoxyethoxy)phenylI acetamide
71230-65-4 N-[ 3 -Amino~4-(2-methoxyethoxy)pbeny i I propionamide
71077-38-8 N-13-(Ethy 1 amino) -4-(2 -methoxyethox y )pheny 1 ] acetamide
71077-37-7 4-[2-Methoxyethoxy]-1,3-benzenediamine
72175-36-1 2 -[2-(2-Methoxy ethoxy) ethoxy ]-9,10-anthracenedione
17869-10-2 1 -Amino-4~hydroxy-2-(2-methoxyethoxy )-9,10-anthracenedione
67846-62-2 N-I2 -[(2-Chloro-4,6-dinitropheoy l)azo] -5 -(ethy lamino)-4- (2 -methox y ethoxy) 
phenyl] propanamide
65059-45-2 1 >4-Diamino-9110-dihydro-N-[3-(2-methoxyethoxy)propyl]-9,10-dioxo- 
2,3 anthracenedicarboximide
68597-67-5 N- [2 - [(2-Chloro-4,6-dinitrapheny l)azo] -5 -(ethy lamino)-4- (2-methoxyethoxy ) 
phenyl] acetamide
71889-11-7 N-[2-[(2 Bromo-4,6-dinitropheny l)azo]-5-(die thy lamino)-4- (2 -methoxy ethoxy) 
phenyl] propionamide
71889-12-8 N - [2'Bromo-4,6-4i nitiopheny I)azo]-5 -(diethylamino)- 4 -(2 -methoxyethoxy) 
phenyl] acetamide
72066-86-5 N- [2 - [(2-Bromo-4>6-dinitrophettyl)azo] -5-(ethylami no)-4-(2 -methox y ethoxy) 
phenyl] acetamide
72066-87-6 N-[2-[(2-Bromo-4,6-dinitropheDyl)azo]-5-(ethylaimiK>)-4-(2-methoxyethoxy) 
phenyl] propionamide
75198-92-4 1 -Amino-4- [[2-[[I2-chloro-4- (2-methoxyethoxy) 1,3,5 -triazin- 6 -y 1] 
amino]methyl]-4-methyl-6-suIfophenyl]amino]-2-anthraquinonesulfonicacid, 
disodium salt
73398-97-7 4-[[4-[[5-Cyano-2-[(8-methoxyoctyl)amino]-6-[(3-methoxy-propy[)amino]- 
4-methyl-3-pyridinyI]azo]-2,5-di-methylphenyl]azo]'N-[3-(2-phenoxyethoxy) 
propyl] benzamide
* Adapted from TSCA [1977] and SANSS/CIS [1988].
^Chemical Abstracts Service.
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Table E-10.—Ethoxy-ethanol based glycol ethers
CAS* number Name
41771-35-1 l-Chloro-2-(2-ethoxyethoxy) ethane
629-14-1 Ethylene glycol diethyl ether
112-36-7 bis (2-EthoxyethyI) ether
10143-53-0 Diethylene glycol ethylvinyl ether
51422-54-9 Ethylene glycol tert-butyl ethyl ether
52788-80-4 Diethylene glycol ethyl-tert-butyl ether
* Adapted from TSCA [1977] and SANSS/CIS [1988].
Chemical Abstracts Service.
Table E - l l .—SUoxy glycol ethers
CAS* number Name
2157-45-1 Silicic acid (H4Si04), tetrakis (2-methoxyethyl) ester
1067-53-4 Tris (2-methoxyethoxy) vinyl silane
45117-69-9 Methylvinylbis (2-methoxyethyl) silane
57069-48-4 [(3-Methacryloxy)propyl] tris (2-methoxyethoxy) silane
17903-05-8 Tris(2-methoxyethoxy) phenyl silane
17980-64-2 Tris(2-methoxy ethoxy) methyl silane
73545-23-0 N-[2-[[2-[[2-[(2-Amiooethyl) amino] ethyl] amino] ethyl] amino] ethylj-N1111- 
[3-[tris(2-methoxyethoxy) silyl] propyl]nonanainide hydrochloride
24685-89-0 Ethanol, 2-(2-methoxyethoxy)-, tetraester with silicic acid (HtSi04)
18407-94-8 Ethanol, 2-ethoxy-, tetraester with silicic acid (FUSiCU)
18765-38-3 Ethanol, 2-butoxy-, tetraester with silicic acid (H4SiC>4)
68400-59-9 4,7,10-T rioxaundecy Idimethylsi ly 1 chloride
Chemical Abstracts Service.
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Table E-12. —Ethoxy-ethanol based glycol ether esters, amides, etc.
CAS number Name
112-15-2 Ethanol, 2-(2-ethoxy ethoxy)-, acetate
54396-97-3 Propanoic acid, 2-methyl-, 2-ethoxyethyI ester
106-74-1 2-Propenoic acid, 2-ethoxyethyl ester
7328-17-8 2-Propenoic acid, 2-(2-ethoxyethoxy) ethyl ester
2370-63*0 2-Propenoic acid, 2-methy]-, 2-ethoxyethyI ester
39670-09-2 Triethylene glycol monoethyl ether acrylate
104-28-9 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-ethoxyethyl ester
106-13-8 2-Ethoxyethyl dodecanoate
67906-29-0 Octadecanoic acid, IO-hydroxy-9-sulfo-, 1 -(2~ethoxyethyI) ester, monosodium 
salt
68134-05-4 9-Octadecenoic acid, 2-ethoxyethyl ester
37460-43-8 Ethanol, 2-ethoxy-, 4-mtrobenzoate
605-54-9 Diethylglycol phthalate
624-10-2 Sebacic acid, bis (2-ethoxy ethyl) ester
109-44-4 Hexanedioic acid, bis (2-ethoxyethyl) ester
15484-00-1 2-(2-Ethoxy ethoxy) ethyl carbonate
68214-66-4 Carbamic acid, [2 - [(2 -chloro-4-nitropheny l)azo] -5-(diethy Iamino)pheny 1]-, 
2-ethoxyethyl ester
628-65-9 Carbamic acid, (2-ethoxyethyl) ester
21578-97-2 2-Ethoxyethyl N-(7-hydroxynaphth-l-yI) carbamate
70146-08-6 Carbamic acid, [3-(diethylamino)phenyI]-, 2-ethoxyethyl ester
*Cheraical Ahstracts Service.
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Table E-13.—Acids and salts of glycol ethers
CAS number Name
67990*17-4 2-[(2-Butoxy)ethoxy] acetic acid, sodium salt
67990-18 5 2-[2-[(2-HexyIoxy)ethoxyJethoxy] acetic acid, sodium salt
7420-07-7 Butoxyethoxypropionic acid
3139-99-9 2-Methoxyethanol, sodium salt
38321-18-5 Sodium 2-(2-butoxyethoxy) ethanolate
28099-67-4 bis (2-Methoxethoxy) calcium
14064-03-0 Magnesium ethoxyethoxide
52663-57-7 Sodium 2-butox yethoxide
4084-36-0 Ethoxyethanol, compound with trifluoroborane
109-86-4 beta-Methoxyethanol
111-77-3 Diethylene glycol methyl ether
112-35-6 Methoxy triethylene glycol
111-90-9 Carbitol or 2-(2-ethoxyethoxy) ethanol
112-50-5 Ethoxytriethylene glycol
4353-29-1 3,6,9,12,15-Pentaoxaheptadecan-1 -ol
2807-30-9 Ethylene glycol mono-N-propyl ether
6881-94-3 2-(2-Propoxyethoxy) ethanol
109-59-1 beta-Hydroxyethyl isopropyl ether
111-45-5 Ethylene glycol monoallyl ether
33065-62-2 1 -(2-Hydroxyethoxy) -3 -(2-propeny loxy) -2-propanol
3973-18-0 Ethylene glycol monopropargyl ether
111-76-2 Butoxyethanol
112-34-5 Butoxy diethylene glycol
143-22-6 Triethylene glycol mono-n-butyl ether
4439-24-1 Ethylene glycol isobutyl ether
18912-80-6 Diethylene glycol monoisobutyl ether
1606-85-5 bis(Hydroxy ethyl) ether butynediol
(Continued)
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Table E-13 (Continued).—Acids and salts of glycol ethers
CAS number Name
112-25-4 Ethylene glycol monohexyl ether
112-59-4 Diethylene glycol hexyl ether
25961-89-1 Triethylene glycol monohexyl ether
16394-44-8 2,2'-( 1,4-CycIohexylenedioxy) diethanol
1559-35-9 Ethylene glycol ethylhexyl ether
1559-37-1 Triethylene glycol 2-e thy I hexyl ether
4536-30-5 Ethylene glycol monolauryl ether or Iauryl alcohol oxy ethanol
3055-93-4 Lauryl alcohol mono (oxyethylene) ethanol
3055-94-5 Dodecyl triethylene glycol ether
14663-73-1 2-[2(TridecyIoxy) ethoxy] ethanol
4403-12-7 2-[2-[2-(Tridecyloxy) ethoxy] ethoxyl ethanol
56049-80-0 Diethylene glycol monopentadecyl ether
628-89-7 Ethylene glycol mono (2-chloroethyI) ether
68003-29-2 bis [2-(2-Hydroxyethoxy) ethyl] octylamine
53815-85-3 2-{2-(I-NaphthaIenyIammo) ethoxy) ethanol
1704-62-7 Dimethy laminoethoxyethanol
112-33-4 Diethylene glycol mono (aminopropyl) ether
140-82-9 Diethy laminoethoxyethanol
929-06-6 Aminoethoxyethanol
68141-01-5 2-[2-(3-Ammopropoxy) ethoxy] ethanol hydroxyacetic acid salt
68156-16-1 2-[2-(3-Aminopropoxy) ethoxy] ethanol hydrochloride
622-08-2 Benzyl hydroxyethyl ether
122-99-6 beta-Hydroxethyl phenyl ether
104-68-7 Diethylene glycol phenyl ether
711-82-0 Ethylene glycol alpha-naphthyl ether
901-44-0 Bisphenol A bis (2-hydroxyethyl) ether
15149-10-7 beta-Hydroxyethyl p-methylphenyl ether
104-39-2 2-[2-(p-Tolyloxy) ethoxy] ethanol
104-38-1 p-Di(2-hy droxy ethox y )benzene
(Continued)
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Table E-13 (Continued).—Acids and salts of glycol ethers
CAS number Name
102-40-9 m-bis (2-Hydroxyethoxy) benzene
6382-07-6 2-(p-teit-Pentylphenoxy) ethanol
20427-84-3 Diethylene glycol p-nony I phenyl ether
27176-93-8 Diethylene glycol mono(nonylphenyl) ether
61886-41-7 2-(p-Aminophenoxy) ethanol hydrochloride
18790-97-1 2 -12-[2-(p-Aminophenoxy) ethoxy] ethoxy] ethanol
66422-95-5 2-(2,4-Diaminophenoxy) ethanol dihydrochloride
16365-27-8 2-(p-Nitrophenoxy) ethanol
63134-26-9 2 - [2-[2-(4-Nitiophenoxy) ethoxy] ethoxy] ethanol
1892-43-9 p-Chlorophenyl glycol ether
60593-02-4 Hydroxyethyl pentabromophenyl ether
15480-00-9 2-(o-Chlorophenoxy) ethanol
23976-66-1 2-{2,4I6-Tribromophenoxy) ethanol
70715-17-2 2-[ 3-(6-Methyl-2-py ridiny I) propoxy] ethanol
64346-25-4 2-[(2,2,6,6-TetrainethyI-4-piperidinyl) oxy] ethanol
65104-24-7 2-[2-[[4-[(2-Bromo-4,6-dinitrophenyl) azo]-l-naphthalenyl] amino] ethoxy] 
ethanol
68039-37-2 2-[(3a,4,5,6,7,7a-Hexahydro-4,7-methano- !H-inden-5-yI)oxy] ethanol
67906-59-6 2-[4-[(4-Amino-5-methoxy-o-tolyl) azo] phenoxy] ethanol
57119-91-2 2-[2-[[4-[(2-Chloro-4,6-dinitrophenyl) azo]-l-napthalenyl] amino] ethoxy] 
ethanol
2192-20-3 2-[2[I4-(p-Chloro-aIpha-phenylbenzyI)-l-piperazinyI] ethoxy] ethanol 
dihydrochloride
7070-15-7 beta-Hydroxyethyl isobomyl ether
4162-45-2 2,2'-[Isopropylidenebis [(2,6-dibroTno-p-phenylene)oxy]] diethanol
2831-60-9 2-{2,4-Dinitrophenoxy) ethanol
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Table E-14.—Miscellaneous glycol ethers
CAS number Name
72403-65-7
71673-20-6
71673-19-3
71673-14-8
71637-13-7
71637-12-6
71673-02-4
70210-27-4
65208-31-3
65916-12-3
67338-58-3
23119-35-9
55993-15-2
68298-23-7
68140-97-6
68140-96-5
52788-78-0
1120-23-6
764-99-8
143-29-3
Chromate (5-), bis [4- [[6-[[4-chloro-6-(2-ethoxyethoxy) -1,3,5-triazin-2-yl] 
amino]-1-hydroxy-3-sulfo-2-naphthaIenyl] azo]-l-hydroxy-7-nitro-I-naph- 
thalenesulfonato(4-)]-, pentasodium
1-[2-(2 -Ethoxyethoxy )ethyl]-2,2,4 -triraethy 1 -1,2,3,4-tetrahydroquinoli ne
7-Nitro-1 -[2-(2-ethoxyethoxy) ethyl]-2,2,4-trimethyI-l,2,3.4- tetrahydro- 
qui noline
7 -Amino-1 - [2-(2-ethoxyeihoxy) ethyl]-2,2,4-trimethyI-l ,2,3,4- letrahydro- 
qui noline
7 - Acetamido -6 - (2 -bromo-4,6-dini tropheny lazo)- l-[2-(2-ethoxyethoxy) ethyl] -
1.2.3.4-letrahydro-22,4-trimethylquinolme
7 - Acetamido-6-(2 -cyano-4,6-dini trophetiy lazo)-1 - [2-(2 -ethoxyethoxy) ethy 1 ] -
1.2.3.4-tetrahydro-2,2,4 - trimethy Iquinoli ne
7-Acetamido -1 - [2-(2-ethoxyethoxy) ethyl]-2,2,4-trimethyI -1,2,3,4- tetrahydro- 
qui noline
1 -Amino-4-[[3-[[4-chloro-6-(2-ethoxyethoxy) -l,3,5-triazin-2-yI] amino] -2,4,6- 
rimethyl -5-sulfophenyl] amino]-9,10-dihydro-9,10-dioxo-2-anthracenesul- 
fonicacid, disodium salt
N-[2-[(2,6-Dibromo-4-nitropheny 1) azol -5-[I2-(2-ethoxyethoxy) ethyll 
e thy lami no] phenyl] acetamide
4-[(2,6-Dicyano-4-nitrophenoI) azo]-N-[2-(2-ethoxyethoxy )ethyl] -N-ethyl-3- 
acetamidoanil ine
N-[2-(2-Ethoxyethoxy) ethyl] -N-ethyi-m-acetamidoaniline
l,5-Dihydroxy-4,8-diamino-2-[4-(2-etboxyethoxy) phenyl] anthraquinone
2-[2-{2-Ethoxyethoxy) ethyl]-6-hydroxy -5-[(2-methyl 4-ni tropheny I) azo]- 1H- 
benzfde] isoquinoline -1,3 (2H)-dione
Propanoic acid, 3-(2-butoxyethoxy)-, sodium salt
Propanoic acid, 3-(2-butoxyethoxy)-, potassium salt
3-(2-Butoxyethoxy) propanenitrile 
Diethylene glycol butyl tert-butyl ether 
2-Butoxyethyl 2-chloroethyI ether 
Diethylene glycol divinyl ether
bis (Butoxyethoxyethoxy) methane
(Continued)
Adapted from TSCA [19771 and SANSS/CIS [1988].
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Table E-I4 (Continued).—Miscellaneous glycol ethers
CAS num ber Name
124-16-3
112-73-2
51-03-6
7529-27-3
57947-82-7
18854-51-8
68134-24-7
112-26-5
13483-18-6
66028-01-1
66028-00-0
65925-28-2
2997-01-5
4246-51-9
5442-83-1
21697-94-9
66027-99-4
66027-97-2
2224-15-9
22397-31-5
3386-87-6
68132-81-0
70198-21-9
71550-69-1
61166-00-5
104-66-5
3753-05-7
22616-31-5
Butoxy ethoxy propanol 
Dibutoxy diethylene glycol
aIpha-[2-[2-)n-Butoxy)ethoxy] ethoxy] -4,5-methylene dioxy-2-propyl toluene
Ethylene glycol diallyl ether
Diethylene glycol bis (allyl) ether
1 -[2-I2-Propenyloxy)ethoxyI butane
1 -(2-(1,1 -Dimethy lethoxy )ethoxy) butane
Triethylene glycol dichloride
Ethylene glycol bis (chloromethyl ether)
1 -[2-[2-(2-Chloroethoxy) ethoxy ]ethoxy]-4-octyl benzene 
Diisobutylphenoxyethoxyethylchloride
1 -[2-(2-Chloroethoxy)ethoxy]-4-(l, 1,3,3-tetramethy Ibutyl) benzene
di (3-Aminopropoxy) ethane
Diethylene glycol bis (3-aminopropyI) ether
N,N-DimethyI-2- [2- [4-(1,1,3,3-tetramethy 1 butyl) phenoxy]ethoxy - ethanamine
3,3'-(EthyIenedioxy) bis (propylammonium) adipate
Diisobutylphenoxyethoxy ethy Idimethy lami ne
Diisohutylcresoxyethoxyethyldimethylamine
Ethylene diglycidyl ether
Diethylene glycol bis (2-cyanoethyl) ether
Ethylene glycol bis (2-cyanoethyl) ether
(Diisobutylphenoxy) ethoxyethoxyethane sulfonic acid, sodium salt
2-[2-[[2,2,4(or 2,4,4)-Trimethylpentyl]phenoxyIethoxy] ethanesulfonic acid, 
sodium salt
N,N-DimethyI-2-[2-I2-methyl-4-(l,l,3,3-tetramethylbutyl)phenoxy]ethoxy]
ethanamine
1.2-bis (3-Hydroxyphenoxy) ethane 
Ethylene glycol diphenyl ether
1.2-bis (4-Carboxyphenoxy) ethane
Benzyldiisobutyl [2-(2-phenoxyethoxy)ethyl] ammonium chloride
(Continued)
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Table E-14 (Continued).—Miscellaneous glycol ethers
CAS number Name
14417-67-5 1,2-bis (Pyridinomethoxy) ethane dichloride
17418-59-6 1 -Amino-4-hydroxy-2-(2-phenoxyethoxy) anthraquinone
41312-86-1 l,4-Diamino2-chJoro-3-(2-phenoxyethoxy) anthraquinone
63833-78-3 5-[(2-Cyano-4-nitrophenyl) azo]-6-[2-hydroxy ethyl) amino]-4-methyI-2-[[3- 
(2-phenoxy ethoxy) propyl] amino]-3-pyridinecarbonitriIe
63281-10-7 5 - [ [2-Chloro-4-(methy Isul forty I) phenyl] azol-4-methyl-2,6-bis [[3- 
(2-phenoxy ethoxy) propyl] amino]-3-pyridinecarbonitriIe
63281-05-0 4-Methyl-2,6-bis [[3-(2-phenoxyethoxy) propyl] amino]-5-[[4-(phenyIazo) 
phenyl] azo]-3-pyridinecarbonitrile
63281-03-8 5-[[2-Chloro-4-(phenylzap) phenyl] azo]-4-methyI-2,6-bis[[3- 
(2-phenoxyethoxy) propyl] amino]-3-pyridinecarbonitrile
68299-27-4 Nonabromomonochloro -1 p. -diphenoxy ethane
121-54-0 p-DiisobutyI(phenoxy ethoxy) ethyl] dimetbylbenzylammonium chloride
61262-53-1 1,1'- [1,2-Ethanediylbis (oxy)] bis [2,3.4,5,6-pentabromo-benzene
23421-22-9 4,4"-[Oxybis(ethyIeneoxy)]bis [2-hydroxy benzophenone]
37853-59-1 1,2-bis(2,4,6-Tribromophenoxy) ethane
67923-87-2 2- [2-[2-(OctyIphenoxy) ethoxy] ethoxy] ethanesulfonic acid, sodium salt
72953-52-7 1-Amino-2-[2-(bromophenoxy) ethoxy ]-4-hydroxyanthraquinone
72953-51-61 1-Amino-2-[2-(dibromophenoxy) ethoxy] -4-hydioxyanthraquinone
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BACKGROUND OF METHODS USED FOR ANALYSIS 
OF EAA and MAA IN URINE
*Smallwood et al. [1984] developed a method for analyzing the glycol ether metabolites 
EAA and MAA in urine. The method was based on (1) methylene chloride extraction of 
“spiked” acidified human urine, (2) pentafluorobenzyl bromide (PFBB) derivitization, and 
(3) gas chromatography analysis using ñame ionization detection (FID). Urine (1 ml) was 
adjusted to pH 2 with HC1 and extracted three times with methylene chloride. Phase transfer 
catalysis (a combination of ion-pair extraction and ñuoroanhydride derivitization) was done 
by adding alkaline tetrabutylammonium hydrogen sulfate and PFBB to the methylene 
chloride extract. The mixture was rotated for 2 hr. Gas chromatography was employed to 
analyze 5 (jl of the methylene chloride layer (bottom layer) using FID and a 6 ft x 1/4 in 
(4-mm id) glass column (packed with 1.95% QF-1 and 1.5% OV-17 on 80/100 mesh 
Supelcoport). Detection limits for MAA and EAA were 11.4 and 5.0 mg/liter of urine, 
respectively. Average recoveries (and relative standard deviations) were 78% (0.17) for 
MAA and 91 % (0.14) for EAA.
Groeseneken et al. [1986a] developed a method for determining MAA and EAA in urine 
based on lyophilization of urine samples followed by derivitization with diazomethane. 
After adjustment of urine specimens to pH 8 to 8.5 with KOH, 1 ml of urine and 50 fig of 
2-furonic acid (FA) (internal standard) were added, and the sample was lyophilized. The 
dry residue was redissolved in 1 ml methylene chloride with added HC1 and derivitized 
with diazomethane in methylene chloride. Gas chromatographic analysis using FID was 
performed on a fused silica capillary column (CP WAX 57 CB, 25 m x 0.33 mm id) with a 
split ratio of 10:1. The detection limits of MAA and EAA were 0.15 and 0.07 mg/liter of 
urine, respectively. Mean recoveries of MAA, EAA, and FA added to “blank” urine samples 
were 31.4%, 62.5%, and 58.4%, respectively; the recoveries of MAA and EAA were well 
correlated with those of the internal standard. Day-to-day variability for MAA and EAA 
was 6.0% and 6.4%, respectively; the corresponding within-day variability was 6.2% and 
8.9%.
*
See References beginning on page 262.
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Smallwood et al. [1988] developed and validated a method for analysis of EAA in urine. 
Two ml of urine, along with potassium carbonate, tetrabutylammonium hydrogen sulfate, 
methylene chloride, and PFBB were added to a screw-top culture tube. After 2 hr of mixing 
on a rotator at 60 rpm, the tube was heated for 20 min in a 50°C water bath. Additional 
mixing at room temperature, removal of the upper aqueous layer, and washing of the lower 
methylene chloride layers with distilled water removed unreacted reagents. The methylene 
chloride extract was dried with anhydrous sodium sulfate and loaded into an autosampler 
vial. Automated gas chromatographic analysis using FID was conducted with the use of a 
6 ft x 4 mm id glass column packed with 4% SE-30 and 6% OV-210 on 100/120 mesh 
Chromosorb WHP. Standards were prepared in pooled urine. The analytical range for EAA 
was 5 to 100 mg/liter of urine; the limit o f detection was 4 mg/liter; and the limit of 
quantitation was 7 mg/liter. Within-day variation was 0.5% to 1.8%, and day-to-day 
variation was 3.0% to 4.7%. Sample stability was confirmed for at least 8 months when 
specimens were stored at -20°C. The authors stated that the method could also be used for 
MAA and butoxyacetic acid (BAA) in urine. Preliminary data were presented in the paper 
indicating that the technique has the potential for assessing EGEE exposure in shipyard 
painters who use paints containing EGEE.
Groeseneken et al. [1989b] observed that MAA appeared in the chromatogram of control 
subjects not exposed to EGME. Further investigation revealed that the diazomethane 
procedure was producing MAA by reacting with the hydroxyl group of naturally occurring 
glycolic acid. Groeseneken et al. [1989b] further evaluated the existing methods for 
determining alkoxyacetic acids and concluded that the phase transfer catalysis procedures 
had the required specificity, without the production of artifacts, but lacked sufficient 
sensitivity to detect these metabolites at low occupational exposure concentrations. On the 
other hand, the methods utilizing diazomethane derivitization had the required sensitivity 
but lacked the specificity. Therefore, Groeseneken et al. [1989a] developed an improved 
method that combined the best attributes of the two basic existing methods.
The procedure developed by Groeseneken et al. [1989b] was described as follows. Urine 
was adjusted to pH 7; l-ml aliquots were placed in small vials with 3-chloropropionic acid 
(internal standard) and lyophilized overnight. The dry residue was redissolved in methanol 
containing PFBB, and the vials were capped. The vials were heated at 90°C for 3 hr. After 
cooling, sample cleanup was done by adding distilled water and extracting the penta- 
fluorobenzyl-esters (PFB-esters) with methylene chloride. The methylene chloride extract 
was analyzed by gas chromatography using FID. A fused silica capillary column was used 
(CP Sil 5,25 m x 0.32 mm id, 0.21 pm film thickness) with a split ratio of 5:1. Temperature 
programming was employed. All PFB-esters showed baseline resolution; retention times 
of 6.53 min (MAA), 7.77 min (EAA), and 8.59 min (internal standard) were observed. A 
typical gas chromatographic run, including cool-down and equilibration times, required 
about 30 min.
Optimization studies were done for reagent concentrations as well as for urinaiy pH and 
reaction time. After correction for the partial solubility of methylene chloride in the 50:50 
methanol: urine phase, recoveries of alkoxyacetic acids from urine averaged 95.0% (MAA), 
94.8% (EAA), and 95.1 % (BAA). The yield for the derivitization reaction averaged 99.5%
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(MAA) and 101.8% (EAA). Standard curves were set up for urine and were linear over the 
range of 0.1 to 200 mg/liter. The limit of detection, at a signal-to-noise ratio o f 5, for the 
two acids was 0.03 mg/liter. Precision of the method, calculated from triplicate injections 
of 40 urine samples, averaged 3.5% (RSD), ranging from 1.1% at 25 mg/liter to 20% at
0.1 mg/1 iter.
NIOSH has not validated the Groeseneken et al. methods [1986a, 1989b],
2 4 8
APPENDIX G
GUIDELINES FOR BIOLOGICAL MONITORING
G.1 Monitoring
The frequency of biological monitoring should be tied to work practices and the use of the 
glycol ethers. Dermal absorption of glycol ethers can be significant. Compliance with the 
NIOSH RELs without a biological monitoring evaluation may not protect workers from the 
potential adverse effects of glycol ethers.
Urine samples should be evaluated for alkoxyacetic acid metabolites using the method of 
Groeseneken et al. [1989b) or an equivalent method. Expression of results as milligrams 
of metabolite per gram of creatinine (mg/g creatinine) is suggested.
Factors that may affect the urinary levels o f EAA and MAA include ethanol consumption 
(which lowers urinary metabolite levels) and dermal contact, heavy work, and nonoccupa- 
tional exposures (all of which raise urinary levels).
Urine sample collection times are specific for the individual glycol ethers:
• EGEE and EGEEA: Urine samples should be collected at the beginning of the 
shift on the last working day of the workweek. This specimen would represent the 
integrated weekly exposure (dermal and inhalation).
• EGME and EGMEA: Urine samples should be collected preshift on the first day of 
the workweek following a typical workweek of exposure. This specimen would 
reflect the integrated exposure (dermal and inhalation) from the previous week.
Measurable concentrations of EAA or MAA in the urine are an indication of uptake of the 
respective glycol ethers by either inhalation or skin exposure. The concentrations reflect 
nonoccupational as well as occupational exposure and are not likely to correlate with the 
NIOSH RELs. If concentrations of EAA and MAA exceed the estimated guidelines below, 
then exposure to glycol ethers has occurred, but not necessarily at concentrations above the 
NIOSH RELs. A thorough industrial hygiene evaluation, with specific emphasis on possible 
dermal absorption, should be conducted to determine the source of exposure. The following 
guidelines are suggested until better documented guidelines are developed.
See References beginning on page 262.
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1. The presence o f EAA in urine specimens (collected as specified) above a concentra­
tion of approximately 5 mg EAA/g creatinine is evidence for a single EGEE and/or 
EGEEA inhalation exposure corresponding to an 8-hr exposure to 0.5 ppm EGEE 
and/or EGEEA at 60 W of exercise. This value was extrapolated from 4-hr experimental 
exposures at 5 ppm at 60-W workload to an 8-hr exposure at 0.5 ppm at 60-W 
workload [Groeseneken et al. 1986c, 1987b] using the principle of superposition 
[Gibaldi and Perrier 1982].
2. The presence of MAA in urine specimens (collected as specified) above a concentra­
tion o f approximately 1 pg/ml (equivalent to approximately 0.8 mg/g creatinine) is 
evidence of inhalation-only exposure to EGME and/or EGMEA. This value was 
extrapolated from 4-hr laboratory exposures at 5.1 ppm EGME at rest to 8-hr exposure 
to 0.5 ppm at 60-W workload [Groeseneken et al. 1989a]. The excretion of MAA 
was relatively constant 4 hr after the end of a 4-hr exposure. Therefore, doubling the 
urinary EAA concentration after a 4-hr exposure is a reasonable estimate of urinary 
values following an 8-hr exposure (based on Figure 1 [Groesenken et al. 1989a]). 
Extrapolation to 0.1 ppm may produce MAA levels below the detection limit of the 
method. There are no data on occupational exposures, but based on EGEE data and 
on the strong possibility of concurrent dermal absorption of EGME, concentrations 
of MAA may be higher than 0.8 mg/g creatinine in urine specimens collected from 
workers.
G.2 Justification For Recommendations
Biological monitoring for glycol ether exposure is recommended, even though no validated 
guidelines can be provided as to the relationship between airborne exposure to glycol ethers 
and the alkoxyacetic acid urinary metabolites. The alkoxyacetic acid metabolites (EAA and 
MAA) are not only an index of exposure or uptake of EGEE or EGME by the worker, but 
they are also an index of potential adverse health effects from these glycol ethers.
Dermal absorption may be a major route o f exposure to EGME and EGEE and their 
respective acetates. The potential exists for absorption of glycol ether vapors through wet 
skin.
The influence of workload is significant for inhalation exposure. Doubling the workload 
results in twice the uptake of the glycol ethers.
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MEDICAL ASPECTS OF WEARING RESPIRATORS*
In recommending medical evaluation criteria for respirator use, one should apply rigorous 
decision-making principles [Halperin et al. 1986];* tests used should be chosen for operating 
characteristics such as sensitivity, specificity, and predictive value. Unfortunately, many 
knowledge gaps exist in this area. The problem is complicated by the large variety of 
respirators, their conditions of use, and individual differences in the physiologic and 
psychologic responses to them. The following guidelines are intended primarily to assist 
the physician in developing medical evaluation criteria for respirator use.
H.1 BACKGROUND INFORMATION
Brief descriptions of the health effects associated with wearing respirators are summarized 
below. More detailed analyses of the data are available in recent reviews by James [1977] 
and Raven et al. [1979].
H.1.1 Pulmonary Effects
In general, the added inspiratory and expiratory resistances and dead space of most 
respirators cause an increase in tidal volume and a decrease in respiratory rate and ventilation 
(including a small decrease in alveolar ventilation). These respirator effects have usually 
been small both among healthy individuals and, in limited studies, among individuals with 
impaired lung function [Gee et al. 1968; Altose et al. 1977; Raven et al. 1981; Hodous et al. 
1983; Hodous et al. 1986]. This generalization is applicable to most respirators when 
resistances (particularly expiratory resistance) are low [Bentley et al. 1973; Love et al. 1977]. 
Although most studies report minimal physiologic effects during submaximal exercise, the 
resistances commonly lead to reduced endurance and reduced maximal exercise perform­
ance [Craig et al. 1970; Raven et al. 1977; Stemler and Craig 1977; Myhre etal. 1979; Deno 
et al. 1981], The dead space of a respirator (reflecting the amount of expired air that must 
be rebreathed before fresh air is obtained) tends to cause increased ventilation. At least one 
study has shown substantially increased ventilation with a full-face respirator, a type that 
can have a large effective dead space [James et al. 1984]. However, the net effect of a 
respirator’s added resistances and dead space is usually a small decrease in ventilation [Craig
Adapted from NIOSH Respiratory Decision Logic [NIOSH 1987b].
* References for Appendix H are at the end of this Appendix.
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et al. 1970; Hermansen et al. 1972; Raven et al. 1977; Stemler and Craig 1977; Deno et al. 
1981;Hodouset al. 1983],
The potential for adverse effects, particularly decreased cardiac output, from the positive 
pressure feature o f some respirators has been reported [Meyer et al. 1975]. However, several 
recent studies suggest that this is not a practical concern, at least not in healthy individuals 
[Bjurstedt et al. 1979; Arborelius et al. 1983; Dahlback and Balldin 1984].
Theoretically, the increased fluctuations in thoracic pressure caused by breathing with a 
respirator might constitute an increased risk to subjects with a history of spontaneous 
pneumothorax. Few data are available in this area. While an individual is using a 
negative-pressure respirator with relatively high resistance during very heavy exercise, 
the usual maximal-peak negative oral pressure during inhalation is about 15 to 17 cm of 
water [Dahlback and Balldin 1984]. Similarly, the usual maximal-peak positive oral 
pressure during exhalation is about 15 to 17 cm of water, which might occur with a 
respirator in a positive-pressure mode, again during very heavy exercise [Dahlback and 
Balldin 1984]. By comparison, maximal positive pressures such as those during a 
vigorous cough can generate 200 cm of water pressure [Black and Hyatt 1969]. The 
normal maximal negative pleural pressure at full inspiration is -4 0  cm o f water [Bates et 
al. 1971], and normal subjects can generate -8 0  to -160 cm of negative water pressure 
[Black and Hyatt 1969]. Thus vigorous exercise with a respirator does alter pleural 
pressures, but the risk of barotrauma is substantially less with exercise than with coughing.
In some asthmatics, an asthmatic attack may be exacerbated or induced by a variety of factors 
including exercise, cold air, and stress, all of which may be associated with wearing a 
respirator. Although most asthmatics who are able to control their condition should not have 
problems with respirators, a physician’s judgment and a field trial may be needed in selected 
cases.
H.1.2 Cardiac Effects
The added work of breathing from respirators is small and could not be detected in several 
studies [Gee et al. 1968; Hodous et al. 1983]. A typical respirator might double the work 
of breathing (from 3% to 6% of the total oxygen consumption), but this is probably not of 
clinical significance [Gee et al. 1968]. In concordance with this view, several other studies 
indicated that at the same workloads heart rate does not change with the wearing o f a 
respirator [Raven et al. 1982; Harber et al. 1982; Hodous et al. 1983; Arborelius et al. 1983; 
Petsonk et al. 1983].
In contrast, the added cardiac stress due to the weight o f a heavy respirator may be 
considerable. A self-contained breathing apparatus (SCBA) may weigh up to 35 lb. Heavier 
respirators can reduce maximum external workloads by 20% and similarly increase heart 
rate at a given submaximal workload [Raven et al. 1977]. In addition, it should be noted 
that many uses of SCBA (e.g., for firefighting and hazardous waste site work) also 
necessitate the wearing of 10 to 25 lb of protective clothing. Raven et al. [1982] found
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statistically significant higher systolic and/or diastolic blood pressures during exercise for 
persons wearing respirators. Arborelius et al. [1983] did not find significant differences for 
persons wearing respirators during exercise.
H.1.3 Body Temperature Effects
Proper regulation of body temperature is primarily of concern with the closed circuit SCBA 
that produces oxygen via an exothermic chemical reaction. Inspired air within these 
respirators may reach 120°F (49°C), thus depriving the wearer of a minor cooling mechanism 
and causing discomfort. Obviously this can be more of a problem with heavy exercise and 
when ambient conditions and/or protective clothing further reduce the body’s ability to lose 
heat. The increase in heart rate because of increasing temperature represents an additional 
cardiac stress.
Closed-circuit breathing units of any type have the potential for causing heat stress since 
warm expired gases (after exothermic carbon dioxide removal with or without oxygen 
addition) are rebreathed. Respirators with large dead spaces also have this potential 
problem, again because of partial rebreathing of wanned expired air [James et al. 1984],
H.1.4 Sensory Effects
Respirators may reduce visual fields, decrease voice clarity and loudness, and decrease 
hearing ability. Besides the potential for reduced productivity, these effects may result in 
reduced industrial safety. These factors may also contribute to a general feeling of stress 
[Morgan 1983a].
H.1.5 Psychologic Effects
This important topic is discussed in recent reviews by Morgan [Morgan 1983a, 1983b]. 
There is little doubt that virtually everyone suffers some discomfort when wearing a 
respirator. The large variability and the subjective nature o f the psychophysiologic 
aspects o f wearing a respirator, however, make studies and specific recommendations 
difficult. Fit testing obviously serves an important additional function by providing a 
trial to determine if the wearer can psychologically tolerate the respirator. The great 
majority o f workers can tolerate respirators, and experience in wearing them aids in this 
tolerance [Morgan 1983b]. However, some individuals are likely to remain psychologi­
cally unfit for wearing respirators.
H.1.6 Local Irritation Effects
Allergic skin reactions may occur occasionally from wearing a respirator, and skin occlusion 
may cause irritation or exacerbation of preexisting conditions such as pseudofolliculitis 
barbae. Facial discomfort from the pressure of the mask may occur, particularly when the 
fit is unsatisfactory.
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H.1.7 Miscellaneous Health Effects
In addition to the health effects (described above) associated with wearing respirators, 
specific groups of respirator wearers may be affected by the following factors:
a. Perforated tympanic membrane
Although inhalation of toxic materials through a perforated tympanic membrane (ear 
drum) is possible, recent evidence indicates that the airflow would be minimal and 
rarely if ever of clinical importance [Cantekin et al. 1979; Ronk and White 1985], In 
highly toxic or unknown atmospheres, use of positive pressure respirators should 
ensure adequate protection [Ronk and White 1985],
b. Contact lenses
Contact lenses are generally not recommended for use with respirators, although little 
documented evidence exists to support this viewpoint [daRoza and Weaver 1985]. 
Several possible reasons for this recommendation are noted below:
(1) Corneal irritation or abrasion
Comeal irritation or abrasion might occur with the exposure. This would, of course, 
be a problem primarily with quarter- and half-face masks, especially with particulate 
exposures. However, exposures could occur with full-face respirators because of 
leaks or inadvisable removal of the respirator for any reason. Although corneal 
irritation or abrasion might also occur without contact lenses, their presence is 
known to substantially increase this risk.
(2) Loss or misplacement of a contact lens
The loss or misplacement of a contact lens by an individual wearing a respirator 
might prompt the wearer to remove the respirator, thereby resulting in exposure to 
the hazard as well as to the potential problems noted above.
(3) Eye irritation from respirator airflow
The constant airflow of some respirators, such as powered air-purifying respirators 
(P APR’s) or continuous flow air-line respirators, might irritate the eyes of a contact 
lens wearer.
H.2 SUGGESTED MEDICAL EVALUATION AND CRITERIA FOR 
RESPIRATOR USE
The following NIOSH recommendations allow latitude for the physician in determining a 
medical evaluation for a specific situation. More specific guidelines may become available 
as knowledge increases regarding human stresses from the complex interactions of worker
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health status, respirator usage, and job tasks. Although some of the following recommen­
dations should be part of any medical evaluation of workers who wear respirators, others 
are applicable for specific situations.
• A physician should determine fitness to wear a respirator by considering the 
worker’s health, the type of respirator, and the conditions of respirator use.
The recommendation above leaves the final decision of an individual’s fitness to wear a 
respirator to the person who is best qualified to evaluate the multiple clinical and other 
variables. Much of the clinical and other data could be gathered by other personnel. It 
should be emphasized that the clinical examination alone is only one part o f the fitness 
determination. Collaboration with foremen, industrial hygienists, and others may often be 
needed to better assess the work conditions and other factors that affect an individual’s 
fitness to wear a respirator.
• A medical history and at least a limited physical examination are recommended.
The medical history and physical examination should emphasize the evaluation of the 
cardiopulmonary system and should elicit any history of respirator use. The history is ah 
important tool in medical diagnosis and can be used to detect most problems that might 
require further evaluation. Objectives of the physical examination should be to confirm the 
clinical impression based on the history and to detect important medical conditions (such as 
hypertension) that may be essentially asymptomatic.
• Although chest X-ray and/or spirometry may be medically indicated in some fitness 
determinations, these should not be routinely performed.
In most cases, the hazardous situations requiring the wearing o f respirators will also mandate 
periodic chest X-rays and/or spirometry for exposed workers. When such information is 
available, it should be used in the determination of fitness to wear respirators.
Data from routine chest X-rays and spirometry are not recommended solely for determining 
if a respirator should be worn. In most cases, with an essentially normal clinical examination 
(history and physical), these data are unlikely to influence the respirator fitness determina­
tion; additionally, the X-ray would be an unnecessary source of radiation exposure to the 
worker. Chest X-rays in general do not accurately reflect a person’s cardiopulmonary 
physiologic status, and limited studies suggest that mild to moderate impairment detected 
by spirometry would not preclude the wearing of respirators in most cases. Thus it is 
recommended that chest X-rays and/or spirometry be done only when clinically indicated.
• The recommended periodicity of medical fitness determinations varies according 
to several factors but could be as infrequent as every 5 years.
Federal or other applicable regulations shall be followed regarding the frequency of 
respirator fitness determinations. The guidelines for most work conditions for which 
respirators are required are shown in Table H -l.
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Table H -l.—Suggested frequency of medical fitness determinations
Type of  
working 
condition«
Worker age (yr)
<35 35 to 45 >45
Most work conditions 
requiring respiratois
Every 5 yr Every 2 yr 1-2 yr
Strenuous working 
conditions with a SCBA*
Every 3 yr Every 18 mo Annually
’interim testing would be needed if  changes in health status occur. 
*SCBA -  self-contained breathing apparatus.
These guidelines are similar to those recommended by ANSI, which recommends annual 
determinations after age 45 [ANSI 1984]. The more frequent examinations with advancing 
age relate to the increased prevalence of most diseases in older people. More frequent 
examinations are recommended for individuals performing strenuous work involving the 
use of a SCBA. These guidelines are based on clinical judgment and, like the other 
recommendations in this section, should be adjusted as clinically indicated.
• The respirator wearer should be observed during a trial period to evaluate potential 
physiological problems.
In addition to considering the physical effects o f wearing respirators, the physician should 
determine if wearing a given respirator would cause extreme anxiety or claustrophobic 
reaction in the individual. This could be done during training while the worker is wearing 
the respirator and is engaged in some exercise that approximates the actual work situation.
Present OSHA regulations state that a worker should be provided the opportunity to wear 
the respirator “in normal air for a long familiarity period . . [ 2 9  CFR 1910.134(e)(5)]. 
This trial period should also be used to evaluate the ability and tolerance of the worker to 
wear the respirator [Harber 1984]. This trial period need not be associated with respirator 
fit testing and should not compromise the effectiveness of the vital fit testing procedure.
• Examining physicians should realize that the main stress of heavy exercise while 
using a respirator is usually on the cardiovascular system and that heavy respirators 
(e.g., SCBA) can substantially increase this stress. Accordingly, physicians may 
want to consider exercise stress tests with electrocardiographic monitoring when 
heavy respirators are used, when cardiovascular risk factors are present, or when 
extremely stressful conditions are expected.
*
Code o f Federal Regulations. See CFR in references.
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Some respirators may weigh up to 35 lb and may increase workloads by 20%. Although a 
lower activity level could compensate for this added stress [Manning and Griggs 1983], a 
lower activity level might not always be possible. Physicians should also be aware o f other 
added stresses, such as heavy protective clothing and intense ambient heat, that would 
increase the wor Iter’s cardiac demand. As an extreme example, fire fighters who use a SCBA 
inside burning buildings may work at maximal exercise levels under life-threatening 
conditions. In such cases, the detection of occult cardiac disease, which might manifest 
itself during heavy stress, may be important. Some authors have either recommended stress 
testing [Kilbom 1980] or at least its consideration in the fitness determination [ANSI 1984]. 
Kilbom [1980] has recommended stress testing at 5-yr intervals for fire fighters below age 
40 who use SCBA and at 2-yr intervals for those aged 40 to 50. He further suggested that 
firemen over age 50 not be allowed to wear SCBA.
Exercise stress testing has not been recommended for medical screening for coronary artery 
disease in the general population [Weiner et al. 1979; Epstein 1979]. It has an estimated 
sensitivity and specificity of 78% and 69%, respectively, when the disease is defined by 
coronary angiography [Weiner et al. 1979; Nicklin and Balaban 1984], In a recent 6-yr 
prospective study, stress testing to determine the potential for heart attacks indicated a 
positive predictive value of 27 % when the prevalence of disease was 3.5% [Giagnoni et al. 
1983; Folli 1984]. Although stress testing has limited effectiveness in medical screening, 
it could detect individuals who may not be able to complete the heavy exercise required in 
some jobs.
A definitive recommendation regarding exercise stress testing cannot be made at this time. 
Further research may determine whether this is a useful tool in selected circumstances.
• An important concept is that “general work limitations and restrictions identified 
for other work activities also shall apply for respirator use” [ANSI 1984].
In many cases, if a worker is physically able to do an assigned job while not wearing a 
respirator, the worker will in most situations not be at increased risk when performing the 
same job while wearing a respirator.
• Because of the variability in the types of respirators, work conditions, and workers’ 
health status, many employers may wish to designate categories of fitness to wear 
respirators, thereby excluding some workers from strenuous work situations in­
volving the wearing of respirators.
Depending on the various circumstances, several permissible categories of respirator usage 
are possible. One conceivable scheme would consist o f three overall categories: full 
respirator use, no respirator use, and limited respirator use including “escape only” respirators. 
The latter category excludes heavy respirators and strenuous work conditions. Before 
identifying the conditions that would be used to classify workers into various categories, it 
is critical that the physician be aware that these conditions have not been validated and are 
presented only for consideration. The physician should modify the use of these conditions 
based on actual experience, further research, and individual worker sensitivities. He may
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also wish to consider the following conditions in selecting or permitting the use of 
respirators:
• History of spontaneous pneumothorax
• Claustrophobia/anxiety reaction
• Use of contact lenses (for some respirators)
•  Moderate or severe pulmonary disease
•  Angina pectoris, significant arrhythmias, recent myocardial infarction
• Symptomatic or uncontrolled hypertension, and
• Advanced age
Wearing a respirator would probably not play a significant role in causing lung damage such 
as pneumothorax. However, without good evidence that wearing a respirator would not 
cause such lung damage, the physician would be prudent to prohibit the individual with a 
history of spontaneous pneumothorax from wearing a respirator.
Moderate lung disease is defined by the Intermountain Thoracic Society [Kanner and Morris 
1975] as being present when the following conditions exist—a forced expiratory volume in 
1 sec (FEVj) divided by the forced vital capacity (FVC) (i.e., FEVj/FVC) of 0.45 to 0.60, 
or an FVC of 51 % to 65 % of the predicted FVC value. Similar arbitrary limits could be set 
for age and hypertension. It would seem more reasonable, however, to combine several risk 
factors into an overall estimate of fitness to wear respirators under certain conditions. Here 
the judgment and clinical experience of the physician are needed. Many impaired workers 
would even be able to work safely while wearing respirators if  they could control their own 
work pace, including having sufficient time to rest.
H.3 CONCLUSION
Individual judgment is needed to determine the factors affecting an individual’s fitness to 
wear a respirator. Although many of the preceding guidelines are based on limited evidence, 
they should provide a useful starting point for a respirator fitness screening program. Further 
research is needed to validate these and other recommendations currently in use. Of 
particular interest would be laboratory studies involving physiologically impaired in­
dividuals and field studies conducted under actual day-to-day work conditions.
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